{"PMC7167927": [["Viral\u2013bacterial synergy in medical infectionsRespiratory disease represents the best\u2010known example of serious viral\u2013bacterial co\u2010infections (113, 129).", [["viral\u2013bacterial", "ANATOMY", 110, 125], ["infections", "DISEASE", 35, 45], ["Respiratory disease", "DISEASE", 45, 64], ["viral\u2013bacterial co\u2010infections", "DISEASE", 110, 139], ["Viral\u2013bacterial synergy", "PROBLEM", 0, 23], ["medical infections", "PROBLEM", 27, 45], ["Respiratory disease", "PROBLEM", 45, 64], ["serious viral\u2013bacterial co\u2010infections", "PROBLEM", 102, 139], ["synergy", "OBSERVATION_MODIFIER", 16, 23], ["infections", "OBSERVATION", 35, 45], ["Respiratory disease", "OBSERVATION", 45, 64], ["serious", "OBSERVATION_MODIFIER", 102, 109], ["viral\u2013bacterial co\u2010infections", "OBSERVATION", 110, 139]]], ["Worldwide, respiratory infections give rise to more disease and death than any other human infection and are one of the leading causes of morbidity and mortality (121).", [["respiratory", "ANATOMY", 11, 22], ["respiratory infections", "DISEASE", 11, 33], ["death", "DISEASE", 64, 69], ["human infection", "DISEASE", 85, 100], ["human", "ORGANISM", 85, 90], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["respiratory infections", "PROBLEM", 11, 33], ["more disease", "PROBLEM", 47, 59], ["death", "PROBLEM", 64, 69], ["any other human infection", "PROBLEM", 75, 100], ["morbidity", "PROBLEM", 138, 147], ["respiratory", "ANATOMY", 11, 22], ["infections", "OBSERVATION", 23, 33], ["infection", "OBSERVATION", 91, 100]]], ["Seasonal influenza in the USA is estimated to result in more than 200,000 hospitalizations and 36,000 deaths annually (218).", [["influenza", "DISEASE", 9, 18], ["deaths", "DISEASE", 102, 108], ["Seasonal influenza", "PROBLEM", 0, 18], ["influenza", "OBSERVATION", 9, 18]]], ["The great \u2018Spanish flu\u2019 influenza pandemic of 1918\u20131919 caused 20\u201350 million deaths worldwide and an estimated 675,000 deaths in the USA, affecting mostly young adults and not the usual children and old individuals.", [["influenza", "DISEASE", 24, 33], ["deaths", "DISEASE", 77, 83], ["deaths", "DISEASE", 119, 125], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 186, 194], ["great", "OBSERVATION_MODIFIER", 4, 9]]], ["At the peak, half of the world\u2019s population was clinically infected.", [["clinically infected", "PROBLEM", 48, 67], ["infected", "OBSERVATION", 59, 67]]], ["During the influenza pandemic years of 1918\u20131919 (type A influenza, subtype H1N1) and 1957\u20131958 (type A influenza, subtype H2N2), the incidence of secondary bacterial pneumonia, the most common cause of excess mortality during influenza outbreaks, varied between 2 and 18% in different populations (123).", [["influenza pandemic", "DISEASE", 11, 29], ["influenza", "DISEASE", 57, 66], ["type A influenza", "DISEASE", 97, 113], ["bacterial pneumonia", "DISEASE", 157, 176], ["influenza outbreaks", "DISEASE", 227, 246], ["type A influenza", "ORGANISM", 97, 113], ["type A influenza, subtype H1N1", "PROBLEM", 50, 80], ["type A influenza", "PROBLEM", 97, 113], ["subtype H2N2", "PROBLEM", 115, 127], ["secondary bacterial pneumonia", "PROBLEM", 147, 176], ["excess mortality", "PROBLEM", 203, 219], ["influenza outbreaks", "PROBLEM", 227, 246], ["secondary", "OBSERVATION_MODIFIER", 147, 156], ["bacterial", "OBSERVATION_MODIFIER", 157, 166], ["pneumonia", "OBSERVATION", 167, 176]]], ["The influenza A (swine flu) pandemic of 2009 involved a novel H1N1 strain.", [["influenza A (swine flu", "DISEASE", 4, 26], ["influenza A", "ORGANISM", 4, 15], ["swine flu", "ORGANISM", 17, 26], ["swine flu", "SPECIES", 17, 26], ["influenza A (swine flu", "SPECIES", 4, 26], ["The influenza A", "TEST", 0, 15], ["a novel H1N1 strain", "PROBLEM", 54, 73], ["H1N1 strain", "OBSERVATION", 62, 73]]], ["The main bacteria in influenza\u2010associated pneumonia are Streptococcus pneumoniae, alpha\u2010hemolytic streptococci, Haemophilus influenzae, Staphylococcus aureus and Moraxella (Branhamella) catarrhalis (123).", [["pneumonia", "DISEASE", 42, 51], ["Streptococcus pneumoniae", "DISEASE", 56, 80], ["Haemophilus influenzae", "DISEASE", 112, 134], ["Staphylococcus aureus", "DISEASE", 136, 157], ["influenza\u2010associated pneumonia", "ORGANISM", 21, 51], ["Streptococcus pneumoniae", "ORGANISM", 56, 80], ["alpha\u2010hemolytic streptococci", "ORGANISM", 82, 110], ["Haemophilus influenzae", "ORGANISM", 112, 134], ["Staphylococcus aureus", "ORGANISM", 136, 157], ["Moraxella (Branhamella) catarrhalis", "ORGANISM", 162, 197], ["Streptococcus pneumoniae", "SPECIES", 56, 80], ["Haemophilus influenzae", "SPECIES", 112, 134], ["Staphylococcus aureus", "SPECIES", 136, 157], ["Branhamella) catarrhalis", "SPECIES", 173, 197], ["Streptococcus pneumoniae", "SPECIES", 56, 80], ["Haemophilus influenzae", "SPECIES", 112, 134], ["Staphylococcus aureus", "SPECIES", 136, 157], ["Branhamella) catarrhalis", "SPECIES", 173, 197], ["The main bacteria", "TEST", 0, 17], ["influenza\u2010associated pneumonia", "PROBLEM", 21, 51], ["Streptococcus pneumoniae", "PROBLEM", 56, 80], ["alpha\u2010hemolytic streptococci", "PROBLEM", 82, 110], ["Haemophilus influenzae", "PROBLEM", 112, 134], ["Staphylococcus aureus", "PROBLEM", 136, 157], ["Moraxella (Branhamella) catarrhalis", "PROBLEM", 162, 197], ["main", "OBSERVATION_MODIFIER", 4, 8], ["bacteria", "OBSERVATION_MODIFIER", 9, 17], ["pneumonia", "OBSERVATION", 42, 51], ["Streptococcus pneumoniae", "OBSERVATION", 56, 80], ["alpha\u2010hemolytic streptococci", "OBSERVATION", 82, 110], ["Haemophilus influenzae", "OBSERVATION", 112, 134], ["Staphylococcus aureus", "OBSERVATION", 136, 157], ["Moraxella", "OBSERVATION_MODIFIER", 162, 171]]], ["A combined infection with influenza viruses and S. aureus causes particularly severe and fatal pneumonia in both children and adults (29).", [["infection", "DISEASE", 11, 20], ["influenza viruses", "DISEASE", 26, 43], ["S. aureus", "DISEASE", 48, 57], ["pneumonia", "DISEASE", 95, 104], ["influenza viruses", "ORGANISM", 26, 43], ["S. aureus", "ORGANISM", 48, 57], ["children", "ORGANISM", 113, 121], ["S. aureus", "SPECIES", 48, 57], ["children", "SPECIES", 113, 121], ["S. aureus", "SPECIES", 48, 57], ["A combined infection", "PROBLEM", 0, 20], ["influenza viruses", "PROBLEM", 26, 43], ["S. aureus", "PROBLEM", 48, 57], ["fatal pneumonia", "PROBLEM", 89, 104], ["infection", "OBSERVATION", 11, 20], ["influenza viruses", "OBSERVATION", 26, 43], ["aureus", "OBSERVATION", 51, 57], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["fatal", "OBSERVATION_MODIFIER", 89, 94], ["pneumonia", "OBSERVATION", 95, 104]]], ["Respiratory viruses other than the influenza viruses can also interact pathogenically with bacterial pathogens, for example human parainfluenza virus with S. pneumoniae (50) and adenovirus with Bordetella pertussis (185).", [["influenza viruses", "DISEASE", 35, 52], ["parainfluenza virus", "DISEASE", 130, 149], ["Bordetella pertussis", "DISEASE", 194, 214], ["Respiratory viruses", "ORGANISM", 0, 19], ["influenza viruses", "ORGANISM", 35, 52], ["human", "ORGANISM", 124, 129], ["parainfluenza virus", "ORGANISM", 130, 149], ["S. pneumoniae", "ORGANISM", 155, 168], ["adenovirus", "ORGANISM", 178, 188], ["Bordetella pertussis", "ORGANISM", 194, 214], ["human", "SPECIES", 124, 129], ["parainfluenza virus", "SPECIES", 130, 149], ["S. pneumoniae", "SPECIES", 155, 168], ["Bordetella pertussis", "SPECIES", 194, 214], ["human parainfluenza virus", "SPECIES", 124, 149], ["S. pneumoniae", "SPECIES", 155, 168], ["adenovirus", "SPECIES", 178, 188], ["Bordetella pertussis", "SPECIES", 194, 214], ["Respiratory viruses", "PROBLEM", 0, 19], ["the influenza viruses", "PROBLEM", 31, 52], ["bacterial pathogens", "PROBLEM", 91, 110], ["human parainfluenza virus", "PROBLEM", 124, 149], ["S. pneumoniae", "PROBLEM", 155, 168], ["adenovirus", "PROBLEM", 178, 188], ["Bordetella pertussis", "PROBLEM", 194, 214], ["viruses", "OBSERVATION", 12, 19], ["influenza viruses", "OBSERVATION", 35, 52]]], ["A study of community\u2010acquired childhood pneumonia revealed that mixed viral\u2013bacterial infections, which comprised about 75% of the pneumonias studied, resulted in more severe inflammation and clinical illness than single viral or bacterial infections (87).Viral\u2013bacterial synergy in medical infectionsViruses can induce alterations in the respiratory tract, which allow resident bacteria to multiply to levels capable of inducing inflammation (6).", [["respiratory tract", "ANATOMY", 339, 356], ["pneumonia", "DISEASE", 40, 49], ["viral\u2013bacterial infections", "DISEASE", 70, 96], ["pneumonias", "DISEASE", 131, 141], ["inflammation", "DISEASE", 175, 187], ["viral or bacterial infections", "DISEASE", 221, 250], ["infections", "DISEASE", 291, 301], ["alterations in the respiratory tract", "DISEASE", 320, 356], ["inflammation", "DISEASE", 430, 442], ["respiratory tract", "ORGANISM_SUBDIVISION", 339, 356], ["A study", "TEST", 0, 7], ["community\u2010acquired childhood pneumonia", "PROBLEM", 11, 49], ["mixed viral\u2013bacterial infections", "PROBLEM", 64, 96], ["the pneumonias", "PROBLEM", 127, 141], ["more severe inflammation", "PROBLEM", 163, 187], ["clinical illness", "PROBLEM", 192, 208], ["single viral or bacterial infections", "PROBLEM", 214, 250], ["Viral\u2013bacterial synergy", "PROBLEM", 256, 279], ["medical infections", "PROBLEM", 283, 301], ["Viruses", "PROBLEM", 301, 308], ["alterations in the respiratory tract", "PROBLEM", 320, 356], ["bacteria", "PROBLEM", 379, 387], ["inducing inflammation", "PROBLEM", 421, 442], ["pneumonia", "OBSERVATION", 40, 49], ["mixed", "OBSERVATION_MODIFIER", 64, 69], ["viral\u2013bacterial infections", "OBSERVATION", 70, 96], ["pneumonias", "OBSERVATION", 131, 141], ["more", "OBSERVATION_MODIFIER", 163, 167], ["severe", "OBSERVATION_MODIFIER", 168, 174], ["inflammation", "OBSERVATION", 175, 187], ["bacterial", "OBSERVATION_MODIFIER", 230, 239], ["infections", "OBSERVATION", 240, 250], ["synergy", "OBSERVATION", 272, 279], ["medical infections", "OBSERVATION", 283, 301], ["respiratory tract", "ANATOMY", 339, 356], ["inflammation", "OBSERVATION", 430, 442]]], ["Respiratory tract viruses can inhibit the ciliary activity of the respiratory epithelium and thereby increase the risk for bacterial superinfection (6).", [["ciliary", "ANATOMY", 42, 49], ["respiratory epithelium", "ANATOMY", 66, 88], ["superinfection", "DISEASE", 133, 147], ["Respiratory tract viruses", "ORGANISM", 0, 25], ["ciliary", "MULTI-TISSUE_STRUCTURE", 42, 49], ["respiratory epithelium", "TISSUE", 66, 88], ["Respiratory tract viruses", "PROBLEM", 0, 25], ["the respiratory epithelium", "PROBLEM", 62, 88], ["bacterial superinfection", "PROBLEM", 123, 147], ["tract viruses", "OBSERVATION", 12, 25], ["ciliary activity", "OBSERVATION", 42, 58], ["respiratory epithelium", "OBSERVATION", 66, 88], ["risk for", "UNCERTAINTY", 114, 122], ["bacterial", "OBSERVATION_MODIFIER", 123, 132], ["superinfection", "OBSERVATION", 133, 147]]], ["Respiratory cells infected with influenza A virus, respiratory syncytial viruses or adenoviruses show enhanced bacterial adherence in both in vitro and in vivo model systems (69).", [["Respiratory cells", "ANATOMY", 0, 17], ["influenza A virus", "DISEASE", 32, 49], ["respiratory syncytial viruses", "DISEASE", 51, 80], ["Respiratory cells", "CELL", 0, 17], ["influenza A virus", "ORGANISM", 32, 49], ["respiratory syncytial viruses", "ORGANISM", 51, 80], ["adenoviruses", "ORGANISM", 84, 96], ["Respiratory cells", "CELL_TYPE", 0, 17], ["influenza A virus", "SPECIES", 32, 49], ["influenza A virus", "SPECIES", 32, 49], ["respiratory syncytial viruses", "SPECIES", 51, 80], ["Respiratory cells", "PROBLEM", 0, 17], ["influenza A virus", "PROBLEM", 32, 49], ["respiratory syncytial viruses", "PROBLEM", 51, 80], ["adenoviruses", "PROBLEM", 84, 96], ["enhanced bacterial adherence", "PROBLEM", 102, 130], ["syncytial viruses", "OBSERVATION", 63, 80], ["enhanced", "OBSERVATION_MODIFIER", 102, 110], ["bacterial adherence", "OBSERVATION", 111, 130]]], ["The influenza virus may predispose to secondary bacterial pneumonia by denudating the respiratory epithelium and exposing basement membrane elements (e.g. fibrinogen) to which bacteria can attach (47, 123).", [["respiratory epithelium", "ANATOMY", 86, 108], ["basement membrane", "ANATOMY", 122, 139], ["influenza virus", "DISEASE", 4, 19], ["pneumonia", "DISEASE", 58, 67], ["influenza virus", "ORGANISM", 4, 19], ["respiratory epithelium", "TISSUE", 86, 108], ["basement membrane elements", "CELLULAR_COMPONENT", 122, 148], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 155, 165], ["basement membrane elements", "DNA", 122, 148], ["fibrinogen", "PROTEIN", 155, 165], ["influenza virus", "SPECIES", 4, 19], ["The influenza virus", "PROBLEM", 0, 19], ["secondary bacterial pneumonia", "PROBLEM", 38, 67], ["the respiratory epithelium", "PROBLEM", 82, 108], ["exposing basement membrane elements", "PROBLEM", 113, 148], ["fibrinogen", "TEST", 155, 165], ["bacteria", "PROBLEM", 176, 184], ["influenza virus", "OBSERVATION", 4, 19], ["secondary", "OBSERVATION_MODIFIER", 38, 47], ["bacterial", "OBSERVATION_MODIFIER", 48, 57], ["pneumonia", "OBSERVATION", 58, 67], ["respiratory epithelium", "OBSERVATION", 86, 108], ["basement membrane elements", "OBSERVATION", 122, 148]]], ["An influenza virus infection can also cause prolonged desensitization of lung sentinel cells to toll\u2010like receptor ligands, resulting in a reduced presence of neutrophils and an increased secondary bacterial load (39).", [["lung sentinel cells", "ANATOMY", 73, 92], ["neutrophils", "ANATOMY", 159, 170], ["influenza virus infection", "DISEASE", 3, 28], ["influenza virus", "ORGANISM", 3, 18], ["lung sentinel cells", "CELL", 73, 92], ["neutrophils", "CELL", 159, 170], ["lung sentinel cells", "CELL_TYPE", 73, 92], ["neutrophils", "CELL_TYPE", 159, 170], ["influenza virus", "SPECIES", 3, 18], ["influenza virus", "SPECIES", 3, 18], ["An influenza virus infection", "PROBLEM", 0, 28], ["lung sentinel cells", "PROBLEM", 73, 92], ["receptor ligands", "PROBLEM", 106, 122], ["a reduced presence of neutrophils", "PROBLEM", 137, 170], ["an increased secondary bacterial load", "PROBLEM", 175, 212], ["influenza virus infection", "OBSERVATION", 3, 28], ["lung", "ANATOMY", 73, 77], ["sentinel cells", "OBSERVATION", 78, 92], ["increased", "OBSERVATION_MODIFIER", 178, 187], ["secondary", "OBSERVATION_MODIFIER", 188, 197], ["bacterial load", "OBSERVATION", 198, 212]]], ["In addition, alteration of neutrophil functions by the influenza virus may decrease the clearance of pulmonary bacteria (97, 104).Viral\u2013bacterial synergy in medical infectionsAcute otitis media has been linked to synergistic interactions between viruses and bacteria (7).", [["neutrophil", "ANATOMY", 27, 37], ["pulmonary", "ANATOMY", 101, 110], ["infections", "DISEASE", 165, 175], ["otitis", "DISEASE", 181, 187], ["neutrophil", "CELL", 27, 37], ["influenza virus", "ORGANISM", 55, 70], ["pulmonary", "ORGAN", 101, 110], ["influenza virus", "SPECIES", 55, 70], ["neutrophil functions", "PROBLEM", 27, 47], ["the influenza virus", "PROBLEM", 51, 70], ["pulmonary bacteria", "PROBLEM", 101, 119], ["Viral\u2013bacterial synergy", "PROBLEM", 130, 153], ["medical infections", "PROBLEM", 157, 175], ["Acute otitis media", "PROBLEM", 175, 193], ["synergistic interactions between viruses and bacteria", "PROBLEM", 213, 266], ["neutrophil functions", "OBSERVATION", 27, 47], ["pulmonary", "ANATOMY", 101, 110], ["synergy", "OBSERVATION", 146, 153], ["medical infections", "OBSERVATION", 157, 175], ["otitis", "OBSERVATION", 181, 187]]], ["Otitis media is often associated with viruses, such as rhinovirus, respiratory syncytial virus, adenovirus, coronavirus, influenza virus (232), cytomegalovirus (238) and other herpesviruses (20), as well as with bacteria, including H. influenzae, S. pneumoniae, M. catarrhalis, and Prevotella and Peptostreptococcus species (19).", [["Otitis", "DISEASE", 0, 6], ["respiratory syncytial virus", "DISEASE", 67, 94], ["coronavirus", "DISEASE", 108, 119], ["influenza virus (232), cytomegalovirus (238) and other herpesviruses", "DISEASE", 121, 189], ["H. influenzae", "DISEASE", 232, 245], ["rhinovirus", "ORGANISM", 55, 65], ["respiratory syncytial virus", "ORGANISM", 67, 94], ["adenovirus", "ORGANISM", 96, 106], ["coronavirus", "ORGANISM", 108, 119], ["influenza virus", "ORGANISM", 121, 136], ["cytomegalovirus", "ORGANISM", 144, 159], ["H. influenzae", "ORGANISM", 232, 245], ["S. pneumoniae", "ORGANISM", 247, 260], ["M. catarrhalis", "ORGANISM", 262, 276], ["Peptostreptococcus species", "ORGANISM", 297, 323], ["respiratory syncytial virus", "SPECIES", 67, 94], ["coronavirus, influenza virus", "SPECIES", 108, 136], ["H. influenzae", "SPECIES", 232, 245], ["S. pneumoniae", "SPECIES", 247, 260], ["M. catarrhalis", "SPECIES", 262, 276], ["respiratory syncytial virus", "SPECIES", 67, 94], ["H. influenzae", "SPECIES", 232, 245], ["S. pneumoniae", "SPECIES", 247, 260], ["M. catarrhalis", "SPECIES", 262, 276], ["Otitis media", "PROBLEM", 0, 12], ["viruses", "PROBLEM", 38, 45], ["rhinovirus", "PROBLEM", 55, 65], ["respiratory syncytial virus", "PROBLEM", 67, 94], ["adenovirus", "PROBLEM", 96, 106], ["coronavirus", "PROBLEM", 108, 119], ["influenza virus", "PROBLEM", 121, 136], ["cytomegalovirus", "PROBLEM", 144, 159], ["other herpesviruses", "PROBLEM", 170, 189], ["bacteria", "PROBLEM", 212, 220], ["H. influenzae", "PROBLEM", 232, 245], ["S. pneumoniae", "PROBLEM", 247, 260], ["M. catarrhalis", "PROBLEM", 262, 276], ["Prevotella", "PROBLEM", 282, 292], ["Peptostreptococcus species", "PROBLEM", 297, 323], ["viruses", "OBSERVATION", 38, 45], ["respiratory syncytial", "ANATOMY", 67, 88], ["pneumoniae", "OBSERVATION", 250, 260], ["catarrhalis", "OBSERVATION", 265, 276]]], ["Acute otitis media with a tympanostomy tube showed S. pneumoniae, S. aureus, H. influenzae, Pseudomonas aeruginosa and yeast (166).", [["otitis", "DISEASE", 6, 12], ["S. pneumoniae", "ORGANISM", 51, 64], ["S. aureus", "ORGANISM", 66, 75], ["H. influenzae", "ORGANISM", 77, 90], ["Pseudomonas aeruginosa", "ORGANISM", 92, 114], ["S. pneumoniae", "SPECIES", 51, 64], ["S. aureus", "SPECIES", 66, 75], ["H. influenzae", "SPECIES", 77, 90], ["Pseudomonas aeruginosa", "SPECIES", 92, 114], ["yeast", "SPECIES", 119, 124], ["S. pneumoniae", "SPECIES", 51, 64], ["S. aureus", "SPECIES", 66, 75], ["H. influenzae", "SPECIES", 77, 90], ["Pseudomonas aeruginosa", "SPECIES", 92, 114], ["yeast", "SPECIES", 119, 124], ["Acute otitis media", "PROBLEM", 0, 18], ["a tympanostomy tube", "TREATMENT", 24, 43], ["S. pneumoniae", "PROBLEM", 51, 64], ["S. aureus", "PROBLEM", 66, 75], ["H. influenzae", "PROBLEM", 77, 90], ["Pseudomonas aeruginosa", "PROBLEM", 92, 114], ["yeast", "PROBLEM", 119, 124], ["otitis", "OBSERVATION", 6, 12], ["tympanostomy tube", "OBSERVATION", 26, 43], ["pneumoniae", "OBSERVATION", 54, 64], ["aureus", "OBSERVATION", 69, 75]]], ["Viruses were detected in 65% of acute otitis media samples that were positive for H. influenzae, in 77% of samples that were positive for S. pneumoniae and in 73% of samples that were positive for M. catarrhalis (170).", [["samples", "ANATOMY", 51, 58], ["samples", "ANATOMY", 107, 114], ["samples", "ANATOMY", 166, 173], ["otitis", "DISEASE", 38, 44], ["H. influenzae", "DISEASE", 82, 95], ["H. influenzae", "ORGANISM", 82, 95], ["samples", "CANCER", 107, 114], ["S. pneumoniae", "ORGANISM", 138, 151], ["samples", "CANCER", 166, 173], ["M. catarrhalis", "ORGANISM", 197, 211], ["H. influenzae", "SPECIES", 82, 95], ["S. pneumoniae", "SPECIES", 138, 151], ["M. catarrhalis", "SPECIES", 197, 211], ["H. influenzae", "SPECIES", 82, 95], ["S. pneumoniae", "SPECIES", 138, 151], ["M. catarrhalis", "SPECIES", 197, 211], ["Viruses", "PROBLEM", 0, 7], ["acute otitis media samples", "PROBLEM", 32, 58], ["H. influenzae", "PROBLEM", 82, 95], ["S. pneumoniae", "PROBLEM", 138, 151], ["M. catarrhalis", "PROBLEM", 197, 211], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["otitis", "OBSERVATION", 38, 44], ["pneumoniae", "OBSERVATION", 141, 151], ["catarrhalis", "OBSERVATION", 200, 211]]], ["Tympanic membrane changes with acute otitis media are more severe in patients co\u2010infected with respiratory viruses and bacteria than in patients who have a single infection with either of the two types of infectious agents (237).", [["Tympanic membrane", "ANATOMY", 0, 17], ["otitis", "DISEASE", 37, 43], ["respiratory viruses", "DISEASE", 95, 114], ["infection", "DISEASE", 163, 172], ["Tympanic membrane", "MULTI-TISSUE_STRUCTURE", 0, 17], ["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 136, 144], ["Tympanic membrane changes", "PROBLEM", 0, 25], ["acute otitis media", "PROBLEM", 31, 49], ["respiratory viruses", "PROBLEM", 95, 114], ["bacteria", "PROBLEM", 119, 127], ["a single infection", "PROBLEM", 154, 172], ["infectious agents", "TREATMENT", 205, 222], ["membrane", "OBSERVATION", 9, 17], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["otitis", "OBSERVATION", 37, 43], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["respiratory", "ANATOMY", 95, 106], ["viruses", "OBSERVATION", 107, 114], ["infection", "OBSERVATION", 163, 172], ["infectious", "OBSERVATION", 205, 215]]], ["Viruses interact with bacteria in acute otitis media to boost the local inflammatory process and also have a profound adverse effect on resolution of the disease (75).Viral\u2013bacterial synergy in medical infectionsOther human diseases seem also to have a combined viral\u2013bacterial etiopathogeny.", [["otitis", "DISEASE", 40, 46], ["infections", "DISEASE", 202, 212], ["human", "ORGANISM", 218, 223], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 218, 223], ["Viruses", "PROBLEM", 0, 7], ["bacteria", "PROBLEM", 22, 30], ["acute otitis media", "PROBLEM", 34, 52], ["the local inflammatory process", "PROBLEM", 62, 92], ["a profound adverse effect", "PROBLEM", 107, 132], ["the disease", "PROBLEM", 150, 161], ["Viral\u2013bacterial synergy", "PROBLEM", 167, 190], ["medical infections", "PROBLEM", 194, 212], ["Other human diseases", "PROBLEM", 212, 232], ["a combined viral\u2013bacterial etiopathogeny", "PROBLEM", 251, 291], ["bacteria", "OBSERVATION_MODIFIER", 22, 30], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["otitis", "OBSERVATION", 40, 46], ["local", "OBSERVATION_MODIFIER", 66, 71], ["inflammatory", "OBSERVATION", 72, 84], ["profound", "OBSERVATION_MODIFIER", 109, 117], ["adverse effect", "OBSERVATION", 118, 132], ["resolution", "OBSERVATION_MODIFIER", 136, 146], ["disease", "OBSERVATION", 154, 161], ["synergy", "OBSERVATION", 183, 190], ["medical infections", "OBSERVATION", 194, 212], ["viral\u2013bacterial etiopathogeny", "OBSERVATION", 262, 291]]], ["Recurrent bacterial sinusitis may develop as a complication to viral colds (5).", [["bacterial sinusitis", "DISEASE", 10, 29], ["colds", "DISEASE", 69, 74], ["Recurrent bacterial sinusitis", "PROBLEM", 0, 29], ["a complication to viral colds", "PROBLEM", 45, 74], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["sinusitis", "OBSERVATION", 20, 29]]], ["Infectious mononucleosis caused by infection with Epstein\u2013Barr virus can give rise to tonsillar upgrowth of Prevotella intermedia and Fusobacterium nucleatum, and subsequently pharyngotonsillitis (18).", [["tonsillar", "ANATOMY", 86, 95], ["Infectious mononucleosis", "DISEASE", 0, 24], ["infection", "DISEASE", 35, 44], ["Prevotella intermedia", "DISEASE", 108, 129], ["pharyngotonsillitis", "DISEASE", 176, 195], ["Epstein\u2013Barr virus", "ORGANISM", 50, 68], ["Prevotella intermedia", "GENE_OR_GENE_PRODUCT", 108, 129], ["Fusobacterium nucleatum", "GENE_OR_GENE_PRODUCT", 134, 157], ["Prevotella intermedia", "SPECIES", 108, 129], ["Fusobacterium nucleatum", "SPECIES", 134, 157], ["Epstein\u2013Barr virus", "SPECIES", 50, 68], ["Prevotella intermedia", "SPECIES", 108, 129], ["Fusobacterium nucleatum", "SPECIES", 134, 157], ["Infectious mononucleosis", "PROBLEM", 0, 24], ["infection", "PROBLEM", 35, 44], ["Epstein\u2013Barr virus", "PROBLEM", 50, 68], ["Prevotella intermedia", "PROBLEM", 108, 129], ["Fusobacterium nucleatum", "PROBLEM", 134, 157], ["infection", "OBSERVATION", 35, 44], ["Barr virus", "OBSERVATION", 58, 68], ["tonsillar", "ANATOMY", 86, 95], ["Prevotella intermedia", "ANATOMY", 108, 129], ["Fusobacterium nucleatum", "OBSERVATION", 134, 157]]], ["The Lemierre\u2019s syndrome, which is characterized by severe pharyngitis and sepsis, can occur as a sequel to Epstein\u2013Barr virus\u2010induced mononucleosis and is frequently associated with an overgrowth of Fusobacterium necrophorum (53).", [["Lemierre\u2019s syndrome", "DISEASE", 4, 23], ["pharyngitis", "DISEASE", 58, 69], ["sepsis", "DISEASE", 74, 80], ["Epstein\u2013Barr virus\u2010induced mononucleosis", "DISEASE", 107, 147], ["Fusobacterium necrophorum", "DISEASE", 199, 224], ["Epstein\u2013Barr virus\u2010induced mononucleosis", "ORGANISM", 107, 147], ["Fusobacterium necrophorum", "ORGANISM", 199, 224], ["Fusobacterium necrophorum", "SPECIES", 199, 224], ["Epstein\u2013Barr virus\u2010induced mononucleosis", "SPECIES", 107, 147], ["Fusobacterium necrophorum", "SPECIES", 199, 224], ["The Lemierre\u2019s syndrome", "PROBLEM", 0, 23], ["severe pharyngitis", "PROBLEM", 51, 69], ["sepsis", "PROBLEM", 74, 80], ["Epstein\u2013Barr virus\u2010induced mononucleosis", "PROBLEM", 107, 147], ["an overgrowth of Fusobacterium necrophorum", "PROBLEM", 182, 224], ["Lemierre", "OBSERVATION", 4, 12], ["\u2019s syndrome", "OBSERVATION", 12, 23], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["pharyngitis", "OBSERVATION", 58, 69], ["sepsis", "OBSERVATION", 74, 80], ["Barr virus\u2010induced mononucleosis", "OBSERVATION", 115, 147], ["overgrowth", "OBSERVATION", 185, 195]]], ["Gastroenteritis is often associated with mixed infections of viruses (rotavirus, adenovirus, norovirus, astrovirus) and bacteria (pathogenic Escherichia coli, Salmonella, Shigella, Campylobacter jejuni), and the combined viral\u2013bacterial infection can lead to enhanced pathosis (117).", [["Gastroenteritis", "DISEASE", 0, 15], ["infections", "DISEASE", 47, 57], ["rotavirus, adenovirus, norovirus, astrovirus)", "DISEASE", 70, 115], ["Campylobacter jejuni", "DISEASE", 181, 201], ["infection", "DISEASE", 237, 246], ["rotavirus", "ORGANISM", 70, 79], ["adenovirus, norovirus", "ORGANISM", 81, 102], ["astrovirus", "ORGANISM", 104, 114], ["Escherichia coli", "ORGANISM", 141, 157], ["Salmonella, Shigella", "ORGANISM", 159, 179], ["Campylobacter jejuni", "ORGANISM", 181, 201], ["Escherichia coli", "SPECIES", 141, 157], ["Campylobacter jejuni", "SPECIES", 181, 201], ["Escherichia coli", "SPECIES", 141, 157], ["Campylobacter jejuni", "SPECIES", 181, 201], ["Gastroenteritis", "PROBLEM", 0, 15], ["mixed infections of viruses", "PROBLEM", 41, 68], ["rotavirus", "PROBLEM", 70, 79], ["adenovirus", "PROBLEM", 81, 91], ["norovirus", "PROBLEM", 93, 102], ["astrovirus", "PROBLEM", 104, 114], ["bacteria", "PROBLEM", 120, 128], ["pathogenic Escherichia coli", "PROBLEM", 130, 157], ["Salmonella", "PROBLEM", 159, 169], ["Shigella", "PROBLEM", 171, 179], ["Campylobacter jejuni", "PROBLEM", 181, 201], ["the combined viral\u2013bacterial infection", "PROBLEM", 208, 246], ["enhanced pathosis", "PROBLEM", 259, 276], ["often associated with", "UNCERTAINTY", 19, 40], ["mixed", "OBSERVATION_MODIFIER", 41, 46], ["infections", "OBSERVATION", 47, 57], ["Escherichia coli", "OBSERVATION", 141, 157], ["Campylobacter jejuni", "ANATOMY", 181, 201], ["viral\u2013bacterial", "OBSERVATION_MODIFIER", 221, 236], ["infection", "OBSERVATION", 237, 246], ["enhanced", "OBSERVATION_MODIFIER", 259, 267], ["pathosis", "OBSERVATION", 268, 276]]], ["Appendicitis has been associated with measles virus, adenovirus and herpesviruses, as well as with Bacteroides fragilis, E. coli, Yersinia, Salmonella and Shigella (91).", [["Appendicitis", "DISEASE", 0, 12], ["measles virus, adenovirus and herpesviruses", "DISEASE", 38, 81], ["Bacteroides fragilis", "DISEASE", 99, 119], ["measles virus", "ORGANISM", 38, 51], ["adenovirus", "ORGANISM", 53, 63], ["herpesviruses", "ORGANISM", 68, 81], ["Bacteroides fragilis", "ORGANISM", 99, 119], ["E. coli", "ORGANISM", 121, 128], ["Yersinia, Salmonella", "ORGANISM", 130, 150], ["Shigella", "ORGANISM", 155, 163], ["measles virus", "SPECIES", 38, 51], ["Bacteroides fragilis", "SPECIES", 99, 119], ["E. coli", "SPECIES", 121, 128], ["measles virus", "SPECIES", 38, 51], ["adenovirus", "SPECIES", 53, 63], ["Bacteroides fragilis", "SPECIES", 99, 119], ["E. coli", "SPECIES", 121, 128], ["Appendicitis", "PROBLEM", 0, 12], ["measles virus", "PROBLEM", 38, 51], ["adenovirus", "PROBLEM", 53, 63], ["herpesviruses", "PROBLEM", 68, 81], ["Bacteroides fragilis", "PROBLEM", 99, 119], ["E. coli", "PROBLEM", 121, 128], ["Yersinia", "PROBLEM", 130, 138], ["Salmonella", "PROBLEM", 140, 150], ["Shigella", "PROBLEM", 155, 163], ["associated with", "UNCERTAINTY", 22, 37], ["measles virus", "OBSERVATION", 38, 51], ["E. coli", "OBSERVATION_MODIFIER", 121, 128], ["Yersinia", "OBSERVATION_MODIFIER", 130, 138]]], ["In Helicobacter pylori\u2010associated gastritis, the activation of a latent Epstein\u2013Barr virus infection by monochloramine from infiltrating neutrophils can aggravate the gastric disease (128).", [["neutrophils", "ANATOMY", 137, 148], ["gastric", "ANATOMY", 167, 174], ["Helicobacter pylori\u2010associated gastritis", "DISEASE", 3, 43], ["infection", "DISEASE", 91, 100], ["monochloramine", "CHEMICAL", 104, 118], ["gastric disease", "DISEASE", 167, 182], ["monochloramine", "CHEMICAL", 104, 118], ["Helicobacter pylori\u2010associated gastritis", "PATHOLOGICAL_FORMATION", 3, 43], ["Epstein\u2013Barr virus", "ORGANISM", 72, 90], ["monochloramine", "SIMPLE_CHEMICAL", 104, 118], ["neutrophils", "CELL", 137, 148], ["gastric", "ORGAN", 167, 174], ["infiltrating neutrophils", "CELL_TYPE", 124, 148], ["Helicobacter pylori\u2010associated", "SPECIES", 3, 33], ["Helicobacter pylori\u2010associated", "SPECIES", 3, 33], ["Epstein\u2013Barr virus", "SPECIES", 72, 90], ["Helicobacter pylori\u2010associated gastritis", "PROBLEM", 3, 43], ["a latent Epstein\u2013Barr virus infection", "PROBLEM", 63, 100], ["monochloramine", "TREATMENT", 104, 118], ["infiltrating neutrophils", "PROBLEM", 124, 148], ["the gastric disease", "PROBLEM", 163, 182], ["Helicobacter pylori\u2010associated gastritis", "OBSERVATION", 3, 43], ["latent", "OBSERVATION_MODIFIER", 65, 71], ["Epstein", "OBSERVATION_MODIFIER", 72, 79], ["Barr virus infection", "OBSERVATION", 80, 100], ["gastric", "ANATOMY", 167, 174], ["disease", "OBSERVATION", 175, 182]]], ["In organ transplant recipients, cytomegalovirus and human herpesviruses type 6 or type 7 can induce serious opportunistic infections with bacteria, fungi, protozoa and other viruses, probably as a result of immunomodulation by the herpesviruses (12, 137, 150).", [["organ", "ANATOMY", 3, 8], ["cytomegalovirus", "DISEASE", 32, 47], ["opportunistic infections", "DISEASE", 108, 132], ["organ", "ORGAN", 3, 8], ["cytomegalovirus", "ORGANISM", 32, 47], ["human herpesviruses type 6", "ORGANISM", 52, 78], ["type 7", "ORGANISM", 82, 88], ["herpesviruses", "ORGANISM", 231, 244], ["human", "SPECIES", 52, 57], ["human herpesviruses type 6", "SPECIES", 52, 78], ["organ transplant recipients", "TREATMENT", 3, 30], ["cytomegalovirus", "PROBLEM", 32, 47], ["serious opportunistic infections", "PROBLEM", 100, 132], ["bacteria", "PROBLEM", 138, 146], ["fungi", "PROBLEM", 148, 153], ["protozoa", "PROBLEM", 155, 163], ["other viruses", "PROBLEM", 168, 181], ["the herpesviruses", "TEST", 227, 244], ["organ", "ANATOMY", 3, 8], ["transplant recipients", "OBSERVATION", 9, 30], ["cytomegalovirus", "OBSERVATION", 32, 47], ["serious", "OBSERVATION_MODIFIER", 100, 107], ["opportunistic", "OBSERVATION_MODIFIER", 108, 121], ["infections", "OBSERVATION", 122, 132], ["viruses", "OBSERVATION", 174, 181], ["immunomodulation", "OBSERVATION", 207, 223]]], ["A renal transplant patient developed a subhepatic abscess as a result of infection with cytomegalovirus and P. gingivalis (103).", [["renal", "ANATOMY", 2, 7], ["subhepatic abscess", "ANATOMY", 39, 57], ["subhepatic abscess", "DISEASE", 39, 57], ["infection", "DISEASE", 73, 82], ["cytomegalovirus and P. gingivalis", "DISEASE", 88, 121], ["renal", "ORGAN", 2, 7], ["patient", "ORGANISM", 19, 26], ["subhepatic abscess", "PATHOLOGICAL_FORMATION", 39, 57], ["cytomegalovirus", "ORGANISM", 88, 103], ["P. gingivalis", "ORGANISM", 108, 121], ["patient", "SPECIES", 19, 26], ["P. gingivalis", "SPECIES", 108, 121], ["P. gingivalis", "SPECIES", 108, 121], ["A renal transplant", "TREATMENT", 0, 18], ["a subhepatic abscess", "PROBLEM", 37, 57], ["infection", "PROBLEM", 73, 82], ["cytomegalovirus", "PROBLEM", 88, 103], ["P. gingivalis", "PROBLEM", 108, 121], ["renal", "ANATOMY", 2, 7], ["transplant", "OBSERVATION", 8, 18], ["subhepatic", "ANATOMY", 39, 49], ["abscess", "OBSERVATION", 50, 57], ["infection", "OBSERVATION", 73, 82], ["cytomegalovirus", "OBSERVATION", 88, 103]]], ["Vascular diseases occur at a higher frequency as a result of a combined infection with herpes simplex virus and Chlamydia pneumoniae (165) or periodontopathic bacteria (224) than from a single infection with either of these agents.", [["Vascular", "ANATOMY", 0, 8], ["Vascular diseases", "DISEASE", 0, 17], ["infection", "DISEASE", 72, 81], ["herpes simplex virus", "DISEASE", 87, 107], ["Chlamydia pneumoniae", "DISEASE", 112, 132], ["infection", "DISEASE", 193, 202], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["herpes simplex virus", "ORGANISM", 87, 107], ["Chlamydia pneumoniae", "ORGANISM", 112, 132], ["herpes simplex virus", "SPECIES", 87, 107], ["Chlamydia pneumoniae", "SPECIES", 112, 132], ["herpes simplex virus", "SPECIES", 87, 107], ["Chlamydia pneumoniae", "SPECIES", 112, 132], ["Vascular diseases", "PROBLEM", 0, 17], ["a combined infection", "PROBLEM", 61, 81], ["herpes simplex virus", "PROBLEM", 87, 107], ["Chlamydia pneumoniae", "PROBLEM", 112, 132], ["periodontopathic bacteria", "PROBLEM", 142, 167], ["a single infection", "PROBLEM", 184, 202], ["these agents", "TREATMENT", 218, 230], ["diseases", "OBSERVATION", 9, 17], ["higher frequency", "OBSERVATION_MODIFIER", 29, 45], ["infection", "OBSERVATION", 72, 81], ["periodontopathic", "OBSERVATION_MODIFIER", 142, 158], ["infection", "OBSERVATION", 193, 202]]], ["Rheumatic heart disease and autoimmune myocarditis may involve dual infection with coxsackievirus and group A streptococci, which have the potential to dysregulate immune mechanisms and trigger an autoimmune reaction (167).", [["heart", "ANATOMY", 10, 15], ["Rheumatic heart disease", "DISEASE", 0, 23], ["autoimmune myocarditis", "DISEASE", 28, 50], ["infection", "DISEASE", 68, 77], ["heart", "ORGAN", 10, 15], ["coxsackievirus", "ORGANISM", 83, 97], ["group A streptococci", "ORGANISM", 102, 122], ["Rheumatic heart disease", "PROBLEM", 0, 23], ["autoimmune myocarditis", "PROBLEM", 28, 50], ["dual infection", "PROBLEM", 63, 77], ["coxsackievirus", "PROBLEM", 83, 97], ["group A streptococci", "PROBLEM", 102, 122], ["immune mechanisms", "PROBLEM", 164, 181], ["an autoimmune reaction", "PROBLEM", 194, 216], ["heart", "ANATOMY", 10, 15], ["disease", "OBSERVATION", 16, 23], ["autoimmune myocarditis", "OBSERVATION", 28, 50], ["dual", "OBSERVATION_MODIFIER", 63, 67], ["infection", "OBSERVATION", 68, 77], ["coxsackievirus", "OBSERVATION", 83, 97], ["streptococci", "OBSERVATION", 110, 122]]], ["HIV infection causes a variety of severe bacterial, fungal and viral infections (46, 100, 174, 242).", [["HIV infection", "DISEASE", 0, 13], ["bacterial, fungal and viral infections", "DISEASE", 41, 79], ["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV infection", "PROBLEM", 0, 13], ["severe bacterial, fungal and viral infections", "PROBLEM", 34, 79], ["infection", "OBSERVATION", 4, 13], ["variety", "OBSERVATION_MODIFIER", 23, 30], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["bacterial", "OBSERVATION_MODIFIER", 41, 50], ["fungal", "OBSERVATION_MODIFIER", 52, 58], ["viral", "OBSERVATION_MODIFIER", 63, 68], ["infections", "OBSERVATION", 69, 79]]], ["Moreover, P. gingivalis may up\u2010regulate expression of the HIV\u20101 R5\u2010specific co\u2010receptor CCR5 in oral keratinocytes and thereby increase the risk for oral infection and dissemination of R5\u2010tropic HIV\u20101 strains (58).", [["oral keratinocytes", "ANATOMY", 96, 114], ["oral", "ANATOMY", 149, 153], ["oral infection", "DISEASE", 149, 163], ["P. gingivalis", "ORGANISM", 10, 23], ["HIV\u20101 R5", "ORGANISM", 58, 66], ["CCR5", "GENE_OR_GENE_PRODUCT", 88, 92], ["oral keratinocytes", "CELL", 96, 114], ["oral", "ORGANISM_SUBDIVISION", 149, 153], ["HIV\u20101 R5\u2010specific co\u2010receptor CCR5", "PROTEIN", 58, 92], ["oral keratinocytes", "CELL_TYPE", 96, 114], ["P. gingivalis", "SPECIES", 10, 23], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 195, 198], ["P. gingivalis", "SPECIES", 10, 23], ["HIV\u20101 R5", "SPECIES", 58, 66], ["HIV\u20101", "SPECIES", 195, 200], ["R5\u2010specific co\u2010receptor CCR5", "TREATMENT", 64, 92], ["oral keratinocytes", "TREATMENT", 96, 114], ["oral infection", "PROBLEM", 149, 163], ["R5\u2010tropic HIV", "PROBLEM", 185, 198], ["infection", "OBSERVATION", 154, 163]]], ["Also, various gram\u2010positive and gram\u2010negative bacteria of the periodontitis biofilm have the capacity to re\u2010activate HIV in latently infected T cells, macrophages and dendritic cells (80), and the vaginosis bacteria Prevotella bivia and Peptostreptococcus asaccharolyticus, but no other vaginal bacteria studied, are potential activators of HIV expression in monocytoid cells and T\u2010lymphocytic cells (72).Viral\u2013bacterial synergy in medical infectionsAnimal models have been used to study viral\u2013bacterial interactions.", [["biofilm", "ANATOMY", 76, 83], ["T cells", "ANATOMY", 142, 149], ["macrophages", "ANATOMY", 151, 162], ["dendritic cells", "ANATOMY", 167, 182], ["monocytoid cells", "ANATOMY", 359, 375], ["T\u2010lymphocytic cells", "ANATOMY", 380, 399], ["viral\u2013bacterial", "ANATOMY", 488, 503], ["periodontitis", "DISEASE", 62, 75], ["vaginosis", "DISEASE", 197, 206], ["infections", "DISEASE", 440, 450], ["HIV", "ORGANISM", 117, 120], ["T cells", "CELL", 142, 149], ["macrophages", "CELL", 151, 162], ["dendritic cells", "CELL", 167, 182], ["Prevotella bivia", "ORGANISM", 216, 232], ["Peptostreptococcus asaccharolyticus", "ORGANISM", 237, 272], ["HIV", "ORGANISM", 341, 344], ["monocytoid cells", "CELL", 359, 375], ["T\u2010lymphocytic cells", "CELL", 380, 399], ["latently infected T cells", "CELL_TYPE", 124, 149], ["macrophages", "CELL_TYPE", 151, 162], ["dendritic cells", "CELL_TYPE", 167, 182], ["monocytoid cells", "CELL_TYPE", 359, 375], ["T\u2010lymphocytic cells", "CELL_TYPE", 380, 399], ["HIV", "SPECIES", 117, 120], ["Prevotella bivia", "SPECIES", 216, 232], ["Peptostreptococcus asaccharolyticus", "SPECIES", 237, 272], ["HIV", "SPECIES", 117, 120], ["Prevotella bivia", "SPECIES", 216, 232], ["Peptostreptococcus asaccharolyticus", "SPECIES", 237, 272], ["HIV", "SPECIES", 341, 344], ["various gram\u2010positive and gram\u2010negative bacteria", "PROBLEM", 6, 54], ["the periodontitis biofilm", "PROBLEM", 58, 83], ["the capacity", "PROBLEM", 89, 101], ["HIV in latently infected T cells", "PROBLEM", 117, 149], ["macrophages", "PROBLEM", 151, 162], ["dendritic cells", "PROBLEM", 167, 182], ["the vaginosis bacteria", "PROBLEM", 193, 215], ["Prevotella bivia", "TEST", 216, 232], ["Peptostreptococcus asaccharolyticus", "PROBLEM", 237, 272], ["other vaginal bacteria", "PROBLEM", 281, 303], ["HIV expression in monocytoid cells", "PROBLEM", 341, 375], ["T\u2010lymphocytic cells", "TEST", 380, 399], ["Viral\u2013bacterial synergy", "PROBLEM", 405, 428], ["medical infections", "PROBLEM", 432, 450], ["periodontitis", "OBSERVATION", 62, 75], ["latently", "OBSERVATION_MODIFIER", 124, 132], ["infected T cells", "OBSERVATION", 133, 149], ["dendritic cells", "OBSERVATION", 167, 182], ["no other", "UNCERTAINTY", 278, 286], ["vaginal", "ANATOMY", 287, 294], ["bacteria", "OBSERVATION", 295, 303], ["monocytoid cells", "OBSERVATION", 359, 375], ["T\u2010lymphocytic cells", "OBSERVATION", 380, 399], ["synergy", "OBSERVATION", 421, 428], ["medical infections", "OBSERVATION", 432, 450]]], ["Respiratory pathosis was enhanced in mice when the influenza virus or other viruses co\u2010infected with bacteria (198).", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory pathosis", "DISEASE", 0, 20], ["mice", "ORGANISM", 37, 41], ["influenza virus", "ORGANISM", 51, 66], ["mice", "SPECIES", 37, 41], ["influenza virus", "SPECIES", 51, 66], ["mice", "SPECIES", 37, 41], ["influenza virus", "SPECIES", 51, 66], ["Respiratory pathosis", "PROBLEM", 0, 20], ["the influenza virus", "PROBLEM", 47, 66], ["other viruses", "PROBLEM", 70, 83], ["bacteria", "PROBLEM", 101, 109], ["pathosis", "OBSERVATION", 12, 20]]], ["In a mouse model of pathogenetic synergy, an influenza virus infection antecedent to an S. pneumoniae challenge caused pneumonia and led to 100% mortality, whereas an infection with S. pneumoniae prior to an influenza virus infection provided protection from influenza and improved survival rates (123).", [["influenza virus infection", "DISEASE", 45, 70], ["pneumonia", "DISEASE", 119, 128], ["infection", "DISEASE", 167, 176], ["S. pneumoniae", "DISEASE", 182, 195], ["influenza virus infection", "DISEASE", 208, 233], ["influenza", "DISEASE", 259, 268], ["mouse", "ORGANISM", 5, 10], ["influenza virus", "ORGANISM", 45, 60], ["S. pneumoniae", "ORGANISM", 88, 101], ["S. pneumoniae", "ORGANISM", 182, 195], ["influenza virus", "ORGANISM", 208, 223], ["mouse", "SPECIES", 5, 10], ["influenza virus", "SPECIES", 45, 60], ["S. pneumoniae", "SPECIES", 88, 101], ["S. pneumoniae", "SPECIES", 182, 195], ["influenza virus", "SPECIES", 208, 223], ["mouse", "SPECIES", 5, 10], ["influenza virus", "SPECIES", 45, 60], ["S. pneumoniae", "SPECIES", 88, 101], ["S. pneumoniae", "SPECIES", 182, 195], ["influenza virus", "SPECIES", 208, 223], ["pathogenetic synergy", "PROBLEM", 20, 40], ["an influenza virus infection", "PROBLEM", 42, 70], ["an S. pneumoniae challenge", "TREATMENT", 85, 111], ["pneumonia", "PROBLEM", 119, 128], ["an infection", "PROBLEM", 164, 176], ["S. pneumoniae", "PROBLEM", 182, 195], ["an influenza virus infection", "PROBLEM", 205, 233], ["influenza", "PROBLEM", 259, 268], ["pathogenetic synergy", "OBSERVATION", 20, 40], ["pneumoniae", "OBSERVATION", 91, 101], ["pneumonia", "OBSERVATION", 119, 128], ["infection", "OBSERVATION", 167, 176], ["pneumoniae", "OBSERVATION", 185, 195]]], ["Immune mediators, including cytokines and chemokines, through toll\u2010like receptors/mitogen\u2010activated protein kinase pathways, seem to play important roles in the pathogenesis of the influenza virus\u2013S. pneumoniae co\u2010infection (184).", [["influenza virus\u2013S", "DISEASE", 181, 198], ["mitogen\u2010activated protein kinase", "GENE_OR_GENE_PRODUCT", 82, 114], ["influenza virus\u2013S", "ORGANISM", 181, 198], ["pneumoniae", "ORGANISM", 200, 210], ["Immune mediators", "PROTEIN", 0, 16], ["cytokines", "PROTEIN", 28, 37], ["chemokines", "PROTEIN", 42, 52], ["toll\u2010like receptors", "PROTEIN", 62, 81], ["mitogen\u2010activated protein kinase", "PROTEIN", 82, 114], ["pneumoniae", "SPECIES", 200, 210], ["pneumoniae", "SPECIES", 200, 210], ["Immune mediators", "TEST", 0, 16], ["cytokines", "TEST", 28, 37], ["chemokines", "TEST", 42, 52], ["mitogen\u2010activated protein kinase pathways", "PROBLEM", 82, 123], ["the influenza virus\u2013S", "PROBLEM", 177, 198], ["pneumoniae co\u2010infection", "PROBLEM", 200, 223], ["influenza", "OBSERVATION", 181, 190]]], ["Calves dually infected with bovine respiratory syncytial virus and Haemophilus somnus, both bovine respiratory pathogens, contracted lung disease and harbored H. somnus in the lungs, whereas the lungs of monoinfected calves showed neither pathosis nor H. somnus infection (57).", [["lung", "ANATOMY", 133, 137], ["somnus", "ANATOMY", 162, 168], ["lungs", "ANATOMY", 176, 181], ["lungs", "ANATOMY", 195, 200], ["respiratory syncytial virus", "DISEASE", 35, 62], ["Haemophilus somnus", "DISEASE", 67, 85], ["respiratory pathogens", "DISEASE", 99, 120], ["lung disease", "DISEASE", 133, 145], ["H. somnus infection", "DISEASE", 252, 271], ["Calves", "ORGANISM", 0, 6], ["bovine", "ORGANISM", 28, 34], ["respiratory syncytial virus", "ORGANISM", 35, 62], ["Haemophilus somnus", "ORGANISM", 67, 85], ["bovine", "ORGANISM", 92, 98], ["lung", "ORGAN", 133, 137], ["H. somnus", "ORGANISM", 159, 168], ["lungs", "ORGAN", 176, 181], ["lungs", "ORGAN", 195, 200], ["calves", "ORGANISM", 217, 223], ["H. somnus", "ORGANISM", 252, 261], ["Calves", "SPECIES", 0, 6], ["bovine", "SPECIES", 28, 34], ["respiratory syncytial virus", "SPECIES", 35, 62], ["Haemophilus somnus", "SPECIES", 67, 85], ["bovine", "SPECIES", 92, 98], ["H. somnus", "SPECIES", 159, 168], ["calves", "SPECIES", 217, 223], ["H. somnus", "SPECIES", 252, 261], ["bovine respiratory syncytial virus", "SPECIES", 28, 62], ["Haemophilus somnus", "SPECIES", 67, 85], ["bovine", "SPECIES", 92, 98], ["H. somnus", "SPECIES", 159, 168], ["H. somnus", "SPECIES", 252, 261], ["Calves dually infected", "PROBLEM", 0, 22], ["bovine respiratory syncytial virus", "PROBLEM", 28, 62], ["Haemophilus somnus", "PROBLEM", 67, 85], ["both bovine respiratory pathogens", "PROBLEM", 87, 120], ["contracted lung disease", "PROBLEM", 122, 145], ["harbored H. somnus in the lungs", "PROBLEM", 150, 181], ["monoinfected calves", "PROBLEM", 204, 223], ["neither pathosis", "PROBLEM", 231, 247], ["H. somnus infection", "PROBLEM", 252, 271], ["infected", "OBSERVATION", 14, 22], ["respiratory syncytial virus", "OBSERVATION", 35, 62], ["Haemophilus somnus", "OBSERVATION", 67, 85], ["bovine", "OBSERVATION_MODIFIER", 92, 98], ["respiratory pathogens", "OBSERVATION", 99, 120], ["contracted", "OBSERVATION_MODIFIER", 122, 132], ["lung", "ANATOMY", 133, 137], ["somnus", "OBSERVATION", 162, 168], ["lungs", "ANATOMY", 176, 181], ["lungs", "ANATOMY", 195, 200], ["monoinfected", "OBSERVATION", 204, 216], ["neither", "UNCERTAINTY", 231, 238], ["pathosis", "OBSERVATION", 239, 247], ["somnus infection", "OBSERVATION", 255, 271]]], ["Acute otitis media was induced in 63% of mice that had been stably colonized by S. pneumoniae and then infected with the influenza virus, whereas all mock\u2010infected mice remained free of disease (122).", [["otitis", "DISEASE", 6, 12], ["influenza virus", "DISEASE", 121, 136], ["mice", "ORGANISM", 41, 45], ["S. pneumoniae", "ORGANISM", 80, 93], ["influenza virus", "ORGANISM", 121, 136], ["mice", "ORGANISM", 164, 168], ["mice", "SPECIES", 41, 45], ["S. pneumoniae", "SPECIES", 80, 93], ["influenza virus", "SPECIES", 121, 136], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 41, 45], ["S. pneumoniae", "SPECIES", 80, 93], ["influenza virus", "SPECIES", 121, 136], ["mice", "SPECIES", 164, 168], ["Acute otitis media", "PROBLEM", 0, 18], ["S. pneumoniae", "PROBLEM", 80, 93], ["the influenza virus", "PROBLEM", 117, 136], ["disease", "PROBLEM", 186, 193], ["otitis", "OBSERVATION", 6, 12], ["pneumoniae", "OBSERVATION", 83, 93], ["influenza virus", "OBSERVATION", 121, 136]]], ["Mice infected with herpes simplex virus, adenovirus or vaccinia virus revealed enhanced susceptibility to E. coli pyelonephritis (59).", [["herpes simplex virus", "DISEASE", 19, 39], ["E. coli pyelonephritis", "DISEASE", 106, 128], ["Mice", "ORGANISM", 0, 4], ["herpes simplex virus", "ORGANISM", 19, 39], ["adenovirus", "ORGANISM", 41, 51], ["vaccinia virus", "ORGANISM", 55, 69], ["E. coli", "ORGANISM", 106, 113], ["Mice", "SPECIES", 0, 4], ["herpes simplex virus", "SPECIES", 19, 39], ["vaccinia virus", "SPECIES", 55, 69], ["E. coli", "SPECIES", 106, 113], ["herpes simplex virus", "SPECIES", 19, 39], ["adenovirus", "SPECIES", 41, 51], ["vaccinia virus", "SPECIES", 55, 69], ["E. coli", "SPECIES", 106, 113], ["herpes simplex virus", "PROBLEM", 19, 39], ["adenovirus", "PROBLEM", 41, 51], ["vaccinia virus", "PROBLEM", 55, 69], ["E. coli pyelonephritis", "PROBLEM", 106, 128], ["herpes simplex virus", "OBSERVATION", 19, 39], ["E. coli", "OBSERVATION_MODIFIER", 106, 113], ["pyelonephritis", "OBSERVATION", 114, 128]]], ["Mice inoculated intraperitoneally with murine cytomegalovirus together with P. aeruginosa, S. aureus or Candida albicans exhibited mortality rates of 80\u2013100%, whereas immunization against murine cytomegalovirus abrogated the synergistic effect on mortality for all combinations of the infectious agents studied (70).", [["intraperitoneally", "ANATOMY", 16, 33], ["cytomegalovirus", "DISEASE", 195, 210], ["Mice", "ORGANISM", 0, 4], ["murine", "ORGANISM", 39, 45], ["cytomegalovirus", "ORGANISM", 46, 61], ["P. aeruginosa", "ORGANISM", 76, 89], ["S. aureus", "ORGANISM", 91, 100], ["Candida albicans", "ORGANISM", 104, 120], ["murine", "ORGANISM", 188, 194], ["cytomegalovirus", "ORGANISM", 195, 210], ["Mice", "SPECIES", 0, 4], ["murine", "SPECIES", 39, 45], ["P. aeruginosa", "SPECIES", 76, 89], ["S. aureus", "SPECIES", 91, 100], ["Candida albicans", "SPECIES", 104, 120], ["murine", "SPECIES", 188, 194], ["murine cytomegalovirus", "SPECIES", 39, 61], ["P. aeruginosa", "SPECIES", 76, 89], ["S. aureus", "SPECIES", 91, 100], ["Candida albicans", "SPECIES", 104, 120], ["murine cytomegalovirus", "SPECIES", 188, 210], ["murine cytomegalovirus", "PROBLEM", 39, 61], ["P. aeruginosa", "PROBLEM", 76, 89], ["S. aureus", "PROBLEM", 91, 100], ["Candida albicans", "PROBLEM", 104, 120], ["mortality rates", "TEST", 131, 146], ["immunization", "TREATMENT", 167, 179], ["murine cytomegalovirus", "PROBLEM", 188, 210], ["the infectious agents", "TREATMENT", 281, 302], ["cytomegalovirus", "OBSERVATION", 46, 61], ["aureus", "OBSERVATION", 94, 100]]], ["In immunocompromised rats, a symptomatic infection with rat cytomegalovirus induced severe neutropenia and subsequently a high rate of enteric gram\u2010negative rod bacteremia (201).", [["infection", "DISEASE", 41, 50], ["cytomegalovirus", "DISEASE", 60, 75], ["neutropenia", "DISEASE", 91, 102], ["bacteremia", "DISEASE", 161, 171], ["rats", "ORGANISM", 21, 25], ["rat", "ORGANISM", 56, 59], ["cytomegalovirus", "ORGANISM", 60, 75], ["rats", "SPECIES", 21, 25], ["rat", "SPECIES", 56, 59], ["rat cytomegalovirus", "SPECIES", 56, 75], ["immunocompromised rats", "PROBLEM", 3, 25], ["a symptomatic infection", "PROBLEM", 27, 50], ["rat cytomegalovirus", "PROBLEM", 56, 75], ["severe neutropenia", "PROBLEM", 84, 102], ["enteric gram\u2010negative rod bacteremia", "PROBLEM", 135, 171], ["immunocompromised", "OBSERVATION", 3, 20], ["symptomatic", "OBSERVATION_MODIFIER", 29, 40], ["infection", "OBSERVATION", 41, 50], ["cytomegalovirus", "OBSERVATION", 60, 75], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["neutropenia", "OBSERVATION", 91, 102], ["high", "OBSERVATION_MODIFIER", 122, 126], ["enteric", "ANATOMY", 135, 142], ["gram\u2010negative rod bacteremia", "OBSERVATION", 143, 171]]], ["A markedly higher mortality rate was found in mice co\u2010infected with murine cytomegalovirus and P. gingivalis than in mice mono\u2010infected with either cytomegalovirus or P. gingivalis (203).", [["murine cytomegalovirus and P. gingivalis", "DISEASE", 68, 108], ["cytomegalovirus or P. gingivalis", "DISEASE", 148, 180], ["mice", "ORGANISM", 46, 50], ["murine", "ORGANISM", 68, 74], ["cytomegalovirus", "ORGANISM", 75, 90], ["P. gingivalis", "ORGANISM", 95, 108], ["mice", "ORGANISM", 117, 121], ["cytomegalovirus", "ORGANISM", 148, 163], ["P. gingivalis", "ORGANISM", 167, 180], ["mice", "SPECIES", 46, 50], ["murine", "SPECIES", 68, 74], ["P. gingivalis", "SPECIES", 95, 108], ["mice", "SPECIES", 117, 121], ["P. gingivalis", "SPECIES", 167, 180], ["mice", "SPECIES", 46, 50], ["murine cytomegalovirus", "SPECIES", 68, 90], ["P. gingivalis", "SPECIES", 95, 108], ["mice", "SPECIES", 117, 121], ["P. gingivalis", "SPECIES", 167, 180], ["A markedly higher mortality rate", "PROBLEM", 0, 32], ["murine cytomegalovirus", "PROBLEM", 68, 90], ["P. gingivalis", "PROBLEM", 95, 108], ["cytomegalovirus", "PROBLEM", 148, 163], ["P. gingivalis", "PROBLEM", 167, 180], ["markedly", "OBSERVATION_MODIFIER", 2, 10], ["higher", "OBSERVATION_MODIFIER", 11, 17], ["cytomegalovirus", "OBSERVATION", 75, 90], ["cytomegalovirus", "OBSERVATION", 148, 163]]], ["A significantly lower level of systemic interferon\u2010gamma was detected in the dually infected mice than in the mono\u2010infected mice, suggesting that P. gingivalis was able to reduce the antiviral interferon\u2010gamma response and thus increase the pathogenicity of the co\u2010infecting cytomegalovirus (203).Viral\u2013bacterial synergy in medical infectionsFor completeness, a latent herpesvirus infection may, in some experimental settings, up\u2010regulate the activation state of the innate immunity, thereby providing immune benefits for the host.", [["infections", "DISEASE", 332, 342], ["herpesvirus infection", "DISEASE", 369, 390], ["interferon\u2010gamma", "GENE_OR_GENE_PRODUCT", 40, 56], ["mice", "ORGANISM", 93, 97], ["mice", "ORGANISM", 124, 128], ["P. gingivalis", "ORGANISM", 146, 159], ["cytomegalovirus", "ORGANISM", 275, 290], ["herpesvirus", "ORGANISM", 369, 380], ["systemic interferon\u2010gamma", "PROTEIN", 31, 56], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 124, 128], ["P. gingivalis", "SPECIES", 146, 159], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 124, 128], ["P. gingivalis", "SPECIES", 146, 159], ["A significantly lower level of systemic interferon\u2010gamma", "PROBLEM", 0, 56], ["P. gingivalis", "PROBLEM", 146, 159], ["the antiviral interferon\u2010gamma response", "TREATMENT", 179, 218], ["the co\u2010infecting cytomegalovirus", "PROBLEM", 258, 290], ["Viral\u2013bacterial synergy", "PROBLEM", 297, 320], ["medical infections", "PROBLEM", 324, 342], ["a latent herpesvirus infection", "PROBLEM", 360, 390], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["lower", "OBSERVATION_MODIFIER", 16, 21], ["systemic", "OBSERVATION_MODIFIER", 31, 39], ["interferon\u2010gamma", "OBSERVATION", 40, 56], ["dually", "OBSERVATION_MODIFIER", 77, 83], ["infected", "OBSERVATION", 84, 92], ["cytomegalovirus", "OBSERVATION", 275, 290], ["infections", "OBSERVATION", 332, 342], ["latent", "OBSERVATION_MODIFIER", 362, 368], ["herpesvirus", "OBSERVATION_MODIFIER", 369, 380], ["infection", "OBSERVATION", 381, 390]]], ["Mice latently infected with murine Epstein\u2013Barr virus or cytomegalovirus can show resistance to infection with the bacterial pathogens Listeria monocytogenes and Yersinia pestis (10).", [["infection", "DISEASE", 96, 105], ["Yersinia pestis", "DISEASE", 162, 177], ["Mice", "ORGANISM", 0, 4], ["murine", "ORGANISM", 28, 34], ["Epstein\u2013Barr virus", "ORGANISM", 35, 53], ["cytomegalovirus", "ORGANISM", 57, 72], ["Listeria monocytogenes", "ORGANISM", 135, 157], ["Yersinia pestis", "ORGANISM", 162, 177], ["Mice", "SPECIES", 0, 4], ["murine", "SPECIES", 28, 34], ["Listeria monocytogenes", "SPECIES", 135, 157], ["Yersinia pestis", "SPECIES", 162, 177], ["Epstein\u2013Barr virus", "SPECIES", 35, 53], ["Listeria monocytogenes", "SPECIES", 135, 157], ["Yersinia pestis", "SPECIES", 162, 177], ["murine Epstein", "TREATMENT", 28, 42], ["Barr virus", "PROBLEM", 43, 53], ["cytomegalovirus", "PROBLEM", 57, 72], ["resistance to infection", "PROBLEM", 82, 105], ["the bacterial pathogens Listeria monocytogenes", "PROBLEM", 111, 157], ["Yersinia pestis", "PROBLEM", 162, 177], ["Barr virus", "OBSERVATION", 43, 53], ["infection", "OBSERVATION", 96, 105], ["bacterial", "OBSERVATION_MODIFIER", 115, 124], ["pathogens", "OBSERVATION_MODIFIER", 125, 134], ["Listeria monocytogenes", "OBSERVATION", 135, 157], ["Yersinia", "OBSERVATION_MODIFIER", 162, 170]]], ["However, the herpesvirus\u2010induced protection against bacterial infection seems to be transient, lasting only a few months (236).Viral\u2013bacterial synergy in medical infectionsCollectively, numerous studies of natural diseases and experimental infections conclude that viral\u2013bacterial co\u2010infections produce more disease than single infections with either of the two types of infectious agents.", [["bacterial infection", "DISEASE", 52, 71], ["infections", "DISEASE", 162, 172], ["infections", "DISEASE", 240, 250], ["viral\u2013bacterial co\u2010infections", "DISEASE", 265, 294], ["infections", "DISEASE", 328, 338], ["the herpesvirus\u2010induced protection", "TREATMENT", 9, 43], ["bacterial infection", "PROBLEM", 52, 71], ["Viral\u2013bacterial synergy", "PROBLEM", 127, 150], ["medical infections", "PROBLEM", 154, 172], ["natural diseases", "PROBLEM", 206, 222], ["experimental infections", "PROBLEM", 227, 250], ["viral\u2013bacterial co\u2010infections", "PROBLEM", 265, 294], ["single infections", "PROBLEM", 321, 338], ["infectious agents", "TREATMENT", 371, 388], ["infection", "OBSERVATION", 62, 71], ["transient", "OBSERVATION_MODIFIER", 84, 93], ["infections", "OBSERVATION", 162, 172], ["natural diseases", "OBSERVATION", 206, 222], ["infections", "OBSERVATION", 240, 250], ["infections", "OBSERVATION", 328, 338], ["infectious", "OBSERVATION", 371, 381]]], ["Early studies on viral\u2013bacterial synergism emphasized a decreased clearance or an enhanced pathogenicity of the bacteria involved in the infectious complex, but more recent investigations also point to the possibility of an increased virulence of the virus.", [["Early studies", "TEST", 0, 13], ["viral\u2013bacterial synergism", "PROBLEM", 17, 42], ["a decreased clearance", "PROBLEM", 54, 75], ["the bacteria", "PROBLEM", 108, 120], ["the infectious complex", "PROBLEM", 133, 155], ["an increased virulence of the virus", "PROBLEM", 221, 256], ["decreased", "OBSERVATION_MODIFIER", 56, 65], ["bacteria", "OBSERVATION", 112, 120], ["infectious", "OBSERVATION_MODIFIER", 137, 147], ["increased", "OBSERVATION_MODIFIER", 224, 233], ["virulence", "OBSERVATION", 234, 243]]], ["As millions of herpesviruses and bacteria can inhabit individual periodontitis sites (179), it is reasonable to assume that herpesviral\u2013bacterial interactions also play a role in the development of human periodontitis.Clinical status of the study subjects ::: Diagnostic considerations ::: Herpesviruses in periodontal diseasesIdentification of periodontal herpesviruses is influenced by the sample site and method utilized.", [["periodontal", "ANATOMY", 307, 318], ["periodontal", "ANATOMY", 345, 356], ["periodontitis", "DISEASE", 65, 78], ["periodontitis", "DISEASE", 204, 217], ["Herpesviruses", "DISEASE", 290, 303], ["periodontal diseases", "DISEASE", 307, 327], ["periodontal herpesviruses", "DISEASE", 345, 370], ["herpesviruses", "ORGANISM", 15, 28], ["periodontitis sites", "MULTI-TISSUE_STRUCTURE", 65, 84], ["human", "ORGANISM", 198, 203], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["herpesviruses", "PROBLEM", 15, 28], ["bacteria", "PROBLEM", 33, 41], ["individual periodontitis sites", "PROBLEM", 54, 84], ["herpesviral\u2013bacterial interactions", "PROBLEM", 124, 158], ["human periodontitis", "PROBLEM", 198, 217], ["Herpesviruses in periodontal diseases", "PROBLEM", 290, 327], ["periodontal herpesviruses", "PROBLEM", 345, 370], ["herpesviruses", "OBSERVATION", 15, 28], ["bacteria", "OBSERVATION_MODIFIER", 33, 41], ["periodontitis", "OBSERVATION", 65, 78], ["human", "OBSERVATION_MODIFIER", 198, 203], ["periodontitis", "OBSERVATION", 204, 217], ["periodontal", "ANATOMY", 307, 318], ["diseases", "OBSERVATION", 319, 327], ["periodontal herpesviruses", "OBSERVATION", 345, 370]]], ["Because pathogen loads typically peak during periods of active disease, herpesvirus recovery from periodontal sites depends greatly on the accuracy of the clinical diagnosis.", [["periodontal sites", "ANATOMY", 98, 115], ["herpesvirus", "DISEASE", 72, 83], ["herpesvirus", "ORGANISM", 72, 83], ["periodontal sites", "MULTI-TISSUE_STRUCTURE", 98, 115], ["pathogen loads", "PROBLEM", 8, 22], ["active disease", "PROBLEM", 56, 70], ["herpesvirus recovery", "PROBLEM", 72, 92], ["periodontal sites", "PROBLEM", 98, 115], ["active", "OBSERVATION_MODIFIER", 56, 62], ["disease", "OBSERVATION", 63, 70], ["herpesvirus recovery", "OBSERVATION", 72, 92], ["periodontal", "OBSERVATION_MODIFIER", 98, 109]]], ["The difficulty of defining periodontitis for the purpose of research was recently pointed out (156).", [["periodontitis", "DISEASE", 27, 40], ["defining periodontitis", "PROBLEM", 18, 40], ["periodontitis", "OBSERVATION", 27, 40]]], ["The use of patient age as a main criterion for distinguishing between \u2018aggressive\u2019 and \u2018chronic\u2019 periodontitis may not be a reliable indicator of active or stable disease.", [["periodontitis", "DISEASE", 97, 110], ["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["\u2018chronic\u2019 periodontitis", "PROBLEM", 87, 110], ["active or stable disease", "PROBLEM", 146, 170], ["chronic", "OBSERVATION_MODIFIER", 88, 95], ["periodontitis", "OBSERVATION", 97, 110], ["stable", "OBSERVATION_MODIFIER", 156, 162], ["disease", "OBSERVATION", 163, 170]]], ["The term \u2018normal\u2019 periodontal site is sometimes used to suggest absence of attachment loss rather than inflammation\u2010free gingiva.", [["periodontal site", "ANATOMY", 18, 34], ["gingiva", "ANATOMY", 121, 128], ["attachment loss", "DISEASE", 75, 90], ["periodontal site", "MULTI-TISSUE_STRUCTURE", 18, 34], ["gingiva", "ORGAN", 121, 128], ["attachment loss", "PROBLEM", 75, 90], ["inflammation\u2010free gingiva", "PROBLEM", 103, 128], ["normal", "OBSERVATION", 10, 16], ["periodontal", "ANATOMY", 18, 29], ["attachment loss", "OBSERVATION", 75, 90]]], ["As herpesviruses may enter even slightly inflamed periodontal sites, sensitive polymerase chain reaction (PCR) techniques may show viruses in \u2018unhealthy\u2019 control sites.", [["periodontal sites", "ANATOMY", 50, 67], ["herpesviruses", "ORGANISM", 3, 16], ["periodontal sites", "MULTI-TISSUE_STRUCTURE", 50, 67], ["herpesviruses", "PROBLEM", 3, 16], ["slightly inflamed periodontal sites", "PROBLEM", 32, 67], ["sensitive polymerase chain reaction", "PROBLEM", 69, 104], ["PCR) techniques", "TEST", 106, 121], ["viruses", "PROBLEM", 131, 138], ["slightly", "OBSERVATION_MODIFIER", 32, 40], ["inflamed", "OBSERVATION", 41, 49], ["viruses", "OBSERVATION", 131, 138]]], ["Conversely, periodontal therapy can markedly reduce herpesvirus subgingival counts and thus cause a significant underestimation of the viral load associated with untreated disease (177).", [["periodontal", "ANATOMY", 12, 23], ["subgingival", "ANATOMY", 64, 75], ["herpesvirus", "ORGANISM", 52, 63], ["periodontal therapy", "TREATMENT", 12, 31], ["herpesvirus subgingival counts", "TEST", 52, 82], ["the viral load", "PROBLEM", 131, 145], ["untreated disease", "PROBLEM", 162, 179], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["underestimation", "OBSERVATION", 112, 127], ["viral load", "OBSERVATION", 135, 145]]], ["Reliable data on the prevalence and quantity of periodontal herpesviruses may require study of virgin lesions with a well\u2010defined disease\u2010activity status.Clinical status of the study subjects ::: Diagnostic considerations ::: Herpesviruses in periodontal diseasesStudies that examine a small number of periodontal sites in each subject will inevitably underestimate the prevalence of herpesviruses in the study population and the total number of herpesvirus genome\u2010copies in the entire periodontium.", [["periodontal", "ANATOMY", 48, 59], ["lesions", "ANATOMY", 102, 109], ["periodontal", "ANATOMY", 243, 254], ["periodontal sites", "ANATOMY", 302, 319], ["periodontium", "ANATOMY", 486, 498], ["periodontal herpesviruses", "DISEASE", 48, 73], ["Herpesviruses", "DISEASE", 226, 239], ["periodontal diseases", "DISEASE", 243, 263], ["herpesviruses", "DISEASE", 384, 397], ["virgin lesions", "CANCER", 95, 109], ["periodontal sites", "MULTI-TISSUE_STRUCTURE", 302, 319], ["herpesviruses", "ORGANISM", 384, 397], ["herpesvirus", "ORGANISM", 446, 457], ["periodontium", "ORGAN", 486, 498], ["periodontal herpesviruses", "PROBLEM", 48, 73], ["virgin lesions", "PROBLEM", 95, 109], ["a well\u2010defined disease\u2010activity status", "PROBLEM", 115, 153], ["Herpesviruses in periodontal diseases", "PROBLEM", 226, 263], ["a small number of periodontal sites", "PROBLEM", 284, 319], ["herpesviruses", "PROBLEM", 384, 397], ["the study population", "TEST", 401, 421], ["herpesvirus genome\u2010copies in the entire periodontium", "PROBLEM", 446, 498], ["periodontal", "ANATOMY", 48, 59], ["herpesviruses", "OBSERVATION", 60, 73], ["periodontal", "ANATOMY", 243, 254], ["diseases", "OBSERVATION", 255, 263], ["small", "OBSERVATION_MODIFIER", 286, 291], ["number", "OBSERVATION_MODIFIER", 292, 298], ["periodontal sites", "OBSERVATION", 302, 319], ["herpesviruses", "OBSERVATION", 384, 397], ["total", "OBSERVATION_MODIFIER", 430, 435], ["herpesvirus genome\u2010copies", "OBSERVATION", 446, 471], ["entire", "ANATOMY_MODIFIER", 479, 485], ["periodontium", "ANATOMY", 486, 498]]], ["Studies of herpesviruses in subgingival sites will also not account for the substantial herpesvirus counts residing within inflamed gingival tissue (98, 168).Viral diagnostic methods ::: Diagnostic considerations ::: Herpesviruses in periodontal diseasesThe era of relying upon in vitro cell culture for routine laboratory diagnosis of viral infections has truly passed.", [["subgingival sites", "ANATOMY", 28, 45], ["gingival tissue", "ANATOMY", 132, 147], ["periodontal", "ANATOMY", 234, 245], ["cell", "ANATOMY", 287, 291], ["Herpesviruses", "DISEASE", 217, 230], ["periodontal diseases", "DISEASE", 234, 254], ["viral infections", "DISEASE", 336, 352], ["herpesviruses", "ORGANISM", 11, 24], ["subgingival sites", "MULTI-TISSUE_STRUCTURE", 28, 45], ["herpesvirus", "ORGANISM", 88, 99], ["gingival tissue", "TISSUE", 132, 147], ["cell", "CELL", 287, 291], ["herpesviruses in subgingival sites", "PROBLEM", 11, 45], ["the substantial herpesvirus counts", "PROBLEM", 72, 106], ["Herpesviruses in periodontal diseases", "PROBLEM", 217, 254], ["vitro cell culture", "TEST", 281, 299], ["viral infections", "PROBLEM", 336, 352], ["herpesviruses", "OBSERVATION", 11, 24], ["not account for", "UNCERTAINTY", 56, 71], ["substantial", "OBSERVATION_MODIFIER", 76, 87], ["herpesvirus counts", "OBSERVATION", 88, 106], ["inflamed", "OBSERVATION_MODIFIER", 123, 131], ["gingival tissue", "ANATOMY", 132, 147], ["periodontal", "ANATOMY", 234, 245], ["diseases", "OBSERVATION", 246, 254], ["viral infections", "OBSERVATION", 336, 352]]], ["Viral isolation indicates an active and possibly disease\u2010producing infection, but isolation of viruses is difficult, costly and time\u2010consuming.", [["infection", "DISEASE", 67, 76], ["Viral isolation", "PROBLEM", 0, 15], ["disease\u2010producing infection", "PROBLEM", 49, 76], ["isolation of viruses", "PROBLEM", 82, 102], ["active", "OBSERVATION_MODIFIER", 29, 35], ["possibly", "UNCERTAINTY", 40, 48], ["disease\u2010producing", "OBSERVATION_MODIFIER", 49, 66], ["infection", "OBSERVATION", 67, 76], ["viruses", "OBSERVATION", 95, 102]]], ["High\u2010fidelity PCR\u2010based techniques have become the standard for identification and quantification of periodontal herpesviruses (99, 146), and the transcription of late herpesvirus genes for structural proteins is understood to signify productive viral replication and is commonly used to indicate an active herpesvirus infection (60, 124).", [["periodontal herpesviruses", "DISEASE", 101, 126], ["herpesvirus infection", "DISEASE", 307, 328], ["herpesvirus", "ORGANISM", 168, 179], ["herpesvirus", "ORGANISM", 307, 318], ["late herpesvirus genes", "DNA", 163, 185], ["structural proteins", "PROTEIN", 190, 209], ["High\u2010fidelity PCR", "TEST", 0, 17], ["periodontal herpesviruses", "PROBLEM", 101, 126], ["late herpesvirus genes", "PROBLEM", 163, 185], ["structural proteins", "PROBLEM", 190, 209], ["productive viral replication", "PROBLEM", 235, 263], ["an active herpesvirus infection", "PROBLEM", 297, 328], ["periodontal herpesviruses", "ANATOMY", 101, 126], ["active", "OBSERVATION_MODIFIER", 300, 306], ["herpesvirus", "OBSERVATION_MODIFIER", 307, 318], ["infection", "OBSERVATION", 319, 328]]], ["PCR identification of oral herpes simplex virus may yield two\u2010 to fourfold more positive samples than viral culture (42, 227).", [["oral", "ANATOMY", 22, 26], ["samples", "ANATOMY", 89, 96], ["herpes simplex virus", "DISEASE", 27, 47], ["oral herpes simplex virus", "ORGANISM", 22, 47], ["herpes simplex virus", "SPECIES", 27, 47], ["herpes simplex virus", "SPECIES", 27, 47], ["PCR identification", "TEST", 0, 18], ["oral herpes simplex virus", "PROBLEM", 22, 47], ["viral culture", "TEST", 102, 115]]], ["Nested PCR may unveil more periodontal sites that are positive for cytomegalovirus than viral culture or real\u2010time PCR (16) or end\u2010point detection PCR (23).", [["periodontal sites", "ANATOMY", 27, 44], ["periodontal sites", "MULTI-TISSUE_STRUCTURE", 27, 44], ["cytomegalovirus", "ORGANISM", 67, 82], ["Nested PCR", "TEST", 0, 10], ["unveil more periodontal sites", "PROBLEM", 15, 44], ["cytomegalovirus", "PROBLEM", 67, 82], ["viral culture", "TEST", 88, 101], ["real\u2010time PCR", "TEST", 105, 118], ["end\u2010point detection PCR", "TEST", 127, 150]]], ["Nested PCR technology is particularly efficient in detecting low viral loads (168).", [["low viral loads", "PROBLEM", 61, 76]]], ["However, PCR primers that amplify templates of microbial communities at different efficiencies may yield biased results (86).", [["PCR primers", "DNA", 9, 20], ["PCR primers", "TEST", 9, 20]]], ["Misamplification and false\u2010positive herpesvirus results may emerge when there are shared regions of nucleotide sequences between herpesvirus species and unknown infectious agents.", [["nucleotide", "CHEMICAL", 100, 110], ["nucleotide", "CHEMICAL", 100, 110], ["herpesvirus", "ORGANISM", 36, 47], ["herpesvirus", "ORGANISM", 129, 140], ["Misamplification", "TEST", 0, 16], ["false\u2010positive herpesvirus", "PROBLEM", 21, 47], ["nucleotide sequences", "PROBLEM", 100, 120], ["herpesvirus species", "PROBLEM", 129, 148], ["infectious", "OBSERVATION_MODIFIER", 161, 171]]], ["Nevertheless, as periodontal Epstein\u2013Barr virus and cytomegalovirus have been identified using a variety of PCR primers in platforms of end\u2010point detection PCR, nested PCR, reverse transcription PCR and real\u2010time PCR, the risk of a systematic misidentification of these viruses is small.", [["periodontal Epstein\u2013Barr virus", "ORGANISM", 17, 47], ["cytomegalovirus", "ORGANISM", 52, 67], ["PCR primers", "DNA", 108, 119], ["Epstein\u2013Barr virus", "SPECIES", 29, 47], ["periodontal Epstein\u2013Barr virus", "PROBLEM", 17, 47], ["cytomegalovirus", "PROBLEM", 52, 67], ["PCR primers", "TEST", 108, 119], ["end\u2010point detection PCR", "TEST", 136, 159], ["nested PCR", "TEST", 161, 171], ["reverse transcription PCR", "TEST", 173, 198], ["real\u2010time PCR", "TEST", 203, 216], ["a systematic misidentification of these viruses", "PROBLEM", 230, 277], ["Barr virus", "OBSERVATION", 37, 47], ["viruses", "OBSERVATION", 270, 277], ["small", "OBSERVATION_MODIFIER", 281, 286]]], ["However, different PCR primers and protocols may detect herpesviruses with a varying degree of proficiency (28), and technical expertise and quality assurance methods vary among laboratories (102, 144, 183).", [["herpesviruses", "ORGANISM", 56, 69], ["PCR primers", "DNA", 19, 30], ["different PCR primers", "TEST", 9, 30], ["protocols", "TEST", 35, 44], ["herpesviruses", "PROBLEM", 56, 69]]], ["Preparation of the target nucleic acid constitutes a particularly vulnerable stage of PCR protocols.Geographical/ethnic differences in herpesviral occurrence ::: Diagnostic considerations ::: Herpesviruses in periodontal diseasesThe genotype distribution and seroprevalence of Epstein\u2013Barr virus (82, 175) and cytomegalovirus (147, 168) differ among populations.", [["periodontal", "ANATOMY", 209, 220], ["nucleic acid", "CHEMICAL", 26, 38], ["Herpesviruses", "DISEASE", 192, 205], ["periodontal diseases", "DISEASE", 209, 229], ["Epstein\u2013Barr virus", "ORGANISM", 277, 295], ["cytomegalovirus", "ORGANISM", 310, 325], ["Epstein\u2013Barr virus", "SPECIES", 277, 295], ["the target nucleic acid", "TEST", 15, 38], ["PCR protocols", "TREATMENT", 86, 99], ["Herpesviruses in periodontal diseases", "PROBLEM", 192, 229], ["Epstein\u2013Barr virus", "TEST", 277, 295], ["cytomegalovirus", "TEST", 310, 325], ["periodontal", "ANATOMY", 209, 220], ["diseases", "OBSERVATION", 221, 229], ["cytomegalovirus", "OBSERVATION", 310, 325]]], ["Similarly to medical infections (157), some herpesvirus subtypes may exhibit increased periodontopathogenicity.", [["infections", "DISEASE", 21, 31], ["periodontopathogenicity", "DISEASE", 87, 110], ["herpesvirus", "ORGANISM", 44, 55], ["medical infections", "PROBLEM", 13, 31], ["some herpesvirus subtypes", "PROBLEM", 39, 64], ["increased periodontopathogenicity", "PROBLEM", 77, 110], ["infections", "OBSERVATION", 21, 31], ["herpesvirus subtypes", "OBSERVATION", 44, 64], ["may exhibit", "UNCERTAINTY", 65, 76], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["periodontopathogenicity", "OBSERVATION", 87, 110]]], ["Glycoprotein B (gB) homologues within the herpesvirus family participate in virus entry and cell\u2010to\u2010cell spread, and the encoding gene is commonly used in genotyping (145).", [["cell\u2010to\u2010cell", "ANATOMY", 92, 104], ["Glycoprotein B", "GENE_OR_GENE_PRODUCT", 0, 14], ["gB", "GENE_OR_GENE_PRODUCT", 16, 18], ["herpesvirus", "ORGANISM", 42, 53], ["Glycoprotein B (gB) homologues", "PROTEIN", 0, 30], ["herpesvirus family", "PROTEIN", 42, 60], ["Glycoprotein B (gB) homologues", "TREATMENT", 0, 30]]], ["The cytomegalovirus gB\u2010II genotype seems to predominate in chronic periodontitis, whereas the cytomegalovirus gB\u2010I genotype is more closely related to gingivitis and a healthy periodontium (235).", [["periodontium", "ANATOMY", 176, 188], ["periodontitis", "DISEASE", 67, 80], ["gingivitis", "DISEASE", 151, 161], ["cytomegalovirus", "ORGANISM", 4, 19], ["gB\u2010II", "GENE_OR_GENE_PRODUCT", 20, 25], ["cytomegalovirus", "ORGANISM", 94, 109], ["periodontium", "ORGAN", 176, 188], ["The cytomegalovirus gB", "TEST", 0, 22], ["chronic periodontitis", "PROBLEM", 59, 80], ["the cytomegalovirus gB", "TEST", 90, 112], ["gingivitis", "PROBLEM", 151, 161], ["cytomegalovirus", "OBSERVATION", 4, 19], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["periodontitis", "OBSERVATION", 67, 80], ["cytomegalovirus", "OBSERVATION", 94, 109], ["gingivitis", "OBSERVATION", 151, 161]]], ["In addition, herpesviruses occur at a higher prevalence in low\u2010income countries than in affluent countries (3), and the herpesvirus seroprevalence in high\u2010income countries exhibits significant racial, educational and socioeconomic disparities, starting at an early age and persisting into middle age (43, 44, 243).Periodontal herpesviruses ::: Herpesviruses in periodontal diseasesEpstein\u2013Barr virus and cytomegalovirus genomes have been identified in periodontitis lesions with prevalences ranging from a few per cent to more than 80% (Table 1).", [["Periodontal", "ANATOMY", 314, 325], ["periodontitis lesions", "ANATOMY", 452, 473], ["herpesvirus", "DISEASE", 120, 131], ["Herpesviruses", "DISEASE", 344, 357], ["periodontal diseases", "DISEASE", 361, 381], ["periodontitis", "DISEASE", 452, 465], ["herpesviruses", "ORGANISM", 13, 26], ["herpesvirus", "ORGANISM", 120, 131], ["Epstein\u2013Barr virus", "ORGANISM", 381, 399], ["cytomegalovirus", "ORGANISM", 404, 419], ["periodontitis lesions", "PATHOLOGICAL_FORMATION", 452, 473], ["cytomegalovirus genomes", "DNA", 404, 427], ["Epstein\u2013Barr virus", "SPECIES", 381, 399], ["herpesviruses", "PROBLEM", 13, 26], ["the herpesvirus seroprevalence", "PROBLEM", 116, 146], ["significant racial, educational and socioeconomic disparities", "PROBLEM", 181, 242], ["Periodontal herpesviruses", "PROBLEM", 314, 339], ["Herpesviruses in periodontal diseases", "PROBLEM", 344, 381], ["Barr virus", "PROBLEM", 389, 399], ["cytomegalovirus genomes", "PROBLEM", 404, 427], ["periodontitis lesions", "PROBLEM", 452, 473], ["herpesviruses", "OBSERVATION", 13, 26], ["significant", "OBSERVATION_MODIFIER", 181, 192], ["racial", "OBSERVATION_MODIFIER", 193, 199], ["middle", "ANATOMY_MODIFIER", 289, 295], ["herpesviruses", "OBSERVATION", 326, 339], ["periodontal", "ANATOMY", 361, 372], ["Barr virus", "OBSERVATION", 389, 399], ["cytomegalovirus genomes", "OBSERVATION", 404, 427], ["periodontitis", "OBSERVATION_MODIFIER", 452, 465], ["lesions", "OBSERVATION", 466, 473], ["few", "OBSERVATION_MODIFIER", 506, 509]]], ["Cytomegalovirus seropositivity was identified in 95% of patients with periodontitis but in only 74% of patients with gingivitis (P = 0.057) (88).", [["Cytomegalovirus seropositivity", "DISEASE", 0, 30], ["periodontitis", "DISEASE", 70, 83], ["gingivitis", "DISEASE", 117, 127], ["Cytomegalovirus", "ORGANISM", 0, 15], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 103, 111], ["Cytomegalovirus seropositivity", "PROBLEM", 0, 30], ["periodontitis", "PROBLEM", 70, 83], ["gingivitis", "PROBLEM", 117, 127], ["periodontitis", "OBSERVATION", 70, 83]]], ["Epstein\u2013Barr virus (105) and cytomegalovirus (240) are also common inhabitants of peri\u2010apical lesions of endodontic origin.", [["peri\u2010apical lesions", "ANATOMY", 82, 101], ["Epstein\u2013Barr virus (105) and cytomegalovirus", "DISEASE", 0, 44], ["Epstein\u2013Barr virus", "ORGANISM", 0, 18], ["cytomegalovirus", "ORGANISM", 29, 44], ["peri\u2010apical lesions", "PATHOLOGICAL_FORMATION", 82, 101], ["Epstein\u2013Barr virus", "SPECIES", 0, 18], ["Epstein\u2013Barr virus", "PROBLEM", 0, 18], ["cytomegalovirus", "PROBLEM", 29, 44], ["peri\u2010apical lesions of endodontic origin", "PROBLEM", 82, 122], ["Barr virus", "OBSERVATION", 8, 18], ["cytomegalovirus", "OBSERVATION", 29, 44], ["peri\u2010apical", "ANATOMY", 82, 93], ["lesions", "OBSERVATION", 94, 101], ["endodontic origin", "OBSERVATION", 105, 122]]], ["Cytomegalovirus was detected in 32% of peri\u2010apical abscesses exhibiting spontaneous pain (23).Periodontal herpesviruses ::: Herpesviruses in periodontal diseasesTo assess, in more detail, the linkage between herpesviruses and periodontitis, patients have been grouped according to disease severity.", [["peri\u2010apical abscesses", "ANATOMY", 39, 60], ["Periodontal", "ANATOMY", 94, 105], ["periodontal", "ANATOMY", 141, 152], ["abscesses", "DISEASE", 51, 60], ["pain", "DISEASE", 84, 88], ["Herpesviruses", "DISEASE", 124, 137], ["periodontal diseases", "DISEASE", 141, 161], ["herpesviruses", "DISEASE", 208, 221], ["periodontitis", "DISEASE", 226, 239], ["Cytomegalovirus", "ORGANISM", 0, 15], ["peri\u2010apical", "PATHOLOGICAL_FORMATION", 39, 50], ["abscesses", "PATHOLOGICAL_FORMATION", 51, 60], ["herpesviruses", "ORGANISM", 208, 221], ["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["Cytomegalovirus", "PROBLEM", 0, 15], ["peri\u2010apical abscesses", "PROBLEM", 39, 60], ["spontaneous pain", "PROBLEM", 72, 88], ["Periodontal herpesviruses", "PROBLEM", 94, 119], ["Herpesviruses in periodontal diseases", "PROBLEM", 124, 161], ["herpesviruses", "PROBLEM", 208, 221], ["periodontitis", "PROBLEM", 226, 239], ["disease severity", "PROBLEM", 281, 297], ["abscesses", "OBSERVATION", 51, 60], ["spontaneous", "OBSERVATION_MODIFIER", 72, 83], ["pain", "OBSERVATION", 84, 88], ["herpesviruses", "OBSERVATION", 106, 119], ["periodontal", "ANATOMY", 141, 152], ["diseases", "OBSERVATION", 153, 161], ["herpesviruses", "OBSERVATION", 208, 221], ["periodontitis", "OBSERVATION", 226, 239]]], ["Table 1 reveals the presence of Epstein\u2013Barr virus in 65% of aggressive periodontitis lesions and in 49% of chronic periodontitis lesions and of cytomegalovirus in 44% of aggressive periodontitis lesions and in 44% of chronic periodontitis lesions.", [["periodontitis lesions", "ANATOMY", 72, 93], ["lesions", "ANATOMY", 130, 137], ["periodontitis lesions", "ANATOMY", 182, 203], ["lesions", "ANATOMY", 240, 247], ["Epstein\u2013Barr virus", "DISEASE", 32, 50], ["periodontitis", "DISEASE", 72, 85], ["periodontitis", "DISEASE", 116, 129], ["cytomegalovirus", "DISEASE", 145, 160], ["periodontitis", "DISEASE", 182, 195], ["periodontitis", "DISEASE", 226, 239], ["Epstein\u2013Barr virus", "ORGANISM", 32, 50], ["periodontitis lesions", "PATHOLOGICAL_FORMATION", 72, 93], ["lesions", "PATHOLOGICAL_FORMATION", 130, 137], ["cytomegalovirus", "ORGANISM", 145, 160], ["periodontitis lesions", "CANCER", 182, 203], ["lesions", "PATHOLOGICAL_FORMATION", 240, 247], ["Epstein\u2013Barr virus", "SPECIES", 32, 50], ["Epstein\u2013Barr virus", "PROBLEM", 32, 50], ["aggressive periodontitis lesions", "PROBLEM", 61, 93], ["chronic periodontitis lesions", "PROBLEM", 108, 137], ["cytomegalovirus", "PROBLEM", 145, 160], ["aggressive periodontitis lesions", "PROBLEM", 171, 203], ["chronic periodontitis lesions", "PROBLEM", 218, 247], ["Barr virus", "OBSERVATION", 40, 50], ["aggressive", "OBSERVATION_MODIFIER", 61, 71], ["periodontitis", "OBSERVATION_MODIFIER", 72, 85], ["lesions", "OBSERVATION", 86, 93], ["49%", "OBSERVATION_MODIFIER", 101, 104], ["chronic", "OBSERVATION_MODIFIER", 108, 115], ["periodontitis", "OBSERVATION_MODIFIER", 116, 129], ["lesions", "OBSERVATION", 130, 137], ["cytomegalovirus", "OBSERVATION", 145, 160], ["44%", "OBSERVATION_MODIFIER", 164, 167], ["aggressive", "OBSERVATION_MODIFIER", 171, 181], ["periodontitis", "OBSERVATION_MODIFIER", 182, 195], ["lesions", "OBSERVATION", 196, 203], ["44%", "OBSERVATION_MODIFIER", 211, 214], ["chronic", "OBSERVATION_MODIFIER", 218, 225], ["periodontitis", "OBSERVATION_MODIFIER", 226, 239], ["lesions", "OBSERVATION", 240, 247]]], ["Although the prevalence of Epstein\u2013Barr virus and cytomegalovirus was similar in aggressive and chronic periodontitis, the herpesvirus infection may differ qualitatively in the two diseases.", [["Epstein\u2013Barr virus and cytomegalovirus", "DISEASE", 27, 65], ["periodontitis", "DISEASE", 104, 117], ["herpesvirus infection", "DISEASE", 123, 144], ["Epstein\u2013Barr virus", "ORGANISM", 27, 45], ["cytomegalovirus", "ORGANISM", 50, 65], ["herpesvirus", "ORGANISM", 123, 134], ["Epstein\u2013Barr virus", "SPECIES", 27, 45], ["Epstein\u2013Barr virus", "PROBLEM", 27, 45], ["cytomegalovirus", "PROBLEM", 50, 65], ["chronic periodontitis", "PROBLEM", 96, 117], ["the herpesvirus infection", "PROBLEM", 119, 144], ["the two diseases", "PROBLEM", 173, 189], ["Barr virus", "OBSERVATION", 35, 45], ["aggressive", "OBSERVATION_MODIFIER", 81, 91], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["periodontitis", "OBSERVATION", 104, 117], ["herpesvirus infection", "OBSERVATION", 123, 144]]], ["An active (\u2018productive\u2019) cytomegalovirus infection tends to be associated with periodontal sites showing no radiographic evidence of alveolar crestal lamina dura (211, 219), a finding consistent with disease\u2010active periodontitis (158).", [["periodontal sites", "ANATOMY", 79, 96], ["alveolar crestal lamina dura", "ANATOMY", 133, 161], ["cytomegalovirus infection", "DISEASE", 25, 50], ["periodontitis", "DISEASE", 215, 228], ["cytomegalovirus", "ORGANISM", 25, 40], ["alveolar crestal lamina dura", "MULTI-TISSUE_STRUCTURE", 133, 161], ["An active (\u2018productive\u2019) cytomegalovirus infection", "PROBLEM", 0, 50], ["periodontal sites", "PROBLEM", 79, 96], ["alveolar crestal lamina dura", "PROBLEM", 133, 161], ["disease\u2010active periodontitis", "PROBLEM", 200, 228], ["active", "OBSERVATION_MODIFIER", 3, 9], ["cytomegalovirus infection", "OBSERVATION", 25, 50], ["no radiographic evidence of", "UNCERTAINTY", 105, 132], ["alveolar", "ANATOMY_MODIFIER", 133, 141], ["crestal", "ANATOMY_MODIFIER", 142, 149], ["lamina dura", "ANATOMY", 150, 161], ["consistent with", "UNCERTAINTY", 184, 199], ["disease\u2010active", "OBSERVATION_MODIFIER", 200, 214], ["periodontitis", "OBSERVATION", 215, 228]]], ["An active cytomegalovirus infection has also been linked to increased gingival inflammation in immunosuppressed organ\u2010transplant recipients (141).", [["gingival", "ANATOMY", 70, 78], ["cytomegalovirus infection", "DISEASE", 10, 35], ["gingival inflammation", "DISEASE", 70, 91], ["cytomegalovirus", "ORGANISM", 10, 25], ["gingival", "TISSUE", 70, 78], ["An active cytomegalovirus infection", "PROBLEM", 0, 35], ["increased gingival inflammation", "PROBLEM", 60, 91], ["immunosuppressed organ\u2010transplant recipients", "TREATMENT", 95, 139], ["active", "OBSERVATION_MODIFIER", 3, 9], ["cytomegalovirus", "OBSERVATION", 10, 25], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["gingival", "OBSERVATION_MODIFIER", 70, 78], ["inflammation", "OBSERVATION", 79, 91], ["immunosuppressed", "OBSERVATION_MODIFIER", 95, 111]]], ["An acute herpes simplex virus\u2010type 1 infection in a 26\u2010year\u2010old patient caused, within a few hours, extensive gingival recession (155).", [["gingival", "ANATOMY", 110, 118], ["herpes simplex virus\u2010type 1 infection", "DISEASE", 9, 46], ["gingival recession", "DISEASE", 110, 128], ["herpes simplex virus\u2010type 1", "ORGANISM", 9, 36], ["patient", "ORGANISM", 64, 71], ["gingival", "PATHOLOGICAL_FORMATION", 110, 118], ["herpes simplex virus\u2010type", "SPECIES", 9, 34], ["patient", "SPECIES", 64, 71], ["herpes simplex virus\u2010type 1", "SPECIES", 9, 36], ["An acute herpes simplex virus\u2010type 1 infection", "PROBLEM", 0, 46], ["extensive gingival recession", "PROBLEM", 100, 128], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["herpes simplex virus\u2010type", "OBSERVATION", 9, 34], ["extensive", "OBSERVATION_MODIFIER", 100, 109], ["gingival recession", "OBSERVATION", 110, 128]]], ["By contrast, a latent (\u2018nonproductive\u2019) herpesvirus infection is generally associated with chronic periodontitis sites exhibiting little propensity for disease progression (16).Periodontal herpesviruses ::: Herpesviruses in periodontal diseasesQuantitatively, significantly more herpesvirus genomic copies inhabit progressive and untreated periodontitis lesions than stable or treated periodontitis sites (89, 90, 179).", [["Periodontal", "ANATOMY", 177, 188], ["periodontal", "ANATOMY", 224, 235], ["periodontitis lesions", "ANATOMY", 340, 361], ["herpesvirus infection", "DISEASE", 40, 61], ["periodontitis", "DISEASE", 99, 112], ["Herpesviruses", "DISEASE", 207, 220], ["periodontal diseases", "DISEASE", 224, 244], ["periodontitis", "DISEASE", 340, 353], ["periodontitis", "DISEASE", 385, 398], ["herpesvirus", "ORGANISM", 40, 51], ["herpesvirus", "ORGANISM", 279, 290], ["periodontitis lesions", "PATHOLOGICAL_FORMATION", 340, 361], ["a latent (\u2018nonproductive\u2019) herpesvirus infection", "PROBLEM", 13, 61], ["chronic periodontitis sites", "PROBLEM", 91, 118], ["disease progression", "PROBLEM", 152, 171], ["Herpesviruses in periodontal diseases", "PROBLEM", 207, 244], ["significantly more herpesvirus genomic copies inhabit progressive and untreated periodontitis lesions", "PROBLEM", 260, 361], ["treated periodontitis sites", "PROBLEM", 377, 404], ["latent", "OBSERVATION_MODIFIER", 15, 21], ["herpesvirus", "OBSERVATION_MODIFIER", 40, 51], ["infection", "OBSERVATION", 52, 61], ["generally associated with", "UNCERTAINTY", 65, 90], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["periodontitis", "OBSERVATION", 99, 112], ["little propensity", "OBSERVATION_MODIFIER", 130, 147], ["herpesviruses", "OBSERVATION", 189, 202], ["periodontal", "ANATOMY", 224, 235], ["diseases", "OBSERVATION", 236, 244], ["significantly", "OBSERVATION_MODIFIER", 260, 273], ["more herpesvirus", "OBSERVATION_MODIFIER", 274, 290], ["inhabit", "OBSERVATION_MODIFIER", 306, 313], ["progressive", "OBSERVATION_MODIFIER", 314, 325], ["untreated", "OBSERVATION_MODIFIER", 330, 339], ["periodontitis", "OBSERVATION_MODIFIER", 340, 353], ["lesions", "OBSERVATION", 354, 361], ["stable", "OBSERVATION_MODIFIER", 367, 373], ["treated", "OBSERVATION_MODIFIER", 377, 384], ["periodontitis", "OBSERVATION", 385, 398]]], ["As many as 8.3 \u00d7 108 Epstein\u2013Barr virus DNA copies and 4.6 \u00d7 105 cytomegalovirus DNA copies have been detected in samples of individual periodontal pockets (179), and even higher viral loads may reside within the gingival tissue of periodontitis lesions (98).", [["samples", "ANATOMY", 114, 121], ["periodontal pockets", "ANATOMY", 136, 155], ["gingival tissue", "ANATOMY", 213, 228], ["periodontitis lesions", "ANATOMY", 232, 253], ["periodontitis", "DISEASE", 232, 245], ["Epstein\u2013Barr virus", "ORGANISM", 21, 39], ["DNA", "ORGANISM", 40, 43], ["cytomegalovirus", "ORGANISM", 65, 80], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["periodontal pockets", "MULTI-TISSUE_STRUCTURE", 136, 155], ["gingival tissue", "TISSUE", 213, 228], ["periodontitis lesions", "PATHOLOGICAL_FORMATION", 232, 253], ["cytomegalovirus DNA copies", "DNA", 65, 91], ["Epstein\u2013Barr virus", "SPECIES", 21, 39], ["Epstein\u2013Barr virus DNA copies", "TEST", 21, 50], ["cytomegalovirus DNA copies", "TEST", 65, 91], ["individual periodontal pockets", "PROBLEM", 125, 155], ["higher viral loads", "PROBLEM", 172, 190], ["periodontitis lesions", "PROBLEM", 232, 253], ["periodontal pockets", "ANATOMY", 136, 155], ["viral loads", "OBSERVATION", 179, 190], ["gingival tissue", "ANATOMY", 213, 228], ["periodontitis", "OBSERVATION_MODIFIER", 232, 245], ["lesions", "OBSERVATION", 246, 253]]], ["Sunde et al. (208) identified up to one million genome\u2010copies of Epstein\u2013Barr virus in periodontal sites of a 63 year\u2010old patient with refractory periodontitis.", [["periodontal sites", "ANATOMY", 87, 104], ["periodontitis", "DISEASE", 146, 159], ["Epstein\u2013Barr virus", "ORGANISM", 65, 83], ["periodontal sites", "MULTI-TISSUE_STRUCTURE", 87, 104], ["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["Epstein\u2013Barr virus", "SPECIES", 65, 83], ["Barr virus", "PROBLEM", 73, 83], ["refractory periodontitis", "PROBLEM", 135, 159], ["Epstein\u2013", "OBSERVATION", 65, 73], ["Barr virus", "OBSERVATION", 73, 83], ["refractory", "OBSERVATION_MODIFIER", 135, 145], ["periodontitis", "OBSERVATION", 146, 159]]], ["Herpesviruses other than Epstein\u2013Barr virus and cytomegalovirus (110, 118, 138, 152, 168), as well as papillomavirus and other viruses (189), can also inhabit periodontitis lesions.", [["periodontitis lesions", "ANATOMY", 159, 180], ["Epstein\u2013Barr virus and cytomegalovirus", "DISEASE", 25, 63], ["periodontitis", "DISEASE", 159, 172], ["Epstein\u2013Barr virus", "ORGANISM", 25, 43], ["cytomegalovirus", "ORGANISM", 48, 63], ["papillomavirus", "ORGANISM", 102, 116], ["periodontitis lesions", "PATHOLOGICAL_FORMATION", 159, 180], ["Epstein\u2013Barr virus", "SPECIES", 25, 43], ["Herpesviruses", "PROBLEM", 0, 13], ["Epstein\u2013Barr virus", "TEST", 25, 43], ["cytomegalovirus", "TEST", 48, 63], ["papillomavirus and other viruses", "PROBLEM", 102, 134], ["inhabit periodontitis lesions", "PROBLEM", 151, 180], ["Barr virus", "OBSERVATION", 33, 43], ["papillomavirus", "OBSERVATION", 102, 116], ["inhabit", "OBSERVATION_MODIFIER", 151, 158], ["periodontitis", "OBSERVATION", 159, 172]]], ["Indeed, the total count of viruses approaches that of bacteria in some advanced periodontitis lesions.", [["periodontitis lesions", "ANATOMY", 80, 101], ["periodontitis", "DISEASE", 80, 93], ["periodontitis lesions", "PATHOLOGICAL_FORMATION", 80, 101], ["the total count", "TEST", 8, 23], ["viruses", "PROBLEM", 27, 34], ["bacteria", "PROBLEM", 54, 62], ["some advanced periodontitis lesions", "PROBLEM", 66, 101], ["viruses", "OBSERVATION", 27, 34], ["bacteria", "OBSERVATION_MODIFIER", 54, 62], ["some", "OBSERVATION_MODIFIER", 66, 70], ["advanced", "OBSERVATION_MODIFIER", 71, 79], ["periodontitis", "OBSERVATION_MODIFIER", 80, 93], ["lesions", "OBSERVATION", 94, 101]]], ["The abundance of herpesvirus genomic copies in individual periodontitis lesions translates into a heavy viral load for the entire periodontium of patients with severe and widespread periodontal disease.", [["periodontitis lesions", "ANATOMY", 58, 79], ["periodontium", "ANATOMY", 130, 142], ["periodontal", "ANATOMY", 182, 193], ["periodontitis", "DISEASE", 58, 71], ["periodontal disease", "DISEASE", 182, 201], ["herpesvirus", "ORGANISM", 17, 28], ["periodontitis lesions", "PATHOLOGICAL_FORMATION", 58, 79], ["periodontium", "ORGAN", 130, 142], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["herpesvirus genomic copies", "PROBLEM", 17, 43], ["individual periodontitis lesions", "PROBLEM", 47, 79], ["a heavy viral load", "PROBLEM", 96, 114], ["severe and widespread periodontal disease", "PROBLEM", 160, 201], ["abundance", "OBSERVATION_MODIFIER", 4, 13], ["herpesvirus genomic copies", "OBSERVATION", 17, 43], ["individual", "OBSERVATION_MODIFIER", 47, 57], ["periodontitis", "OBSERVATION_MODIFIER", 58, 71], ["lesions", "OBSERVATION", 72, 79], ["heavy", "OBSERVATION_MODIFIER", 98, 103], ["viral load", "OBSERVATION", 104, 114], ["periodontium", "ANATOMY", 130, 142], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["widespread", "OBSERVATION_MODIFIER", 171, 181], ["periodontal disease", "OBSERVATION", 182, 201]]], ["The high number of herpesviral copies in progressive periodontitis has implications for our understanding of the etiology of the disease.Herpesviral\u2013bacterial periodontal associations ::: Herpesviruses in periodontal diseases", [["periodontal", "ANATOMY", 159, 170], ["periodontal", "ANATOMY", 205, 216], ["periodontitis", "DISEASE", 53, 66], ["Herpesviruses", "DISEASE", 188, 201], ["periodontal diseases", "DISEASE", 205, 225], ["herpesviral copies", "PROBLEM", 19, 37], ["progressive periodontitis", "PROBLEM", 41, 66], ["the disease", "PROBLEM", 125, 136], ["Herpesviruses in periodontal diseases", "PROBLEM", 188, 225], ["high", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["herpesviral copies", "OBSERVATION", 19, 37], ["progressive", "OBSERVATION_MODIFIER", 41, 52], ["periodontitis", "OBSERVATION", 53, 66], ["disease", "OBSERVATION", 129, 136], ["periodontal", "ANATOMY", 205, 216], ["diseases", "OBSERVATION", 217, 225]]]], "PMC7357516": [["Burn ward functioning, burns admissions and treatment during the State of Emergency ::: Hospital adjustment to international and national evolution of the pandemicOn March 16 a State of Emergency was instituted, which lasted for two months, which virtually meant a complete lockdown for all people not involved in vital activities.", [["burns", "DISEASE", 23, 28], ["people", "ORGANISM", 291, 297], ["people", "SPECIES", 291, 297], ["treatment", "TREATMENT", 44, 53]]], ["As per Ministry of Health instructions, we reduced to one half the number of beds available for emergency burns and trauma patients, in order to ensure proper distancing.", [["burns", "DISEASE", 106, 111], ["trauma", "DISEASE", 116, 122], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["emergency burns", "TREATMENT", 96, 111], ["trauma patients", "TREATMENT", 116, 131]]], ["All patients and accompanying persons were instructed not to leave their rooms except for dressing changes and room cleaning; they stayed inside until discharge, as was also recommended by other burn centers [3].", [["patients", "ORGANISM", 4, 12], ["persons", "ORGANISM", 30, 37], ["patients", "SPECIES", 4, 12], ["persons", "SPECIES", 30, 37], ["dressing changes", "TREATMENT", 90, 106]]], ["Following hospital regulations, every burn patient underwent RT-PCR testing for COVID-19, and they were considered potentially infected until the negative result came out.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["RT-PCR testing", "TEST", 61, 75], ["COVID", "TEST", 80, 85], ["considered potentially", "UNCERTAINTY", 104, 126], ["infected", "OBSERVATION", 127, 135]]], ["From admission until the RT-PCR result came out, they were set in a tampon area of the ward, separated from the other patients.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["the RT-PCR", "TEST", 21, 31]]], ["During the studied period (March 16-May 15 2020), we did not register any COVID-19 positive case among the hospitalized children with burns.", [["burns", "DISEASE", 134, 139], ["children", "ORGANISM", 120, 128], ["children", "SPECIES", 120, 128], ["burns", "PROBLEM", 134, 139]]], ["At the same time, we did not register any COVID-19 positive case among the staff members.Burn ward functioning, burns admissions and treatment during the State of Emergency ::: Hospital adjustment to international and national evolution of the pandemicAs expected, the consequence of the lockdown, with schools, parks and playgrounds closed and parents working from home was a dramatic dropdown in the total number of patients coming to the ER with trauma and burns.", [["burns", "DISEASE", 112, 117], ["trauma", "DISEASE", 449, 455], ["burns", "DISEASE", 460, 465], ["patients", "ORGANISM", 418, 426], ["ER", "GENE_OR_GENE_PRODUCT", 441, 443], ["patients", "SPECIES", 418, 426], ["any COVID", "TEST", 38, 47], ["treatment", "TREATMENT", 133, 142], ["trauma", "PROBLEM", 449, 455], ["burns", "PROBLEM", 460, 465], ["burns", "OBSERVATION", 460, 465]]], ["The decrease was statistically significant (p < 0.001).", [["decrease", "OBSERVATION_MODIFIER", 4, 12], ["statistically", "OBSERVATION_MODIFIER", 17, 30], ["significant", "OBSERVATION_MODIFIER", 31, 42]]], ["When analyzing the admissions, we have seen a decrease with 41% of admitted cases, as compared with the same period in 2019 (39 patients in 2020, 66 burn patients in 2019, p < 0.001).", [["burn", "DISEASE", 149, 153], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 154, 162], ["decrease", "OBSERVATION_MODIFIER", 46, 54]]], ["Although reports from other pediatric burn centers showed an increase of admitted cases [4], our findings are more in accordance with adult centers communications [5].", [["burn", "DISEASE", 38, 42], ["increase", "OBSERVATION_MODIFIER", 61, 69]]], ["The most surprising finding was that the number of moderate and severe burns (10 to 80% TBSA) was essentially the same (19 in 2020, 20 in 2019).", [["burns", "DISEASE", 71, 76], ["moderate and severe burns", "PROBLEM", 51, 76], ["TBSA", "TEST", 88, 92], ["moderate", "OBSERVATION_MODIFIER", 51, 59], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["burns", "OBSERVATION", 71, 76]]], ["Therefore, the difference between the two years was given by the decrease in admissions of minor burns, under 10% TBSA.", [["burns", "DISEASE", 97, 102], ["TBSA", "CHEMICAL", 114, 118], ["minor burns", "PROBLEM", 91, 102], ["decrease", "OBSERVATION_MODIFIER", 65, 73], ["minor", "OBSERVATION_MODIFIER", 91, 96], ["burns", "OBSERVATION", 97, 102]]], ["Considering these data, we could comment that serious accidents keep happening at home, despite the presence of adults, and that causes might be related to parents\u2019 unawareness of potential indoor dangers that may lead to thermal or electrical lesions (like fire bursting when lighting a match after alcoholic disinfectant use).Burn ward functioning, burns admissions and treatment during the State of Emergency ::: Hospital adjustment to international and national evolution of the pandemicHaving a consistent number of severe cases that need burn wound excision and skin grafting we continued performing surgeries during the whole State of Emergency.", [["electrical lesions", "ANATOMY", 233, 251], ["wound", "ANATOMY", 549, 554], ["skin", "ANATOMY", 568, 572], ["unawareness", "DISEASE", 165, 176], ["burns", "DISEASE", 351, 356], ["lesions", "PATHOLOGICAL_FORMATION", 244, 251], ["wound", "PATHOLOGICAL_FORMATION", 549, 554], ["skin", "ORGAN", 568, 572], ["thermal or electrical lesions", "PROBLEM", 222, 251], ["treatment", "TREATMENT", 372, 381], ["severe cases", "PROBLEM", 521, 533], ["burn wound excision", "TREATMENT", 544, 563], ["skin grafting", "TREATMENT", 568, 581], ["surgeries", "TREATMENT", 606, 615], ["lesions", "OBSERVATION", 244, 251], ["severe", "OBSERVATION_MODIFIER", 521, 527], ["burn", "OBSERVATION_MODIFIER", 544, 548], ["wound excision", "OBSERVATION", 549, 563], ["skin", "ANATOMY", 568, 572], ["grafting", "OBSERVATION", 573, 581]]], ["The operations were scheduled and all necessary staff called in order to achieve the procedure within the shortest time possible.", [["the procedure", "TREATMENT", 81, 94]]], ["We did not have any problem of blood shortage for burn patients\u2019 transfusions during this period, as predicted elsewhere [6], probably because in the medium run, Romania was not as badly hit by the pandemic as some Western European countries (27,296 total confirmed cases of COVID-19 infection and 1,667 deaths to the date of this letter, July 1st 2020).", [["blood", "ANATOMY", 31, 36], ["burn", "DISEASE", 50, 54], ["COVID-19", "CHEMICAL", 275, 283], ["infection", "DISEASE", 284, 293], ["deaths", "DISEASE", 304, 310], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["transfusions", "TREATMENT", 65, 77], ["COVID", "TEST", 275, 280], ["infection", "PROBLEM", 284, 293]]], ["In non-operating days, the surgeons shifted in order to ensure patient care and to reduce potential COVID-19 contamination.Burn ward functioning, burns admissions and treatment during the State of Emergency ::: Hospital adjustment to international and national evolution of the pandemicAnother important aspect of our activity is that we kept receiving patients from all over the country, despite the fact that general recommendations were not to move patients to distant places, for limiting the risk of infection spreading.", [["burns", "DISEASE", 146, 151], ["infection", "DISEASE", 505, 514], ["patient", "ORGANISM", 63, 70], ["patients", "ORGANISM", 353, 361], ["patients", "ORGANISM", 452, 460], ["patient", "SPECIES", 63, 70], ["patients", "SPECIES", 353, 361], ["patients", "SPECIES", 452, 460], ["potential COVID", "TEST", 90, 105], ["treatment", "TREATMENT", 167, 176], ["infection spreading", "PROBLEM", 505, 524], ["infection", "OBSERVATION", 505, 514]]], ["As mentioned, we are the only burn center in Romania dedicated to children, and therefore we could not deny access to care to any of those needing our specialized service (extensive burns, very young patients etc.).Burn ward functioning, burns admissions and treatment during the State of Emergency ::: Hospital adjustment to international and national evolution of the pandemicGlobally, few cases of COVID-19 were reported in children, generally mild ones [7].", [["burns", "DISEASE", 182, 187], ["burns", "DISEASE", 238, 243], ["children", "ORGANISM", 66, 74], ["patients", "ORGANISM", 200, 208], ["children", "ORGANISM", 427, 435], ["children", "SPECIES", 66, 74], ["patients", "SPECIES", 200, 208], ["children", "SPECIES", 427, 435], ["treatment", "TREATMENT", 259, 268], ["COVID", "TEST", 401, 406], ["mild", "OBSERVATION_MODIFIER", 447, 451]]], ["Considering this, and also recommendations made by other European fellows [8], we think that when dealing with burned children we should firstly focus on burn assessment and scoring, and on burn treatment strategy.", [["children", "ORGANISM", 118, 126], ["children", "SPECIES", 118, 126], ["burn assessment", "TEST", 154, 169], ["burn treatment strategy", "TREATMENT", 190, 213]]], ["The COVID-19 status of the patient should not influence on how fast we start general or surgical treatment for burns, for any delay may have devastating impact on the prognosis of the patient, especially in the severe cases.", [["burns", "DISEASE", 111, 116], ["patient", "ORGANISM", 27, 34], ["patient", "ORGANISM", 184, 191], ["patient", "SPECIES", 27, 34], ["patient", "SPECIES", 184, 191], ["The COVID", "TEST", 0, 9], ["surgical treatment", "TREATMENT", 88, 106], ["burns", "PROBLEM", 111, 116]]], ["On the other hand, the national authorities should make awareness campaigns during lockdown, with regard to potential dangers at home, both for adults and children, in order to avoid preventable accidents.Conflicts of InterestThe authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.", [["accidents", "DISEASE", 195, 204], ["NO", "CHEMICAL", 261, 263], ["NO", "CHEMICAL", 261, 263], ["children", "ORGANISM", 155, 163], ["NO", "SIMPLE_CHEMICAL", 261, 263], ["children", "SPECIES", 155, 163], ["patent", "OBSERVATION", 537, 543]]]], "PMC7378467": [["IntroductionA novel Corona Virus Disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has occurred in Wuhan, Hubei, China since December 2019 [1].", [["Corona Virus Disease", "DISEASE", 20, 40], ["COVID-19", "CHEMICAL", 42, 50], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 69, 107], ["SARS-CoV-2", "CHEMICAL", 111, 121], ["Corona Virus", "ORGANISM", 20, 32], ["COVID-19", "ORGANISM", 42, 50], ["SARS-CoV-2", "ORGANISM", 111, 121], ["Corona Virus Disease (COVID-19", "SPECIES", 20, 50], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 62, 121], ["IntroductionA novel Corona Virus Disease", "PROBLEM", 0, 40], ["COVID", "TEST", 42, 47], ["Severe Acute Respiratory Syndrome", "PROBLEM", 62, 95], ["Coronavirus 2", "PROBLEM", 96, 109], ["Corona Virus Disease", "OBSERVATION", 20, 40], ["Severe", "OBSERVATION_MODIFIER", 62, 68], ["Acute", "OBSERVATION_MODIFIER", 69, 74], ["Respiratory Syndrome", "OBSERVATION", 75, 95]]], ["SARS-CoV-2 virus is a novel beta coronavirus based on gene sequencing [2].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2 virus", "ORGANISM", 0, 16], ["beta coronavirus", "ORGANISM", 28, 44], ["CoV-2 virus", "SPECIES", 5, 16], ["SARS-CoV-2 virus", "SPECIES", 0, 16], ["beta coronavirus", "SPECIES", 28, 44], ["SARS", "PROBLEM", 0, 4], ["CoV-2 virus", "PROBLEM", 5, 16], ["a novel beta coronavirus", "TREATMENT", 20, 44]]], ["By June 23th 2020, there are 9,195,635 laboratory or clinical confirmed cases in more than 100 countries, 473,127 people have lost their lives.", [["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120]]], ["Compared with the 10% death rate of SARS-CoV [3] and 37% death rate of MERS-CoV [4], SARS-CoV-2 has a lower death rate of 2% in China [5].", [["death", "DISEASE", 22, 27], ["SARS", "DISEASE", 36, 40], ["death", "DISEASE", 57, 62], ["SARS", "DISEASE", 85, 89], ["death", "DISEASE", 108, 113], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 71, 79], ["SARS-CoV", "SPECIES", 36, 44], ["MERS-CoV", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 85, 93], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["death rate", "TEST", 57, 67], ["MERS", "TEST", 71, 75], ["SARS", "TEST", 85, 89], ["CoV", "TEST", 90, 93], ["a lower death rate", "TEST", 100, 118]]], ["More and more evidences show that COVID-19 spreads from person to person in hospital and family settings [[6], [7], [8]], the WHO had announced that COVID-19 was a global pandemic.", [["COVID-19", "CHEMICAL", 149, 157], ["person", "SPECIES", 56, 62], ["person", "SPECIES", 66, 72], ["COVID", "TEST", 34, 39], ["COVID", "TEST", 149, 154], ["a global pandemic", "PROBLEM", 162, 179]]], ["The main clinical symptoms of COVID-19 patients are fever, cough, fatigue or myalgia, sputum production, headache, diarrhea and haemoptysis were less common symptoms.", [["sputum", "ANATOMY", 86, 92], ["COVID", "DISEASE", 30, 35], ["fever", "DISEASE", 52, 57], ["cough", "DISEASE", 59, 64], ["fatigue", "DISEASE", 66, 73], ["myalgia", "DISEASE", 77, 84], ["headache", "DISEASE", 105, 113], ["diarrhea", "DISEASE", 115, 123], ["haemoptysis", "DISEASE", 128, 139], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["The main clinical symptoms", "PROBLEM", 0, 26], ["COVID", "TEST", 30, 35], ["fever", "PROBLEM", 52, 57], ["cough", "PROBLEM", 59, 64], ["fatigue", "PROBLEM", 66, 73], ["myalgia", "PROBLEM", 77, 84], ["sputum production", "PROBLEM", 86, 103], ["headache", "PROBLEM", 105, 113], ["diarrhea", "PROBLEM", 115, 123], ["haemoptysis", "PROBLEM", 128, 139], ["less common symptoms", "PROBLEM", 145, 165], ["main", "OBSERVATION_MODIFIER", 4, 8], ["haemoptysis", "OBSERVATION", 128, 139]]], ["About 50% patients developed dyspnea, among which one third were admitted to ICU [9], while the severe patients often have dyspnea after one week, which rapidly progress to acute respiratory distress syndrome (ARDS), sepsis and multiple organ dysfunction (MODS) [10].IntroductionSepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [11].", [["respiratory", "ANATOMY", 179, 190], ["organ", "ANATOMY", 237, 242], ["organ", "ANATOMY", 317, 322], ["dyspnea", "DISEASE", 29, 36], ["dyspnea", "DISEASE", 123, 130], ["acute respiratory distress syndrome", "DISEASE", 173, 208], ["ARDS", "DISEASE", 210, 214], ["sepsis", "DISEASE", 217, 223], ["multiple organ dysfunction", "DISEASE", 228, 254], ["MODS", "DISEASE", 256, 260], ["IntroductionSepsis", "DISEASE", 267, 285], ["organ dysfunction", "DISEASE", 317, 334], ["infection", "DISEASE", 377, 386], ["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 103, 111], ["organ", "ORGAN", 237, 242], ["organ", "ORGAN", 317, 322], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 103, 111], ["dyspnea", "PROBLEM", 29, 36], ["dyspnea", "PROBLEM", 123, 130], ["acute respiratory distress syndrome", "PROBLEM", 173, 208], ["ARDS)", "PROBLEM", 210, 215], ["sepsis", "PROBLEM", 217, 223], ["multiple organ dysfunction", "PROBLEM", 228, 254], ["IntroductionSepsis", "TREATMENT", 267, 285], ["threatening organ dysfunction", "PROBLEM", 305, 334], ["a dysregulated host response to infection", "PROBLEM", 345, 386], ["dyspnea", "OBSERVATION", 29, 36], ["dyspnea", "OBSERVATION", 123, 130], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["respiratory distress", "OBSERVATION", 179, 199], ["sepsis", "OBSERVATION", 217, 223], ["multiple", "OBSERVATION_MODIFIER", 228, 236], ["organ", "ANATOMY", 237, 242], ["dysfunction", "OBSERVATION", 243, 254]]], ["Sepsis can be caused by a variety of pathogens.", [["Sepsis", "DISEASE", 0, 6], ["Sepsis", "PROBLEM", 0, 6], ["pathogens", "PROBLEM", 37, 46], ["variety", "OBSERVATION_MODIFIER", 26, 33], ["pathogens", "OBSERVATION", 37, 46]]], ["Bacterial infection is the main cause of sepsis.", [["Bacterial infection", "DISEASE", 0, 19], ["sepsis", "DISEASE", 41, 47], ["Bacterial infection", "PROBLEM", 0, 19], ["sepsis", "PROBLEM", 41, 47], ["infection", "OBSERVATION", 10, 19], ["main", "OBSERVATION_MODIFIER", 27, 31], ["sepsis", "OBSERVATION", 41, 47]]], ["However, as high as 42% of sepsis patients showed culture negative, suggesting a non-bacterial cause [12].", [["sepsis", "DISEASE", 27, 33], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["sepsis", "PROBLEM", 27, 33], ["culture", "TEST", 50, 57], ["a non-bacterial cause", "PROBLEM", 79, 100], ["non-bacterial", "OBSERVATION_MODIFIER", 81, 94]]], ["Although almost any virus can lead to sepsis in susceptible patients, the clinical diagnosis of viral sepsis is very rare.", [["sepsis", "DISEASE", 38, 44], ["viral sepsis", "DISEASE", 96, 108], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["any virus", "PROBLEM", 16, 25], ["sepsis", "PROBLEM", 38, 44], ["viral sepsis", "PROBLEM", 96, 108], ["virus", "OBSERVATION", 20, 25], ["sepsis", "OBSERVATION", 38, 44], ["viral", "OBSERVATION_MODIFIER", 96, 101], ["sepsis", "OBSERVATION", 102, 108]]], ["Increased awareness, early recognition of viral sepsis, rapid administration of appropriate antiviral drugs, and urgent treatment can significantly reduce deaths of viral sepsis [13].IntroductionGiven the rapid global spread of COVID-19, coupled with the high rate of missed diagnosis of viral sepsis caused by SARS-CoV-2, it is urgent to evaluate viral sepsis and multiple organ failure score in COVID-19 patients, so as to determine the clinical characteristics of viral sepsis more accurately and reveal the risk factors related to mortality.", [["organ", "ANATOMY", 374, 379], ["viral sepsis", "DISEASE", 42, 54], ["deaths", "DISEASE", 155, 161], ["viral sepsis", "DISEASE", 165, 177], ["viral sepsis", "DISEASE", 288, 300], ["sepsis", "DISEASE", 354, 360], ["multiple organ failure", "DISEASE", 365, 387], ["sepsis", "DISEASE", 473, 479], ["SARS-CoV-2", "ORGANISM", 311, 321], ["organ", "ORGAN", 374, 379], ["patients", "ORGANISM", 406, 414], ["COVID-19", "DNA", 228, 236], ["patients", "SPECIES", 406, 414], ["SARS-CoV", "SPECIES", 311, 319], ["Increased awareness", "PROBLEM", 0, 19], ["viral sepsis", "PROBLEM", 42, 54], ["appropriate antiviral drugs", "TREATMENT", 80, 107], ["urgent treatment", "TREATMENT", 113, 129], ["viral sepsis", "PROBLEM", 165, 177], ["COVID", "TEST", 228, 233], ["viral sepsis", "PROBLEM", 288, 300], ["SARS", "PROBLEM", 311, 315], ["viral sepsis", "PROBLEM", 348, 360], ["multiple organ failure score", "PROBLEM", 365, 393], ["COVID", "TEST", 397, 402], ["viral sepsis", "PROBLEM", 467, 479], ["the risk factors", "PROBLEM", 507, 523], ["viral sepsis", "OBSERVATION", 42, 54], ["viral sepsis", "OBSERVATION", 165, 177], ["rapid", "OBSERVATION_MODIFIER", 205, 210], ["global", "OBSERVATION_MODIFIER", 211, 217], ["spread", "OBSERVATION_MODIFIER", 218, 224], ["viral", "OBSERVATION_MODIFIER", 288, 293], ["sepsis", "OBSERVATION", 294, 300], ["sepsis", "OBSERVATION", 354, 360], ["organ", "ANATOMY", 374, 379], ["failure", "OBSERVATION", 380, 387], ["viral", "OBSERVATION_MODIFIER", 467, 472], ["sepsis", "OBSERVATION", 473, 479]]], ["In our study, we collected fifteen confirmed cases of COVID-19 caused by SARS-CoV-2 infection imported to Guiyang from Wuhan, among which, three cases (20%) were severe or critically-ill patients with viral sepsis.", [["COVID", "DISEASE", 54, 59], ["SARS-CoV-2 infection", "DISEASE", 73, 93], ["critically-ill", "DISEASE", 172, 186], ["viral sepsis", "DISEASE", 201, 213], ["SARS-CoV-2", "ORGANISM", 73, 83], ["patients", "ORGANISM", 187, 195], ["CoV-2", "SPECIES", 78, 83], ["patients", "SPECIES", 187, 195], ["SARS-CoV-2", "SPECIES", 73, 83], ["our study", "TEST", 3, 12], ["COVID", "TEST", 54, 59], ["SARS", "PROBLEM", 73, 77], ["CoV-2 infection", "PROBLEM", 78, 93], ["viral sepsis", "PROBLEM", 201, 213], ["viral sepsis", "OBSERVATION", 201, 213]]], ["We provided a full description of laboratory examinations, imaging data and treatment methods of the patients, aim to attract enough attention by clinicians and provide treatment experience of viral sepsis.Methods", [["viral sepsis", "DISEASE", 193, 205], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["laboratory examinations", "TEST", 34, 57], ["imaging data", "TEST", 59, 71], ["viral sepsis", "PROBLEM", 193, 205], ["Methods", "TREATMENT", 206, 213], ["viral", "OBSERVATION_MODIFIER", 193, 198], ["sepsis", "OBSERVATION", 199, 205]]]], "540910fb1cfc428c60525bbeca0038cee66b20af": [["Eine nosokomiale Infektion (griechisch: nosokome\u00edon = Krankenhaus) ist laut Infektionsschutzgesetz defi niert als eine \u00bbInfektion mit lokalen oder systemischen Infektionszeichen als Reaktion auf das Vorhandensein von Erregern oder ihrer Toxine, die im zeitlichen Zusammenhang mit einer station\u00e4ren oder einer ambulanten medizinischen Ma\u00dfnahme steht, soweit die Infektion nicht bereits vorher bestand\u00ab.", [["Eine nosokomiale Infektion (griechisch: nosokome\u00edon = Krankenhaus) ist laut Infektionsschutzgesetz defi niert als eine \u00bbInfektion mit lokalen oder systemischen Infektionszeichen als Reaktion auf das Vorhandensein von Erregern oder ihrer Toxine, die im zeitlichen Zusammenhang mit einer station\u00e4ren oder einer ambulanten medizinischen Ma\u00dfnahme steht", "SPECIES", 0, 348], ["ist laut Infektionsschutzgesetz defi", "TREATMENT", 67, 103], ["mit lokalen", "TREATMENT", 130, 141], ["ihrer Toxine", "TREATMENT", 231, 243]]], ["Grund daf\u00fcr ist, dass bei vielen Patienten durch ihre Grunderkrankung eine Schw\u00e4chung des Immunsystems besteht und/oder invasive Ma\u00dfnahmen durchgef\u00fchrt werden, die das Eindringen von Erregern in das K\u00f6rperinnere und das Entstehen einer Infektion erleichtern.", [["Grund daf\u00fcr ist, dass bei vielen Patienten durch ihre Grunderkrankung eine Schw\u00e4chung des Immunsystems besteht und/oder invasive Ma\u00dfnahmen durchgef\u00fchrt werden, die das Eindringen von Erregern in das K\u00f6rperinnere und das Entstehen einer Infektion erleichtern", "SPECIES", 0, 257]]], ["Dabei k\u00f6nnen auch fakultativ pathogene Mikroorganismen zu einer Infektion f\u00fchren.", [["Dabei k\u00f6nnen", "TREATMENT", 0, 12]]], ["Um Infektionen durch \u00dcbertragungen von Krankheitserregern \u00fcber das Personal oder indirekt \u00fcber andere Patienten bzw. auch \u00fcber die patienteneigene Flora zu vermeiden, ist es essenziell, die m\u00f6glichen \u00dcbertragungswege von Krankheitserregern zu kennen und geeignete Ma\u00dfnahmen zu treff en, um eine \u00dcbertragung zu vermeiden.\u00dcbertragungswegeMan unterscheidet bei der \u00dcbertragung von Krankheitserregern den direkten vom indirekten \u00dcbertragungsweg:\u00dcbertragungswege\u00dcbertragung von Patienten auf Personal.", [["Man", "SPECIES", 336, 339], ["auch \u00fcber die patienteneigene Flora zu vermeiden, ist es essenziell, die m\u00f6glichen \u00dcbertragungswege von Krankheitserregern zu kennen und geeignete Ma\u00dfnahmen zu treff en, um eine \u00dcbertragung zu vermeiden", "SPECIES", 117, 319]]], ["Personal kann bei Kontakt mit infekti\u00f6sen Patienten bei Nichtbeachten der erforderlichen Schutzma\u00dfnahmen bzw. bei unerkannt infekti\u00f6sen Patienten ebenfalls erkranken.", [["kann bei Kontakt mit infekti\u00f6sen Patienten bei Nichtbeachten der erforderlichen Schutzma\u00dfnahmen bzw", "SPECIES", 9, 108]]], ["B. Infl uenza), viralen Durchfallerkrankungen (z.", [["B. Infl uenza", "ORGANISM", 0, 13], ["viralen Durchfallerkrankungen", "ORGANISM", 16, 45], ["B. Infl uenza", "SPECIES", 0, 13]]], ["Bei unzureichenden Hygienema\u00dfnahmen (H\u00e4ndehygiene) kann au\u00dferdem eine \u00dcbertragung mit multiresistenten Erregern wie z.", [["Bei unzureichenden Hygienema\u00dfnahmen (H\u00e4ndehygiene) kann au\u00dferdem eine \u00dcbertragung mit multiresistenten Erregern wie z.", "SPECIES", 0, 118], ["Bei unzureichenden Hygienema\u00dfnahmen (H\u00e4ndehygiene)", "TREATMENT", 0, 50]]], ["B. Methicillin-resistentem Staphylococcus aureus (MRSA) zwischen Patient und Personal erfolgen.\u00dcbertragungswegeNadelstichverletzungen sind eine h\u00e4ufi ge Ursache f\u00fcr parenteralen Blutkontakt.", [["B. Methicillin-resistentem Staphylococcus aureus", "ORGANISM", 0, 48], ["Staphylococcus aureus", "SPECIES", 27, 48], ["MRSA", "SPECIES", 50, 54], ["Patient", "SPECIES", 65, 72], ["Staphylococcus aureus (MRSA) zwischen Patient und Personal erfolgen", "SPECIES", 27, 94], ["Methicillin", "TEST", 3, 14], ["resistentem Staphylococcus aureus", "PROBLEM", 15, 48], ["MRSA", "PROBLEM", 50, 54], ["Staphylococcus aureus", "OBSERVATION", 27, 48]]], ["Dabei besteht grunds\u00e4tzlich das Risiko der \u00dcbertragung einer Infektion mit HBV, HCV oder HIV.", [["HCV oder HIV", "DISEASE", 80, 92], ["Dabei besteht grunds\u00e4tzlich das Risiko der \u00dcbertragung einer Infektion mit HBV", "SPECIES", 0, 78], ["HCV oder HIV", "SPECIES", 80, 92], ["HIV", "PROBLEM", 89, 92]]], ["Das \u00dcbertragungsrisiko h\u00e4ngt von mehreren Faktoren ab: Zum einen von der Viruskonzentration im Blut des Patienten, die z.", [["Das \u00dcbertragungsrisiko h\u00e4ngt von mehreren Faktoren ab: Zum einen von der Viruskonzentration im Blut des Patienten, die z.", "SPECIES", 0, 121]]], ["B. bei HBsAg-Tr\u00e4gern, die zus\u00e4tzlich HBeAg-positiv sind, sehr hoch sein kann, weshalb das HBV-Risiko bei derartigen Kontakten bis zu 30% betragen kann.", [["HBsAg", "CHEMICAL", 7, 12], ["HBeAg", "CHEMICAL", 37, 42], ["B. bei HBsAg", "ORGANISM", 0, 12], ["B. bei HBsAg-Tr\u00e4gern, die zus\u00e4tzlich HBeAg-positiv sind, sehr hoch sein kann, weshalb das HBV-Risiko bei derartigen Kontakten bis zu 30% betragen kann", "SPECIES", 0, 150], ["B. bei HBsAg", "TEST", 0, 12], ["Tr\u00e4gern", "TEST", 13, 20], ["zus\u00e4tzlich", "TEST", 26, 36], ["HBeAg", "TEST", 37, 42], ["HBV", "TEST", 90, 93], ["Risiko bei derartigen", "TREATMENT", 94, 115]]], ["Das HIV-Risiko ist bei einer Nadelstichverletzung mit 0,2-0,4% wesentlich niedriger, das HCV-Risiko wird mit 2-3% angegeben.", [["HIV-Risiko ist bei einer Nadelstichverletzung mit 0,2-0,4% wesentlich niedriger, das HCV-Risiko wird mit 2-3% angegeben", "SPECIES", 4, 123], ["mit", "TEST", 50, 53]]], ["Das geringere Infektionsrisiko bei HIV und HCV h\u00e4ngt wahrscheinlich mit der geringeren Viruskonzentration im Blut infi zierter Personen zusammen.", [["Das geringere Infektionsrisiko bei HIV und HCV h\u00e4ngt wahrscheinlich mit der geringeren Viruskonzentration im Blut infi zierter Personen zusammen", "SPECIES", 0, 144], ["HCV h\u00e4ngt wahrscheinlich mit der geringeren Viruskonzentration", "TREATMENT", 43, 105]]], ["Diese h\u00e4ngt von der Gr\u00f6\u00dfe der Kan\u00fcle und ihrer Eindringtiefe ab.", [["Diese h\u00e4ngt von der Gr\u00f6\u00dfe der Kan\u00fcle und ihrer Eindringtiefe ab", "SPECIES", 0, 63]]], ["Wichtig ist, dass nach einer Nadelstich-oder Schnittverletzung sofort die erforderlichen Ma\u00dfnahmen eingeleitet werden (v. a. gr\u00fcndliche Desinfektion der verletzten Haut) und im Krankenhaus der betriebs\u00e4rztliche Dienst informiert wird, damit dieser die weiteren erforderlichen Ma\u00dfnahmen einleiten kann.\u00dcbertragungswege\u00dcbertragung durch Kontakt.", [["dass nach einer Nadelstich-oder Schnittverletzung sofort die erforderlichen Ma\u00dfnahmen eingeleitet werden (v. a. gr\u00fcndliche Desinfektion der verletzten Haut) und im Krankenhaus der betriebs\u00e4rztliche Dienst informiert wird, damit dieser die weiteren erforderlichen Ma\u00dfnahmen einleiten kann", "SPECIES", 13, 300], ["Schnittverletzung sofort", "TREATMENT", 45, 69]]], ["B. Masern, Windpocken, Mumps und R\u00f6teln werden oft als \u00bbfl iegende Infektionen\u00ab bezeichnet, weil sie hochkontagi\u00f6s sind.", [["Mumps", "PROBLEM", 23, 28]]], ["Sie sind jedoch \u00fcberwiegend Kontaktinfektionen: Das infekti\u00f6se respiratorische Sekret (bei Windpocken zus\u00e4tzlich das Bl\u00e4schensekret) kommt dabei in direkten Kontakt z.", [["Sie sind jedoch \u00fcberwiegend Kontaktinfektionen: Das infekti\u00f6se respiratorische Sekret (bei Windpocken zus\u00e4tzlich das Bl\u00e4schensekret) kommt dabei", "SPECIES", 0, 144]]], ["B. mit Mund, Nase oder Konjunktiven oder wird indirekt \u00fcber Fl\u00e4chen oder Gegenst\u00e4nde, die mit erregerhaltigem Sekret kontaminiert sind, \u00fcbertragen.\u00dcbertragungswege\u00dcbertragung durch respiratorische Tr\u00f6pfchen.", [["\u00fcbertragen", "TREATMENT", 136, 146]]], ["Von der \u00bbechten\u00ab aerogenen \u00dcbertragung, die mit dem Luft strom auch \u00fcber mehrere Meter erfolgen kann, muss die Tr\u00f6pfchen\u00fcbertragung unterschieden werden.", [["Von der \u00bbechten\u00ab aerogenen \u00dcbertragung", "TREATMENT", 0, 38]]], ["B. Bordatella pertusssis, R\u00f6telnviren, Infl uenzaviren, Adenoviren, Rhinoviren, Mycoplasma pneumoniae, SARS-Viren, A-Streptokokken und Meningokokken.", [["Mycoplasma pneumoniae", "DISEASE", 80, 101], ["SARS", "DISEASE", 103, 107], ["B. Bordatella pertusssis", "ORGANISM", 0, 24], ["Infl uenzaviren", "ORGANISM", 39, 54], ["Mycoplasma pneumoniae", "ORGANISM", 80, 101], ["B. Bordatella pertusssis", "SPECIES", 0, 24], ["Mycoplasma pneumoniae", "SPECIES", 80, 101], ["B. Bordatella pertusssis", "SPECIES", 0, 24], ["Mycoplasma pneumoniae", "SPECIES", 80, 101], ["R\u00f6telnviren", "TREATMENT", 26, 37], ["Infl uenzaviren", "TREATMENT", 39, 54], ["Adenoviren", "TREATMENT", 56, 66], ["Rhinoviren", "TREATMENT", 68, 78], ["Mycoplasma pneumoniae", "PROBLEM", 80, 101], ["SARS", "PROBLEM", 103, 107], ["Mycoplasma pneumoniae", "OBSERVATION", 80, 101]]], ["Diese Erreger k\u00f6nnen jedoch alle auch durch Kontakt mit der Mund-/Nasenschleimhaut oder der Bindehaut \u00fcbertragen werden.\u00dcbertragungswegeAerogene \u00dcbertragung.", [["Diese Erreger k\u00f6nnen jedoch alle auch durch Kontakt mit der Mund-/Nasenschleimhaut oder der Bindehaut \u00fcbertragen werden", "SPECIES", 0, 119], ["\u00dcbertragungswegeAerogene \u00dcbertragung", "TREATMENT", 120, 156]]], ["Beim H\u00e4ndewaschen mit Seife ohne Antiseptikazusatz erreicht man eine Keimreduktion um 2 log 10 Stufen, beim Waschen mit antiseptischer Seife betr\u00e4gt er 2-3 log 10 und bei der Desinfektion mit 60-bzw.", [["Beim H\u00e4ndewaschen mit Seife ohne Antiseptikazusatz erreicht man eine Keimreduktion um 2 log 10 Stufen, beim Waschen mit antiseptischer Seife betr\u00e4gt er 2-3 log 10 und bei der Desinfektion mit 60-bzw", "SPECIES", 0, 198], ["Seife betr\u00e4gt er", "TREATMENT", 135, 151]]], ["70%igem Alkohol 3-4 log 10 Stufen.\u00dcbertragungswegeZuSpezielle Hygienema\u00dfnahmenSie sind dann notwendig, wenn Infektionen und/oder Kolonisationen diagnostiziert oder auch vermutet werden, bei denen das Risiko einer \u00dcbertragung besteht.", [["\u00dcbertragungswegeZuSpezielle Hygienema\u00dfnahmenSie sind dann notwendig, wenn Infektionen und/oder Kolonisationen diagnostiziert oder auch vermutet werden, bei denen das Risiko einer \u00dcbertragung besteht", "SPECIES", 34, 232], ["Alkohol", "TREATMENT", 8, 15], ["\u00dcbertragungswegeZuSpezielle", "TREATMENT", 34, 61]]], ["Das Personal kann sich selbst infizieren, wenn es sich mit den H\u00e4nden ins Gesicht oder in die Augen fasst.Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeEpidemien mit Parainfl uenzaviren waren in der Vergangenheit oft mit den Serotypen 1 und 2 assoziiert.", [["Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeEpidemien mit Parainfl uenzaviren waren in der Vergangenheit oft mit den Serotypen 1 und 2 assoziiert", "SPECIES", 106, 258], ["Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeEpidemien", "TREATMENT", 106, 166]]], ["Meist wechseln sich diese Serotypen bei den Ausbr\u00fcchen im Herbst und Winter jeden Jahres ab.", [["Meist wechseln sich diese Serotypen bei den Ausbr\u00fcchen im Herbst und Winter jeden Jahres ab", "SPECIES", 0, 91]]], ["Man vermutet eine \u00dcbertragung durch respiratorische Tr\u00f6pfchen oder direkten Kontakt.Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeAdenoviren, die zu den unbeh\u00fcllten DNA-Viren z\u00e4hlen, sind gegen\u00fcber Umgebungsfaktoren und Desinfektionsma\u00dfnahmen besonders stabil und tolerieren Temperaturen zwischen 4 und 36\u00b0C sowie einen weiten pH-Bereich.", [["Adenoviren", "SIMPLE_CHEMICAL", 135, 145], ["Man", "SPECIES", 0, 3], ["Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorische", "SPECIES", 84, 135], ["zu den unbeh\u00fcllten DNA-Viren z\u00e4hlen, sind gegen\u00fcber Umgebungsfaktoren und Desinfektionsma\u00dfnahmen besonders stabil und tolerieren Temperaturen zwischen 4 und 36\u00b0", "SPECIES", 151, 311], ["Ma\u00dfnahmen", "TREATMENT", 84, 93], ["Adenoviren", "TREATMENT", 135, 145]]], ["Der \u00dcbertragungsweg ist v. a. bei j\u00fcngeren Kindern f\u00e4kal-oral, kann aber auch \u00fcber Aerosol erfolgen.", [["oral", "ORGANISM_SUBDIVISION", 57, 61], ["Aerosol erfolgen", "OBSERVATION", 83, 99]]], ["Die Kontagiosit\u00e4t ist hoch: Bei 46-67% aller Kontakte im Haushalt oder Kindergarten kommt es zu einer Infektion.Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeRhinoviren sind unbeh\u00fcllte RNA-Viren, die ebenfalls schlecht durch Alkohole oder Detergenzien zu inaktivieren sind.", [["Die Kontagiosit\u00e4t ist hoch: Bei 46-67% aller Kontakte im Haushalt oder Kindergarten kommt es zu einer", "SPECIES", 0, 101], ["Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorische", "SPECIES", 112, 163], ["Ma\u00dfnahmen", "TREATMENT", 112, 121], ["Rhinoviren", "TREATMENT", 163, 173]]], ["Sie k\u00f6nnen auf glatten Oberfl \u00e4chen und auf menschlicher Haut bis zu 3 h \u00fcberleben.", [["Sie k\u00f6nnen auf glatten Oberfl \u00e4chen und auf menschlicher Haut bis zu 3 h \u00fcberleben", "SPECIES", 0, 82]]], ["Tab.", [["Tab", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Erregerspektrum nosokomialer Infektionen auf p\u00e4diatrischen Intensivstationen nach Lokalisation in Prozent (NNIS 1992 (NNIS -1997 Richards et al. 1999 Noroviren k\u00f6nnen au\u00dfer \u00fcber den f\u00e4kal-oralen Weg auch aerogen beim Erbrechen durch virushaltige Aerosole \u00fcbertragen werden.", [["Erregerspektrum nosokomialer Infektionen auf p\u00e4diatrischen Intensivstationen nach Lokalisation in Prozent (NNIS 1992 (NNIS -1997", "SPECIES", 0, 128], ["Noroviren", "TEST", 150, 159]]], ["Durch das typischerweise pl\u00f6tzlich auft retende Erbrechen kann der Erreger sich \u00fcber die Aerosolbildung oft \u00fcber mehrere Meter ausbreiten.", [["Durch das typischerweise pl\u00f6tzlich", "TREATMENT", 0, 34]]], ["Die Infektiosit\u00e4t ist sehr hoch, schon 10-100 Viruspartikel sind wie auch bei den Rotaviren ausreichend, um eine Infektion hervorzurufen.", [["hervorzurufen", "CHEMICAL", 123, 136], ["Die Infektiosit\u00e4t ist sehr hoch, schon 10-100 Viruspartikel sind wie auch bei den Rotaviren ausreichend, um eine Infektion hervorzurufen", "SPECIES", 0, 136], ["schon", "TEST", 33, 38]]], ["Die Ansteckungsf\u00e4higkeit kann schon vor dem Auft reten erster Symptome bestehen und der Erreger ist noch mindestens 2 Tage nach Sistieren der Symptome, teilweise auch noch \u00fcber mehrere Wochen (Cave: Immunsupprimierte) im Stuhl nachweisbar.Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeNach durchgemachter Infektion h\u00e4lt die Immunit\u00e4t nicht sehr lange an und ist au\u00dferdem nur gegen einen Genotyp gerichtet.", [["Ma\u00dfnahmen", "TREATMENT", 239, 248]]], ["Eine Infektion mit einem anderen Genotyp (von bisher insgesamt 20 bekannten human-pathogenen Genotypen) ist m\u00f6glich.", [["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["Eine Infektion mit einem anderen Genotyp (von bisher insgesamt 20 bekannten human-pathogenen Genotypen) ist m\u00f6glich", "SPECIES", 0, 115], ["human-pathogenen Genotypen", "TREATMENT", 76, 102]]], ["Typischerweise sind bei Ausbr\u00fcchen mit Noroviren in Kliniken nicht nur die Patienten, sondern auch Personal betroff en.", [["Typischerweise", "TREATMENT", 0, 14]]], ["Zus\u00e4tzlich k\u00f6nnen Handschuhe die Kontamination der H\u00e4nde in Grenzen halten.", [["Zus\u00e4tzlich", "TREATMENT", 0, 10]]], ["U. mit erh\u00f6hten Konzentrationen erfolgen (s.", [["U. mit erh\u00f6hten Konzentrationen erfolgen", "SPECIES", 0, 40]]], ["Herstellerangaben), da Noroviren relativ desinfektionsmittelresistent sind.Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeBei nahrungsmittelassoziierten nosokomialen Infektionen fi ndet man in der Regel ein anderes Erregerspektrum: Am h\u00e4ufi gsten sind Bakterien wie Salmonellen, Campylobacter, darmpathogene E. coli (z.", [["E. coli", "ORGANISM", 312, 319], ["man", "SPECIES", 190, 193], ["E. coli", "SPECIES", 312, 319], ["E. coli", "SPECIES", 312, 319], ["Ma\u00dfnahmen", "TREATMENT", 75, 84], ["Salmonellen", "PROBLEM", 270, 281], ["Campylobacter", "PROBLEM", 283, 296], ["darmpathogene E. coli", "PROBLEM", 298, 319], ["E. coli", "OBSERVATION", 312, 319]]], ["B. enteroh\u00e4morrhagische E. coli, EHEC) und S. aureus daf\u00fcr verantwortlich, seltener Parasiten oder auch Viren.", [["B. enteroh\u00e4morrhagische E. coli", "ORGANISM", 0, 31], ["S. aureus daf\u00fcr verantwortlich", "ORGANISM", 43, 73], ["B. enteroh\u00e4morrhagische", "SPECIES", 0, 23], ["E. coli", "SPECIES", 24, 31], ["S. aureus", "SPECIES", 43, 52], ["B. enteroh\u00e4morrhagische E. coli", "SPECIES", 0, 31], ["EHEC", "SPECIES", 33, 37], ["S. aureus daf\u00fcr verantwortlich", "SPECIES", 43, 73], ["B. enteroh\u00e4morrhagische E. coli", "PROBLEM", 0, 31], ["EHEC", "PROBLEM", 33, 37], ["aureus", "PROBLEM", 46, 52], ["coli", "OBSERVATION", 27, 31]]], ["Hier muss nach einer gemeinsamen Risikolebensmittelquelle geforscht werden.Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeDie wichtigste krankenhaushygienische Ma\u00dfnahme ist wiederum die H\u00e4ndedesinfektion.", [["Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorische", "SPECIES", 75, 126], ["Ma\u00dfnahmen", "TREATMENT", 75, 84]]], ["Die Benutzung von Handschuhen bei Kontakt mit Stuhl bzw. der Genitalregion (Windelwechsel, Fiebermessen, Hautpfl ege) ist selbstverst\u00e4ndlich.", [["Die Benutzung von Handschuhen bei Kontakt mit Stuhl bzw", "SPECIES", 0, 55]]], ["\u00dcber die Standardhygienema\u00dfnahmen hinausgehende Ma\u00dfnahmen wie Kittelpfl ege sind bei m\u00f6glicher Kontamination der Kleidung mit Stuhl erforderlich.", [["\u00dcber die Standardhygienema\u00dfnahmen hinausgehende Ma\u00dfnahmen wie Kittelpfl ege sind bei m\u00f6glicher Kontamination der Kleidung mit Stuhl erforderlich", "SPECIES", 0, 144]]], ["Bei Bedarf ben\u00f6tigen die Patienten eine eigene Toilette.", [["Bei Bedarf ben\u00f6tigen die Patienten eine eigene", "SPECIES", 0, 46]]], ["Rotaviren erkrankt sind, sollten nach M\u00f6glichkeit in einem Einzelzimmer untergebracht werden bzw. k\u00f6nnen mit gleichartig Erkrankten zusammen in einer Kohorte isoliert werden.", [["Rotaviren", "TREATMENT", 0, 9], ["sollten nach M\u00f6glichkeit", "TREATMENT", 25, 49]]], ["Auch bei bakteriellen Durchfallerkrankungen, bei der eine geringe Anzahl an Erregern eine Infektion hervorrufen kann, wie bei Shigellose, Typhus, Parathyphus u. a. sollte eine Einzelzimmerunterbringung erfolgen.Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeDa eine Durchfallerkrankung auch durch Personal \u00fcbertragen werden kann, sollten Mitarbeiter mit Durchfallkrankheiten von der direkten Patientenversorgung ausschlossen werden.HarnwegsinfektionenAuf p\u00e4diatrischen Intensivstationen treten in deutschen Kliniken, die an KISS teilnehmen, durchschnittlich 1-2 Harnwegsinfektionen/1000 Blasenkathetertage auf (.", [["Parathyphus u. a. sollte eine Einzelzimmerunterbringung erfolgen", "SPECIES", 146, 210], ["Ma\u00dfnahmen gegen \u00dcbertragungen durch respiratorischeDa eine Durchfallerkrankung auch durch Personal \u00fcbertragen werden kann, sollten Mitarbeiter mit Durchfallkrankheiten von der direkten Patientenversorgung ausschlossen werden", "SPECIES", 211, 435], ["Typhus", "PROBLEM", 138, 144], ["Ma\u00dfnahmen", "TREATMENT", 211, 220]]], ["Tab.", [["Tab", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Sie k\u00f6nnen sich als Infektionen der Eintrittsstelle von intravasalen Kathetern, Impetigo, Soor, Phlegmone oder nekrotisierende Fasziitis manifestieren.ZNS-InfektionenDas Erregerspektrum der nosokomialen Meningitis unterscheidet sich von dem der ambulant erworbenen: Der h\u00e4ufi gste Erreger bei Kindern \u00fcber 3 Monaten ist S. aureus, sehr viel seltener fi nden sich Enterokokken und gramnegative St\u00e4bchen.", [["Der h\u00e4ufi gste Erreger bei Kindern \u00fcber 3 Monaten ist S. aureus, sehr viel seltener fi nden sich Enterokokken und gramnegative St\u00e4bchen", "SPECIES", 266, 401], ["Impetigo", "PROBLEM", 80, 88], ["ZNS", "TREATMENT", 151, 154], ["aureus", "PROBLEM", 323, 329], ["aureus", "OBSERVATION", 323, 329]]], ["Bei der Staphylokokken-Meningitis ist meist ein chirurgischer Eingriff oder ein Trauma vorangegangen.ZNS-InfektionenDie \u00dcbertragung von Meningokokken und H. infl uenzae erfolgt \u00fcber respiratorische Tr\u00f6pfchen und kann auch im Krankenhaus stattfi nden.ZNS-InfektionenBei Kindern mit Meningitis durch Neisseria meningitidis (Meningokokken), Streptococcus pneumoniae (Pneumokokken) oder H. infl uenzae muss in den ersten 24 h nach Beginn einer antibiotischen Behandlung eine respiratorische Isolierung (7 Abschn.", [["Trauma vorangegangen", "DISEASE", 80, 100], ["ZNS", "CHEMICAL", 250, 253], ["Meningitis durch Neisseria meningitidis", "DISEASE", 281, 320], ["Streptococcus pneumoniae", "DISEASE", 338, 362], ["ZNS", "SIMPLE_CHEMICAL", 250, 253], ["Meningitis durch Neisseria meningitidis", "ORGANISM", 281, 320], ["Streptococcus pneumoniae", "ORGANISM", 338, 362], ["Neisseria meningitidis", "SPECIES", 298, 320], ["Streptococcus pneumoniae", "SPECIES", 338, 362], ["Bei der Staphylokokken-Meningitis ist meist ein chirurgischer Eingriff oder ein Trauma vorangegangen", "SPECIES", 0, 100], ["ZNS-InfektionenDie \u00dcbertragung von Meningokokken und H. infl uenzae erfolgt \u00fcber respiratorische Tr\u00f6pfchen und kann auch im Krankenhaus stattfi nden", "SPECIES", 101, 249], ["Neisseria meningitidis", "SPECIES", 298, 320], ["Streptococcus pneumoniae", "SPECIES", 338, 362], ["Bei der Staphylokokken", "TEST", 0, 22], ["Meningitis", "PROBLEM", 23, 33], ["ZNS", "TREATMENT", 101, 104], ["Infektionen", "TREATMENT", 105, 116], ["uenzae", "TEST", 162, 168], ["ZNS", "TREATMENT", 250, 253], ["InfektionenBei", "TREATMENT", 254, 268], ["Meningitis", "PROBLEM", 281, 291], ["Neisseria meningitidis", "PROBLEM", 298, 320], ["Streptococcus pneumoniae", "PROBLEM", 338, 362], ["Meningitis", "OBSERVATION", 23, 33], ["Streptococcus pneumoniae", "OBSERVATION", 338, 362]]], ["Bei jedem Kontakt mit potenziell infekti\u00f6sen Sekreten (z.", [["Bei jedem Kontakt mit potenziell infekti\u00f6sen Sekreten (z.", "SPECIES", 0, 57]]], ["Bei pfl egerischem Kontakt ist ein Mundschutz erforderlich.", [["Bei pfl egerischem Kontakt ist ein Mundschutz erforderlich", "SPECIES", 0, 58], ["Bei pfl egerischem Kontakt ist ein Mundschutz erforderlich", "TREATMENT", 0, 58]]], ["Diese hygienischen Ma\u00dfnahmen gelten nicht f\u00fcr Meningitiden auf Grund von Pilzen oder Mycobacterium tuberculosis.", [["Mycobacterium tuberculosis", "DISEASE", 85, 111], ["Mycobacterium tuberculosis", "SPECIES", 85, 111], ["Mycobacterium tuberculosis", "SPECIES", 85, 111], ["Mycobacterium tuberculosis", "PROBLEM", 85, 111], ["Mycobacterium tuberculosis", "OBSERVATION", 85, 111]]], ["Bei der viralen Meningitis kann der Stuhl infekti\u00f6s sein, sodass bei m\u00f6glicher Kontamination der Kleidung Schutzkittel erforderlich sind.Varicella-Zoster-VirusDas Varicella-Zoster-Virus (VZV) ist in den frischen Hautl\u00e4sionen der Windpocken in hohen Konzentrationen nachweisbar, in respiratorischem Sekret nur selten.", [["Varicella-Zoster-Virus (VZV) ist", "DISEASE", 163, 195], ["Varicella-Zoster-VirusDas Varicella-Zoster-Virus", "ORGANISM", 137, 185], ["VZV", "ORGANISM", 187, 190], ["Varicella", "SPECIES", 163, 172], ["Zoster-Virus", "SPECIES", 173, 185], ["Bei der viralen Meningitis kann der Stuhl infekti\u00f6s sein, sodass bei m\u00f6glicher Kontamination der Kleidung Schutzkittel erforderlich sind", "SPECIES", 0, 136], ["Varicella-Zoster-VirusDas Varicella-Zoster-Virus (VZV) ist in den frischen Hautl\u00e4sionen der Windpocken in hohen Konzentrationen nachweisbar", "SPECIES", 137, 276], ["Bei der viralen Meningitis", "TEST", 0, 26], ["Varicella", "TEST", 137, 146], ["Zoster", "PROBLEM", 147, 153], ["VirusDas Varicella", "PROBLEM", 154, 172], ["Zoster", "PROBLEM", 173, 179], ["Virus", "PROBLEM", 180, 185], ["Zoster", "OBSERVATION", 147, 153]]], ["Die Infektion mit Windpocken kann f\u00fcr bestimmte Patienten lebensbedrohlich sein.Varicella-Zoster-VirusMan sollte nur Personal mit ausreichenden Antik\u00f6rpertitern gegen VZV bei der Betreuung von VZV-infi zierten Patienten einsetzen.", [["Varicella-Zoster", "DISEASE", 80, 96], ["Varicella-Zoster-Virus", "ORGANISM", 80, 102], ["Man", "SPECIES", 102, 105], ["Varicella-Zoster-VirusMan sollte nur Personal mit ausreichenden Antik\u00f6rpertitern gegen VZV bei der Betreuung von VZV-infi zierten Patienten einsetzen", "SPECIES", 80, 229], ["Varicella", "PROBLEM", 80, 89], ["Zoster", "PROBLEM", 90, 96], ["Virus", "PROBLEM", 97, 102], ["Personal mit ausreichenden Antik\u00f6rpertitern", "TREATMENT", 117, 160], ["lebensbedrohlich sein", "OBSERVATION", 58, 79], ["Zoster", "OBSERVATION", 90, 96]]], ["Bei fraglicher Windpockenanamnese und gleichzeitigem Fehlen eines Impfschutzes sollten Antik\u00f6rpertiter bestimmt werden und bei Bedarf geimpft werden.", [["Bei fraglicher Windpockenanamnese und gleichzeitigem Fehlen eines Impfschutzes sollten Antik\u00f6rpertiter bestimmt werden und bei Bedarf geimpft werden", "SPECIES", 0, 148], ["Bei fraglicher Windpockenanamnese", "TREATMENT", 0, 33]]], ["Nach einer mutma\u00dflichen Exposition sollte auch geimpft es Personal getestet werden.", [["Nach einer mutma\u00dflichen", "TREATMENT", 0, 23]]], ["Stellt man 5-6 Tage nach der Exposition keine Antik\u00f6rperantwort fest, muss die betreff ende Person beurlaubt werden.", [["man", "SPECIES", 7, 10]]], ["Tag nach der ersten Exposition bis zum 21.", [["Tag", "GENE_OR_GENE_PRODUCT", 0, 3], ["Tag nach der ersten Exposition bis zum", "SPECIES", 0, 38]]], ["Tag nach der letzten Exposition nicht in der direkten Patientenversorgung t\u00e4tig sein.", [["Tag", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["In Hochrisikobereichen sollte auch niemand mit einem lokalisierten Herpes zoster arbeiten, es sei denn, die L\u00e4sionen sind eingetrocknet und inkrustiert.", [["Herpes zoster", "DISEASE", 67, 80], ["Herpes", "SPECIES", 67, 73]]], ["Bei der Arbeit in anderen Bereichen m\u00fcssen die L\u00e4sionen gut abgedeckt sein, nach Kontakt mit den L\u00e4sionen m\u00fcssen die H\u00e4nde desinfi ziert werden.Varicella-Zoster-VirusBei Patienten mit Windpocken oder disseminiertem Herpes zoster sowie bei immunsupprimierten Patienten mit lokalisiertem Zoster ist eine Isolierung n\u00f6tig, um eine \u00dcbertragung durch direkten Kontakt wie auch eine aerogene \u00dcbertragung zu verhindern.", [["Herpes zoster", "DISEASE", 215, 228], ["Herpes", "ORGANISM", 215, 221], ["Herpes", "SPECIES", 215, 221], ["Varicella-Zoster-VirusBei Patienten mit Windpocken oder disseminiertem Herpes zoster sowie bei immunsupprimierten Patienten mit lokalisiertem Zoster ist eine Isolierung n\u00f6tig, um eine \u00dcbertragung durch direkten Kontakt wie auch eine aerogene \u00dcbertragung zu verhindern", "SPECIES", 144, 411], ["Varicella", "PROBLEM", 144, 153], ["Zoster", "PROBLEM", 154, 160], ["VirusBei", "PROBLEM", 161, 169], ["Herpes zoster", "PROBLEM", 215, 228], ["mit lokalisiertem Zoster ist eine Isolierung n\u00f6tig", "TREATMENT", 268, 318], ["um eine \u00dcbertragung durch direkten", "TREATMENT", 320, 354], ["Zoster", "OBSERVATION", 154, 160]]], ["Personen ohne ausreichende Antik\u00f6rpertiter sollten das Zimmer nicht betreten.", [["Personen ohne ausreichende Antik\u00f6rpertiter sollten das Zimmer nicht betreten", "SPECIES", 0, 76]]], ["Neugeborene von M\u00fcttern mit fl oriden Windpocken m\u00fcssen von der Mutter getrennt und isoliert werden.", [["Neugeborene von M\u00fcttern mit fl oriden Windpocken m\u00fcssen von der Mutter getrennt und isoliert werden", "SPECIES", 0, 99], ["Neugeborene von M\u00fcttern mit fl oriden", "TREATMENT", 0, 37]]], ["Bei immunkompetenten Patienten mit lokalisiertem Zoster gen\u00fcgt eine Bedeckung der L\u00e4sionen.Nosokomiale Infektionen bei NeugeborenenFortschritte in der Neugeborenenintensivmedizin haben das \u00dcberleben von immer kleineren und auch kr\u00e4nkeren Kindern erm\u00f6glicht.", [["Bei immunkompetenten Patienten mit lokalisiertem Zoster gen\u00fcgt eine Bedeckung der L\u00e4sionen", "SPECIES", 0, 90], ["mit lokalisiertem Zoster", "TREATMENT", 31, 55]]], ["Invasive Ma\u00dfnahmen aller Art f\u00fchren aber zu einem erh\u00f6hten nosokomialen Infektionsrisiko.Nosokomiale Infektionen bei NeugeborenenDefi nition.", [["Ma\u00dfnahmen aller", "SPECIES", 9, 24], ["Nosokomiale Infektionen bei NeugeborenenDefi nition", "SPECIES", 89, 140]]], ["Entsprechend der Defi nition der Centers for Disease Control and Prevention (CDC) in Atlanta (USA) werden alle neonatalen Infektionen als nosokomial bezeichnet, unabh\u00e4ngig davon, ob sie intra-oder postpartal erworben wurden.", [["Disease Control", "TREATMENT", 45, 60], ["Atlanta (USA)", "TREATMENT", 85, 98]]], ["Ob der Erreger aus dem endogenen Reservoir der Mutter (intrapartale Infektion) oder aus einem exogenen Reservoir im Krankenhaus (postpartale Infektion) stammt, ist f\u00fcr die Feststellung einer nosokomialen Infektion nicht relevant.Nosokomiale Infektionen bei NeugeborenenH\u00e4ufi gkeit.", [["Nosokomiale Infektionen bei NeugeborenenH\u00e4ufi gkeit", "SPECIES", 229, 280], ["Ob der Erreger aus dem endogenen Reservoir der Mutter (intrapartale Infektion)", "TREATMENT", 0, 78], ["aus einem exogenen Reservoir", "TREATMENT", 84, 112]]], ["Die H\u00e4ufi gkeit von nosokomialen Infektionen auf Neugeborenenintensivstationen wird zwischen 5 und 25% angegeben.", [["angegeben", "CHEMICAL", 103, 112], ["Die H\u00e4ufi gkeit von nosokomialen Infektionen auf Neugeborenenintensivstationen wird zwischen 5 und 25% angegeben", "SPECIES", 0, 112], ["auf Neugeborenenintensivstationen wird zwischen", "TREATMENT", 45, 92]]], ["Bei NEO-KISS werden Infektionen ab einem 72-h-Intervall als nosokomial angesehen, es sei denn, eine Infektion vor diesem Zeitpunkt ist eindeutig nosokomial bedingt bzw.", [["Bei NEO", "TREATMENT", 0, 7], ["ab einem", "TEST", 32, 40]]], ["Pr\u00e4vention von Augeninfektionen mit Gonokokken oder Chlamydia trachomatis.", [["Chlamydia trachomatis", "DISEASE", 52, 73], ["Chlamydia trachomatis", "SPECIES", 52, 73], ["Chlamydia trachomatis", "SPECIES", 52, 73], ["Chlamydia trachomatis", "PROBLEM", 52, 73]]], ["Die Augen des Neugeborenen sollten mit einem sterilen Tupfer von Sekret gereinigt werden.", [["Die Augen des Neugeborenen sollten mit einem sterilen Tupfer von Sekret gereinigt werden", "SPECIES", 0, 88], ["Augen des Neugeborenen sollten mit einem sterilen", "TREATMENT", 4, 53]]], ["Zur topischen Prophylaxe gegen Gonokokken-Infektionen der Augen (Gonoblennorh\u00f6) kann sofort nach der Geburt 1%iges Silbernitrat (Cred\u00e9-Prophylaxe) in die Konjunktiven eingebracht werden.", [["Zur topischen Prophylaxe", "TREATMENT", 0, 24], ["Infektionen der Augen (Gonoblennorh\u00f6)", "TREATMENT", 42, 79], ["kann sofort nach der Geburt", "TREATMENT", 80, 107], ["Silbernitrat (Cred\u00e9-Prophylaxe)", "TREATMENT", 115, 146]]], ["Alternativ kann auch 1%ige Tetrazyklin-oder 0,5%ige Erythromycin-Salbe ins Auge appliziert werden.", [["Erythromycin", "CHEMICAL", 52, 64], ["Erythromycin", "CHEMICAL", 52, 64], ["Alternativ kann auch", "TREATMENT", 0, 20], ["Tetrazyklin", "TREATMENT", 27, 38], ["Erythromycin", "TREATMENT", 52, 64]]], ["Diese routinem\u00e4\u00dfige Prophylaxe wird heutzutage nicht mehr generell empfohlen, ggf. kann sie bei der Entbindung von Risikopatientinnen (keine Schwangerenvorsorge oder keine Gew\u00e4hrleistung der Nachbetreuung des Neugeborenen) oder nach Absprache mit der Mutter durchgef\u00fchrt werden.", [["kann sie bei der Entbindung von Risikopatientinnen (keine Schwangerenvorsorge oder keine Gew\u00e4hrleistung der Nachbetreuung des Neugeborenen) oder nach Absprache mit der Mutter durchgef\u00fchrt werden", "SPECIES", 83, 277], ["Diese routinem\u00e4\u00dfige Prophylaxe", "TREATMENT", 0, 30], ["kann sie bei der Entbindung von Risikopatientinnen (keine Schwangerenvorsorge oder keine Gew\u00e4hrleistung der Nachbetreuung des Neugeborenen)", "TREATMENT", 83, 222]]], ["Ist bei der Mutter eine Gonokokken-Infektion bekannt, sollte zus\u00e4tzlich zur topischen Prophylaxe eine einmalige Gabe von Ceft riaxon oder Cefotaxim erfolgen, um auch eine disseminierte Infektion zu verhindern.Nosokomiale Infektionen bei NeugeborenenEine gleichzeitge Pr\u00e4vention der Chlamydien-Konjunktivitis wird mit der Anwendung von Tetrazyklin-oder Erythromycin-Salbe nicht sicher erreicht, u. a. wegen des noch weiter bestehenden Reservoirs im Nasen-Rachen-Raum.", [["Erythromycin", "CHEMICAL", 352, 364], ["Ist bei der Mutter eine Gonokokken-Infektion bekannt, sollte zus\u00e4tzlich zur topischen Prophylaxe eine einmalige Gabe von Ceft riaxon oder Cefotaxim erfolgen, um auch eine disseminierte Infektion zu verhindern", "SPECIES", 0, 208], ["Nosokomiale Infektionen bei NeugeborenenEine gleichzeitge Pr\u00e4vention der Chlamydien-Konjunktivitis wird mit der Anwendung von Tetrazyklin-oder Erythromycin-Salbe nicht sicher erreicht, u. a. wegen des noch weiter bestehenden Reservoirs im Nasen-Rachen-Raum", "SPECIES", 209, 465], ["sollte zus\u00e4tzlich zur topischen", "TREATMENT", 54, 85], ["Prophylaxe", "TREATMENT", 86, 96], ["Cefotaxim erfolgen", "TREATMENT", 138, 156], ["Nosokomiale Infektionen bei NeugeborenenEine gleichzeitge Pr\u00e4vention der Chlamydien", "TREATMENT", 209, 292], ["Tetrazyklin", "TREATMENT", 335, 346], ["Erythromycin", "TREATMENT", 352, 364], ["Salbe nicht sicher erreicht", "TREATMENT", 365, 392]]], ["Daher ist die fr\u00fchzeitige Diagnose und Th erapie einer Chlamydien-Infektion bei der Mutter vor der Entbindung besonders wichtig.Nosokomiale Infektionen bei NeugeborenenAuf Neugeborenenintensivstationen ist die nosokomiale Konjunktivitis ein h\u00e4ufi ges Problem.", [["Daher ist die fr\u00fchzeitige Diagnose und Th erapie einer Chlamydien-Infektion bei der Mutter vor der Entbindung besonders wichtig", "SPECIES", 0, 127], ["Nosokomiale", "TREATMENT", 128, 139]]], ["Daher muss man unbedingt vermeiden, dass beim endotrachealen oder pharyngealen Absaugen Sekret in die Augen gelangt.", [["man", "SPECIES", 11, 14]]], ["B. eine respiratorische Infektion haben und den dringenden Wunsch \u00e4u\u00dfern, ihr Kind zu besuchen, bevor die Infektion ausgeheilt ist, muss man ihnen die potenzielle Infektionsgefahr f\u00fcr ihr Kind und die besondere Bedeutung der H\u00e4ndehygiene erkl\u00e4ren.", [["B. eine respiratorische Infektion haben und den dringenden Wunsch \u00e4u\u00dfern, ihr Kind zu besuchen, bevor die Infektion ausgeheilt ist, muss man ihnen die potenzielle Infektionsgefahr f\u00fcr ihr Kind und die besondere Bedeutung der H\u00e4ndehygiene erkl\u00e4ren", "SPECIES", 0, 246]]], ["Man muss allerdings die Eltern darauf hinweisen, dass sie auf der Station m\u00f6glichst wenig ber\u00fchren sollen und sich nach jedem Niesen oder Naseputzen die H\u00e4nde waschen bzw. desinfi zieren m\u00fcssen.", [["Man", "SPECIES", 0, 3], ["dass sie auf der Station m\u00f6glichst wenig ber\u00fchren sollen und sich nach jedem Niesen oder Naseputzen die H\u00e4nde waschen bzw", "SPECIES", 49, 170]]], ["Kann das Kind jedoch auf den Arm genommen werden, sollten Eltern mit Erk\u00e4ltungen eine Maske anlegen, um das Kind vor dem Kontakt mit respiratorischem Sekret zu sch\u00fctzen.", [["Kann das Kind jedoch auf den Arm genommen werden, sollten Eltern mit Erk\u00e4ltungen eine Maske anlegen, um das Kind vor dem Kontakt mit respiratorischem Sekret zu sch\u00fctzen", "SPECIES", 0, 168]]], ["B. an den H\u00e4nden, kann man zuverl\u00e4ssigen Eltern erlauben, die Intensivstation zu betreten, indem man sie beispielsweise \u00fcber den gut schlie\u00dfenden Verband Einmalhandschuhe anziehen l\u00e4sst.Ern\u00e4hrung.", [["man", "SPECIES", 23, 26]]], ["Auch in der modernenEltern mit Herpes labialis m\u00fcssen darauf hingewiesen werden, dass sie mit ihrem Kind nicht schmusen d\u00fcrfen.", [["Herpes labialis", "DISEASE", 31, 46], ["Herpes", "ORGANISM", 31, 37], ["Herpes labialis", "SPECIES", 31, 46]]], ["Au\u00dferdem sollten auch sie einen Mundschutz tragen, wenn sie das Kind auf dem Arm halten k\u00f6nnen.Ern\u00e4hrung.", [["wenn sie das Kind auf dem Arm halten k\u00f6nnen", "SPECIES", 51, 94]]], ["Dar\u00fcber hinaus ist es wichtig zu kl\u00e4ren, ob ein Kontakt mit einem an einer typischen infekti\u00f6sen Kinderkrankheit erkrankten Kind stattgefunden hat und ob deshalb mit einer Infektiosit\u00e4t des Geschwisterkindes gerechnet werden muss.", [["Dar\u00fcber hinaus ist es wichtig zu kl\u00e4ren, ob ein Kontakt mit einem an einer typischen infekti\u00f6sen Kinderkrankheit erkrankten Kind stattgefunden hat und ob deshalb mit einer Infektiosit\u00e4t des Geschwisterkindes gerechnet werden muss", "SPECIES", 0, 229], ["ob", "ANATOMY", 41, 43]]], ["Au\u00dferdem muss sichergestellt sein, dass die Eltern gut auf das Geschwisterkind aufpassen und es in ihrer N\u00e4he behalten.", [["Au\u00dferdem muss sichergestellt sein, dass die Eltern gut auf das Geschwisterkind aufpassen und es in ihrer N\u00e4he behalten", "SPECIES", 0, 118]]], ["Auch dem Geschwisterkind m\u00fcssen vor und nach dem Kontakt mit dem kranken Kind die H\u00e4nde gewaschen und desinfi ziert werden.Ern\u00e4hrung.", [["Auch dem Geschwisterkind m\u00fcssen vor und nach dem Kontakt mit dem kranken Kind die H\u00e4nde gewaschen und desinfi ziert werden", "SPECIES", 0, 122]]], ["H\u00e4ufi g wird bei Neugeborenen auf Intensivstationen routinem\u00e4\u00dfig (z.", [["H\u00e4ufi g wird bei Neugeborenen auf Intensivstationen routinem\u00e4\u00dfig", "SPECIES", 0, 64], ["H\u00e4ufi g", "TREATMENT", 0, 7]]], ["B. Ohr, Nase, Augen, Rektum, Nabel, respiratorischem Sekret (bei endotrachealer Intubation) und/oder Urin \u00fcberpr\u00fcft , um durch diese Ergebnisse bei Verdacht auf eine Infektion fr\u00fchzeitig Hinweise auf ein m\u00f6glicherweise wirksames Antibiotikum zu haben.", [["respiratorischem Sekret (bei endotrachealer Intubation) und/oder Urin \u00fcberpr\u00fcft , um durch diese Ergebnisse bei Verdacht auf eine Infektion fr\u00fchzeitig Hinweise auf ein m\u00f6glicherweise wirksames Antibiotikum zu haben", "SPECIES", 36, 250], ["bei endotrachealer Intubation", "TREATMENT", 61, 90], ["Urin \u00fcberpr\u00fcft", "TREATMENT", 101, 115], ["Hinweise auf ein m\u00f6glicherweise wirksames", "TREATMENT", 187, 228]]], ["Schutzkittel, die \u00fcber der normalen Arbeitskleidung, also auf einer Intensivstation \u00fcber der Bereichskleidung, getragen werden, sollten deshalb nur bei direktem Kontakt mit dem Kind verwendet werden.", [["sollten deshalb nur bei direktem Kontakt mit dem Kind verwendet werden", "SPECIES", 128, 198]]], ["Dies gilt auch f\u00fcr Neugeborene mit Infektionen, bei denen ein zus\u00e4tzlicher Schutzkittel nur dann einen Sinn hat, wenn es bei direktem Kontakt mit dem infi zierten Kind zu einer Kontamination der Arbeitskleidung des Personals kommen kann.", [["Dies gilt auch f\u00fcr Neugeborene mit Infektionen, bei denen ein zus\u00e4tzlicher Schutzkittel nur dann einen Sinn hat, wenn es bei direktem Kontakt mit dem infi zierten Kind zu einer Kontamination der Arbeitskleidung des Personals kommen kann", "SPECIES", 0, 236], ["Neugeborene mit Infektionen", "TREATMENT", 19, 46], ["Kontakt mit dem infi zierten", "TREATMENT", 134, 162]]], ["Beispielsweise konnte gezeigt werden, dass durch das Tragen von Schutzkitteln (und von Handschuhen) bei direktem Kontakt mit den Kindern die H\u00e4ufi gkeit nosokomialer RSV-Infektionen erheblich reduziert wurde.", [["Beispielsweise konnte gezeigt werden, dass durch das Tragen von Schutzkitteln (und von Handschuhen) bei direktem Kontakt mit den Kindern die H\u00e4ufi gkeit nosokomialer RSV-Infektionen erheblich reduziert wurde", "SPECIES", 0, 207], ["Tragen von Schutzkitteln (und von Handschuhen)", "TREATMENT", 53, 99], ["RSV", "PROBLEM", 166, 169]]], ["Das routinem\u00e4\u00dfige Anziehen eines Schutzkittels beim Betreten oder Verlassen der Intensivstation hat weder einen Einfl uss auf das hygienische Verhalten des Personals noch auf die Krankenhausinfektionsrate.Ern\u00e4hrung.", [["Das routinem\u00e4\u00dfige Anziehen eines Schutzkittels", "TREATMENT", 0, 46]]], ["Auch in der modernenBettw\u00e4sche, Kinderkleidung, Windeln.", [["der modernenBettw\u00e4sche", "OBSERVATION", 8, 30]]], ["Weder Bettw\u00e4sche noch Kinderkleidung stellt bei \u00fcblichen deinfi zierenden Waschverfahren ein Infektionsrisiko f\u00fcr p\u00e4diatrische Intensivpatienten dar, weil man i.d.R. nur Keime der Hautfl ora in sehr geringer Keimzahl nachweisen kann.", [["man", "SPECIES", 155, 158]]], ["Deshalb ist es nicht erforderlich, die W\u00e4sche zu sterilisieren.", [["Deshalb ist es nicht erforderlich", "TREATMENT", 0, 33]]], ["Felle m\u00fcssen wasch-bar sein.", [["Felle m\u00fcssen wasch-bar sein", "DNA", 0, 27], ["Felle m\u00fcssen wasch-bar sein", "SPECIES", 0, 27], ["bar", "ANATOMY_MODIFIER", 19, 22], ["sein", "ANATOMY", 23, 27]]], ["Obwohl damit kein konkretes Infektionsrisiko verbunden ist, muss man ber\u00fccksichtigen, dass off enbar bei Verwendung von Stoff windeln die Umgebungskontamination beim Windelwechseln gr\u00f6\u00dfer ist als bei Verwendung von Einmalwindeln, sodass z.", [["Obwohl damit kein konkretes Infektionsrisiko verbunden ist, muss man ber\u00fccksichtigen, dass off enbar bei Verwendung von Stoff windeln die Umgebungskontamination beim Windelwechseln gr\u00f6\u00dfer ist als bei Verwendung von Einmalwindeln, sodass z.", "SPECIES", 0, 239]]], ["B. bei Rotavirus-Infektionen oder bei Ausbr\u00fcchen mit Salmonellen Einmalwindeln verwendet werden sollten.Infektionen des oberen RespirationstraktesKinder mit geringen Symptomen einer viralen Infektion des oberen Respirationstraktes wie Rhinitis, Husten, Pharyngitis oder Otitis media k\u00f6nnen in der Gemeinschaft seinrichtung weiter betreut werden.", [["Rhinitis", "DISEASE", 235, 243], ["Otitis", "DISEASE", 270, 276], ["B. bei Rotavirus", "ORGANISM", 0, 16], ["B. bei Rotavirus-Infektionen oder bei Ausbr\u00fcchen mit Salmonellen Einmalwindeln verwendet werden sollten", "SPECIES", 0, 103], ["Infektionen des", "TREATMENT", 104, 119], ["Respirationstraktes", "TEST", 127, 146], ["Kinder mit geringen", "TREATMENT", 146, 165], ["Symptomen", "TEST", 166, 175], ["Rhinitis", "PROBLEM", 235, 243], ["Husten", "PROBLEM", 245, 251], ["Pharyngitis", "PROBLEM", 253, 264], ["Otitis", "PROBLEM", 270, 276], ["Rhinitis", "OBSERVATION", 235, 243], ["Pharyngitis", "OBSERVATION", 253, 264]]], ["Diese kann durch h\u00e4ufi ges H\u00e4ndewaschen der Kinder verringert werden.", [["Diese kann durch h\u00e4ufi ges", "TREATMENT", 0, 26]]], ["B. A-Streptokokken, s. oben), oder das Kind in seinem Befi nden derart eingeschr\u00e4nkt ist, dass es an den \u00fcblichen Aktivit\u00e4ten nicht mehr teilnehmen kann.Infektionen des oberen Respirationstraktes\u00dcbertragungen von H. infl uenzae Typ b sind zwischen ungeimpft en Kindern leicht m\u00f6glich.", [["s. oben", "ORGANISM", 20, 27], ["Infektionen", "TEST", 153, 164], ["Respirationstraktes", "TEST", 176, 195], ["\u00dcbertragungen", "TEST", 195, 208], ["infl", "TEST", 216, 220], ["uenzae", "TEST", 221, 227], ["Typ", "TEST", 228, 231]]], ["Infektionsquelle kann auch ein asymptomatischer Tr\u00e4ger sein.", [["ein asymptomatischer", "OBSERVATION", 27, 47], ["Tr\u00e4ger sein", "OBSERVATION", 48, 59]]], ["Bei Auft reten von invasiven Infektionen wie Epiglottitis, Meningitis oder Pneumonie muss der Impfstatus aller exponierten Kinder erhoben werden.", [["Meningitis", "DISEASE", 59, 69], ["Bei Auft reten von invasiven Infektionen wie Epiglottitis, Meningitis oder Pneumonie muss der Impfstatus aller exponierten Kinder erhoben werden", "SPECIES", 0, 144], ["Epiglottitis", "PROBLEM", 45, 57], ["Meningitis", "PROBLEM", 59, 69], ["Pneumonie", "PROBLEM", 75, 84], ["Epiglottitis", "OBSERVATION", 45, 57], ["Meningitis", "OBSERVATION", 59, 69]]], ["In einer Ausbruchssituation, d. h. bei Auft reten von 2 oder mehr invasiven Erkrankungen, ist eine Postexpositionsprophylaxe mit z.", [["d. h. bei Auft reten von 2 oder mehr invasiven Erkrankungen, ist eine Postexpositionsprophylaxe mit z.", "SPECIES", 29, 131], ["Erkrankungen", "TREATMENT", 76, 88]]], ["B. Rifampicin angezeigt.", [["Rifampicin", "CHEMICAL", 3, 13], ["Rifampicin", "CHEMICAL", 3, 13], ["Rifampicin angezeigt", "TREATMENT", 3, 23], ["Rifampicin", "OBSERVATION", 3, 13]]], ["Bei einem einzelnen Fall kann keine eindeutige Empfehlung gegeben werden: Man muss die Probleme, die eine Prophylaxe mit Rifampicin mit sich bringt, gegen die im Vergleich zu Haushaltskontakten etwas geringere Infektionsgefahr im Kindergarten abw\u00e4gen.", [["Rifampicin", "CHEMICAL", 121, 131], ["Man", "SPECIES", 74, 77], ["Bei einem einzelnen Fall kann keine eindeutige Empfehlung gegeben werden: Man muss die Probleme, die eine Prophylaxe mit Rifampicin mit sich bringt, gegen die im Vergleich zu Haushaltskontakten etwas geringere Infektionsgefahr im Kindergarten abw\u00e4gen", "SPECIES", 0, 250], ["Bei einem einzelnen", "TREATMENT", 0, 19]]], ["Eine Prophylaxe", [["Eine Prophylaxe", "TREATMENT", 0, 15]]]], "11177685e9e94601cb2eb976d1dcc0a3322e463b": [["Article 2 also specifically charges the WHO with stimulating and advancing work to eradicate epidemic, endemic and other diseases.", [["other diseases", "PROBLEM", 115, 129]]]], "PMC7508676": [["IntroductionSince December 2019, many cases of viral pneumonia have been found in Wuhan City, Hubei Province, China.", [["viral pneumonia", "DISEASE", 47, 62], ["viral pneumonia", "PROBLEM", 47, 62], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["pneumonia", "OBSERVATION", 53, 62]]], ["It has been determined that the viral infection is transmitted from human to human, which seriously affects public health safety [1].", [["viral infection", "DISEASE", 32, 47], ["human", "ORGANISM", 68, 73], ["human", "ORGANISM", 77, 82], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 77, 82], ["the viral infection", "PROBLEM", 28, 47], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infection", "OBSERVATION", 38, 47]]], ["The World Health Organization (WHO) has named the new coronavirus that caused the Wuhan pneumonia epidemic for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and declared a pandemic.", [["coronavirus", "DISEASE", 54, 65], ["pneumonia", "DISEASE", 88, 97], ["acute respiratory syndrome coronavirus", "DISEASE", 118, 156], ["coronavirus", "ORGANISM", 54, 65], ["SARS-CoV-2", "ORGANISM", 160, 170], ["severe acute respiratory syndrome coronavirus", "SPECIES", 111, 156], ["SARS-CoV-2", "SPECIES", 160, 170], ["the new coronavirus", "PROBLEM", 46, 65], ["the Wuhan pneumonia epidemic", "PROBLEM", 78, 106], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 111, 156], ["SARS", "TEST", 160, 164], ["CoV", "TEST", 165, 168], ["a pandemic", "PROBLEM", 185, 195], ["pneumonia", "OBSERVATION", 88, 97], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory syndrome", "OBSERVATION", 124, 144], ["pandemic", "OBSERVATION", 187, 195]]], ["The new coronavirus-infected disease was named coronavirus disease 2019 (COVID-19).IntroductionSARS-CoV-2 belongs to the genus beta coronavirus and has higher homology with severe acute respiratory syndromes-associated coronavirus (SARS-CoV) than with Middle East respiratory syndrome-associated coronavirus (MERS-CoV) [2, 3].", [["coronavirus-infected disease", "DISEASE", 8, 36], ["coronavirus disease", "DISEASE", 47, 66], ["acute respiratory syndromes-associated coronavirus", "DISEASE", 180, 230], ["SARS-CoV)", "DISEASE", 232, 241], ["Middle East respiratory syndrome-associated coronavirus", "DISEASE", 252, 307], ["coronavirus", "ORGANISM", 8, 19], ["coronavirus", "ORGANISM", 47, 58], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 83, 105], ["beta coronavirus", "ORGANISM", 127, 143], ["SARS-CoV", "ORGANISM", 232, 240], ["Middle East respiratory syndrome-associated coronavirus", "ORGANISM", 252, 307], ["MERS-CoV", "ORGANISM", 309, 317], ["coronavirus", "SPECIES", 8, 19], ["beta coronavirus", "SPECIES", 127, 143], ["beta coronavirus", "SPECIES", 127, 143], ["SARS-CoV", "SPECIES", 232, 240], ["Middle East respiratory syndrome-associated coronavirus", "SPECIES", 252, 307], ["MERS-CoV", "SPECIES", 309, 317], ["The new coronavirus-infected disease", "PROBLEM", 0, 36], ["coronavirus disease", "PROBLEM", 47, 66], ["COVID", "TEST", 73, 78], ["IntroductionSARS", "TEST", 83, 99], ["the genus beta coronavirus", "PROBLEM", 117, 143], ["severe acute respiratory syndromes", "PROBLEM", 173, 207], ["associated coronavirus (SARS-CoV)", "PROBLEM", 208, 241], ["Middle East respiratory syndrome", "PROBLEM", 252, 284], ["associated coronavirus", "PROBLEM", 285, 307], ["new", "OBSERVATION_MODIFIER", 4, 7], ["coronavirus", "OBSERVATION_MODIFIER", 8, 19], ["infected", "OBSERVATION_MODIFIER", 20, 28], ["disease", "OBSERVATION", 29, 36], ["coronavirus disease", "OBSERVATION", 47, 66], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["respiratory syndromes", "OBSERVATION", 186, 207], ["coronavirus", "OBSERVATION", 219, 230], ["Middle", "ANATOMY_MODIFIER", 252, 258], ["respiratory syndrome", "OBSERVATION", 264, 284], ["coronavirus", "OBSERVATION", 296, 307]]], ["SARS-CoV-2 is distinct from SARS-CoV, but the common outgroup with SARS-CoV is a HPU9-1 coronavirus parasitic to fruit bats [2].", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 28, 32], ["SARS", "DISEASE", 67, 71], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "ORGANISM", 28, 36], ["SARS-CoV", "ORGANISM", 67, 75], ["HPU9-1 coronavirus", "ORGANISM", 81, 99], ["HPU9-1 coronavirus", "SPECIES", 81, 99], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 28, 36], ["SARS-CoV", "SPECIES", 67, 75], ["HPU9-1 coronavirus", "SPECIES", 81, 99], ["SARS", "PROBLEM", 28, 32], ["SARS", "PROBLEM", 67, 71]]], ["It was recently found that the similarity between SARS-CoV-2 and RaTG13 isolated from Yunnan chrysanthemum bat was 96.2% [4].", [["SARS-CoV-2", "ORGANISM", 50, 60], ["RaTG13", "GENE_OR_GENE_PRODUCT", 65, 71], ["Yunnan chrysanthemum bat", "ORGANISM", 86, 110], ["RaTG13", "DNA", 65, 71], ["Yunnan chrysanthemum bat", "SPECIES", 86, 110], ["SARS-CoV", "SPECIES", 50, 58], ["Yunnan chrysanthemum bat", "SPECIES", 86, 110], ["SARS", "TEST", 50, 54], ["CoV", "TEST", 55, 58], ["RaTG13", "TEST", 65, 71], ["Yunnan chrysanthemum bat", "TEST", 86, 110]]], ["Therefore, the natural host of the virus is almost certainly bat.", [["the virus", "PROBLEM", 31, 40], ["virus", "OBSERVATION", 35, 40]]], ["However, during the transmission of SARS-CoV-2 to humans by bats, snakes [5], mink [6], and pangolins may be intermediate hosts.", [["SARS", "DISEASE", 36, 40], ["SARS-CoV-2", "ORGANISM", 36, 46], ["humans", "ORGANISM", 50, 56], ["snakes [5", "ORGANISM", 66, 75], ["mink", "ORGANISM", 78, 82], ["pangolins", "GENE_OR_GENE_PRODUCT", 92, 101], ["humans", "SPECIES", 50, 56], ["mink", "SPECIES", 78, 82], ["SARS-CoV", "SPECIES", 36, 44], ["humans", "SPECIES", 50, 56], ["mink", "SPECIES", 78, 82], ["SARS", "PROBLEM", 36, 40], ["CoV", "TEST", 41, 44], ["pangolins", "TREATMENT", 92, 101]]], ["It is worth noting that asymptomatic infection may also be a potential way of transmission.", [["infection", "DISEASE", 37, 46], ["asymptomatic infection", "PROBLEM", 24, 46], ["asymptomatic", "OBSERVATION_MODIFIER", 24, 36], ["infection", "OBSERVATION", 37, 46], ["may also be a potential", "UNCERTAINTY", 47, 70]]], ["Wuhan South China Seafood Market is currently considered to be the origin of SARS-CoV-2 [7].", [["SARS", "DISEASE", 77, 81], ["SARS-CoV", "SPECIES", 77, 85], ["CoV", "TEST", 82, 85]]], ["However, it remains unclear if the South China Seafood Market is the sole source of the virus [8].", [["the virus", "PROBLEM", 84, 93]]], ["This review summarizes the current COVID-19 transmission pathways, high-risk factors, diagnostic points, pathogenesis, and therapeutic drugs to provide a plan for the scientific control of COVID-19.Ways of TransmissionThe SARS-CoV-2 transmission routes are mainly direct transmission, aerosol transmission, and contact transmission.", [["SARS", "DISEASE", 222, 226], ["COVID-19", "CHEMICAL", 189, 197], ["the current COVID", "TEST", 23, 40], ["high-risk factors", "PROBLEM", 67, 84], ["pathogenesis", "PROBLEM", 105, 117], ["therapeutic drugs", "TREATMENT", 123, 140], ["COVID", "TEST", 189, 194], ["The SARS", "TEST", 218, 226]]], ["The size of the droplet cores containing SARS-CoV-2 is in the sub-micron to micron range.", [["SARS", "DISEASE", 41, 45], ["the droplet cores", "TEST", 12, 29], ["SARS", "PROBLEM", 41, 45], ["CoV", "TEST", 46, 49], ["size", "OBSERVATION_MODIFIER", 4, 8], ["droplet cores", "OBSERVATION", 16, 29], ["SARS", "OBSERVATION_MODIFIER", 41, 45], ["CoV", "OBSERVATION_MODIFIER", 46, 49]]], ["Sub-micron range droplets necessarily imply aerosol transmission.", [["Sub-micron range droplets", "TREATMENT", 0, 25], ["aerosol transmission", "OBSERVATION", 44, 64]]], ["Larger droplets, as one sees with droplet/contact transmission, are more in the > 10 um range (lots of debate around the exact size of \u201cdroplets\u201d that can aerosolize, but most would agree that those < 2 um would certainly fall into that category of aerosolization).", [["droplets", "ANATOMY", 7, 15], ["droplets", "OBSERVATION", 7, 15], ["aerosolization", "OBSERVATION", 249, 263]]], ["SARS-CoV-2 in the droplet core is protected by a protein envelope, which may remain active for a long time.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV-2", "DNA", 0, 10], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["active", "OBSERVATION", 84, 90]]], ["If the droplet is aerosolized and inhaled by humans, it may cause infection.", [["infection", "DISEASE", 66, 75], ["humans", "ORGANISM", 45, 51], ["humans", "SPECIES", 45, 51], ["humans", "SPECIES", 45, 51], ["infection", "PROBLEM", 66, 75], ["aerosolized", "OBSERVATION", 18, 29], ["may cause", "UNCERTAINTY", 56, 65], ["infection", "OBSERVATION", 66, 75]]], ["It is also worth noting that SARS-CoV-2 can be detected in the conjunctival sac of COVID-19 patients [9].", [["conjunctival sac", "ANATOMY", 63, 79], ["SARS", "DISEASE", 29, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 29, 39], ["conjunctival sac", "MULTI-TISSUE_STRUCTURE", 63, 79], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["SARS", "PROBLEM", 29, 33], ["COVID", "TEST", 83, 88], ["conjunctival sac", "ANATOMY", 63, 79]]], ["Meanwhile, an analysis of 9 pregnant women infected with COVID-19 found that there was no vertical transmission between mothers and infants [10].Characteristics of High-Risk Warning and DeathsA study involving 1099 patients in China found that all populations were susceptible to SARS-CoV-2, with an average age of 47.0 years (35.0\u201358.0).", [["SARS", "DISEASE", 280, 284], ["women", "ORGANISM", 37, 42], ["mothers", "ORGANISM", 120, 127], ["patients", "ORGANISM", 215, 223], ["women", "SPECIES", 37, 42], ["infants", "SPECIES", 132, 139], ["patients", "SPECIES", 215, 223], ["SARS-CoV", "SPECIES", 280, 288], ["an analysis", "TEST", 11, 22], ["COVID", "TEST", 57, 62], ["A study", "TEST", 192, 199], ["High", "OBSERVATION_MODIFIER", 164, 168]]], ["The proportion of patients \u2265 65 yrs. was 153/1011 (15.1%) [1].", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Among the 422 medical institutions providing diagnosis and treatment services for patients with COVID-19, a total of 3019 medical staff were infected with the new coronavirus (1716 confirmed cases), of whom 5 died and the crude case fatality rate was 0.3%.", [["coronavirus", "DISEASE", 163, 174], ["patients", "ORGANISM", 82, 90], ["coronavirus", "ORGANISM", 163, 174], ["patients", "SPECIES", 82, 90], ["treatment services", "TREATMENT", 59, 77], ["COVID", "TEST", 96, 101], ["fatality rate", "TEST", 233, 246]]], ["There may be infections from non-occupational exposures.", [["infections", "DISEASE", 13, 23], ["infections", "PROBLEM", 13, 23], ["may be", "UNCERTAINTY", 6, 12], ["infections", "OBSERVATION", 13, 23], ["non-occupational exposures", "OBSERVATION", 29, 55]]], ["The proportion of severe cases diagnosed by medical staff was 17.7% in Wuhan, 10.4% in Hubei, and 7.0% outside Hubei nationwide.", [["severe", "OBSERVATION_MODIFIER", 18, 24]]], ["On the whole, most cases were mild (85.4%) [11].Characteristics of High-Risk Warning and DeathsThe risk of COVID-19 death is mainly related to age, underlying chronic disease, and the time interval from the onset of initial symptoms to dyspnea [12].", [["death", "DISEASE", 116, 121], ["chronic disease", "DISEASE", 159, 174], ["dyspnea", "DISEASE", 236, 243], ["COVID-19 death", "PROBLEM", 107, 121], ["underlying chronic disease", "PROBLEM", 148, 174], ["initial symptoms", "PROBLEM", 216, 232], ["dyspnea", "PROBLEM", 236, 243], ["mild", "OBSERVATION_MODIFIER", 30, 34], ["High", "OBSERVATION_MODIFIER", 67, 71], ["chronic", "OBSERVATION_MODIFIER", 159, 166], ["disease", "OBSERVATION", 167, 174]]], ["The deaths caused by SARS-CoV-2 mainly occur in elderly patients and usually the elderly with underlying diseases [13].", [["deaths", "DISEASE", 4, 10], ["SARS", "DISEASE", 21, 25], ["SARS-CoV-2", "ORGANISM", 21, 31], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 21, 29], ["The deaths", "PROBLEM", 0, 10], ["SARS", "PROBLEM", 21, 25], ["underlying diseases", "PROBLEM", 94, 113]]], ["A study of statistical analysis of public case data found that the median time from symptom onset to death was 13.8 days and the median time from hospitalization to death was 8.3 days [14].", [["death", "DISEASE", 101, 106], ["death", "DISEASE", 165, 170], ["A study", "TEST", 0, 7], ["statistical analysis", "TEST", 11, 31], ["public case data", "TEST", 35, 51]]], ["For the risk of chronic disease, the cardiovascular mortality rate was 10.5%, diabetes was 7.3%, chronic respiratory disease was 6.3%, hypertension was 6.0%, and cancer was 5.6%.", [["cardiovascular", "ANATOMY", 37, 51], ["respiratory", "ANATOMY", 105, 116], ["cancer", "ANATOMY", 162, 168], ["chronic disease", "DISEASE", 16, 31], ["diabetes", "DISEASE", 78, 86], ["chronic respiratory disease", "DISEASE", 97, 124], ["hypertension", "DISEASE", 135, 147], ["cancer", "DISEASE", 162, 168], ["cardiovascular", "ANATOMICAL_SYSTEM", 37, 51], ["cancer", "CANCER", 162, 168], ["chronic disease", "PROBLEM", 16, 31], ["the cardiovascular mortality rate", "TEST", 33, 66], ["diabetes", "TEST", 78, 86], ["chronic respiratory disease", "PROBLEM", 97, 124], ["hypertension", "PROBLEM", 135, 147], ["cancer", "PROBLEM", 162, 168], ["chronic", "OBSERVATION_MODIFIER", 16, 23], ["disease", "OBSERVATION", 24, 31], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["respiratory disease", "OBSERVATION", 105, 124]]], ["Severe cases accounted for 13.8%, and critical cases (includes both mechanically ventilated patients and anyone admitted to ICU) accounted for 4.7%.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["Severe cases", "PROBLEM", 0, 12]]], ["The crude case fatality rate in critical cases was 49% [11].The Gold Standard for Diagnosing COVID-19: Virological Testing or Combined with Computed Tomography (CT)?WHO has launched the \u201cClinical management of severe acute respiratory infection when SARS-CoV-2 infection is suspected: Interim Guidance\u201d (referred as \u201cWHO guidelines\u201d) to strengthen outbreak control and patient management [15].", [["respiratory", "ANATOMY", 223, 234], ["respiratory infection", "DISEASE", 223, 244], ["SARS-CoV-2 infection", "DISEASE", 250, 270], ["patient", "ORGANISM", 369, 376], ["patient", "SPECIES", 369, 376], ["Diagnosing COVID", "TEST", 82, 98], ["Virological Testing", "TEST", 103, 122], ["Computed Tomography (CT)", "TEST", 140, 164], ["Clinical management", "TREATMENT", 187, 206], ["severe acute respiratory infection", "PROBLEM", 210, 244], ["SARS", "PROBLEM", 250, 254], ["CoV-2 infection", "PROBLEM", 255, 270], ["severe", "OBSERVATION_MODIFIER", 210, 216], ["acute", "OBSERVATION_MODIFIER", 217, 222], ["respiratory", "ANATOMY", 223, 234], ["infection", "OBSERVATION", 235, 244]]], ["The gold standard for WHO guidelines emphasizes the SARS-CoV-2 nucleic acid testing.", [["nucleic acid", "CHEMICAL", 63, 75], ["WHO guidelines", "TREATMENT", 22, 36], ["the SARS", "TEST", 48, 56], ["CoV", "TEST", 57, 60], ["nucleic acid testing", "TEST", 63, 83]]], ["However, there were large numbers of suspected patients with clinical symptoms, pulmonary imaging findings, and abnormal routine blood tests, for whom the virological nucleic acid test is negative.", [["pulmonary", "ANATOMY", 80, 89], ["blood", "ANATOMY", 129, 134], ["nucleic acid", "CHEMICAL", 167, 179], ["patients", "ORGANISM", 47, 55], ["pulmonary", "ORGAN", 80, 89], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["patients", "SPECIES", 47, 55], ["clinical symptoms", "PROBLEM", 61, 78], ["pulmonary imaging findings", "TEST", 80, 106], ["abnormal routine blood tests", "PROBLEM", 112, 140], ["the virological nucleic acid test", "TEST", 151, 184], ["large", "OBSERVATION_MODIFIER", 20, 25], ["numbers", "OBSERVATION_MODIFIER", 26, 33], ["pulmonary", "ANATOMY", 80, 89]]], ["Therefore, the National Health and Medical Commission of China issued the \u201cPneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 5)\u201d (referred as \u201cChinese Guideline\u201d) has re-defined the confirmed cases [16].The Gold Standard for Diagnosing COVID-19: Virological Testing or Combined with Computed Tomography (CT)?The patients in other provinces outside Hubei were still divided into \u201csuspected cases\u201d and \u201cconfirmed cases.\u201d", [["Pneumonitis", "DISEASE", 75, 86], ["Coronavirus Infection", "DISEASE", 127, 148], ["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 351, 359], ["the \u201cPneumonitis", "PROBLEM", 70, 86], ["Treatment Program", "TREATMENT", 101, 118], ["New Coronavirus Infection", "PROBLEM", 123, 148], ["Diagnosing COVID", "TEST", 264, 280], ["Virological Testing", "TEST", 285, 304], ["Computed Tomography (CT)", "TEST", 322, 346], ["Pneumonitis", "OBSERVATION", 75, 86]]], ["However, the patients who have no clear epidemiological history but fulfilled 3 of the clinical manifestations, namely, \u201cfever and/or respiratory symptoms,\u201d \u201cimaging characteristics of pneumonia,\u201d and \u201cthe total number of white blood cells was normal or decreased, or the lymphocyte count was reduced in the early onset\u201d, could be defined as confirmed cases awaiting verification.", [["respiratory", "ANATOMY", 134, 145], ["white blood cells", "ANATOMY", 222, 239], ["lymphocyte", "ANATOMY", 272, 282], ["fever", "DISEASE", 121, 126], ["respiratory symptoms", "DISEASE", 134, 154], ["pneumonia", "DISEASE", 185, 194], ["patients", "ORGANISM", 13, 21], ["blood cells", "CELL", 228, 239], ["lymphocyte", "CELL", 272, 282], ["white blood cells", "CELL_TYPE", 222, 239], ["patients", "SPECIES", 13, 21], ["the clinical manifestations", "PROBLEM", 83, 110], ["fever", "PROBLEM", 121, 126], ["respiratory symptoms", "PROBLEM", 134, 154], ["pneumonia", "PROBLEM", 185, 194], ["white blood cells", "TEST", 222, 239], ["the lymphocyte count", "TEST", 268, 288], ["pneumonia", "OBSERVATION", 185, 194], ["decreased", "OBSERVATION_MODIFIER", 254, 263]]], ["The diagnostic criteria for confirmed cases require positive nucleic acid results.The Gold Standard for Diagnosing COVID-19: Virological Testing or Combined with Computed Tomography (CT)?It is particularly noteworthy that for cases in Hubei Province, a new category of \u201cclinically diagnosed cases\u201d has been added.", [["nucleic acid", "CHEMICAL", 61, 73], ["positive nucleic acid results", "PROBLEM", 52, 81], ["Diagnosing COVID", "TEST", 104, 120], ["Virological Testing", "TEST", 125, 144], ["Computed Tomography (CT)", "TEST", 162, 186]]], ["Suspected cases with pneumonia imaging features are defined \u201cclinically diagnosed cases.\u201d", [["pneumonia", "DISEASE", 21, 30], ["pneumonia imaging features", "PROBLEM", 21, 47], ["pneumonia", "OBSERVATION", 21, 30]]], ["The \u201csuspected case\u201d standard is defined as a case that meets the two clinical manifestations of \u201cfever and/or respiratory symptoms\u201d and \u201cnormal or reduced white blood cell count in early onset, or decreased lymphocyte count\u201d whether there is epidemiological link.", [["respiratory", "ANATOMY", 111, 122], ["white blood cell", "ANATOMY", 156, 172], ["lymphocyte", "ANATOMY", 208, 218], ["fever", "DISEASE", 98, 103], ["blood cell", "CELL", 162, 172], ["lymphocyte", "CELL", 208, 218], ["\u201cfever", "PROBLEM", 97, 103], ["respiratory symptoms", "PROBLEM", 111, 131], ["reduced white blood cell count", "PROBLEM", 148, 178], ["decreased lymphocyte count", "PROBLEM", 198, 224], ["early onset", "OBSERVATION_MODIFIER", 182, 193], ["decreased", "OBSERVATION_MODIFIER", 198, 207], ["lymphocyte count", "OBSERVATION", 208, 224]]], ["The diagnostic criteria for confirmed cases have not changed.The Gold Standard for Diagnosing COVID-19: Virological Testing or Combined with Computed Tomography (CT)?As a result, the number of confirmed cases in Hubei Province dramatically rose to 14,840 on the second day after the Chinese Guideline being issued (that is, February 13, 2020).", [["The diagnostic criteria", "TEST", 0, 23], ["Diagnosing COVID", "TEST", 83, 99], ["Virological Testing", "TEST", 104, 123], ["Computed Tomography (CT)", "TEST", 141, 165]]], ["In our opinion, nucleic acid testing is no longer the gold standard for the diagnosis of COVID-19 infection.", [["nucleic acid", "CHEMICAL", 16, 28], ["COVID-19", "CHEMICAL", 89, 97], ["infection", "DISEASE", 98, 107], ["COVID-19", "CELL", 89, 97], ["COVID-19", "SPECIES", 89, 97], ["nucleic acid testing", "TEST", 16, 36], ["COVID-19 infection", "PROBLEM", 89, 107], ["infection", "OBSERVATION", 98, 107]]], ["For the huge number patients with negative nucleic acid testing results, reasonable use of CT and clinical symptoms as a diagnostic basis is more conducive to the prevention and control of COVID-19.Possible Pathogenesis for COVID-19: Cytokine StormThe \u201ccytokine storm\u201d was first proposed in 1993 in graft versus host disease (GVHD) [17].", [["graft", "ANATOMY", 299, 304], ["nucleic acid", "CHEMICAL", 43, 55], ["graft versus host disease", "DISEASE", 299, 324], ["GVHD", "DISEASE", 326, 330], ["COVID-19", "CHEMICAL", 189, 197], ["patients", "ORGANISM", 20, 28], ["Cytokine", "GENE_OR_GENE_PRODUCT", 234, 242], ["graft", "TISSUE", 299, 304], ["Cytokine", "PROTEIN", 234, 242], ["cytokine", "PROTEIN", 253, 261], ["patients", "SPECIES", 20, 28], ["nucleic acid testing", "TEST", 43, 63], ["CT", "TEST", 91, 93], ["clinical symptoms", "PROBLEM", 98, 115], ["COVID", "TEST", 189, 194], ["Pathogenesis", "PROBLEM", 207, 219], ["COVID", "TEST", 224, 229], ["graft versus host disease", "OBSERVATION", 299, 324]]], ["Pro-inflammatory factors include interleukin (IL), chemokines, colony-stimulating factors (CSFs), and tumor necrosis factor (TNF).", [["tumor necrosis", "DISEASE", 102, 116], ["interleukin", "GENE_OR_GENE_PRODUCT", 33, 44], ["IL", "GENE_OR_GENE_PRODUCT", 46, 48], ["colony-stimulating factors", "GENE_OR_GENE_PRODUCT", 63, 89], ["CSFs", "GENE_OR_GENE_PRODUCT", 91, 95], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 102, 123], ["TNF", "GENE_OR_GENE_PRODUCT", 125, 128], ["Pro-inflammatory factors", "PROTEIN", 0, 24], ["interleukin", "PROTEIN", 33, 44], ["IL", "PROTEIN", 46, 48], ["chemokines", "PROTEIN", 51, 61], ["colony-stimulating factors", "PROTEIN", 63, 89], ["CSFs", "PROTEIN", 91, 95], ["tumor necrosis factor", "PROTEIN", 102, 123], ["TNF", "PROTEIN", 125, 128], ["Pro-inflammatory factors", "PROBLEM", 0, 24], ["interleukin (IL)", "TREATMENT", 33, 49], ["chemokines", "PROBLEM", 51, 61], ["colony-stimulating factors (CSFs)", "PROBLEM", 63, 96], ["tumor necrosis factor", "PROBLEM", 102, 123], ["colony", "ANATOMY", 63, 69], ["tumor", "OBSERVATION_MODIFIER", 102, 107], ["necrosis", "OBSERVATION", 108, 116]]], ["When the immune system is activated due to infection, drugs, or autoimmune diseases, pro-inflammatory factors are activated and recruit other immune cells to secrete more cytokines, thus forming a positive feedback cycle.", [["immune system", "ANATOMY", 9, 22], ["immune cells", "ANATOMY", 142, 154], ["infection", "DISEASE", 43, 52], ["autoimmune diseases", "DISEASE", 64, 83], ["immune cells", "CELL", 142, 154], ["pro-inflammatory factors", "PROTEIN", 85, 109], ["immune cells", "CELL_TYPE", 142, 154], ["cytokines", "PROTEIN", 171, 180], ["infection", "PROBLEM", 43, 52], ["drugs", "TREATMENT", 54, 59], ["autoimmune diseases", "PROBLEM", 64, 83], ["pro-inflammatory factors", "PROBLEM", 85, 109], ["infection", "OBSERVATION", 43, 52]]], ["A large number of pro-inflammatory factors may be secreted, leading to unlimited positive feedback cycles, eventually resulting in cytokine storm [18].", [["pro-inflammatory factors", "PROTEIN", 18, 42], ["cytokine", "PROTEIN", 131, 139], ["A large number of pro-inflammatory factors", "PROBLEM", 0, 42], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["pro-inflammatory factors", "OBSERVATION", 18, 42], ["feedback cycles", "OBSERVATION", 90, 105]]], ["Once cytokine storm occurs, it can quickly cause single or multiple organ failure and eventually threaten life [18].Possible Pathogenesis for COVID-19: Cytokine StormThe prediction of cytokine storm mainly depends on the detection of elevated inflammatory factors in blood.", [["organ", "ANATOMY", 68, 73], ["blood", "ANATOMY", 267, 272], ["organ failure", "DISEASE", 68, 81], ["organ", "ORGAN", 68, 73], ["blood", "ORGANISM_SUBSTANCE", 267, 272], ["cytokine", "PROTEIN", 5, 13], ["Cytokine", "PROTEIN", 152, 160], ["cytokine", "PROTEIN", 184, 192], ["inflammatory factors", "PROTEIN", 243, 263], ["multiple organ failure", "PROBLEM", 59, 81], ["Pathogenesis", "PROBLEM", 125, 137], ["COVID", "TEST", 142, 147], ["cytokine storm", "PROBLEM", 184, 198], ["elevated inflammatory factors in blood", "PROBLEM", 234, 272], ["organ", "ANATOMY", 68, 73], ["failure", "OBSERVATION", 74, 81], ["cytokine storm", "OBSERVATION", 184, 198], ["elevated", "OBSERVATION_MODIFIER", 234, 242], ["inflammatory", "OBSERVATION", 243, 255]]], ["A retrospective study of 41 SARS-CoV-2 infected patients found that the expressions of IL-2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, TNF\u03b1, and other pro-inflammatory factors in plasma were significantly higher in ICU patients than in non-ICU patients [19].", [["plasma", "ANATOMY", 173, 179], ["SARS-CoV-2 infected", "DISEASE", 28, 47], ["SARS-CoV-2", "ORGANISM", 28, 38], ["patients", "ORGANISM", 48, 56], ["IL-2", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL7", "GENE_OR_GENE_PRODUCT", 93, 96], ["IL10", "GENE_OR_GENE_PRODUCT", 98, 102], ["GSCF", "GENE_OR_GENE_PRODUCT", 104, 108], ["IP10", "GENE_OR_GENE_PRODUCT", 110, 114], ["MCP1", "GENE_OR_GENE_PRODUCT", 116, 120], ["MIP1A", "GENE_OR_GENE_PRODUCT", 122, 127], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 129, 133], ["plasma", "ORGANISM_SUBSTANCE", 173, 179], ["patients", "ORGANISM", 213, 221], ["patients", "ORGANISM", 238, 246], ["IL", "PROTEIN", 87, 89], ["IL7", "PROTEIN", 93, 96], ["IL10", "PROTEIN", 98, 102], ["GSCF", "PROTEIN", 104, 108], ["IP10", "PROTEIN", 110, 114], ["MCP1", "PROTEIN", 116, 120], ["MIP1A", "PROTEIN", 122, 127], ["TNF\u03b1", "PROTEIN", 129, 133], ["pro-inflammatory factors", "PROTEIN", 145, 169], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 213, 221], ["patients", "SPECIES", 238, 246], ["A retrospective study", "TEST", 0, 21], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["IL", "TEST", 87, 89], ["IL7", "TEST", 93, 96], ["IL10", "TEST", 98, 102], ["GSCF", "TEST", 104, 108], ["IP10", "TEST", 110, 114], ["MCP1", "TEST", 116, 120], ["MIP1A", "TEST", 122, 127], ["TNF", "TEST", 129, 132], ["other pro-inflammatory factors", "PROBLEM", 139, 169], ["plasma", "TEST", 173, 179]]], ["An analysis of the status of cellular immunity and cytokines in 123 COVID-19 patients found that CD4 + T (52.90% vs. 95.24%) and CD8 + T (28.40% vs. 61.90%) were significantly lower in ICU patients than non-ICU patient.", [["cellular", "ANATOMY", 29, 37], ["CD4 + T", "ANATOMY", 97, 104], ["CD8 + T", "ANATOMY", 129, 136], ["cellular", "CELL", 29, 37], ["patients", "ORGANISM", 77, 85], ["CD4", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD8 + T", "GENE_OR_GENE_PRODUCT", 129, 136], ["patients", "ORGANISM", 189, 197], ["patient", "ORGANISM", 211, 218], ["cytokines", "PROTEIN", 51, 60], ["CD4", "PROTEIN", 97, 100], ["CD8", "PROTEIN", 129, 132], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 189, 197], ["patient", "SPECIES", 211, 218], ["An analysis", "TEST", 0, 11], ["cytokines", "TEST", 51, 60], ["COVID", "TEST", 68, 73], ["CD4", "TEST", 97, 100], ["T", "TEST", 103, 104], ["CD8", "TEST", 129, 132], ["T", "TEST", 135, 136]]], ["T lymphocytes are more likely to be suppressed in the severe patients [20].", [["T lymphocytes", "ANATOMY", 0, 13], ["T lymphocytes", "CELL", 0, 13], ["patients", "ORGANISM", 61, 69], ["T lymphocytes", "CELL_TYPE", 0, 13], ["patients", "SPECIES", 61, 69], ["T lymphocytes", "PROBLEM", 0, 13], ["lymphocytes", "OBSERVATION", 2, 13], ["more likely to be", "UNCERTAINTY", 18, 35], ["suppressed", "OBSERVATION_MODIFIER", 36, 46], ["severe", "OBSERVATION_MODIFIER", 54, 60]]], ["The reduction of NK cells in non-ICU patient group was 34.31% and the ICU patient group was 47.62%, indicating that the activity of NK cells was limited to some extent [20].", [["NK cells", "ANATOMY", 17, 25], ["NK cells", "ANATOMY", 132, 140], ["NK cells", "CELL", 17, 25], ["patient", "ORGANISM", 37, 44], ["patient", "ORGANISM", 74, 81], ["NK cells", "CELL", 132, 140], ["NK cells", "CELL_TYPE", 17, 25], ["NK cells", "CELL_TYPE", 132, 140], ["patient", "SPECIES", 37, 44], ["patient", "SPECIES", 74, 81], ["The reduction of NK cells", "TREATMENT", 0, 25], ["the activity of NK cells", "PROBLEM", 116, 140], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["NK cells", "OBSERVATION", 17, 25]]], ["The IL4, IL10, IL17, and TNF of 21 patients in ICU patient group were all in the normal range.", [["IL4", "GENE_OR_GENE_PRODUCT", 4, 7], ["IL10", "GENE_OR_GENE_PRODUCT", 9, 13], ["IL17", "GENE_OR_GENE_PRODUCT", 15, 19], ["TNF", "GENE_OR_GENE_PRODUCT", 25, 28], ["patients", "ORGANISM", 35, 43], ["patient", "ORGANISM", 51, 58], ["IL4", "PROTEIN", 4, 7], ["IL10", "PROTEIN", 9, 13], ["IL17", "PROTEIN", 15, 19], ["TNF", "PROTEIN", 25, 28], ["patients", "SPECIES", 35, 43], ["patient", "SPECIES", 51, 58], ["The IL4", "TEST", 0, 7], ["IL10", "TEST", 9, 13], ["IL17", "TEST", 15, 19], ["TNF", "TEST", 25, 28], ["IL4", "ANATOMY", 4, 7], ["normal range", "OBSERVATION", 81, 93]]], ["There was no significant difference between ICU and non-ICU patient groups for TNF and IFN levels.", [["patient", "ORGANISM", 60, 67], ["TNF", "GENE_OR_GENE_PRODUCT", 79, 82], ["IFN", "GENE_OR_GENE_PRODUCT", 87, 90], ["TNF", "PROTEIN", 79, 82], ["IFN", "PROTEIN", 87, 90], ["patient", "SPECIES", 60, 67], ["TNF and IFN levels", "TEST", 79, 97], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35]]], ["The proportion of IL6 in ICU patient group was significantly higher than that in non-ICU patient group (76.19% vs. 30.39%) [20].", [["IL6", "GENE_OR_GENE_PRODUCT", 18, 21], ["patient", "ORGANISM", 29, 36], ["patient", "ORGANISM", 89, 96], ["IL6", "PROTEIN", 18, 21], ["patient", "SPECIES", 29, 36], ["patient", "SPECIES", 89, 96], ["IL6", "OBSERVATION_MODIFIER", 18, 21]]], ["These data on inflammatory indicators suggest a cytokine storm in ICU patients, resulting in a worse overall prognosis.Possible Pathogenesis for COVID-19: Cytokine StormFor the specific process of cytokine storm (Fig. 1), SARS-CoV-2 infects lung epithelial cells by binding with ACE2 receptors [21].", [["lung epithelial cells", "ANATOMY", 241, 262], ["patients", "ORGANISM", 70, 78], ["SARS-CoV-2", "ORGANISM", 222, 232], ["lung epithelial cells", "CELL", 241, 262], ["ACE2", "GENE_OR_GENE_PRODUCT", 279, 283], ["cytokine", "PROTEIN", 48, 56], ["Cytokine", "PROTEIN", 155, 163], ["cytokine", "PROTEIN", 197, 205], ["lung epithelial cells", "CELL_TYPE", 241, 262], ["ACE2 receptors", "PROTEIN", 279, 293], ["patients", "SPECIES", 70, 78], ["SARS-CoV-2", "SPECIES", 222, 232], ["Pathogenesis", "PROBLEM", 128, 140], ["COVID", "TEST", 145, 150], ["Cytokine StormFor", "TREATMENT", 155, 172], ["cytokine storm", "TEST", 197, 211], ["SARS", "PROBLEM", 222, 226], ["CoV", "TEST", 227, 230], ["lung epithelial cells", "PROBLEM", 241, 262], ["ACE2 receptors", "TEST", 279, 293], ["cytokine storm", "OBSERVATION", 48, 62], ["cytokine storm", "OBSERVATION", 197, 211], ["lung", "ANATOMY", 241, 245], ["epithelial cells", "OBSERVATION", 246, 262]]], ["Cell death, apoptosis, and pyroptosis occur due to infection-induced production of pro-inflammatory cytokines (IL1\u03b2, IL6, IL8) and chemokines (IP10, MCP1) [19, 22].", [["Cell", "ANATOMY", 0, 4], ["death", "DISEASE", 5, 10], ["pyroptosis", "DISEASE", 27, 37], ["infection", "DISEASE", 51, 60], ["Cell", "CELL", 0, 4], ["IL1\u03b2", "GENE_OR_GENE_PRODUCT", 111, 115], ["IL6", "GENE_OR_GENE_PRODUCT", 117, 120], ["IL8", "GENE_OR_GENE_PRODUCT", 122, 125], ["IP10", "GENE_OR_GENE_PRODUCT", 143, 147], ["MCP1", "GENE_OR_GENE_PRODUCT", 149, 153], ["pro-inflammatory cytokines", "PROTEIN", 83, 109], ["IL1\u03b2", "PROTEIN", 111, 115], ["IL6", "PROTEIN", 117, 120], ["IL8", "PROTEIN", 122, 125], ["chemokines", "PROTEIN", 131, 141], ["IP10", "PROTEIN", 143, 147], ["MCP1", "PROTEIN", 149, 153], ["Cell death", "PROBLEM", 0, 10], ["apoptosis", "PROBLEM", 12, 21], ["pyroptosis", "PROBLEM", 27, 37], ["infection", "PROBLEM", 51, 60], ["pro-inflammatory cytokines", "PROBLEM", 83, 109], ["IL1\u03b2, IL6, IL8)", "TREATMENT", 111, 126], ["chemokines", "TEST", 131, 141], ["apoptosis", "OBSERVATION_MODIFIER", 12, 21], ["pyroptosis", "OBSERVATION", 27, 37], ["infection", "OBSERVATION", 51, 60], ["pro-inflammatory cytokines", "OBSERVATION", 83, 109]]], ["These factors mediate the early recruitment of monocytes/macrophages in lung and promote the production of a unique set of chemokines by activated macrophages, such as MIG, IP-10, and MCP-1 [19].", [["monocytes", "ANATOMY", 47, 56], ["macrophages", "ANATOMY", 57, 68], ["lung", "ANATOMY", 72, 76], ["macrophages", "ANATOMY", 147, 158], ["monocytes", "CELL", 47, 56], ["macrophages", "CELL", 57, 68], ["lung", "ORGAN", 72, 76], ["macrophages", "CELL", 147, 158], ["MIG", "GENE_OR_GENE_PRODUCT", 168, 171], ["IP-10", "GENE_OR_GENE_PRODUCT", 173, 178], ["MCP-1", "GENE_OR_GENE_PRODUCT", 184, 189], ["monocytes", "CELL_TYPE", 47, 56], ["macrophages", "CELL_TYPE", 57, 68], ["chemokines", "PROTEIN", 123, 133], ["activated macrophages", "CELL_TYPE", 137, 158], ["MIG", "PROTEIN", 168, 171], ["MCP", "PROTEIN", 184, 187], ["These factors", "PROBLEM", 0, 13], ["monocytes/macrophages in lung", "PROBLEM", 47, 76], ["IP", "TEST", 173, 175], ["MCP", "TEST", 184, 187], ["early", "OBSERVATION_MODIFIER", 26, 31], ["recruitment", "OBSERVATION_MODIFIER", 32, 43], ["monocytes", "OBSERVATION", 47, 56], ["macrophages", "OBSERVATION", 57, 68], ["lung", "ANATOMY", 72, 76]]], ["These chemokines further recruit neutrophils, monocytes, and T cells into lung tissue [23].", [["neutrophils", "ANATOMY", 33, 44], ["monocytes", "ANATOMY", 46, 55], ["T cells", "ANATOMY", 61, 68], ["lung tissue", "ANATOMY", 74, 85], ["neutrophils", "CELL", 33, 44], ["monocytes", "CELL", 46, 55], ["T cells", "CELL", 61, 68], ["lung tissue", "TISSUE", 74, 85], ["chemokines", "PROTEIN", 6, 16], ["neutrophils", "CELL_TYPE", 33, 44], ["monocytes", "CELL_TYPE", 46, 55], ["T cells", "CELL_TYPE", 61, 68], ["These chemokines", "TEST", 0, 16], ["neutrophils", "TEST", 33, 44], ["monocytes", "TEST", 46, 55], ["T cells into lung tissue", "PROBLEM", 61, 85], ["lung", "ANATOMY", 74, 78]]], ["Activated T cells then migrate into the lung tissue and specifically destroy virus-infected lung cells by releasing perforin [19, 23].", [["T cells", "ANATOMY", 10, 17], ["lung tissue", "ANATOMY", 40, 51], ["lung cells", "ANATOMY", 92, 102], ["T cells", "CELL", 10, 17], ["lung tissue", "TISSUE", 40, 51], ["lung cells", "CELL", 92, 102], ["perforin", "GENE_OR_GENE_PRODUCT", 116, 124], ["Activated T cells", "CELL_TYPE", 0, 17], ["virus-infected lung cells", "CELL_TYPE", 77, 102], ["perforin", "PROTEIN", 116, 124], ["Activated T cells", "TREATMENT", 0, 17], ["destroy virus", "PROBLEM", 69, 82], ["infected lung cells", "PROBLEM", 83, 102], ["lung tissue", "ANATOMY", 40, 51], ["infected", "OBSERVATION_MODIFIER", 83, 91], ["lung", "ANATOMY", 92, 96]]], ["It could lead to extensive tissue damage to the lung parenchyma and ARDS [24].", [["tissue", "ANATOMY", 27, 33], ["lung parenchyma", "ANATOMY", 48, 63], ["damage to the lung parenchyma", "DISEASE", 34, 63], ["ARDS", "DISEASE", 68, 72], ["tissue", "TISSUE", 27, 33], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 48, 63], ["extensive tissue damage to the lung parenchyma", "PROBLEM", 17, 63], ["ARDS", "PROBLEM", 68, 72], ["could lead to", "UNCERTAINTY", 3, 16], ["extensive", "OBSERVATION_MODIFIER", 17, 26], ["tissue", "OBSERVATION_MODIFIER", 27, 33], ["damage", "OBSERVATION", 34, 40], ["lung", "ANATOMY", 48, 52], ["parenchyma", "ANATOMY_MODIFIER", 53, 63], ["ARDS", "OBSERVATION", 68, 72]]], ["On the other hand, SARS-CoV-2 rapidly activates pathogenic T cells to produce cytokines such as granulocyte-macrophage colony-stimulating factors (GM-CSF) and IL6.", [["T cells", "ANATOMY", 59, 66], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 19, 29], ["T cells", "CELL", 59, 66], ["granulocyte-macrophage colony-stimulating factors", "GENE_OR_GENE_PRODUCT", 96, 145], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 147, 153], ["IL6", "GENE_OR_GENE_PRODUCT", 159, 162], ["pathogenic T cells", "CELL_TYPE", 48, 66], ["cytokines", "PROTEIN", 78, 87], ["granulocyte-macrophage colony-stimulating factors", "PROTEIN", 96, 145], ["GM", "PROTEIN", 147, 149], ["CSF", "PROTEIN", 150, 153], ["IL6", "PROTEIN", 159, 162], ["SARS-CoV", "TEST", 19, 27], ["pathogenic T cells", "PROBLEM", 48, 66], ["cytokines", "TEST", 78, 87], ["granulocyte", "TEST", 96, 107], ["macrophage colony", "TEST", 108, 125], ["stimulating factors", "PROBLEM", 126, 145], ["IL6", "PROBLEM", 159, 162]]], ["GM-CSF will further activate CD14 + CD16+ inflammatory monocytes and produce a larger amount of IL6 and other inflammatory factors [25].", [["CD14 + CD16+ inflammatory monocytes", "ANATOMY", 29, 64], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["CD14", "GENE_OR_GENE_PRODUCT", 29, 33], ["CD16", "GENE_OR_GENE_PRODUCT", 36, 40], ["IL6", "GENE_OR_GENE_PRODUCT", 96, 99], ["CSF", "PROTEIN", 3, 6], ["CD14", "PROTEIN", 29, 33], ["CD16", "PROTEIN", 36, 40], ["inflammatory monocytes", "CELL_TYPE", 42, 64], ["IL6", "PROTEIN", 96, 99], ["inflammatory factors", "PROTEIN", 110, 130], ["GM-CSF", "TEST", 0, 6], ["CD14", "TEST", 29, 33], ["CD16", "TEST", 36, 40], ["inflammatory monocytes", "PROBLEM", 42, 64], ["a larger amount of IL6", "PROBLEM", 77, 99], ["other inflammatory factors", "PROBLEM", 104, 130], ["inflammatory monocytes", "OBSERVATION", 42, 64], ["larger", "OBSERVATION_MODIFIER", 79, 85], ["amount", "OBSERVATION_MODIFIER", 86, 92], ["inflammatory", "OBSERVATION_MODIFIER", 110, 122]]], ["Thereby, it forms a cytokine storm, leading to severe immune damage to the lungs and other organs.", [["lungs", "ANATOMY", 75, 80], ["organs", "ANATOMY", 91, 97], ["lungs", "ORGAN", 75, 80], ["organs", "ORGAN", 91, 97], ["cytokine", "PROTEIN", 20, 28], ["a cytokine storm", "PROBLEM", 18, 34], ["severe immune damage to the lungs and other organs", "PROBLEM", 47, 97], ["cytokine storm", "OBSERVATION", 20, 34], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["immune damage", "OBSERVATION", 54, 67], ["lungs", "ANATOMY", 75, 80], ["organs", "ANATOMY", 91, 97]]], ["In summary, the levels of CD4 + T and CD8 + T are generally low; the level of IL-6 is high in the severe patients.", [["CD4 + T", "ANATOMY", 26, 33], ["CD8 + T", "ANATOMY", 38, 45], ["CD4", "GENE_OR_GENE_PRODUCT", 26, 29], ["CD8 + T", "GENE_OR_GENE_PRODUCT", 38, 45], ["IL-6", "GENE_OR_GENE_PRODUCT", 78, 82], ["patients", "ORGANISM", 105, 113], ["CD4", "PROTEIN", 26, 29], ["CD8", "PROTEIN", 38, 41], ["IL-6", "PROTEIN", 78, 82], ["patients", "SPECIES", 105, 113], ["the levels", "TEST", 12, 22], ["CD4", "TEST", 26, 29], ["T", "TEST", 32, 33], ["CD8", "TEST", 38, 41], ["IL", "TEST", 78, 80], ["low", "OBSERVATION_MODIFIER", 60, 63], ["high", "OBSERVATION_MODIFIER", 86, 90], ["severe", "OBSERVATION_MODIFIER", 98, 104]]], ["However, the \u201cwarning value\u201d of CD4+ T, CD8 + T, and IL-6 still needs a large number of samples to confirm.Possible Pathogenesis for COVID-19: Cytokine StormThe main methods to treat cytokine storm are to eliminate the pathogens and suppress inflammatory responses.", [["CD4+ T", "ANATOMY", 32, 38], ["CD8 + T", "ANATOMY", 40, 47], ["samples", "ANATOMY", 88, 95], ["CD4", "GENE_OR_GENE_PRODUCT", 32, 35], ["CD8", "GENE_OR_GENE_PRODUCT", 40, 43], ["IL-6", "GENE_OR_GENE_PRODUCT", 53, 57], ["samples", "CANCER", 88, 95], ["CD4", "PROTEIN", 32, 35], ["CD8", "PROTEIN", 40, 43], ["IL", "PROTEIN", 53, 55], ["Cytokine", "PROTEIN", 143, 151], ["cytokine", "PROTEIN", 183, 191], ["CD4", "TEST", 32, 35], ["T", "TEST", 37, 38], ["CD8", "TEST", 40, 43], ["T", "TEST", 46, 47], ["IL", "TEST", 53, 55], ["Pathogenesis", "PROBLEM", 116, 128], ["COVID", "TEST", 133, 138], ["cytokine storm", "TREATMENT", 183, 197], ["the pathogens", "PROBLEM", 215, 228], ["main", "OBSERVATION_MODIFIER", 161, 165], ["inflammatory", "OBSERVATION_MODIFIER", 242, 254]]], ["Specific drugs against SARS-CoV-2 are still in clinical trials, which will take several months to produce results [26].", [["SARS", "DISEASE", 23, 27], ["SARS-CoV-2", "ORGANISM", 23, 33], ["SARS-CoV", "SPECIES", 23, 31], ["Specific drugs", "TREATMENT", 0, 14], ["SARS", "PROBLEM", 23, 27]]], ["Although the application of glucocorticoids can inhibit normal human immunity and delay the removal of coronavirus, for the severe patients caused by cytokine storm, the most commonly used and effective drug to directly reduce cytokine storm is still glucocorticoids [27, 28].", [["glucocorticoids", "CHEMICAL", 28, 43], ["coronavirus", "DISEASE", 103, 114], ["glucocorticoids", "SIMPLE_CHEMICAL", 28, 43], ["human", "ORGANISM", 63, 68], ["coronavirus", "ORGANISM", 103, 114], ["patients", "ORGANISM", 131, 139], ["glucocorticoids", "SIMPLE_CHEMICAL", 251, 266], ["cytokine", "PROTEIN", 150, 158], ["cytokine", "PROTEIN", 227, 235], ["human", "SPECIES", 63, 68], ["patients", "SPECIES", 131, 139], ["human", "SPECIES", 63, 68], ["glucocorticoids", "TREATMENT", 28, 43], ["the removal", "TREATMENT", 88, 99], ["coronavirus", "PROBLEM", 103, 114], ["cytokine storm", "PROBLEM", 150, 164], ["cytokine storm", "PROBLEM", 227, 241], ["cytokine storm", "OBSERVATION", 150, 164]]], ["In addition, immunosuppressive agents, such as anti-IL-6 monoclonal antibody, gamma globulin, PPARs inhibitors, and sphingosine phosphate 1 (S1P1) receptors inhibitors, cyclooxygenase (COX) inhibitors, antioxidants, and anti-tumor necrosis factor therapy may be effective against cytokine storm [29, 30].", [["gamma globulin", "CHEMICAL", 78, 92], ["sphingosine phosphate", "CHEMICAL", 116, 137], ["necrosis", "DISEASE", 231, 239], ["sphingosine phosphate", "CHEMICAL", 116, 137], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 47, 56], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 78, 92], ["PPARs", "GENE_OR_GENE_PRODUCT", 94, 99], ["sphingosine phosphate 1", "GENE_OR_GENE_PRODUCT", 116, 139], ["S1P1", "GENE_OR_GENE_PRODUCT", 141, 145], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 169, 183], ["COX", "GENE_OR_GENE_PRODUCT", 185, 188], ["anti-tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 220, 246], ["anti-IL-6 monoclonal antibody", "PROTEIN", 47, 76], ["gamma globulin", "PROTEIN", 78, 92], ["PPARs", "PROTEIN", 94, 99], ["sphingosine phosphate 1 (S1P1) receptors", "PROTEIN", 116, 156], ["COX", "PROTEIN", 185, 188], ["cytokine", "PROTEIN", 280, 288], ["immunosuppressive agents", "TREATMENT", 13, 37], ["anti-IL", "TEST", 47, 54], ["monoclonal antibody", "TEST", 57, 76], ["gamma globulin", "TREATMENT", 78, 92], ["PPARs inhibitors", "TREATMENT", 94, 110], ["sphingosine phosphate", "TREATMENT", 116, 137], ["S1P1) receptors inhibitors", "TREATMENT", 141, 167], ["cyclooxygenase (COX) inhibitors", "TREATMENT", 169, 200], ["antioxidants", "TREATMENT", 202, 214], ["anti-tumor necrosis factor therapy", "TREATMENT", 220, 254]]], ["Although most cases have mild symptoms and good prognosis, cytokine storm is still a hidden danger in the mild patients with COVID-19.", [["patients", "ORGANISM", 111, 119], ["cytokine", "PROTEIN", 59, 67], ["patients", "SPECIES", 111, 119], ["mild symptoms", "PROBLEM", 25, 38], ["COVID", "TEST", 125, 130], ["mild", "OBSERVATION_MODIFIER", 106, 110]]], ["Early monitoring and early treatment are the best ways to eliminate this hidden danger.Favipiravir ::: Development and Evaluation of Antiviral DrugsFavipiravir is a guanine analog approved for the treatment of influenza that effectively inhibits RNA viruses such as influenza virus, Ebola virus, yellow fever virus, chikungunya virus, norovirus, and enterovirus [31].", [["Favipiravir", "CHEMICAL", 87, 98], ["DrugsFavipiravir", "CHEMICAL", 143, 159], ["guanine", "CHEMICAL", 165, 172], ["influenza", "DISEASE", 210, 219], ["influenza virus", "DISEASE", 266, 281], ["Ebola virus", "DISEASE", 283, 294], ["yellow fever", "DISEASE", 296, 308], ["chikungunya virus", "DISEASE", 316, 333], ["norovirus", "DISEASE", 335, 344], ["Favipiravir", "CHEMICAL", 87, 98], ["DrugsFavipiravir", "CHEMICAL", 143, 159], ["guanine", "CHEMICAL", 165, 172], ["Favipiravir", "SIMPLE_CHEMICAL", 87, 98], ["DrugsFavipiravir", "SIMPLE_CHEMICAL", 143, 159], ["guanine", "SIMPLE_CHEMICAL", 165, 172], ["influenza virus", "ORGANISM", 266, 281], ["Ebola virus", "ORGANISM", 283, 294], ["yellow fever virus", "ORGANISM", 296, 314], ["chikungunya virus", "ORGANISM", 316, 333], ["influenza virus", "SPECIES", 266, 281], ["Ebola virus", "SPECIES", 283, 294], ["yellow fever virus", "SPECIES", 296, 314], ["chikungunya virus", "SPECIES", 316, 333], ["influenza virus", "SPECIES", 266, 281], ["Ebola virus", "SPECIES", 283, 294], ["yellow fever virus", "SPECIES", 296, 314], ["chikungunya virus", "SPECIES", 316, 333], ["Early monitoring", "TEST", 0, 16], ["early treatment", "TREATMENT", 21, 36], ["Evaluation", "TEST", 119, 129], ["Antiviral DrugsFavipiravir", "TREATMENT", 133, 159], ["a guanine analog", "TREATMENT", 163, 179], ["influenza", "PROBLEM", 210, 219], ["RNA viruses", "PROBLEM", 246, 257], ["influenza virus", "PROBLEM", 266, 281], ["Ebola virus", "PROBLEM", 283, 294], ["yellow fever virus", "PROBLEM", 296, 314], ["chikungunya virus", "PROBLEM", 316, 333], ["norovirus", "PROBLEM", 335, 344], ["enterovirus", "PROBLEM", 350, 361]]], ["Favipiravir is a nucleoside antiviral drug, and its mechanism of action has not been fully elucidated.", [["Favipiravir", "CHEMICAL", 0, 11], ["nucleoside", "CHEMICAL", 17, 27], ["Favipiravir", "CHEMICAL", 0, 11], ["nucleoside", "CHEMICAL", 17, 27], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["nucleoside", "SIMPLE_CHEMICAL", 17, 27], ["Favipiravir", "TREATMENT", 0, 11], ["a nucleoside antiviral drug", "TREATMENT", 15, 42], ["nucleoside antiviral drug", "OBSERVATION", 17, 42]]], ["Its target is a viral RNA-dependent RNA polymerase.", [["viral RNA", "RNA", 16, 25], ["RNA polymerase", "PROTEIN", 36, 50], ["a viral RNA-dependent RNA polymerase", "PROBLEM", 14, 50], ["target", "OBSERVATION_MODIFIER", 4, 10], ["viral RNA", "OBSERVATION", 16, 25], ["dependent", "OBSERVATION_MODIFIER", 26, 35], ["RNA polymerase", "OBSERVATION", 36, 50]]], ["After oral absorption, the drug is converted into a nucleoside triphosphate of biologically active favipiravir.", [["oral", "ANATOMY", 6, 10], ["nucleoside triphosphate", "CHEMICAL", 52, 75], ["favipiravir", "CHEMICAL", 99, 110], ["nucleoside triphosphate", "CHEMICAL", 52, 75], ["favipiravir", "CHEMICAL", 99, 110], ["oral", "ORGANISM_SUBDIVISION", 6, 10], ["nucleoside triphosphate", "SIMPLE_CHEMICAL", 52, 75], ["favipiravir", "SIMPLE_CHEMICAL", 99, 110], ["a nucleoside triphosphate of biologically active favipiravir", "TREATMENT", 50, 110]]], ["Its structure is similar to purine, and it can compete with purine for virus RNA polymerase.", [["purine", "CHEMICAL", 28, 34], ["purine", "CHEMICAL", 60, 66], ["purine", "CHEMICAL", 28, 34], ["purine", "CHEMICAL", 60, 66], ["purine", "SIMPLE_CHEMICAL", 28, 34], ["purine", "SIMPLE_CHEMICAL", 60, 66], ["virus RNA polymerase", "PROTEIN", 71, 91], ["virus RNA polymerase", "PROBLEM", 71, 91]]], ["Favipiravir\u2019s nucleoside triphosphates can also be inserted into the viral RNA chain and induce fatal mutations in the virus [32].", [["Favipiravir", "CHEMICAL", 0, 11], ["nucleoside triphosphates", "CHEMICAL", 14, 38], ["Favipiravir", "CHEMICAL", 0, 11], ["nucleoside triphosphates", "CHEMICAL", 14, 38], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["nucleoside triphosphates", "SIMPLE_CHEMICAL", 14, 38], ["viral RNA chain", "PROTEIN", 69, 84], ["Favipiravir", "TREATMENT", 0, 11], ["nucleoside triphosphates", "TREATMENT", 14, 38], ["the viral RNA chain", "TREATMENT", 65, 84], ["fatal mutations", "PROBLEM", 96, 111], ["viral RNA", "OBSERVATION", 69, 78]]], ["Therefore, mechanistically, favipiravir has potential antiviral effects on various RNA viruses.", [["favipiravir", "CHEMICAL", 28, 39], ["favipiravir", "CHEMICAL", 28, 39], ["favipiravir", "SIMPLE_CHEMICAL", 28, 39], ["favipiravir", "TREATMENT", 28, 39], ["potential antiviral effects", "PROBLEM", 44, 71], ["various RNA viruses", "PROBLEM", 75, 94], ["antiviral effects", "OBSERVATION", 54, 71], ["RNA viruses", "OBSERVATION", 83, 94]]], ["The steady-state trough concentration of favipiravir is 11.3\u201322.6 \u03bcg/mL.", [["favipiravir", "CHEMICAL", 41, 52], ["favipiravir", "CHEMICAL", 41, 52], ["favipiravir", "SIMPLE_CHEMICAL", 41, 52], ["favipiravir", "TEST", 41, 52]]], ["It has been reported that favipiravir has anti-SARS-CoV-2 activity in Vero E6 cells, with an EC50 of 61.88 \u03bcM [33].Remdesivir ::: Development and Evaluation of Antiviral DrugsRemdesivir is a modified prodrug of the adenine nucleoside analog.", [["Vero E6 cells", "ANATOMY", 70, 83], ["favipiravir", "CHEMICAL", 26, 37], ["DrugsRemdesivir", "CHEMICAL", 170, 185], ["adenine nucleoside", "CHEMICAL", 215, 233], ["favipiravir", "CHEMICAL", 26, 37], ["DrugsRemdesivir", "CHEMICAL", 170, 185], ["adenine nucleoside", "CHEMICAL", 215, 233], ["favipiravir", "SIMPLE_CHEMICAL", 26, 37], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 57], ["Vero E6 cells", "CELL", 70, 83], ["DrugsRemdesivir", "SIMPLE_CHEMICAL", 170, 185], ["adenine nucleoside", "SIMPLE_CHEMICAL", 215, 233], ["Vero E6 cells", "CELL_LINE", 70, 83], ["Vero E6", "SPECIES", 70, 77], ["favipiravir", "TEST", 26, 37], ["anti-SARS", "TEST", 42, 51], ["CoV", "TEST", 52, 55], ["an EC50", "TEST", 90, 97], ["Evaluation", "TEST", 146, 156], ["Antiviral DrugsRemdesivir", "TREATMENT", 160, 185], ["the adenine nucleoside analog", "TREATMENT", 211, 240]]], ["It has strong in vitro activity and cell permeability and can be more effectively metabolized into active nucleoside triphosphate (NTP).", [["cell", "ANATOMY", 36, 40], ["nucleoside triphosphate", "CHEMICAL", 106, 129], ["NTP", "CHEMICAL", 131, 134], ["nucleoside triphosphate", "CHEMICAL", 106, 129], ["NTP", "CHEMICAL", 131, 134], ["cell", "CELL", 36, 40], ["nucleoside triphosphate", "SIMPLE_CHEMICAL", 106, 129], ["NTP", "SIMPLE_CHEMICAL", 131, 134], ["cell permeability", "TEST", 36, 53], ["active nucleoside triphosphate (NTP", "TREATMENT", 99, 134], ["strong", "OBSERVATION_MODIFIER", 7, 13], ["vitro activity", "OBSERVATION", 17, 31], ["cell permeability", "OBSERVATION", 36, 53]]], ["NTP acts as a substrate for RNA polymerase in viral RNA polymerase-guided primer extension, thereby terminating the transcription of RNA strand information [34].", [["NTP", "CHEMICAL", 0, 3], ["NTP", "CHEMICAL", 0, 3], ["NTP", "SIMPLE_CHEMICAL", 0, 3], ["RNA polymerase", "PROTEIN", 28, 42], ["viral RNA polymerase", "PROTEIN", 46, 66], ["NTP acts", "TREATMENT", 0, 8], ["a substrate", "TREATMENT", 12, 23], ["RNA polymerase", "PROBLEM", 28, 42], ["guided primer extension", "TREATMENT", 67, 90]]], ["Coronavirus expresses exonuclease in non-structural protein 14, nsp14, and it is conserved across the entire coronavirus family.", [["exonuclease in non-structural protein 14", "GENE_OR_GENE_PRODUCT", 22, 62], ["nsp14", "GENE_OR_GENE_PRODUCT", 64, 69], ["coronavirus", "ORGANISM", 109, 120], ["exonuclease", "PROTEIN", 22, 33], ["non-structural protein 14", "PROTEIN", 37, 62], ["nsp14", "PROTEIN", 64, 69], ["coronavirus family", "PROTEIN", 109, 127], ["Coronavirus", "PROBLEM", 0, 11], ["non-structural protein", "TEST", 37, 59], ["non-structural protein", "OBSERVATION_MODIFIER", 37, 59]]], ["Nucleoside analogs are incorporated into viral RNA and are excised by coronavirus exonucleasees [35].", [["Nucleoside", "CHEMICAL", 0, 10], ["Nucleoside", "CHEMICAL", 0, 10], ["Nucleoside analogs", "SIMPLE_CHEMICAL", 0, 18], ["coronavirus", "ORGANISM", 70, 81], ["viral RNA", "RNA", 41, 50], ["Nucleoside analogs", "TREATMENT", 0, 18], ["viral RNA", "PROBLEM", 41, 50], ["viral RNA", "OBSERVATION", 41, 50]]], ["However, remdesivir is resistant to exonucleases, which is more effective than other nucleoside analogs [36].", [["remdesivir", "CHEMICAL", 9, 19], ["nucleoside", "CHEMICAL", 85, 95], ["remdesivir", "CHEMICAL", 9, 19], ["nucleoside", "CHEMICAL", 85, 95], ["remdesivir", "SIMPLE_CHEMICAL", 9, 19], ["nucleoside", "SIMPLE_CHEMICAL", 85, 95], ["exonucleases", "PROTEIN", 36, 48], ["exonucleases", "TREATMENT", 36, 48]]], ["Remdesivir has broad-spectrum antiviral activity against RNA viruses.", [["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["Remdesivir", "TREATMENT", 0, 10], ["broad-spectrum antiviral activity", "TREATMENT", 15, 48], ["RNA viruses", "PROBLEM", 57, 68], ["antiviral activity", "OBSERVATION", 30, 48]]], ["Remdesivir can effectively inhibit the replication of SARS-CoV and MERS-CoV coronavirus, and the inhibitory effect on coronavirus has a dose-dependent effect.", [["Remdesivir", "CHEMICAL", 0, 10], ["SARS", "DISEASE", 54, 58], ["coronavirus", "DISEASE", 118, 129], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV", "ORGANISM", 54, 62], ["MERS-CoV coronavirus", "ORGANISM", 67, 87], ["coronavirus", "ORGANISM", 118, 129], ["MERS-CoV coronavirus", "SPECIES", 67, 87], ["SARS-CoV", "SPECIES", 54, 62], ["MERS-CoV coronavirus", "SPECIES", 67, 87], ["coronavirus", "SPECIES", 118, 129], ["Remdesivir", "TREATMENT", 0, 10], ["SARS", "PROBLEM", 54, 58], ["CoV", "PROBLEM", 59, 62], ["MERS", "PROBLEM", 67, 71], ["CoV coronavirus", "PROBLEM", 72, 87], ["the inhibitory effect", "PROBLEM", 93, 114], ["coronavirus", "PROBLEM", 118, 129]]], ["It has preventive therapeutic effect on coronavirus and can reduce the symptoms shown in experimental animals after SARS-CoV infection, reduce virus titer in the lungs, and thus reduce lung tissue damage [37].", [["lungs", "ANATOMY", 162, 167], ["lung tissue", "ANATOMY", 185, 196], ["coronavirus", "DISEASE", 40, 51], ["SARS-CoV infection", "DISEASE", 116, 134], ["lung tissue damage", "DISEASE", 185, 203], ["coronavirus", "ORGANISM", 40, 51], ["SARS-CoV", "ORGANISM", 116, 124], ["lungs", "ORGAN", 162, 167], ["lung tissue", "TISSUE", 185, 196], ["SARS-CoV", "SPECIES", 116, 124], ["coronavirus", "PROBLEM", 40, 51], ["the symptoms", "PROBLEM", 67, 79], ["SARS", "PROBLEM", 116, 120], ["CoV infection", "PROBLEM", 121, 134], ["reduce virus titer in the lungs", "PROBLEM", 136, 167], ["lung tissue damage", "PROBLEM", 185, 203], ["therapeutic effect", "OBSERVATION_MODIFIER", 18, 36], ["infection", "OBSERVATION", 125, 134], ["lungs", "ANATOMY", 162, 167], ["lung", "ANATOMY", 185, 189], ["tissue", "OBSERVATION", 190, 196]]], ["SARS-CoV-2 is similar to SARS-CoV and MERS-CoV in terms of structure and genome, as well as clinical manifestations of infection.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 25, 29], ["infection", "DISEASE", 119, 128], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV", "ORGANISM", 25, 33], ["MERS-CoV", "ORGANISM", 38, 46], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 25, 33], ["MERS-CoV", "SPECIES", 38, 46], ["SARS", "PROBLEM", 25, 29], ["CoV", "PROBLEM", 30, 33], ["MERS", "PROBLEM", 38, 42], ["CoV", "PROBLEM", 43, 46], ["infection", "PROBLEM", 119, 128], ["genome", "OBSERVATION", 73, 79], ["infection", "OBSERVATION", 119, 128]]], ["In in vitro and animal models, data confirm its role as an antiviral against coronavirus.", [["coronavirus", "DISEASE", 77, 88], ["coronavirus", "ORGANISM", 77, 88], ["an antiviral", "TREATMENT", 56, 68], ["coronavirus", "PROBLEM", 77, 88]]], ["However, clinical data on remdesivir for the treatment of patients with coronavirus infection are very limited.", [["remdesivir", "CHEMICAL", 26, 36], ["coronavirus infection", "DISEASE", 72, 93], ["remdesivir", "CHEMICAL", 26, 36], ["remdesivir", "SIMPLE_CHEMICAL", 26, 36], ["patients", "ORGANISM", 58, 66], ["coronavirus", "ORGANISM", 72, 83], ["patients", "SPECIES", 58, 66], ["coronavirus", "SPECIES", 72, 83], ["clinical data", "TEST", 9, 22], ["remdesivir", "TREATMENT", 26, 36], ["the treatment", "TREATMENT", 41, 54], ["coronavirus infection", "PROBLEM", 72, 93], ["coronavirus infection", "OBSERVATION", 72, 93]]], ["A recent study reported that remdesivir could inhibit SARS-CoV-2 (EC50 in Vero E6 cells = 0.77 \u03bcM) [33].", [["cells", "ANATOMY", 82, 87], ["remdesivir", "CHEMICAL", 29, 39], ["remdesivir", "CHEMICAL", 29, 39], ["remdesivir", "SIMPLE_CHEMICAL", 29, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["Vero E6 cells", "CELL", 74, 87], ["Vero E6 cells", "CELL_LINE", 74, 87], ["SARS-CoV", "SPECIES", 54, 62], ["A recent study", "TEST", 0, 14], ["remdesivir", "TEST", 29, 39], ["SARS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["EC50", "TEST", 66, 70], ["Vero E6 cells", "TEST", 74, 87]]], ["A patient with SARS-CoV-2 in the USA recovered after receiving intravenous remdesivir [38].", [["intravenous", "ANATOMY", 63, 74], ["SARS", "DISEASE", 15, 19], ["remdesivir", "CHEMICAL", 75, 85], ["remdesivir", "CHEMICAL", 75, 85], ["patient", "ORGANISM", 2, 9], ["SARS-CoV-2", "ORGANISM", 15, 25], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 74], ["patient", "SPECIES", 2, 9], ["SARS", "PROBLEM", 15, 19], ["CoV", "TEST", 20, 23], ["intravenous remdesivir", "TREATMENT", 63, 85]]], ["It is currently in early clinical studies to evaluate the safety and effects of galidesivir in COVID-19 patients.Lopinavir/Ritonavir ::: Development and Evaluation of Antiviral DrugsLopinavir/ritonavir is a class of Mpro (3CLpro) inhibitors and is considered to be a 3-chymotrypsin-like protease that inhibits MERS-CoV and SARS-CoV.", [["galidesivir", "CHEMICAL", 80, 91], ["Lopinavir", "CHEMICAL", 113, 122], ["Ritonavir", "CHEMICAL", 123, 132], ["DrugsLopinavir", "CHEMICAL", 177, 191], ["ritonavir", "CHEMICAL", 192, 201], ["Mpro", "CHEMICAL", 216, 220], ["galidesivir", "CHEMICAL", 80, 91], ["Lopinavir", "CHEMICAL", 113, 122], ["Ritonavir", "CHEMICAL", 123, 132], ["DrugsLopinavir", "CHEMICAL", 177, 191], ["ritonavir", "CHEMICAL", 192, 201], ["Mpro", "CHEMICAL", 216, 220], ["galidesivir", "SIMPLE_CHEMICAL", 80, 91], ["patients", "ORGANISM", 104, 112], ["Lopinavir", "SIMPLE_CHEMICAL", 113, 122], ["Ritonavir", "SIMPLE_CHEMICAL", 123, 132], ["DrugsLopinavir", "SIMPLE_CHEMICAL", 177, 191], ["ritonavir", "SIMPLE_CHEMICAL", 192, 201], ["Mpro", "SIMPLE_CHEMICAL", 216, 220], ["3CLpro", "SIMPLE_CHEMICAL", 222, 228], ["3-chymotrypsin", "SIMPLE_CHEMICAL", 267, 281], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 310, 318], ["SARS-CoV", "ORGANISM", 323, 331], ["chymotrypsin", "PROTEIN", 269, 281], ["protease", "PROTEIN", 287, 295], ["patients", "SPECIES", 104, 112], ["MERS-CoV", "SPECIES", 310, 318], ["SARS-CoV", "SPECIES", 323, 331], ["early clinical studies", "TEST", 19, 41], ["galidesivir in COVID", "TREATMENT", 80, 100], ["Lopinavir", "TREATMENT", 113, 122], ["Ritonavir", "TREATMENT", 123, 132], ["Evaluation", "TEST", 153, 163], ["Antiviral DrugsLopinavir", "TREATMENT", 167, 191], ["ritonavir", "TREATMENT", 192, 201], ["Mpro (3CLpro) inhibitors", "TREATMENT", 216, 240], ["a 3-chymotrypsin-like protease", "TREATMENT", 265, 295]]], ["Compared with ribavirin alone, the combined use of lopinavir/ritonavir significantly improved the prognosis of SARS-CoV patients [39].", [["ribavirin", "CHEMICAL", 14, 23], ["lopinavir/ritonavir", "CHEMICAL", 51, 70], ["SARS-CoV", "DISEASE", 111, 119], ["ribavirin", "CHEMICAL", 14, 23], ["lopinavir", "CHEMICAL", 51, 60], ["ritonavir", "CHEMICAL", 61, 70], ["ribavirin", "SIMPLE_CHEMICAL", 14, 23], ["lopinavir", "SIMPLE_CHEMICAL", 51, 60], ["ritonavir", "SIMPLE_CHEMICAL", 61, 70], ["SARS-CoV", "ORGANISM", 111, 119], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["SARS-CoV", "SPECIES", 111, 119], ["ribavirin", "TREATMENT", 14, 23], ["lopinavir", "TREATMENT", 51, 60], ["ritonavir", "TREATMENT", 61, 70]]], ["In vitro models of MERS-CoV infection demonstrate that lopinavir/ritonavir has no significant antiviral activity and it is rarely used in the treatment of patients with MERS-CoV.", [["MERS-CoV infection", "DISEASE", 19, 37], ["lopinavir/ritonavir", "CHEMICAL", 55, 74], ["lopinavir", "CHEMICAL", 55, 64], ["ritonavir", "CHEMICAL", 65, 74], ["MERS-CoV", "ORGANISM", 19, 27], ["lopinavir", "SIMPLE_CHEMICAL", 55, 64], ["ritonavir", "SIMPLE_CHEMICAL", 65, 74], ["patients", "ORGANISM", 155, 163], ["MERS-CoV", "ORGANISM", 169, 177], ["patients", "SPECIES", 155, 163], ["MERS-CoV", "SPECIES", 19, 27], ["MERS-CoV", "SPECIES", 169, 177], ["MERS", "PROBLEM", 19, 23], ["CoV infection", "PROBLEM", 24, 37], ["lopinavir", "TREATMENT", 55, 64], ["ritonavir", "TREATMENT", 65, 74], ["CoV", "PROBLEM", 174, 177], ["CoV", "OBSERVATION_MODIFIER", 24, 27], ["infection", "OBSERVATION", 28, 37], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["antiviral activity", "OBSERVATION", 94, 112]]], ["However, another study reveals that lopinavir/ritonavir is effective when the MERS marmoset model was infected with MERS-CoV.", [["lopinavir/ritonavir", "CHEMICAL", 36, 55], ["lopinavir", "CHEMICAL", 36, 45], ["ritonavir", "CHEMICAL", 46, 55], ["lopinavir", "SIMPLE_CHEMICAL", 36, 45], ["ritonavir", "SIMPLE_CHEMICAL", 46, 55], ["marmoset", "ORGANISM", 83, 91], ["MERS-CoV", "ORGANISM", 116, 124], ["MERS marmoset", "SPECIES", 78, 91], ["MERS-CoV", "SPECIES", 116, 124], ["another study", "TEST", 9, 22], ["lopinavir/ritonavir", "TREATMENT", 36, 55], ["the MERS marmoset model", "TREATMENT", 74, 97]]], ["The prognosis of marmoset could be significantly improved.", [["marmoset", "ORGANISM", 17, 25], ["significantly", "OBSERVATION_MODIFIER", 35, 48], ["improved", "OBSERVATION_MODIFIER", 49, 57]]], ["A clinical trial of 199 COVID-19 patients found that the effectiveness of lopinavir/ritonavir treatment could not be observed compared to conventional treatment [40].", [["lopinavir/ritonavir", "CHEMICAL", 74, 93], ["lopinavir", "CHEMICAL", 74, 83], ["ritonavir", "CHEMICAL", 84, 93], ["patients", "ORGANISM", 33, 41], ["lopinavir", "SIMPLE_CHEMICAL", 74, 83], ["ritonavir", "SIMPLE_CHEMICAL", 84, 93], ["patients", "SPECIES", 33, 41], ["A clinical trial", "TEST", 0, 16], ["COVID", "TEST", 24, 29], ["lopinavir/ritonavir treatment", "TREATMENT", 74, 103]]], ["Moreover, the combination of interferon (IFN)-\u03b21b achieved better curative effect [41].", [["interferon (IFN)-\u03b21b", "GENE_OR_GENE_PRODUCT", 29, 49], ["interferon (IFN)-\u03b21b", "PROTEIN", 29, 49], ["interferon (IFN)", "TREATMENT", 29, 45]]], ["It is important to pay attention to lopinavir/ritonavir-related adverse reactions and interaction with other drugs.Chloroquine ::: Development and Evaluation of Antiviral DrugsChloroquine has several possible antiviral mechanisms.", [["lopinavir/ritonavir", "CHEMICAL", 36, 55], ["Chloroquine", "CHEMICAL", 115, 126], ["DrugsChloroquine", "CHEMICAL", 171, 187], ["lopinavir", "CHEMICAL", 36, 45], ["ritonavir", "CHEMICAL", 46, 55], ["Chloroquine", "CHEMICAL", 115, 126], ["DrugsChloroquine", "CHEMICAL", 171, 187], ["lopinavir", "SIMPLE_CHEMICAL", 36, 45], ["ritonavir", "SIMPLE_CHEMICAL", 46, 55], ["Chloroquine", "SIMPLE_CHEMICAL", 115, 126], ["DrugsChloroquine", "SIMPLE_CHEMICAL", 171, 187], ["lopinavir", "TREATMENT", 36, 45], ["ritonavir", "TREATMENT", 46, 55], ["adverse reactions", "PROBLEM", 64, 81], ["other drugs", "TREATMENT", 103, 114], ["Chloroquine", "TREATMENT", 115, 126], ["Evaluation", "TEST", 147, 157], ["Antiviral DrugsChloroquine", "TREATMENT", 161, 187], ["antiviral mechanisms", "TREATMENT", 209, 229], ["possible", "UNCERTAINTY", 200, 208], ["antiviral mechanisms", "OBSERVATION", 209, 229]]], ["As a weakly basic drug, chloroquine enters cells in a non-protonated form in extracellular fluid and becomes a protonated form in acidic environments such as endosomes, Golgi apparatus, and lysosomes.", [["cells", "ANATOMY", 43, 48], ["extracellular fluid", "ANATOMY", 77, 96], ["endosomes", "ANATOMY", 158, 167], ["Golgi apparatus", "ANATOMY", 169, 184], ["lysosomes", "ANATOMY", 190, 199], ["chloroquine", "CHEMICAL", 24, 35], ["chloroquine", "CHEMICAL", 24, 35], ["chloroquine", "SIMPLE_CHEMICAL", 24, 35], ["cells", "CELL", 43, 48], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["fluid", "ORGANISM_SUBSTANCE", 91, 96], ["endosomes", "CELLULAR_COMPONENT", 158, 167], ["Golgi apparatus", "CELLULAR_COMPONENT", 169, 184], ["lysosomes", "CELLULAR_COMPONENT", 190, 199], ["chloroquine enters cells", "TREATMENT", 24, 48], ["extracellular fluid", "PROBLEM", 77, 96], ["a protonated form in acidic environments", "PROBLEM", 109, 149], ["Golgi apparatus", "TEST", 169, 184], ["fluid", "OBSERVATION", 91, 96], ["acidic environments", "OBSERVATION", 130, 149]]], ["The alkaline phagosome environment interferes with numerous metabolic enzymes [42, 43].", [["metabolic enzymes", "PROTEIN", 60, 77], ["The alkaline phagosome environment", "TREATMENT", 0, 34], ["numerous metabolic enzymes", "TEST", 51, 77], ["alkaline phagosome", "OBSERVATION", 4, 22]]], ["Because many viruses need to enter cells through phagocytosis under acidic conditions at lower pH, chloroquine can inhibit the penetration, husking, and replication of viruses.", [["cells", "ANATOMY", 35, 40], ["chloroquine", "CHEMICAL", 99, 110], ["chloroquine", "CHEMICAL", 99, 110], ["cells", "CELL", 35, 40], ["chloroquine", "SIMPLE_CHEMICAL", 99, 110], ["many viruses", "PROBLEM", 8, 20], ["chloroquine", "TREATMENT", 99, 110], ["the penetration", "PROBLEM", 123, 138], ["husking", "TREATMENT", 140, 147], ["viruses", "PROBLEM", 168, 175], ["viruses", "OBSERVATION", 13, 20]]], ["For enveloped viruses, processes such as glycoprotein translation modification also require a low pH environment, and chloroquine can inhibit a variety of viruses through its pH dependence [44].", [["chloroquine", "CHEMICAL", 118, 129], ["chloroquine", "CHEMICAL", 118, 129], ["chloroquine", "SIMPLE_CHEMICAL", 118, 129], ["enveloped viruses", "PROBLEM", 4, 21], ["glycoprotein translation modification", "TREATMENT", 41, 78], ["a low pH environment", "TREATMENT", 92, 112], ["chloroquine", "TREATMENT", 118, 129], ["its pH dependence", "PROBLEM", 171, 188], ["viruses", "OBSERVATION", 14, 21], ["low pH", "OBSERVATION_MODIFIER", 94, 100]]], ["For some viruses of the Flaviviridae family, chloroquine can also inhibit the hydrolysis of its proteins and disrupt the viral infection process; chloroquine can also inhibit some non-infectious retroviruses by inhibiting the glycosylation of viral envelope proteins [42].", [["chloroquine", "CHEMICAL", 45, 56], ["viral infection", "DISEASE", 121, 136], ["chloroquine", "CHEMICAL", 146, 157], ["chloroquine", "CHEMICAL", 45, 56], ["chloroquine", "CHEMICAL", 146, 157], ["Flaviviridae", "ORGANISM", 24, 36], ["chloroquine", "SIMPLE_CHEMICAL", 45, 56], ["chloroquine", "SIMPLE_CHEMICAL", 146, 157], ["retroviruses", "ORGANISM", 195, 207], ["viral envelope proteins", "PROTEIN", 243, 266], ["chloroquine", "TREATMENT", 45, 56], ["its proteins", "TREATMENT", 92, 104], ["the viral infection process", "PROBLEM", 117, 144], ["chloroquine", "TREATMENT", 146, 157], ["some non-infectious retroviruses", "PROBLEM", 175, 207], ["viral envelope proteins", "TREATMENT", 243, 266], ["viruses", "OBSERVATION", 9, 16], ["viral", "OBSERVATION_MODIFIER", 121, 126], ["infection", "OBSERVATION", 127, 136]]], ["In addition, the virus needs to attach to cell receptors through mucin to infect cells.", [["cell", "ANATOMY", 42, 46], ["cells", "ANATOMY", 81, 86], ["cell", "CELL", 42, 46], ["mucin", "GENE_OR_GENE_PRODUCT", 65, 70], ["cells", "CELL", 81, 86], ["cell receptors", "PROTEIN", 42, 56], ["the virus", "PROBLEM", 13, 22], ["virus", "OBSERVATION", 17, 22], ["infect cells", "OBSERVATION", 74, 86]]], ["ACE-2 was found to be a receptor protein for SARS-CoV and SARS-CoV-2.", [["ACE-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 45, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["ACE", "PROTEIN", 0, 3], ["SARS-CoV", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 58, 66], ["ACE", "TEST", 0, 3], ["a receptor protein", "TEST", 22, 40], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66]]], ["SARS-CoV-2 enters cells through the ACE-2 receptor.", [["cells", "ANATOMY", 18, 23], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["cells", "CELL", 18, 23], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 36, 50], ["ACE-2 receptor", "PROTEIN", 36, 50], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["the ACE", "TREATMENT", 32, 39]]], ["Chloroquine may interfere with the virus.", [["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Chloroquine", "TREATMENT", 0, 11], ["the virus", "PROBLEM", 31, 40]]], ["The binding of mucin to cellular ACE-2 receptor protein exerts an inhibitory effect on the virus [45].", [["cellular", "ANATOMY", 24, 32], ["mucin", "GENE_OR_GENE_PRODUCT", 15, 20], ["cellular", "CELL", 24, 32], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 33, 47], ["mucin", "PROTEIN", 15, 20], ["cellular ACE-2 receptor protein", "PROTEIN", 24, 55], ["cellular ACE-2 receptor protein", "TREATMENT", 24, 55], ["the virus", "PROBLEM", 87, 96]]], ["In addition to its direct antiviral effect, chloroquine can also regulate immune activity and inhibit inflammatory reactions associated with viral infections [46].", [["chloroquine", "CHEMICAL", 44, 55], ["viral infections", "DISEASE", 141, 157], ["chloroquine", "CHEMICAL", 44, 55], ["chloroquine", "SIMPLE_CHEMICAL", 44, 55], ["its direct antiviral effect", "TREATMENT", 15, 42], ["chloroquine", "TREATMENT", 44, 55], ["immune activity", "PROBLEM", 74, 89], ["inflammatory reactions", "PROBLEM", 102, 124], ["viral infections", "PROBLEM", 141, 157], ["antiviral effect", "OBSERVATION", 26, 42], ["inflammatory", "OBSERVATION_MODIFIER", 102, 114]]], ["Therefore, it is often used in clinical practice to treat immune system diseases such as rheumatoid arthritis.", [["immune system", "ANATOMY", 58, 71], ["immune system diseases", "DISEASE", 58, 80], ["rheumatoid arthritis", "DISEASE", 89, 109], ["immune system diseases", "PROBLEM", 58, 80], ["rheumatoid arthritis", "PROBLEM", 89, 109], ["rheumatoid arthritis", "OBSERVATION", 89, 109]]], ["Immune system diseases often have overexpression of inflammatory cytokines.", [["Immune system", "ANATOMY", 0, 13], ["Immune system diseases", "DISEASE", 0, 22], ["inflammatory cytokines", "PROTEIN", 52, 74], ["Immune system diseases", "PROBLEM", 0, 22], ["inflammatory cytokines", "PROBLEM", 52, 74], ["inflammatory cytokines", "OBSERVATION", 52, 74]]], ["Chloroquine inhibits the inflammatory response by reducing the expression of inflammatory cytokines such as TNF-\u03b1.", [["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 108, 114], ["inflammatory cytokines", "PROTEIN", 77, 99], ["TNF", "PROTEIN", 108, 111], ["Chloroquine", "TREATMENT", 0, 11], ["the inflammatory response", "PROBLEM", 21, 46], ["inflammatory cytokines", "PROBLEM", 77, 99], ["TNF", "TEST", 108, 111], ["inflammatory", "OBSERVATION_MODIFIER", 25, 37], ["inflammatory", "OBSERVATION_MODIFIER", 77, 89]]], ["This may have a positive effect on the activation of the immune system and the severe inflammatory response accompanied by the viral infection [42].", [["immune system", "ANATOMY", 57, 70], ["viral infection", "DISEASE", 127, 142], ["a positive effect", "PROBLEM", 14, 31], ["the severe inflammatory response", "PROBLEM", 75, 107], ["the viral infection", "PROBLEM", 123, 142], ["positive effect", "OBSERVATION", 16, 31], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["inflammatory", "OBSERVATION", 86, 98], ["viral", "OBSERVATION_MODIFIER", 127, 132], ["infection", "OBSERVATION", 133, 142]]], ["Chloroquine may also be used to treat lung damage caused by viral infection by inhibiting cell autophagy [47].Hydroxychloroquine ::: Development and Evaluation of Antiviral DrugsThe difference between hydroxychloroquine and chloroquine is that an ethyl group in chloroquine is replaced by a hydroxyethyl group in hydroxychloroquine [48].", [["lung", "ANATOMY", 38, 42], ["cell", "ANATOMY", 90, 94], ["Chloroquine", "CHEMICAL", 0, 11], ["lung damage", "DISEASE", 38, 49], ["viral infection", "DISEASE", 60, 75], ["Hydroxychloroquine", "CHEMICAL", 110, 128], ["hydroxychloroquine", "CHEMICAL", 201, 219], ["chloroquine", "CHEMICAL", 224, 235], ["ethyl", "CHEMICAL", 247, 252], ["chloroquine", "CHEMICAL", 262, 273], ["hydroxyethyl", "CHEMICAL", 291, 303], ["hydroxychloroquine", "CHEMICAL", 313, 331], ["Chloroquine", "CHEMICAL", 0, 11], ["Hydroxychloroquine", "CHEMICAL", 110, 128], ["hydroxychloroquine", "CHEMICAL", 201, 219], ["chloroquine", "CHEMICAL", 224, 235], ["ethyl", "CHEMICAL", 247, 252], ["chloroquine", "CHEMICAL", 262, 273], ["hydroxyethyl", "CHEMICAL", 291, 303], ["hydroxychloroquine", "CHEMICAL", 313, 331], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["lung", "ORGAN", 38, 42], ["cell", "CELL", 90, 94], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 110, 128], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 201, 219], ["chloroquine", "SIMPLE_CHEMICAL", 224, 235], ["ethyl", "SIMPLE_CHEMICAL", 247, 252], ["chloroquine", "SIMPLE_CHEMICAL", 262, 273], ["hydroxyethyl group", "SIMPLE_CHEMICAL", 291, 309], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 313, 331], ["Chloroquine", "TREATMENT", 0, 11], ["lung damage", "PROBLEM", 38, 49], ["viral infection", "PROBLEM", 60, 75], ["inhibiting cell autophagy", "PROBLEM", 79, 104], ["Hydroxychloroquine", "TREATMENT", 110, 128], ["Evaluation", "TEST", 149, 159], ["Antiviral Drugs", "TREATMENT", 163, 178], ["hydroxychloroquine", "TREATMENT", 201, 219], ["chloroquine", "TREATMENT", 224, 235], ["an ethyl group in chloroquine", "TREATMENT", 244, 273], ["a hydroxyethyl group in hydroxychloroquine", "TREATMENT", 289, 331], ["lung", "ANATOMY", 38, 42], ["damage", "OBSERVATION", 43, 49], ["viral", "OBSERVATION_MODIFIER", 60, 65], ["infection", "OBSERVATION", 66, 75]]], ["The therapeutic effect is similar, but the side effects are significantly reduced compared with chloroquine.", [["chloroquine", "CHEMICAL", 96, 107], ["chloroquine", "CHEMICAL", 96, 107], ["chloroquine", "SIMPLE_CHEMICAL", 96, 107], ["chloroquine", "TREATMENT", 96, 107], ["therapeutic effect", "OBSERVATION", 4, 22], ["similar", "OBSERVATION_MODIFIER", 26, 33], ["significantly", "OBSERVATION_MODIFIER", 60, 73], ["reduced", "OBSERVATION_MODIFIER", 74, 81]]], ["Therefore, hydroxychloroquine is widely used as an immunosuppressive agent in the treatment of rheumatic diseases [48].", [["hydroxychloroquine", "CHEMICAL", 11, 29], ["rheumatic diseases", "DISEASE", 95, 113], ["hydroxychloroquine", "CHEMICAL", 11, 29], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 11, 29], ["hydroxychloroquine", "TREATMENT", 11, 29], ["an immunosuppressive agent", "TREATMENT", 48, 74], ["rheumatic diseases", "PROBLEM", 95, 113], ["rheumatic", "OBSERVATION", 95, 104]]], ["By observing the electrocardiogram of 84 COVID-19 patients who took oral hydroxychloroquine and azithromycin for 5 days, it was found that most of the patients who received hydroxychloroquine and azithromycin showed an extended QT interval.", [["oral", "ANATOMY", 68, 72], ["hydroxychloroquine", "CHEMICAL", 73, 91], ["azithromycin", "CHEMICAL", 96, 108], ["hydroxychloroquine", "CHEMICAL", 173, 191], ["azithromycin", "CHEMICAL", 196, 208], ["hydroxychloroquine", "CHEMICAL", 73, 91], ["azithromycin", "CHEMICAL", 96, 108], ["hydroxychloroquine", "CHEMICAL", 173, 191], ["azithromycin", "CHEMICAL", 196, 208], ["patients", "ORGANISM", 50, 58], ["oral", "ORGANISM_SUBDIVISION", 68, 72], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 73, 91], ["azithromycin", "SIMPLE_CHEMICAL", 96, 108], ["patients", "ORGANISM", 151, 159], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 173, 191], ["azithromycin", "SIMPLE_CHEMICAL", 196, 208], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 151, 159], ["the electrocardiogram", "TEST", 13, 34], ["oral hydroxychloroquine", "TREATMENT", 68, 91], ["azithromycin", "TREATMENT", 96, 108], ["hydroxychloroquine", "TREATMENT", 173, 191], ["azithromycin", "TREATMENT", 196, 208], ["an extended QT interval", "PROBLEM", 216, 239]]], ["Moreover, the severity of other underlying diseases and SARS-CoV-2 infection may aggravate this situation [49].Respiratory Support Therapy ::: Development and Evaluation of Antiviral DrugsSome patients with COVID-19 can progress rapidly to acute respiratory distress syndrome (ARDS) [16, 50].", [["respiratory", "ANATOMY", 246, 257], ["SARS", "DISEASE", 56, 60], ["infection", "DISEASE", 67, 76], ["COVID-19", "CHEMICAL", 207, 215], ["acute respiratory distress syndrome", "DISEASE", 240, 275], ["ARDS", "DISEASE", 277, 281], ["SARS-CoV-2", "ORGANISM", 56, 66], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["SARS-CoV-2", "SPECIES", 56, 66], ["other underlying diseases", "PROBLEM", 26, 51], ["SARS", "PROBLEM", 56, 60], ["CoV-2 infection", "PROBLEM", 61, 76], ["Evaluation", "TEST", 159, 169], ["Antiviral DrugsSome patients", "TREATMENT", 173, 201], ["COVID", "TREATMENT", 207, 212], ["acute respiratory distress syndrome", "PROBLEM", 240, 275], ["ARDS", "PROBLEM", 277, 281], ["diseases", "OBSERVATION", 43, 51], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["respiratory distress", "OBSERVATION", 246, 266]]], ["Among them, severe hypoxemia is a common clinical manifestation of such patients and usually requires respiratory support treatment in the intensive care unit [51].", [["respiratory", "ANATOMY", 102, 113], ["hypoxemia", "DISEASE", 19, 28], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["severe hypoxemia", "PROBLEM", 12, 28], ["respiratory support treatment", "TREATMENT", 102, 131], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["hypoxemia", "OBSERVATION", 19, 28]]], ["Patients with severe COVID-19 need individualized respiratory support technology based on the degree of hypoxia in the patient.", [["respiratory", "ANATOMY", 50, 61], ["hypoxia", "DISEASE", 104, 111], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 119, 126], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 119, 126], ["severe COVID", "PROBLEM", 14, 26], ["individualized respiratory support technology", "TREATMENT", 35, 80], ["hypoxia", "PROBLEM", 104, 111], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["hypoxia", "OBSERVATION", 104, 111]]], ["For patients with mild to moderate hypoxia, nasal catheters, masks, nasal high-flow oxygen therapy, and non-invasive ventilation can be preferred for non-invasive ventilation.", [["nasal", "ANATOMY", 44, 49], ["nasal", "ANATOMY", 68, 73], ["hypoxia", "DISEASE", 35, 42], ["oxygen", "CHEMICAL", 84, 90], ["oxygen", "CHEMICAL", 84, 90], ["patients", "ORGANISM", 4, 12], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["patients", "SPECIES", 4, 12], ["mild to moderate hypoxia", "PROBLEM", 18, 42], ["nasal catheters", "TREATMENT", 44, 59], ["masks", "TREATMENT", 61, 66], ["nasal high-flow oxygen therapy", "TREATMENT", 68, 98], ["non-invasive ventilation", "TREATMENT", 104, 128], ["non-invasive ventilation", "TREATMENT", 150, 174], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["moderate", "OBSERVATION_MODIFIER", 26, 34], ["hypoxia", "OBSERVATION", 35, 42], ["nasal catheters", "OBSERVATION", 44, 59], ["nasal", "ANATOMY", 68, 73], ["flow oxygen therapy", "OBSERVATION", 79, 98]]], ["Self-pronation can also ameliorate blood oxygenation and is a low-tech intervention that can prevent the need for more invasive methods of oxygen delivery.", [["blood", "ANATOMY", 35, 40], ["oxygen", "CHEMICAL", 139, 145], ["oxygen", "CHEMICAL", 139, 145], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["oxygen", "SIMPLE_CHEMICAL", 139, 145], ["blood oxygenation", "TEST", 35, 52], ["a low-tech intervention", "TREATMENT", 60, 83], ["more invasive methods of oxygen delivery", "TREATMENT", 114, 154]]], ["Awake pronation is also used in ICU and other inpatient populations, but it has saved many an emergency department (ED) patient from going on the vent.", [["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["the vent", "TREATMENT", 142, 150]]], ["Non-invasive ventilation, invasive mechanical ventilation, and external membrane oxygenation (ECMO) can be selected for moderate to severe hypoxia.", [["external membrane", "ANATOMY", 63, 80], ["hypoxia", "DISEASE", 139, 146], ["Non-invasive ventilation", "TREATMENT", 0, 24], ["invasive mechanical ventilation", "TREATMENT", 26, 57], ["external membrane oxygenation (ECMO", "TREATMENT", 63, 98], ["moderate to severe hypoxia", "PROBLEM", 120, 146], ["invasive", "OBSERVATION_MODIFIER", 26, 34], ["mechanical ventilation", "OBSERVATION", 35, 57], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["hypoxia", "OBSERVATION", 139, 146]]], ["Severe COVID-19 requires mechanical ventilation in the event of severe hypoxemia and respiratory distress.", [["respiratory", "ANATOMY", 85, 96], ["hypoxemia", "DISEASE", 71, 80], ["respiratory distress", "DISEASE", 85, 105], ["Severe COVID", "PROBLEM", 0, 12], ["mechanical ventilation", "TREATMENT", 25, 47], ["severe hypoxemia", "PROBLEM", 64, 80], ["respiratory distress", "PROBLEM", 85, 105], ["mechanical ventilation", "OBSERVATION", 25, 47], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["hypoxemia", "OBSERVATION", 71, 80], ["respiratory distress", "OBSERVATION", 85, 105]]], ["Clinical studies on MERS-CoV, SARS-CoV, and influenza have shown that non-invasive ventilation has a higher failure rate in such patients [15].", [["SARS-CoV", "DISEASE", 30, 38], ["influenza", "DISEASE", 44, 53], ["MERS-CoV", "ORGANISM", 20, 28], ["SARS-CoV", "ORGANISM", 30, 38], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["MERS-CoV", "SPECIES", 20, 28], ["SARS-CoV", "SPECIES", 30, 38], ["Clinical studies", "TEST", 0, 16], ["MERS", "TEST", 20, 24], ["CoV", "TEST", 25, 28], ["SARS", "PROBLEM", 30, 34], ["CoV", "PROBLEM", 35, 38], ["influenza", "PROBLEM", 44, 53], ["non-invasive ventilation", "TREATMENT", 70, 94], ["a higher failure rate", "PROBLEM", 99, 120]]], ["Delayed intubation can increase patient mortality [52].", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["Delayed intubation", "TREATMENT", 0, 18]]], ["Compared with SARS-CoV, the progression of respiratory failure in COVID-19 patients is slower.", [["respiratory", "ANATOMY", 43, 54], ["SARS", "DISEASE", 14, 18], ["respiratory failure", "DISEASE", 43, 62], ["SARS-CoV", "ORGANISM", 14, 22], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 14, 22], ["respiratory failure", "PROBLEM", 43, 62], ["COVID", "TEST", 66, 71], ["progression", "OBSERVATION_MODIFIER", 28, 39], ["respiratory failure", "OBSERVATION", 43, 62], ["slower", "OBSERVATION_MODIFIER", 87, 93]]], ["Some patients with severe respiratory failure can still be successfully treated with non-invasive ventilation.", [["respiratory", "ANATOMY", 26, 37], ["respiratory failure", "DISEASE", 26, 45], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["severe respiratory failure", "PROBLEM", 19, 45], ["non-invasive ventilation", "TREATMENT", 85, 109], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["respiratory failure", "OBSERVATION", 26, 45]]], ["It is recommended to use non-invasive ventilation as much as possible.", [["non-invasive ventilation", "TREATMENT", 25, 49]]], ["When patients with impaired consciousness level, upper airway obstruction, deterioration of oxygenation, or deterioration of ventilation status [53], invasive artificial airway invasive ventilation should be established immediately.Prevention and Control of Nosocomial Infection ::: Development and Evaluation of Antiviral DrugsAn analysis of data from 138 SARS-CoV-2 cases found that 40 medical staff (29%) and 17 hospitalized patients (12.3%) had nosocomial infection in the hospital.", [["upper airway", "ANATOMY", 49, 61], ["airway", "ANATOMY", 170, 176], ["impaired consciousness", "DISEASE", 19, 41], ["airway obstruction", "DISEASE", 55, 73], ["deterioration of oxygenation", "DISEASE", 75, 103], ["SARS", "DISEASE", 357, 361], ["nosocomial infection", "DISEASE", 449, 469], ["patients", "ORGANISM", 5, 13], ["upper airway", "ORGANISM_SUBDIVISION", 49, 61], ["airway", "MULTI-TISSUE_STRUCTURE", 170, 176], ["SARS-CoV", "ORGANISM", 357, 365], ["patients", "ORGANISM", 428, 436], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 428, 436], ["SARS-CoV", "SPECIES", 357, 365], ["impaired consciousness level", "PROBLEM", 19, 47], ["upper airway obstruction", "PROBLEM", 49, 73], ["deterioration of oxygenation", "PROBLEM", 75, 103], ["deterioration of ventilation status", "PROBLEM", 108, 143], ["invasive artificial airway invasive ventilation", "TREATMENT", 150, 197], ["Nosocomial Infection", "PROBLEM", 258, 278], ["Evaluation", "TEST", 299, 309], ["Antiviral DrugsAn analysis", "TEST", 313, 339], ["SARS", "TEST", 357, 361], ["CoV", "TEST", 362, 365], ["nosocomial infection", "PROBLEM", 449, 469], ["upper", "ANATOMY_MODIFIER", 49, 54], ["airway", "ANATOMY", 55, 61], ["obstruction", "OBSERVATION", 62, 73], ["oxygenation", "OBSERVATION_MODIFIER", 92, 103], ["airway", "ANATOMY", 170, 176], ["invasive ventilation", "OBSERVATION", 177, 197], ["Nosocomial", "OBSERVATION_MODIFIER", 258, 268], ["Infection", "OBSERVATION", 269, 278], ["nosocomial", "OBSERVATION_MODIFIER", 449, 459], ["infection", "OBSERVATION", 460, 469]]], ["In the infected medical staff, 31 worked in the general ward, 7 in the emergency department, and 2 in the intensive care unit [54].", [["infected", "OBSERVATION_MODIFIER", 7, 15]]], ["The invading power of the virus from \u201csuper communicators\u201d cannot be underestimated.", [["invading", "OBSERVATION_MODIFIER", 4, 12], ["power", "OBSERVATION_MODIFIER", 13, 18], ["virus", "OBSERVATION", 26, 31], ["cannot be", "UNCERTAINTY", 59, 68]]], ["In addition, patients with heart disease and diabetes have a low ability to defend themselves against infections.", [["heart", "ANATOMY", 27, 32], ["heart disease", "DISEASE", 27, 40], ["diabetes", "DISEASE", 45, 53], ["infections", "DISEASE", 102, 112], ["patients", "ORGANISM", 13, 21], ["heart", "ORGAN", 27, 32], ["patients", "SPECIES", 13, 21], ["heart disease", "PROBLEM", 27, 40], ["diabetes", "PROBLEM", 45, 53], ["a low ability", "PROBLEM", 59, 72], ["infections", "PROBLEM", 102, 112], ["heart", "ANATOMY", 27, 32], ["disease", "OBSERVATION", 33, 40]]], ["As mentioned above, the best way to prevent nosocomial infection in hospitals is to establish and implement a strict disinfection and isolation system, including airway management, quarantine measures, and disposal of excreta.ConclusionsCOVID-19 is highly contagious and is transmitted mainly through the respiratory tract.", [["airway", "ANATOMY", 162, 168], ["respiratory tract", "ANATOMY", 305, 322], ["nosocomial infection", "DISEASE", 44, 64], ["airway", "MULTI-TISSUE_STRUCTURE", 162, 168], ["excreta", "ORGANISM_SUBDIVISION", 218, 225], ["respiratory tract", "ORGANISM_SUBDIVISION", 305, 322], ["nosocomial infection", "PROBLEM", 44, 64], ["a strict disinfection", "TREATMENT", 108, 129], ["isolation system", "TREATMENT", 134, 150], ["airway management", "TREATMENT", 162, 179], ["quarantine measures", "TREATMENT", 181, 200], ["ConclusionsCOVID", "TEST", 226, 242], ["nosocomial", "OBSERVATION_MODIFIER", 44, 54], ["infection", "OBSERVATION", 55, 64], ["airway", "ANATOMY", 162, 168], ["highly", "OBSERVATION_MODIFIER", 249, 255], ["contagious", "OBSERVATION", 256, 266], ["respiratory tract", "ANATOMY", 305, 322]]], ["Most patients with SARS-CoV-2 infection have milder symptoms.", [["SARS-CoV-2 infection", "DISEASE", 19, 39], ["patients", "ORGANISM", 5, 13], ["SARS-CoV-2", "ORGANISM", 19, 29], ["patients", "SPECIES", 5, 13], ["SARS", "PROBLEM", 19, 23], ["CoV-2 infection", "PROBLEM", 24, 39], ["milder symptoms", "PROBLEM", 45, 60]]], ["Some patients will have mild disease in the early stage, suddenly exacerbate later, and eventually die of multiple organ failure, which must get worldwide attention.", [["organ", "ANATOMY", 115, 120], ["organ failure", "DISEASE", 115, 128], ["patients", "ORGANISM", 5, 13], ["organ", "ORGAN", 115, 120], ["patients", "SPECIES", 5, 13], ["mild disease", "PROBLEM", 24, 36], ["multiple organ failure", "PROBLEM", 106, 128], ["mild", "OBSERVATION_MODIFIER", 24, 28], ["disease", "OBSERVATION", 29, 36], ["early stage", "OBSERVATION_MODIFIER", 44, 55], ["organ", "ANATOMY", 115, 120], ["failure", "OBSERVATION", 121, 128]]], ["It is worth noting that some asymptomatic patients are also potential sources of infection.", [["infection", "DISEASE", 81, 90], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["infection", "PROBLEM", 81, 90], ["infection", "OBSERVATION", 81, 90]]], ["The diagnostic criteria for cytokine storm caused by SARS-CoV-2 need to be further studied.", [["SARS", "DISEASE", 53, 57], ["SARS-CoV-2", "ORGANISM", 53, 63], ["cytokine", "PROTEIN", 28, 36], ["SARS-CoV", "SPECIES", 53, 61], ["cytokine storm", "PROBLEM", 28, 42], ["SARS", "PROBLEM", 53, 57]]], ["The diagnosis of COVID-19 relies on the detection of viral nucleic acids as the gold standard.", [["COVID-19", "CHEMICAL", 17, 25], ["nucleic acids", "CHEMICAL", 59, 72], ["COVID-19", "CHEMICAL", 17, 25], ["COVID", "TEST", 17, 22], ["the detection", "TEST", 36, 49], ["viral nucleic acids", "TREATMENT", 53, 72]]], ["However, diagnostic accuracy is better when combined with clinical symptoms, CT results, and biochemical tests.", [["diagnostic accuracy", "TEST", 9, 28], ["clinical symptoms", "PROBLEM", 58, 75], ["CT results", "TEST", 77, 87], ["biochemical tests", "TEST", 93, 110]]], ["At present, for the treatment of COVID-19, no specific antiviral agents have been developed, except for symptomatic supportive treatments.", [["COVID-19", "CHEMICAL", 33, 41], ["COVID", "TEST", 33, 38], ["specific antiviral agents", "TREATMENT", 46, 71], ["symptomatic supportive treatments", "TREATMENT", 104, 137]]], ["Therefore, based on the present information, the strategies for the prevention and treatment of COVID-19 need be further studied.", [["COVID-19", "CHEMICAL", 96, 104], ["the strategies", "TREATMENT", 45, 59], ["COVID", "TEST", 96, 101]]]], "PMC3666982": [["IntroductionInfluenza pandemics are overwhelmingly large scale phenomena that may result in high morbidity, mortality and large economic impacts worldwide.", [["Influenza pandemics", "DISEASE", 12, 31], ["IntroductionInfluenza pandemics", "PROBLEM", 0, 31], ["large scale phenomena", "PROBLEM", 51, 72], ["high morbidity", "PROBLEM", 92, 106], ["large economic impacts worldwide", "PROBLEM", 122, 154], ["large", "OBSERVATION_MODIFIER", 51, 56], ["high", "OBSERVATION_MODIFIER", 92, 96], ["morbidity", "OBSERVATION", 97, 106], ["large", "OBSERVATION_MODIFIER", 122, 127], ["economic", "OBSERVATION_MODIFIER", 128, 136], ["impacts", "OBSERVATION_MODIFIER", 137, 144]]], ["The influenza pandemic of 1918\u20139 is believed to have caused excess mortality of 20\u201340 million people [1].", [["influenza pandemic", "DISEASE", 4, 22], ["1918\u20139", "CHEMICAL", 26, 32], ["people", "SPECIES", 94, 100], ["The influenza pandemic", "PROBLEM", 0, 22], ["excess mortality", "PROBLEM", 60, 76]]], ["Influenza pandemics have occurred during the 20th century and beginning of the 21st century at intervals of between 10 and 40 years, with the latest pandemics occurring in 1918\u20139, 1957\u20138, 1968\u20139 [2] and 2009\u201310 [3].", [["Influenza pandemics", "DISEASE", 0, 19], ["Influenza pandemics", "PROBLEM", 0, 19]]], ["Pharmaceutical and public health measures can help mitigate the impacts of pandemics [4,5] and were implemented by many governments during the last pandemic in 2009\u201310 [6,7].IntroductionBecause empirical or field studies of population-level strategies to control or mitigate influenza pandemics are generally either infeasible (e.g. controlling movement of people within a city) or unethical (e.g. withholding vaccination of subpopulations to assess the effect on transmission), modelling is one of the only suitable methodologies to enable multiple hypothetical pandemic preparedness and mitigation scenarios to be assessed.", [["influenza pandemics", "DISEASE", 275, 294], ["people", "SPECIES", 357, 363], ["Pharmaceutical and public health measures", "TREATMENT", 0, 41], ["empirical or field studies", "TEST", 194, 220], ["population-level strategies", "TREATMENT", 224, 251], ["influenza pandemics", "PROBLEM", 275, 294], ["vaccination of subpopulations", "TREATMENT", 410, 439], ["multiple hypothetical pandemic preparedness", "TREATMENT", 541, 584], ["mitigation scenarios", "TREATMENT", 589, 609]]], ["Epidemic models are especially useful to address epidemiological, economic, and individuals\u2019 behavioural questions [8-10].", [["Epidemic models", "PROBLEM", 0, 15]]], ["The usefulness of epidemic models in directing mitigation efforts has been supported by empirical findings that have echoed previous modelling predictions.", [["epidemic models", "PROBLEM", 18, 33]]], ["For instance, models predicted that reduced international air travel would be unlikely to stop an influenza pandemic [11], a finding later verified empirically during the 2009 H1N1 pandemic [12,13]; other models predicted the potential of antiviral prophylaxis and contact tracing to control small outbreaks [5], a prediction also verified in real-life outbreaks in semi-closed army camps [14].IntroductionFor epidemic models to produce reasonable predictions on the course of the epidemic and how it can be controlled, we need to be confident that the model captures the essential mechanisms that drive the epidemic dynamics [15].", [["influenza pandemic", "DISEASE", 98, 116], ["H1N1", "DISEASE", 176, 180], ["reduced international air travel", "PROBLEM", 36, 68], ["an influenza pandemic", "PROBLEM", 95, 116], ["antiviral prophylaxis", "TREATMENT", 239, 260], ["contact tracing", "TEST", 265, 280], ["small outbreaks", "PROBLEM", 292, 307], ["epidemic models", "PROBLEM", 410, 425], ["antiviral prophylaxis", "OBSERVATION", 239, 260]]], ["One of the main focuses of this review is to evaluate the trends in the construction and validation of mechanistic models \u2014 models that explicitly incorporate the mechanisms or processes underlying the outcomes of the system \u2014 of infection dynamics for influenza pandemic preparedness, control and mitigation.", [["infection", "DISEASE", 230, 239], ["influenza pandemic", "DISEASE", 253, 271], ["infection dynamics", "PROBLEM", 230, 248], ["influenza pandemic preparedness", "TREATMENT", 253, 284], ["main", "OBSERVATION_MODIFIER", 11, 15], ["infection", "OBSERVATION", 230, 239]]], ["Traditionally, the main approach for mechanistic modelling of influenza pandemics has been based on compartmental models (Table 1) represented by systems of differential equations.", [["influenza pandemics", "DISEASE", 62, 81], ["influenza pandemics", "PROBLEM", 62, 81], ["influenza", "OBSERVATION", 62, 71]]], ["Compartmental models represented the dynamics of a host-disease system for which a tractable analytical solution could in principle be derived through mathematical methods [8,18].", [["a host-disease system", "PROBLEM", 49, 70], ["a tractable analytical solution", "TREATMENT", 81, 112]]], ["It was not until the widespread availability of modern computing power that more complex compartmental models for which analytical solutions could not be derived and agent-based models (ABMs, Table 1) explored using computer simulation became an attractive alternative.", [["analytical solutions", "TREATMENT", 120, 140]]], ["Recent modelling work, dealing with the threat of an influenza pandemic of avian origin (A-H5N1), with the severe acute respiratory syndrome (SARS) crisis in 2003 and the H1N1 2009 pandemic, has exemplified the use of both models solved analytically and through simulation [3,5,19,20].IntroductionPandemic preparedness, control and mitigation modelling has heretofore been reviewed [21-25].", [["influenza", "DISEASE", 53, 62], ["acute respiratory syndrome", "DISEASE", 114, 140], ["SARS", "DISEASE", 142, 146], ["A-H5N1", "ORGANISM", 89, 95], ["A-H5N1", "SPECIES", 89, 95], ["A-H5N1", "SPECIES", 89, 95], ["an influenza pandemic", "PROBLEM", 50, 71], ["the severe acute respiratory syndrome", "PROBLEM", 103, 140], ["SARS) crisis", "PROBLEM", 142, 154], ["IntroductionPandemic preparedness", "TREATMENT", 285, 318], ["influenza", "OBSERVATION", 53, 62], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["respiratory syndrome", "OBSERVATION", 120, 140]]], ["Despite the usefulness of modelling, few public health practitioners or decision makers undergo explicit training in modelling techniques.", [["explicit training", "TREATMENT", 96, 113]]], ["When combined with the rapid growth in modelling capabilities driven by increasing computing power, and the multitude of different disciplines \u2013 e.g. economics, psychology, genetics \u2013 that contribute to modelling epidemics, this makes it daunting to keep abreast of all that modelling is capable of.", [["the rapid growth", "PROBLEM", 19, 35], ["modelling epidemics", "PROBLEM", 203, 222]]], ["Given the diversity of new techniques in these aspects of modelling, a review of common traits would be very helpful for non-expert users to determine which modelling techniques are most useful to address the decisions they face.", [["new techniques", "TREATMENT", 23, 37], ["new", "OBSERVATION_MODIFIER", 23, 26]]], ["In addition, a protocol to guide the reporting of these aspects together with model construction would help modellers and policy makers compare and evaluate models.", [["a protocol", "TREATMENT", 13, 23], ["model construction", "TREATMENT", 78, 96]]], ["To this end, we review and classify models for influenza pandemic preparedness from January 2000 to September 2011, and use the resulting analysis to develop a simple guiding protocol for reporting modelling decisions.Search strategy and selection criteria ::: MethodsWe searched Google Scholar, PubMed and ISI Web of Knowledge to identify articles focusing on influenza pandemic modelling to inform management strategies (see Additional file 1: Figure S1 in the electronic supplementary material (ESM) for a PRISMA flow diagram [28]).", [["influenza pandemic", "DISEASE", 47, 65], ["influenza pandemic", "DISEASE", 361, 379], ["influenza", "PROBLEM", 47, 56], ["a simple guiding protocol", "TREATMENT", 158, 183], ["influenza pandemic modelling", "TREATMENT", 361, 389], ["management strategies", "TREATMENT", 400, 421], ["a PRISMA flow diagram", "TEST", 507, 528]]], ["Our search criterion was: contains pandemic AND model* AND influenza AND policy OR policies.", [["influenza", "PROBLEM", 59, 68]]], ["Our eligibility criteria were articles that: (i) were published in peer reviewed journals from January 2000 to September 2011; (ii) aimed to advise policy makers and made policy recommendations about pandemic influenza preparedness, mitigation or control; and (iii) employed mechanistic models to derive those insights.", [["influenza", "DISEASE", 209, 218], ["pandemic influenza preparedness", "TREATMENT", 200, 231], ["mitigation or control", "TREATMENT", 233, 254]]], ["We further excluded cost-effectiveness and decision tree studies that did not incorporate disease transmission dynamics.", [["decision tree studies", "TEST", 43, 64], ["disease transmission dynamics", "PROBLEM", 90, 119]]], ["After an additional query refinement in Google Scholar (adding to the previous query the terms: AND preparedness OR strateg* AND simulation OR compartment*), screening of articles and further full-text assessment for their eligibility (Additional file 1: Figure S1 in ESM), 91 articles were selected for the analysis.Classification and evaluation of modelling traits ::: MethodsWe classify models into several major groups: compartmental epidemic models, network models, agent-based models, metapopulation models, game theoretic models, optimal control models and partial or general computable equilibrium models (definitions of the models can be found in Table 1).", [["text assessment", "TEST", 197, 212], ["Figure S1 in ESM", "TEST", 255, 271], ["the analysis", "TEST", 304, 316], ["evaluation", "TEST", 336, 346], ["partial or general computable equilibrium models", "PROBLEM", 564, 612], ["partial", "OBSERVATION_MODIFIER", 564, 571]]], ["In some instances models can conform to several categories: e.g. compartmental models combined with metapopulation models.Classification and evaluation of modelling traits ::: MethodsIn addition to classifying the models, we evaluated traits common to several taxa consistent with the focus of the review on evaluating the trends in parameterization and validation, incorporation of economic aspects and host behaviour (Table 2).", [["metapopulation models", "TREATMENT", 100, 121], ["evaluation", "TEST", 141, 151], ["Methods", "TREATMENT", 176, 183], ["validation", "TREATMENT", 354, 364]]], ["We evaluated capacity of the models to answer (i) epidemiological questions: for instance, how many people and which age groups were expected to become infected, hospitalized and die as a result of infection during the pandemic?", [["infection", "DISEASE", 198, 207], ["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106], ["infection", "PROBLEM", 198, 207], ["infected", "OBSERVATION", 152, 160], ["infection", "OBSERVATION", 198, 207]]], ["To what extent would control and treatment interventions mitigate this impact?; (ii) health economic questions: what would be the economic impacts of the pandemic and which interventions would represent better value for money to reduce the health and economic impacts?; (iii) behavioural questions: would changes in the behaviour of the individuals during the pandemic influence the effectiveness of the interventions?Classification and evaluation of modelling traits ::: MethodsTo classify models by their construction and validation techniques, we evaluated whether they (i) incorporated an assessment of the sensitivity of their results to model parameters and assumptions, (ii) were parameterized using parameters directly from other models, and (iii) were validated from empirical data.", [["treatment interventions", "TREATMENT", 33, 56], ["the interventions", "TREATMENT", 400, 417], ["evaluation", "TEST", 437, 447], ["validation techniques", "TEST", 524, 545], ["an assessment", "TEST", 590, 603], ["empirical data", "TEST", 776, 790]]], ["To that end, the articles were categorized according to the type of model used (Table 1), population heterogeneity level considered, parameterization procedure, consideration of economic impacts, inclusion of human behaviour and performance of validation or sensitivity analysis (see the ESM for a full list of the models and their characteristics).Standard reporting protocol ::: MethodsTo facilitate the systematization and comparison of models we develop a guiding protocol for reporting model general Characteristics, Construction, Parameterization and Validation aspects (CCPV protocol), derived from the results of the review.", [["human", "ORGANISM", 209, 214], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 209, 214], ["population heterogeneity level", "PROBLEM", 90, 120], ["parameterization procedure", "TREATMENT", 133, 159], ["validation", "TEST", 244, 254], ["sensitivity analysis", "TEST", 258, 278], ["Methods", "TREATMENT", 381, 388], ["a guiding protocol", "TREATMENT", 458, 476]]], ["The protocol builds upon previous protocols to describe ABMs [31] and retains the description of technical aspects of the models that facilitate its understanding and reproduction, for instance describing the aim of the model, scale, structure, model type, dynamic aspects, initialization, data inputs, the way individuals and their interactions are considered or the inclusion of stochasticity (Table 3).", [["previous protocols", "TREATMENT", 25, 43], ["ABMs", "TEST", 56, 60]]], ["The protocol was then extensively expanded to include aspects relative to models construction, parameterization, sensitivity analysis, verification and validation, incorporation of economics and host behaviour.Review of influenza pandemic modellingThe prevalence of modelling for pandemic influenza has increased dramatically since 2000 (Figure 1B).", [["influenza pandemic", "DISEASE", 220, 238], ["influenza", "DISEASE", 289, 298], ["The protocol", "TREATMENT", 0, 12], ["sensitivity analysis", "TEST", 113, 133], ["verification", "TEST", 135, 147], ["validation", "TEST", 152, 162], ["influenza", "PROBLEM", 220, 229], ["pandemic influenza", "PROBLEM", 280, 298]]], ["Metapopulation models were employed in combination with both compartmental models and ABMs (9 and 3 models respectively).", [["Metapopulation models", "TREATMENT", 0, 21], ["ABMs", "TEST", 86, 90]]], ["The second most common modelling approach were ABMs (22/91, 24%).", [["ABMs", "TEST", 47, 51]]], ["The rest of the models were computable general equilibrium models (CGE) (3/91, 3%), network models (4/91, 4%) and household models (3/91, 3%) (Figure 1A).Review of influenza pandemic modellingMost models that were applied to a specific geographic region focused on high-income countries.", [["influenza pandemic", "DISEASE", 164, 182], ["network models", "TEST", 84, 98], ["influenza pandemic modelling", "TREATMENT", 164, 192]]], ["Very scarce were studies not focusing on high-income economies (5/91, 6% applied to upper-middle income countries like Thailand or Mexico and none applied exclusively to low-income or lower-middle income countries), despite the higher case fatality rate expected in those countries [32].", [["middle", "ANATOMY_MODIFIER", 90, 96]]], ["A few exceptions did, on the other hand, concentrate on the effects of school closures [4,6,33-37] and on hospitals or hospital staff [38-40].Implications for CCPV protocol ::: ParameterizationReporting the combination of data used for parameterization would allow model users to evaluate the reliability of the models, reduce the risk of model overfitting and allow assessing the adequacy of the parameter for a specific setting (Table 3 \u201cmodel parameterization\u201d).", [["parameterization", "TREATMENT", 236, 252], ["model overfitting", "PROBLEM", 339, 356], ["few", "OBSERVATION_MODIFIER", 2, 5], ["overfitting", "OBSERVATION", 345, 356]]], ["Sensitivity and uncertainty analysis are other ways to evaluate the influence of individual parameters and their uncertainty range on model predictions (Table 2).", [["Sensitivity", "TEST", 0, 11], ["uncertainty analysis", "TEST", 16, 36], ["individual parameters", "TEST", 81, 102], ["model predictions", "TEST", 134, 151]]], ["They can be used to direct data collection efforts and should ideally be reported (Table 3 \u201csensitivity and uncertainty analysis\u201d).Implications for CCPV protocol ::: ValidationReporting the underlying assumptions governing the model, as well as their justification, would help model users evaluate the structural validity of the model (Table 3 \u201ccharacteristics, theoretical basis\u201d).", [["uncertainty analysis", "TEST", 108, 128]]], ["In addition, reporting structural and predictive validity together with subsequent structural changes (e.g. spatial explicitness) to models would allow policy makers to assess the reliability of model predictions, and other analysts to assess the robustness of model construction and parameterisation (Table 3 \u201cconstruction aspects, space\u201d and \u201cmodel validation\u201d).", [["subsequent structural changes", "PROBLEM", 72, 101], ["model construction", "TREATMENT", 261, 279], ["space\u201d", "TREATMENT", 333, 339]]], ["Further assistance in evaluating the validity of the model can be obtained through reporting model verification techniques, whether the model has been compared with simpler versions or with other models developed in parallel (Table 3 \u201cmodel verification\u201d and \u201ccomplexity\u201d).Implications for CCPV protocol ::: Economic aspectsReporting the economic aspects considered in the model, the type of analysis employed, heterogeneity of impacts in different groups and disease burden metrics employed, would facilitate model users understanding the capabilities of the model and the adequacy of the economic analysis undertaken (Table 3, \u201cmodel construction, economic aspects\u201d).Implications for CCPV protocol ::: Individual behaviourReporting of the assumptions on how behaviour is modelled would help model users interpreting model results.", [["model verification techniques", "TEST", 93, 122], ["model verification", "TEST", 235, 253], ["disease burden metrics", "PROBLEM", 460, 482], ["the economic analysis", "TEST", 586, 607], ["impacts", "OBSERVATION_MODIFIER", 428, 435]]], ["Reporting of comparisons of model results with and without behaviour would further facility the understanding of behaviour in the model (Table 3, \u201cconstruction aspects, behaviour\u201d).DiscussionInfluenza pandemic models have, over the last decade, proliferated dramatically.", [["Influenza pandemic", "DISEASE", 191, 209], ["Influenza pandemic models", "PROBLEM", 191, 216]]], ["In parallel to the rapid increase in the number of models, many now incorporate sophisticated parameterization and validation techniques, economic analyses and the behaviour of individuals.", [["validation techniques", "TEST", 115, 136], ["economic analyses", "TEST", 138, 155], ["rapid", "OBSERVATION_MODIFIER", 19, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["Techniques such as Bayesian inference, agent-based modelling and the application of game theory are being newly applied to influenza, answering a more diverse set of public health questions.DiscussionThis increase in modelling diversity stems from an increase in diversity of research questions and policy strategies.", [["influenza", "DISEASE", 123, 132], ["agent", "TREATMENT", 39, 44], ["game theory", "TREATMENT", 84, 95], ["influenza", "PROBLEM", 123, 132], ["modelling diversity stems", "TREATMENT", 217, 242], ["policy strategies", "TREATMENT", 299, 316], ["increase", "OBSERVATION_MODIFIER", 251, 259]]], ["Even though models need to be fit for purpose, it is noteworthy that many influenza pandemics models rely on parameters from previous modelling studies and are rarely validated using observed data.DiscussionAlthough model validation is not expected in influenza pandemic modelling, it is considered a basic prerequisite for publication in other fields, such as the related discipline of ecological modelling.", [["influenza pandemics", "DISEASE", 74, 93], ["many influenza pandemics models", "PROBLEM", 69, 100], ["previous modelling studies", "TEST", 125, 151], ["influenza pandemic modelling", "PROBLEM", 252, 280], ["publication in other fields", "PROBLEM", 324, 351]]], ["For instance, the editorial policy of the journal Ecological Modelling states: \u201cPapers that only present a model without support of ecological data for calibration and hopefully also validation of the model will not be accepted because a model has in most cases no interest before it has been held up to ecological reality\u201d [87], and a standardised ODD protocol (overview, design concepts, and details) for documenting ABMs more generally in that field has been published in the same journal [31,88].", [["ODD", "DISEASE", 349, 352], ["documenting ABMs", "PROBLEM", 407, 423]]], ["Examples are guidelines from the National Institute for Clinical Excellence (NICE) in the UK [89], the Drummond Checklist that is required for economic submissions by the British Medical Journal [90], guidelines for cost-effectiveness analysis [91] and modelling guidelines from the International Society for Pharmacoeconomics and Outcomes Research [92].DiscussionGiven the large variety in modelling approaches for influenza pandemic management and to facilitate comparison between models, we developed a simple general modelling Characteristics, Construction, Parameterization and Validation aspects (CCPV) reporting protocol (Table 3).", [["influenza pandemic", "DISEASE", 416, 434], ["influenza pandemic management", "TREATMENT", 416, 445], ["large", "OBSERVATION_MODIFIER", 374, 379], ["variety", "OBSERVATION_MODIFIER", 380, 387]]], ["The use of the protocol together with international data sharing mechanisms would facilitate comparability between models, transparency in decisions about the kinds of models to use, and ultimately increase the confidence in the use of modelling in formulating influenza pandemic policies.Competing interestsThe authors declare no conflict of interests.Authors\u2019 contributionsLRC, ARC made substantial contributions to conception and design.", [["the protocol", "TREATMENT", 11, 23], ["modelling in formulating influenza pandemic policies", "TREATMENT", 236, 288]]], ["LRC performed data collection and analysis.", [["LRC performed data collection", "TEST", 0, 29], ["analysis", "TEST", 34, 42]]], ["LRC, ARC, MJ, MIC, VJL analysed and interpreted the data.", [["ARC", "ANATOMY", 5, 8]]], ["LRC, ARC, MJ, MIC, VJL and GJM have been involved in drafting the manuscript or revising it critically for important intellectual content.", [["ARC", "OBSERVATION_MODIFIER", 5, 8]]], ["LRC, ARC, MJ, MIC, VJL and GJM have given final approval of the version to be published.", [["the version", "TREATMENT", 60, 71], ["ARC", "ANATOMY", 5, 8]]]], "PMC4886426": [["BackgroundNoninvasive ventilation (NIV) is defined as any form of ventilatory support applied without endotracheal intubation [1].", [["endotracheal", "ANATOMY", 102, 114], ["BackgroundNoninvasive ventilation (NIV", "TREATMENT", 0, 38], ["ventilatory support", "TREATMENT", 66, 85], ["endotracheal intubation", "TREATMENT", 102, 125]]], ["Application of NIV is a cornerstone for the treatment of acute respiratory failure of various etiologies [2].", [["respiratory", "ANATOMY", 63, 74], ["respiratory failure", "DISEASE", 63, 82], ["NIV", "CHEMICAL", 15, 18], ["NIV", "TREATMENT", 15, 18], ["a cornerstone", "TREATMENT", 22, 35], ["the treatment", "TREATMENT", 40, 53], ["acute respiratory failure", "PROBLEM", 57, 82], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory failure", "OBSERVATION", 63, 82]]], ["It reduces intubation rate in patients with exacerbations of chronic obstructive pulmonary disease (COPD) and acute cardiogenic pulmonary edema [3] and in immunocompromised patients with hypoxemic respiratory failure [4, 5].", [["pulmonary", "ANATOMY", 81, 90], ["pulmonary", "ANATOMY", 128, 137], ["respiratory", "ANATOMY", 197, 208], ["chronic obstructive pulmonary disease", "DISEASE", 61, 98], ["COPD", "DISEASE", 100, 104], ["cardiogenic pulmonary edema", "DISEASE", 116, 143], ["hypoxemic respiratory failure", "DISEASE", 187, 216], ["patients", "ORGANISM", 30, 38], ["pulmonary", "ORGAN", 81, 90], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 173, 181], ["intubation rate", "TREATMENT", 11, 26], ["exacerbations", "PROBLEM", 44, 57], ["chronic obstructive pulmonary disease", "PROBLEM", 61, 98], ["COPD)", "PROBLEM", 100, 105], ["acute cardiogenic pulmonary edema", "PROBLEM", 110, 143], ["hypoxemic respiratory failure", "PROBLEM", 187, 216], ["intubation", "OBSERVATION", 11, 21], ["chronic", "OBSERVATION_MODIFIER", 61, 68], ["obstructive", "OBSERVATION_MODIFIER", 69, 80], ["pulmonary", "ANATOMY", 81, 90], ["disease", "OBSERVATION", 91, 98], ["COPD", "OBSERVATION", 100, 104], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["cardiogenic", "OBSERVATION_MODIFIER", 116, 127], ["pulmonary", "ANATOMY", 128, 137], ["edema", "OBSERVATION", 138, 143], ["immunocompromised", "OBSERVATION_MODIFIER", 155, 172], ["hypoxemic", "OBSERVATION_MODIFIER", 187, 196], ["respiratory failure", "OBSERVATION", 197, 216]]], ["Using NIV is discussed in mild-to-moderate acute respiratory distress syndrome (ARDS) patients (PaO2/FiO2 > 150) [6].BackgroundFiberoptic bronchoscopy (FOB) may be required in some patients with acute respiratory failure in intensive care units (ICU), mainly as diagnostic tool or to remove abundant secretions [7, 8].", [["respiratory", "ANATOMY", 201, 212], ["secretions", "ANATOMY", 300, 310], ["acute respiratory distress syndrome", "DISEASE", 43, 78], ["ARDS", "DISEASE", 80, 84], ["respiratory failure", "DISEASE", 201, 220], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 181, 189], ["secretions", "ORGANISM_SUBSTANCE", 300, 310], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 181, 189], ["NIV", "TREATMENT", 6, 9], ["mild-to-moderate acute respiratory distress syndrome", "PROBLEM", 26, 78], ["ARDS", "PROBLEM", 80, 84], ["PaO2", "TEST", 96, 100], ["FiO2", "TEST", 101, 105], ["BackgroundFiberoptic bronchoscopy", "TREATMENT", 117, 150], ["acute respiratory failure", "PROBLEM", 195, 220], ["diagnostic tool", "TEST", 262, 277], ["abundant secretions", "PROBLEM", 291, 310], ["moderate", "OBSERVATION_MODIFIER", 34, 42], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["respiratory distress", "OBSERVATION", 49, 69], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["respiratory", "ANATOMY", 201, 212], ["failure", "OBSERVATION", 213, 220], ["secretions", "OBSERVATION", 300, 310]]], ["As a matter of fact it may also be applied to determine the cause of diffuse pulmonary infiltrates (infection, diffuse alveolar hemorrhage, organizing pneumonia) [9].", [["pulmonary", "ANATOMY", 77, 86], ["alveolar", "ANATOMY", 119, 127], ["infection", "DISEASE", 100, 109], ["alveolar hemorrhage", "DISEASE", 119, 138], ["pneumonia", "DISEASE", 151, 160], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 77, 98], ["alveolar", "MULTI-TISSUE_STRUCTURE", 119, 127], ["diffuse pulmonary infiltrates", "PROBLEM", 69, 98], ["infection", "PROBLEM", 100, 109], ["diffuse alveolar hemorrhage", "PROBLEM", 111, 138], ["organizing pneumonia)", "PROBLEM", 140, 161], ["diffuse", "OBSERVATION_MODIFIER", 69, 76], ["pulmonary", "ANATOMY", 77, 86], ["infiltrates", "OBSERVATION", 87, 98], ["infection", "OBSERVATION", 100, 109], ["diffuse", "OBSERVATION_MODIFIER", 111, 118], ["alveolar", "ANATOMY_MODIFIER", 119, 127], ["hemorrhage", "OBSERVATION", 128, 138], ["organizing", "OBSERVATION_MODIFIER", 140, 150], ["pneumonia", "OBSERVATION", 151, 160]]], ["Other indications for FOB in critically ill patients consist of atelectasis, hemoptysis and suspicion of lung neoplasia.", [["lung neoplasia", "ANATOMY", 105, 119], ["critically ill", "DISEASE", 29, 43], ["atelectasis", "DISEASE", 64, 75], ["hemoptysis", "DISEASE", 77, 87], ["lung neoplasia", "DISEASE", 105, 119], ["patients", "ORGANISM", 44, 52], ["lung neoplasia", "CANCER", 105, 119], ["patients", "SPECIES", 44, 52], ["FOB", "TREATMENT", 22, 25], ["atelectasis", "PROBLEM", 64, 75], ["hemoptysis", "PROBLEM", 77, 87], ["lung neoplasia", "PROBLEM", 105, 119], ["atelectasis", "OBSERVATION", 64, 75], ["hemoptysis", "OBSERVATION", 77, 87], ["suspicion of", "UNCERTAINTY", 92, 104], ["lung", "ANATOMY", 105, 109], ["neoplasia", "OBSERVATION", 110, 119]]], ["Patients in ICU for acute respiratory failure often have comorbidities that increase the risk of bronchoscopy related complications.", [["respiratory", "ANATOMY", 26, 37], ["acute respiratory failure", "DISEASE", 20, 45], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["acute respiratory failure", "PROBLEM", 20, 45], ["comorbidities", "PROBLEM", 57, 70], ["bronchoscopy related complications", "PROBLEM", 97, 131], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory", "ANATOMY", 26, 37], ["failure", "OBSERVATION", 38, 45], ["bronchoscopy", "OBSERVATION", 97, 109]]], ["Feasibility of bronchoscopy during NIV in patients with respiratory failure was shown previously and NIV was found to be superior to conventional oxygen supplementation for preventing gas-exchange deterioration during FOB [10, 11].", [["respiratory", "ANATOMY", 56, 67], ["respiratory failure", "DISEASE", 56, 75], ["oxygen", "CHEMICAL", 146, 152], ["NIV", "CHEMICAL", 101, 104], ["oxygen", "CHEMICAL", 146, 152], ["patients", "ORGANISM", 42, 50], ["oxygen", "SIMPLE_CHEMICAL", 146, 152], ["patients", "SPECIES", 42, 50], ["bronchoscopy", "TREATMENT", 15, 27], ["NIV", "TREATMENT", 35, 38], ["respiratory failure", "PROBLEM", 56, 75], ["NIV", "TREATMENT", 101, 104], ["conventional oxygen supplementation", "TREATMENT", 133, 168], ["respiratory", "ANATOMY", 56, 67], ["failure", "OBSERVATION", 68, 75]]], ["In those studies, NIV was used to facilitate bronchoscopy and NIV was not required prior to bronchoscopy.", [["NIV", "CHEMICAL", 18, 21], ["NIV", "TREATMENT", 18, 21], ["bronchoscopy", "TEST", 45, 57], ["NIV", "TREATMENT", 62, 65], ["bronchoscopy", "TEST", 92, 104]]], ["However, there is limited data on the feasibility and usefulness of FOB in patients who are already treated with NIV for acute respiratory failure [12] and in particular there is not enough evidence for using NIV in patients with ARDS [6].", [["respiratory", "ANATOMY", 127, 138], ["acute respiratory failure", "DISEASE", 121, 146], ["ARDS", "DISEASE", 230, 234], ["NIV", "CHEMICAL", 113, 116], ["NIV", "CHEMICAL", 209, 212], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 216, 224], ["the feasibility", "TEST", 34, 49], ["NIV", "TREATMENT", 113, 116], ["acute respiratory failure", "PROBLEM", 121, 146], ["NIV", "TREATMENT", 209, 212], ["ARDS", "PROBLEM", 230, 234], ["respiratory", "ANATOMY", 127, 138], ["failure", "OBSERVATION", 139, 146], ["not enough evidence for", "UNCERTAINTY", 179, 202]]], ["Therefore, we aimed to evaluate the feasibility and safety of FOB in patients with ARDS ventilated with NIV and its contribution in the diagnosis and/or modification of the ongoing therapy.Study population ::: MethodsThe study population was obtained from the specified respiratory intensive care unit (January 2010-December 2014).Study population ::: MethodsInclusion criteria were: 1.", [["ARDS", "DISEASE", 83, 87], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["FOB", "TEST", 62, 65], ["ARDS ventilated", "PROBLEM", 83, 98], ["NIV", "TREATMENT", 104, 107], ["the ongoing therapy", "TREATMENT", 169, 188], ["Methods", "TREATMENT", 210, 217], ["The study population", "TEST", 217, 237]]], ["ARDS diagnosed by Berlin criteria or The American-European Consensus Conference [13, 14], 2.", [["ARDS", "DISEASE", 0, 4], ["ARDS", "PROBLEM", 0, 4]]], ["Treated with NIV before the bronchoscopy 4.", [["NIV", "CHEMICAL", 13, 16], ["NIV", "TREATMENT", 13, 16], ["the bronchoscopy", "TREATMENT", 24, 40]]], ["Requiring FOB with or without bronchoalveolar lavage (BAL) for diagnostic or therapeutic apporach, 5.", [["bronchoalveolar lavage", "ANATOMY", 30, 52], ["BAL", "ANATOMY", 54, 57], ["bronchoalveolar lavage", "TEST", 30, 52]]], ["Refusal of NIV, 2.", [["NIV", "TREATMENT", 11, 14]]], ["Presence of contraindications for NIV such as facial deformity, upper gastrointestinal bleeding, upper airway obstruction, inability to protect the airway, significantly altered mental status, severe haemodynamic instability, respiratory or cardiac arrest and acute coronary syndromes, 3.", [["facial", "ANATOMY", 46, 52], ["gastrointestinal", "ANATOMY", 70, 86], ["airway", "ANATOMY", 103, 109], ["airway", "ANATOMY", 148, 154], ["respiratory", "ANATOMY", 226, 237], ["cardiac", "ANATOMY", 241, 248], ["coronary", "ANATOMY", 266, 274], ["facial deformity", "DISEASE", 46, 62], ["upper gastrointestinal bleeding", "DISEASE", 64, 95], ["airway obstruction", "DISEASE", 103, 121], ["haemodynamic instability", "DISEASE", 200, 224], ["respiratory or cardiac arrest", "DISEASE", 226, 255], ["acute coronary syndromes", "DISEASE", 260, 284], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 64, 86], ["upper airway", "ORGANISM_SUBDIVISION", 97, 109], ["airway", "MULTI-TISSUE_STRUCTURE", 148, 154], ["NIV", "TREATMENT", 34, 37], ["facial deformity", "PROBLEM", 46, 62], ["upper gastrointestinal bleeding", "PROBLEM", 64, 95], ["upper airway obstruction", "PROBLEM", 97, 121], ["inability to protect the airway", "PROBLEM", 123, 154], ["significantly altered mental status", "PROBLEM", 156, 191], ["severe haemodynamic instability", "PROBLEM", 193, 224], ["respiratory or cardiac arrest", "PROBLEM", 226, 255], ["acute coronary syndromes", "PROBLEM", 260, 284], ["facial", "ANATOMY", 46, 52], ["deformity", "OBSERVATION", 53, 62], ["upper", "ANATOMY_MODIFIER", 64, 69], ["gastrointestinal", "ANATOMY", 70, 86], ["bleeding", "OBSERVATION", 87, 95], ["upper", "ANATOMY_MODIFIER", 97, 102], ["airway", "ANATOMY", 103, 109], ["obstruction", "OBSERVATION", 110, 121], ["airway", "ANATOMY", 148, 154], ["significantly", "OBSERVATION_MODIFIER", 156, 169], ["altered", "OBSERVATION_MODIFIER", 170, 177], ["mental status", "OBSERVATION", 178, 191], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["haemodynamic instability", "OBSERVATION", 200, 224], ["cardiac", "ANATOMY", 241, 248], ["arrest", "OBSERVATION", 249, 255], ["acute", "OBSERVATION_MODIFIER", 260, 265], ["coronary", "ANATOMY", 266, 274], ["syndromes", "OBSERVATION", 275, 284]]], ["Tracheostomy or intubation before admission, 4.", [["Tracheostomy", "TREATMENT", 0, 12], ["intubation", "TREATMENT", 16, 26]]], ["Presence of contraindications for bronchoscopy procedure such as insufficient platelet number (<70,000 cells/\u03bcL) and coagulation disorders, 5.", [["platelet", "ANATOMY", 78, 86], ["cells", "ANATOMY", 103, 108], ["insufficient platelet number", "DISEASE", 65, 93], ["coagulation disorders", "DISEASE", 117, 138], ["platelet", "CELL", 78, 86], ["bronchoscopy procedure", "TREATMENT", 34, 56], ["insufficient platelet number", "PROBLEM", 65, 93], ["coagulation disorders", "PROBLEM", 117, 138]]], ["Patients with NIV use at home prior to ICU admission.Study population ::: MethodsDemographic characteristics, comorbid diseases, presence of immunosuppression, Acute Physiology and Chronic Health Evaluation II (APACHE II) score [15] and radiologic and laboratory findings were recorded for each patient.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 295, 302], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 295, 302], ["comorbid diseases", "PROBLEM", 110, 127], ["immunosuppression", "TREATMENT", 141, 158], ["Acute Physiology", "PROBLEM", 160, 176], ["Chronic Health Evaluation", "TEST", 181, 206], ["APACHE II) score", "TEST", 211, 227], ["radiologic and laboratory findings", "TEST", 237, 271], ["comorbid diseases", "OBSERVATION", 110, 127], ["immunosuppression", "OBSERVATION", 141, 158], ["Acute", "OBSERVATION_MODIFIER", 160, 165], ["Chronic", "OBSERVATION_MODIFIER", 181, 188]]], ["Acquired immunodeficiency syndrome, immunosuppressive medication, organ transplantation, high dose chemotherapy during the past 60 days, absolute neutrophil count < 1000/mL were defined as immunosuppression.", [["organ", "ANATOMY", 66, 71], ["neutrophil", "ANATOMY", 146, 156], ["Acquired immunodeficiency syndrome", "DISEASE", 0, 34], ["organ", "ORGAN", 66, 71], ["neutrophil", "CELL", 146, 156], ["Acquired immunodeficiency syndrome", "PROBLEM", 0, 34], ["immunosuppressive medication", "TREATMENT", 36, 64], ["organ transplantation", "TREATMENT", 66, 87], ["high dose chemotherapy", "TREATMENT", 89, 111], ["absolute neutrophil count", "TEST", 137, 162], ["immunosuppression", "TREATMENT", 189, 206], ["immunodeficiency syndrome", "OBSERVATION", 9, 34]]], ["Standard microbiological diagnostic measures before FOB and additional serological studies were ordered in immunosuppressed patients as indicated.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["FOB", "TEST", 52, 55], ["additional serological studies", "TEST", 60, 90], ["immunosuppressed patients", "TREATMENT", 107, 132]]], ["Heart and respiratory rates, blood pressures and arterial blood gases were assessed 15 min before and 1 h after the FOB for this study.", [["Heart", "ANATOMY", 0, 5], ["respiratory", "ANATOMY", 10, 21], ["blood", "ANATOMY", 29, 34], ["arterial blood", "ANATOMY", 49, 63], ["Heart", "ORGAN", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 49, 63], ["Heart and respiratory rates", "TEST", 0, 27], ["blood pressures", "TEST", 29, 44], ["arterial blood gases", "TEST", 49, 69], ["the FOB", "TEST", 112, 119], ["this study", "TEST", 124, 134], ["respiratory rates", "OBSERVATION", 10, 27], ["pressures", "OBSERVATION_MODIFIER", 35, 44], ["arterial", "ANATOMY", 49, 57]]], ["These measurements and ventilator settings were monitored during FOB.Noninvasive ventilation ::: MethodsAll patients were on NIV prior and throughout the bronchoscopic sampling in the ICU.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["These measurements", "TEST", 0, 18], ["ventilator settings", "TREATMENT", 23, 42], ["FOB", "TEST", 65, 68], ["Methods", "TREATMENT", 97, 104], ["NIV", "TREATMENT", 125, 128], ["the bronchoscopic sampling", "TEST", 150, 176]]], ["NIV was applied via simple oro-nasal mask (AF 531 Oro-nasal mask, Philips Respironics) or full-face mask (PerforMax Total face mask, Philips Respironics) (Fig. 1) and the ventilator settings were adjusted by the pulmonologist.", [["oro-nasal", "ANATOMY", 27, 36], ["NIV", "CHEMICAL", 0, 3], ["NIV", "TREATMENT", 0, 3], ["simple oro-nasal mask", "TREATMENT", 20, 41], ["AF 531 Oro-nasal mask", "TREATMENT", 43, 64], ["Philips Respironics", "TREATMENT", 66, 85], ["full-face mask", "TREATMENT", 90, 104], ["PerforMax Total face mask", "TREATMENT", 106, 131], ["Philips Respironics", "TREATMENT", 133, 152], ["the ventilator settings", "TREATMENT", 167, 190]]], ["ICU ventilator (Servo 900C, Siemens) or dedicated NIV ventilator (VIVO 40, General Electric) devices were set with the optimal required FiO2.", [["FiO2", "CHEMICAL", 136, 140], ["ICU ventilator", "TREATMENT", 0, 14], ["dedicated NIV ventilator", "TREATMENT", 40, 64], ["General Electric) devices", "TREATMENT", 75, 100], ["FiO2", "TREATMENT", 136, 140]]], ["Pressure support or inspiratory positive airway pressure (IPAP), external positive end expiratory pressure (PEEP) or expiratory positive airway pressure (EPAP) levels were titrated to achieve an expiratory tidal volume of 8 to 10 ml/kg according to ideal body weight, adjusted to maintain SpO2 > 90 % and respiratory rate below 25/min.Bronchoscopy procedure ::: MethodsThroughout the NIV treatment and bronchoscopy procedure electrocardiography, intra arterial blood pressure, pulse oximeter and ventilator parameters were monitored continuously.", [["airway", "ANATOMY", 41, 47], ["airway", "ANATOMY", 137, 143], ["body", "ANATOMY", 255, 259], ["arterial", "ANATOMY", 452, 460], ["blood", "ANATOMY", 461, 466], ["NIV", "CHEMICAL", 384, 387], ["airway", "MULTI-TISSUE_STRUCTURE", 41, 47], ["airway", "MULTI-TISSUE_STRUCTURE", 137, 143], ["body", "ORGANISM_SUBDIVISION", 255, 259], ["blood", "ORGANISM_SUBSTANCE", 461, 466], ["Pressure support", "TREATMENT", 0, 16], ["inspiratory positive airway pressure", "TREATMENT", 20, 56], ["IPAP", "TEST", 58, 62], ["external positive end expiratory pressure", "TEST", 65, 106], ["PEEP", "TREATMENT", 108, 112], ["expiratory positive airway pressure", "TREATMENT", 117, 152], ["an expiratory tidal volume", "TEST", 192, 218], ["SpO2", "TEST", 289, 293], ["respiratory rate", "TEST", 305, 321], ["Bronchoscopy procedure", "TREATMENT", 335, 357], ["the NIV treatment", "TREATMENT", 380, 397], ["bronchoscopy procedure electrocardiography", "TEST", 402, 444], ["intra arterial blood pressure", "TEST", 446, 475], ["pulse oximeter", "TEST", 477, 491], ["ventilator parameters", "TEST", 496, 517], ["airway pressure", "OBSERVATION", 41, 56], ["expiratory pressure", "OBSERVATION", 87, 106], ["airway pressure", "OBSERVATION", 137, 152]]], ["All bronchoscopies were performed while patients were in upright position and in their own beds.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["All bronchoscopies", "TEST", 0, 18], ["bronchoscopies", "OBSERVATION", 4, 18]]], ["10 % lidocaine spray solution and 2 % lidocaine solution were used for topical anaesthesia of nasopharynx and tracheobronchial tree, respectively.", [["nasopharynx", "ANATOMY", 94, 105], ["tracheobronchial tree", "ANATOMY", 110, 131], ["lidocaine", "CHEMICAL", 5, 14], ["lidocaine", "CHEMICAL", 38, 47], ["lidocaine", "CHEMICAL", 5, 14], ["lidocaine", "CHEMICAL", 38, 47], ["lidocaine", "SIMPLE_CHEMICAL", 5, 14], ["lidocaine", "SIMPLE_CHEMICAL", 38, 47], ["nasopharynx", "ORGAN", 94, 105], ["tracheobronchial tree", "MULTI-TISSUE_STRUCTURE", 110, 131], ["10 % lidocaine spray solution", "TREATMENT", 0, 29], ["2 % lidocaine solution", "TREATMENT", 34, 56], ["topical anaesthesia of nasopharynx", "TREATMENT", 71, 105], ["nasopharynx", "ANATOMY", 94, 105], ["tracheobronchial", "ANATOMY", 110, 126], ["tree", "ANATOMY_MODIFIER", 127, 131]]], ["A connector (bronchoscopy elbow, Philips Respironics) was used between the ventilator tubing and the mask for the insertion of FOB (Olympus BFU 180F) (Fig. 1).", [["A connector (bronchoscopy elbow", "TREATMENT", 0, 31], ["Philips Respironics", "TREATMENT", 33, 52], ["the ventilator tubing", "TREATMENT", 71, 92], ["the mask", "TREATMENT", 97, 105], ["the insertion of FOB", "TREATMENT", 110, 130], ["elbow", "ANATOMY", 26, 31], ["ventilator tubing", "OBSERVATION", 75, 92]]], ["Fiberoptic bronchoscopy was performed via nasal route.", [["nasal", "ANATOMY", 42, 47], ["Fiberoptic bronchoscopy", "TEST", 0, 23]]], ["Short term sedation was administered in some patients according to their respiratory and hemodynamic situations.", [["respiratory", "ANATOMY", 73, 84], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["Short term sedation", "TREATMENT", 0, 19]]], ["Sedation was started using 2 mg midazolam at the beginning of the procedure.", [["midazolam", "CHEMICAL", 32, 41], ["midazolam", "CHEMICAL", 32, 41], ["midazolam", "SIMPLE_CHEMICAL", 32, 41], ["Sedation", "TREATMENT", 0, 8], ["2 mg midazolam", "TREATMENT", 27, 41], ["the procedure", "TREATMENT", 62, 75]]], ["The patients who did not achieve stabilisation received repetitive applications of 1 to 2 mg midazolam.", [["midazolam", "CHEMICAL", 93, 102], ["midazolam", "CHEMICAL", 93, 102], ["patients", "ORGANISM", 4, 12], ["midazolam", "SIMPLE_CHEMICAL", 93, 102], ["patients", "SPECIES", 4, 12], ["repetitive applications", "TREATMENT", 56, 79], ["midazolam", "TREATMENT", 93, 102]]], ["Maximum total dose of midazolam was 5 mg.", [["midazolam", "CHEMICAL", 22, 31], ["midazolam", "CHEMICAL", 22, 31], ["midazolam", "SIMPLE_CHEMICAL", 22, 31], ["midazolam", "TREATMENT", 22, 31]]], ["Patients were supplied with the necessary FiO2 which provided SpO2 > 90 % during FOB procedure (one or more of these procedures were performed in same FOB application: BAL, bronchoscopic brushings and biopsy, aspiration) under NIV.", [["FiO2", "CHEMICAL", 42, 46], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the necessary FiO2", "TREATMENT", 28, 46], ["SpO2", "TEST", 62, 66], ["FOB procedure", "TREATMENT", 81, 94], ["these procedures", "TREATMENT", 111, 127], ["BAL", "TREATMENT", 168, 171], ["bronchoscopic brushings", "TEST", 173, 196], ["biopsy", "TEST", 201, 207], ["aspiration", "PROBLEM", 209, 219], ["NIV", "TREATMENT", 227, 230]]], ["The bronchoscopic samples were sent to microbiology and pathology laboratories.", [["bronchoscopic samples", "ANATOMY", 4, 25], ["bronchoscopic samples", "CANCER", 4, 25], ["The bronchoscopic samples", "TEST", 0, 25], ["pathology laboratories", "TEST", 56, 78]]], ["Antimicrobial treatment was started empirically while the sampling was performed and, later treatment was adjusted according to microbiological results.Outcomes ::: MethodsPrimary outcomes were: 1.", [["Antimicrobial treatment", "TREATMENT", 0, 23], ["the sampling", "TEST", 54, 66]]], ["Safety with the recording of any complications [such as fever, arrhythmia, hypoxemia (SpO2 < 90 %), hypotension (systolic and diastolic blood pressure below 90 mmHg and 60 mmHg, respectively), haemorrhage and pneumothorax].", [["blood", "ANATOMY", 136, 141], ["fever", "DISEASE", 56, 61], ["arrhythmia", "DISEASE", 63, 73], ["hypoxemia", "DISEASE", 75, 84], ["hypotension", "DISEASE", 100, 111], ["haemorrhage", "DISEASE", 193, 204], ["pneumothorax", "DISEASE", 209, 221], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["any complications", "PROBLEM", 29, 46], ["fever", "PROBLEM", 56, 61], ["arrhythmia", "PROBLEM", 63, 73], ["hypoxemia", "PROBLEM", 75, 84], ["SpO2", "TEST", 86, 90], ["hypotension", "PROBLEM", 100, 111], ["systolic", "TEST", 113, 121], ["diastolic blood pressure", "TEST", 126, 150], ["haemorrhage", "PROBLEM", 193, 204], ["pneumothorax", "PROBLEM", 209, 221], ["haemorrhage", "OBSERVATION", 193, 204], ["pneumothorax", "OBSERVATION", 209, 221]]], ["Contribution of FOB in diagnosis and/or modification of the ongoing treatment.", [["FOB", "GENE_OR_GENE_PRODUCT", 16, 19], ["the ongoing treatment", "TREATMENT", 56, 77], ["FOB", "OBSERVATION", 16, 19]]], ["Requirement for endotracheal intubation was specifically observed within two hours and eight hours after the FOB.", [["endotracheal", "ANATOMY", 16, 28], ["endotracheal intubation", "TREATMENT", 16, 39], ["the FOB", "TEST", 105, 112], ["endotracheal intubation", "OBSERVATION", 16, 39]]], ["Criteria of two and eight hour limit for endotracheal intubation were adopted from previous studies [16, 17].Data analyses ::: MethodsData management and analysis of all data were conducted via SPSS for Windows 16.0 software (SPSS, version 16, Chicago).", [["endotracheal", "ANATOMY", 41, 53], ["endotracheal intubation", "TREATMENT", 41, 64], ["previous studies", "TEST", 83, 99], ["MethodsData management", "TREATMENT", 127, 149], ["analysis of all data", "TEST", 154, 174], ["Windows", "TEST", 203, 210], ["SPSS", "TEST", 226, 230]]], ["Kolmogorov-Smirnov test was used to present the distribution of all recorded variables.", [["Kolmogorov-Smirnov test", "TEST", 0, 23]]], ["Arterial blood gases and haemodynamic parameters before and after FOB were compared with Wilcoxon test.", [["Arterial blood", "ANATOMY", 0, 14], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["Arterial blood gases", "TEST", 0, 20], ["haemodynamic parameters", "TEST", 25, 48], ["FOB", "TEST", 66, 69], ["Wilcoxon test", "TEST", 89, 102]]], ["Statistical significance level was set at p < 0.05.Patient characteristics ::: ResultsTwenty eight subjects (mean age 63.3 \u00b1 15.9 years, 15 men, 13 women) were included the study.", [["men", "ORGANISM", 140, 143], ["women", "ORGANISM", 148, 153], ["Patient", "SPECIES", 51, 58], ["men", "SPECIES", 140, 143], ["women", "SPECIES", 148, 153], ["Statistical significance level", "TEST", 0, 30], ["the study", "TEST", 169, 178]]], ["20 patients (71.4 %) had immunosuppression.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["immunosuppression", "TREATMENT", 25, 42]]], ["Patients had hematologic malignancy, solid-organ tumor, renal transplantation, long-term corticosteroid treatment due to interstitial lung disease or connective tissue disease that caused immunosuppression.", [["hematologic malignancy", "ANATOMY", 13, 35], ["solid-organ tumor", "ANATOMY", 37, 54], ["renal", "ANATOMY", 56, 61], ["interstitial lung", "ANATOMY", 121, 138], ["connective tissue", "ANATOMY", 150, 167], ["malignancy", "DISEASE", 25, 35], ["solid-organ tumor", "DISEASE", 37, 54], ["interstitial lung disease", "DISEASE", 121, 146], ["connective tissue disease", "DISEASE", 150, 175], ["Patients", "ORGANISM", 0, 8], ["hematologic malignancy", "CANCER", 13, 35], ["solid-organ tumor", "CANCER", 37, 54], ["renal", "ORGAN", 56, 61], ["lung", "ORGAN", 134, 138], ["connective tissue", "TISSUE", 150, 167], ["Patients", "SPECIES", 0, 8], ["hematologic malignancy", "PROBLEM", 13, 35], ["solid-organ tumor", "PROBLEM", 37, 54], ["renal transplantation", "TREATMENT", 56, 77], ["long-term corticosteroid treatment", "TREATMENT", 79, 113], ["interstitial lung disease", "PROBLEM", 121, 146], ["connective tissue disease", "PROBLEM", 150, 175], ["immunosuppression", "TREATMENT", 188, 205], ["hematologic", "ANATOMY", 13, 24], ["malignancy", "OBSERVATION", 25, 35], ["organ", "ANATOMY", 43, 48], ["tumor", "OBSERVATION", 49, 54], ["renal", "ANATOMY", 56, 61], ["transplantation", "OBSERVATION", 62, 77], ["long-term corticosteroid", "OBSERVATION_MODIFIER", 79, 103], ["interstitial", "ANATOMY_MODIFIER", 121, 133], ["lung", "ANATOMY", 134, 138], ["disease", "OBSERVATION", 139, 146], ["connective tissue disease", "OBSERVATION", 150, 175], ["immunosuppression", "OBSERVATION", 188, 205]]], ["The most common admission diagnosis to ICU was pneumonia (Table 1).", [["pneumonia", "DISEASE", 47, 56], ["pneumonia", "PROBLEM", 47, 56], ["pneumonia", "OBSERVATION", 47, 56]]], ["As shown on Table 2, FOB indications were: suspicion of opportunistic infections in 18 patients (64.3 %), alveolar hemorrhage in 4 patients (14.3 %), suspicion of malignancy in 4 patients (14.3 %), aspiration as therapeutic approach in 4 patients (14.3 %) and other indications were exacerbation of idiopathic pulmonary fibrosis, drug induced pulmonary toxicity and pulmonary involvement of rheumatoid arthritis.", [["alveolar", "ANATOMY", 106, 114], ["malignancy", "ANATOMY", 163, 173], ["pulmonary", "ANATOMY", 310, 319], ["pulmonary", "ANATOMY", 343, 352], ["pulmonary", "ANATOMY", 366, 375], ["opportunistic infections", "DISEASE", 56, 80], ["alveolar hemorrhage", "DISEASE", 106, 125], ["malignancy", "DISEASE", 163, 173], ["idiopathic pulmonary fibrosis", "DISEASE", 299, 328], ["pulmonary toxicity", "DISEASE", 343, 361], ["rheumatoid arthritis", "DISEASE", 391, 411], ["patients", "ORGANISM", 87, 95], ["alveolar", "MULTI-TISSUE_STRUCTURE", 106, 114], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 179, 187], ["patients", "ORGANISM", 238, 246], ["pulmonary", "ORGAN", 310, 319], ["pulmonary", "ORGAN", 343, 352], ["pulmonary", "ORGAN", 366, 375], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 238, 246], ["opportunistic infections", "PROBLEM", 56, 80], ["alveolar hemorrhage", "PROBLEM", 106, 125], ["malignancy", "PROBLEM", 163, 173], ["aspiration", "PROBLEM", 198, 208], ["therapeutic approach", "TREATMENT", 212, 232], ["idiopathic pulmonary fibrosis", "PROBLEM", 299, 328], ["drug induced pulmonary toxicity", "PROBLEM", 330, 361], ["pulmonary involvement", "PROBLEM", 366, 387], ["rheumatoid arthritis", "PROBLEM", 391, 411], ["opportunistic", "OBSERVATION_MODIFIER", 56, 69], ["infections", "OBSERVATION", 70, 80], ["alveolar", "ANATOMY", 106, 114], ["hemorrhage", "OBSERVATION", 115, 125], ["suspicion of", "UNCERTAINTY", 150, 162], ["malignancy", "OBSERVATION", 163, 173], ["aspiration", "OBSERVATION", 198, 208], ["idiopathic", "OBSERVATION_MODIFIER", 299, 309], ["pulmonary", "ANATOMY", 310, 319], ["fibrosis", "OBSERVATION", 320, 328], ["pulmonary", "ANATOMY", 343, 352], ["toxicity", "OBSERVATION", 353, 361], ["pulmonary", "ANATOMY", 366, 375], ["rheumatoid arthritis", "OBSERVATION", 391, 411]]], ["Fiberoptic bronchoscopy was performed with ICU ventilator in 82.1 % of patients and dedicated NIV ventilators were used for the remaining patients.", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 138, 146], ["Fiberoptic bronchoscopy", "TEST", 0, 23], ["ICU ventilator", "TREATMENT", 43, 57], ["dedicated NIV ventilators", "TREATMENT", 84, 109]]], ["PaO2/FiO2 ratio before FOB application was calculated as 132.2 \u00b1 49.8.", [["FiO2", "CHEMICAL", 5, 9], ["PaO2", "TEST", 0, 4], ["FiO2 ratio", "TEST", 5, 15], ["FOB application", "TEST", 23, 38]]], ["Twenty three (82.1 %) patients received 100 % FiO2 during FOB to allow SpO2 levels which must be achieved above 90 %.", [["FiO2", "CHEMICAL", 46, 50], ["FiO2", "CHEMICAL", 46, 50], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["100 % FiO2", "TREATMENT", 40, 50], ["FOB", "TREATMENT", 58, 61], ["SpO2 levels", "TEST", 71, 82]]], ["Pressure support, IPAP and EPAP/PEEP values during FOB were 9 (0\u201318), 20 (8\u201328) and 8 (5\u201312) cmH2O, respectively.Tolerance and safety of fiberoptic bronchoscopy ::: ResultsThe median duration of NIV prior to FOB was 3 h (range 0\u201372 h).", [["Pressure support", "TREATMENT", 0, 16], ["IPAP", "TREATMENT", 18, 22], ["EPAP", "TEST", 27, 31], ["PEEP values", "TEST", 32, 43], ["FOB", "TEST", 51, 54], ["fiberoptic bronchoscopy", "TEST", 137, 160], ["NIV", "TREATMENT", 195, 198]]], ["Vasopressor/inotropic agents before the FOB application were begun in 4 patients (14.3 %) due to hemodynamic instability.", [["hemodynamic instability", "DISEASE", 97, 120], ["Vasopressor", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Vasopressor", "TREATMENT", 0, 11], ["inotropic agents", "TREATMENT", 12, 28], ["the FOB application", "TREATMENT", 36, 55], ["hemodynamic instability", "PROBLEM", 97, 120], ["hemodynamic instability", "OBSERVATION", 97, 120]]], ["Thirteen patients (46.4 %) received sedation for NIV and/or FOB.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["sedation", "TREATMENT", 36, 44], ["NIV", "TREATMENT", 49, 52], ["FOB", "TREATMENT", 60, 63]]], ["Maximum duration of the bronchoscopy was 20 min and FOB application was performed only once for each patients.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["the bronchoscopy", "TREATMENT", 20, 36], ["FOB application", "TEST", 52, 67]]], ["Arterial blood gas analyses, PaO2/FiO2 rates and cardiorespiratory parameters before and after FOB were shown in Table 3.", [["Arterial blood", "ANATOMY", 0, 14], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["Arterial blood gas analyses", "TEST", 0, 27], ["PaO2", "TEST", 29, 33], ["FiO2 rates", "TEST", 34, 44], ["cardiorespiratory parameters", "TEST", 49, 77], ["FOB", "TEST", 95, 98]]], ["There was no impairment in these parameters after bronchoscopy.", [["impairment in these parameters", "PROBLEM", 13, 43], ["bronchoscopy", "TEST", 50, 62], ["no", "UNCERTAINTY", 10, 12], ["impairment", "OBSERVATION", 13, 23]]], ["PaO2/FiO2 rate increased from 132.2 \u00b1 49.8 to 172.9 \u00b1 63.2 after procedure.", [["PaO2", "TEST", 0, 4], ["FiO2 rate", "TEST", 5, 14], ["procedure", "TREATMENT", 65, 74]]], ["Pressure support, IPAP, EPAP/PEEP and FiO2 levels did not change during FOB.Tolerance and safety of fiberoptic bronchoscopy ::: ResultsRespiratory and hemodynamic variables were followed up very closely for the required intubation.", [["FiO2", "CHEMICAL", 38, 42], ["EPAP", "SIMPLE_CHEMICAL", 24, 28], ["Pressure support", "TREATMENT", 0, 16], ["IPAP", "TREATMENT", 18, 22], ["EPAP", "TREATMENT", 24, 28], ["PEEP", "TREATMENT", 29, 33], ["FiO2 levels", "TEST", 38, 49], ["fiberoptic bronchoscopy", "TEST", 100, 123], ["hemodynamic variables", "TEST", 151, 172], ["intubation", "TREATMENT", 220, 230]]], ["Complications other than endotracheal intubation developed in 5 (17.9 %) patients within 12 h after FOB.", [["endotracheal", "ANATOMY", 25, 37], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["endotracheal intubation", "TREATMENT", 25, 48], ["FOB", "TEST", 100, 103], ["endotracheal intubation", "OBSERVATION", 25, 48]]], ["Fever (n = 2), hypoxemia (n = 1) and hypotension (n = 2) occurred as complication of bronchoscopy.", [["Fever", "DISEASE", 0, 5], ["hypoxemia", "DISEASE", 15, 24], ["hypotension", "DISEASE", 37, 48], ["Fever", "PROBLEM", 0, 5], ["hypoxemia", "PROBLEM", 15, 24], ["hypotension", "PROBLEM", 37, 48], ["bronchoscopy", "TREATMENT", 85, 97], ["hypoxemia", "OBSERVATION", 15, 24], ["hypotension", "OBSERVATION", 37, 48], ["bronchoscopy", "OBSERVATION", 85, 97]]], ["In one of these patients, hypotension developed within the first four hours.", [["hypotension", "DISEASE", 26, 37], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["hypotension", "PROBLEM", 26, 37], ["hypotension", "OBSERVATION", 26, 37]]], ["No other adverse effects were observed such as haemorrhage and pneumothorax.Tolerance and safety of fiberoptic bronchoscopy ::: ResultsEndotracheal intubation was not required within 2 h after the bronchoscopy.", [["Endotracheal", "ANATOMY", 135, 147], ["haemorrhage", "DISEASE", 47, 58], ["pneumothorax", "DISEASE", 63, 75], ["other adverse effects", "PROBLEM", 3, 24], ["haemorrhage", "PROBLEM", 47, 58], ["pneumothorax", "PROBLEM", 63, 75], ["fiberoptic bronchoscopy", "TEST", 100, 123], ["Endotracheal intubation", "TREATMENT", 135, 158], ["the bronchoscopy", "TEST", 193, 209], ["adverse", "OBSERVATION_MODIFIER", 9, 16], ["haemorrhage", "OBSERVATION", 47, 58], ["pneumothorax", "OBSERVATION", 63, 75], ["Endotracheal intubation", "OBSERVATION", 135, 158]]], ["Intubation was performed only in three patients (10.7 %) within 8 h.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["Intubation", "TREATMENT", 0, 10]]], ["Two of them had severe coinfection with Cytomegalovirus and Pneumocystis jiroveci.", [["coinfection", "DISEASE", 23, 34], ["Cytomegalovirus", "DISEASE", 40, 55], ["Pneumocystis jiroveci", "DISEASE", 60, 81], ["Cytomegalovirus", "ORGANISM", 40, 55], ["Pneumocystis jiroveci", "ORGANISM", 60, 81], ["Pneumocystis jiroveci", "SPECIES", 60, 81], ["Pneumocystis jiroveci", "SPECIES", 60, 81], ["severe coinfection", "PROBLEM", 16, 34], ["Cytomegalovirus", "PROBLEM", 40, 55], ["Pneumocystis jiroveci", "PROBLEM", 60, 81], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["coinfection", "OBSERVATION", 23, 34], ["Cytomegalovirus", "OBSERVATION", 40, 55], ["Pneumocystis jiroveci", "OBSERVATION", 60, 81]]], ["32.1 and 39.3 % of the patients required IMV within 24 h and 48 h, respectively.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["IMV", "TREATMENT", 41, 44]]], ["Due to deterioration of respiratory failure or septic shock, 6 patients (21.4 %) were intubated after 48 h of the procedure.", [["respiratory", "ANATOMY", 24, 35], ["respiratory failure", "DISEASE", 24, 43], ["septic shock", "DISEASE", 47, 59], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["respiratory failure", "PROBLEM", 24, 43], ["septic shock", "PROBLEM", 47, 59], ["intubated", "TREATMENT", 86, 95], ["the procedure", "TREATMENT", 110, 123], ["deterioration", "OBSERVATION_MODIFIER", 7, 20], ["respiratory failure", "OBSERVATION", 24, 43], ["septic shock", "OBSERVATION", 47, 59]]], ["Five of them had hospital acquired infection in their follow ups.Clinical usefulness of fiberoptic bronchoscopy ::: ResultsBronchoscopy contributed to diagnosis of 27 (96.4 %) patients.", [["infection", "DISEASE", 35, 44], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["hospital acquired infection", "PROBLEM", 17, 44], ["fiberoptic bronchoscopy", "TEST", 88, 111], ["Bronchoscopy", "TEST", 123, 135], ["diagnosis", "TEST", 151, 160], ["infection", "OBSERVATION", 35, 44]]], ["Bacteria (n = 2), fungus (n = 18), cytomegalovirus (n = 12), other viruses (n = 5) and M. tuberculosis (n = 1) were isolated in 23 (82.1 %) patients as underlying infectious agent.", [["cytomegalovirus", "DISEASE", 35, 50], ["M. tuberculosis", "DISEASE", 87, 102], ["cytomegalovirus", "ORGANISM", 35, 50], ["M. tuberculosis", "ORGANISM", 87, 102], ["patients", "ORGANISM", 140, 148], ["M. tuberculosis", "SPECIES", 87, 102], ["patients", "SPECIES", 140, 148], ["M. tuberculosis", "SPECIES", 87, 102], ["Bacteria (n = 2), fungus (n", "TEST", 0, 27], ["cytomegalovirus", "TEST", 35, 50], ["other viruses", "TEST", 61, 74], ["M. tuberculosis", "TEST", 87, 102], ["underlying infectious agent", "PROBLEM", 152, 179], ["tuberculosis", "OBSERVATION", 90, 102], ["infectious", "OBSERVATION", 163, 173]]], ["Candida spp. was accepted as cause of infection for 6 patients, because 3 patients were immunosuppressive and we found no other etiologic opportunistic infection agents in the remaining patients.", [["Candida spp.", "DISEASE", 0, 12], ["infection", "DISEASE", 38, 47], ["opportunistic infection", "DISEASE", 138, 161], ["Candida spp.", "ORGANISM", 0, 12], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 186, 194], ["Candida spp.", "SPECIES", 0, 12], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 186, 194], ["Candida spp.", "SPECIES", 0, 12], ["Candida spp.", "PROBLEM", 0, 12], ["infection", "PROBLEM", 38, 47], ["immunosuppressive", "TREATMENT", 88, 105], ["other etiologic opportunistic infection agents", "PROBLEM", 122, 168], ["infection", "OBSERVATION", 38, 47], ["no other", "UNCERTAINTY", 119, 127], ["opportunistic", "OBSERVATION_MODIFIER", 138, 151], ["infection", "OBSERVATION", 152, 161]]], ["Various combinations of the infectious agents were shown in 12 (42.9 %) patients.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["the infectious agents", "TREATMENT", 24, 45], ["infectious", "OBSERVATION", 28, 38]]], ["Alveolar hemorrhage was diagnosed in 4 patients and malignancy was reported as a result of cytologic examination in 2 patients.", [["Alveolar", "ANATOMY", 0, 8], ["Alveolar hemorrhage", "DISEASE", 0, 19], ["malignancy", "DISEASE", 52, 62], ["Alveolar", "MULTI-TISSUE_STRUCTURE", 0, 8], ["patients", "ORGANISM", 39, 47], ["malignancy", "CANCER", 52, 62], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 118, 126], ["Alveolar hemorrhage", "PROBLEM", 0, 19], ["malignancy", "PROBLEM", 52, 62], ["cytologic examination", "TEST", 91, 112], ["hemorrhage", "OBSERVATION", 9, 19], ["malignancy", "OBSERVATION", 52, 62]]], ["While secretions were being removed in 3 patients, atelectasis was resolved in one patient by FOB.", [["secretions", "ANATOMY", 6, 16], ["atelectasis", "DISEASE", 51, 62], ["secretions", "ORGANISM_SUBSTANCE", 6, 16], ["patients", "ORGANISM", 41, 49], ["patient", "ORGANISM", 83, 90], ["patients", "SPECIES", 41, 49], ["patient", "SPECIES", 83, 90], ["secretions", "PROBLEM", 6, 16], ["atelectasis", "PROBLEM", 51, 62], ["atelectasis", "OBSERVATION", 51, 62]]], ["Appropriate treatment was arranged in 20 patients (71.4 %) according to FOB results.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Appropriate treatment", "TREATMENT", 0, 21], ["FOB results", "TEST", 72, 83]]], ["Initial empirical treatments were appropriate in the remaining patients.DiscussionThe study demonstrated that bronchoscopy under NIV is feasible, safe and an effective diagnostic procedure, therapeutic approach and guide for treatment in ARDS patients.", [["ARDS", "DISEASE", 238, 242], ["NIV", "CHEMICAL", 129, 132], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 243, 251], ["Initial empirical treatments", "TREATMENT", 0, 28], ["The study", "TEST", 82, 91], ["bronchoscopy", "TREATMENT", 110, 122], ["NIV", "TREATMENT", 129, 132], ["an effective diagnostic procedure", "TREATMENT", 155, 188], ["therapeutic approach", "TREATMENT", 190, 210], ["treatment", "TREATMENT", 225, 234], ["ARDS", "PROBLEM", 238, 242]]], ["After the procedure, arterial blood gas values, PaO2/FiO2 rate, and cardiac parameters did not change and none of the patients needed intubation within two hours after bronchoscopy.", [["arterial blood", "ANATOMY", 21, 35], ["cardiac", "ANATOMY", 68, 75], ["arterial", "MULTI-TISSUE_STRUCTURE", 21, 29], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["cardiac", "ORGAN", 68, 75], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["the procedure", "TREATMENT", 6, 19], ["arterial blood gas values", "TEST", 21, 46], ["PaO2", "TEST", 48, 52], ["FiO2 rate", "TEST", 53, 62], ["cardiac parameters", "TEST", 68, 86], ["intubation", "TREATMENT", 134, 144], ["bronchoscopy", "TEST", 168, 180]]], ["Fiberoptic bronchoscopy can be performed safely without major complications in this group of patients.DiscussionDiagnostic or therapeutic bronchoscopy is necessary for some ICU patients treated for acute respiratory failure, however it can be associated with various complications as well as mortality.", [["respiratory", "ANATOMY", 204, 215], ["acute respiratory failure", "DISEASE", 198, 223], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 177, 185], ["Fiberoptic bronchoscopy", "TEST", 0, 23], ["major complications", "PROBLEM", 56, 75], ["therapeutic bronchoscopy", "TREATMENT", 126, 150], ["acute respiratory failure", "PROBLEM", 198, 223], ["various complications", "PROBLEM", 259, 280], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["respiratory", "ANATOMY", 204, 215], ["failure", "OBSERVATION", 216, 223]]], ["Because of these risks, FOB can be challenging in these patients.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["FOB", "TREATMENT", 24, 27]]], ["Bronchoscope covers 10\u201315 % of the tracheal lumen and may increase respiration efforts and decrease PaO2 by 10\u201320 mmHg causing respiratory and cardiac complications [18].", [["tracheal lumen", "ANATOMY", 35, 49], ["respiratory", "ANATOMY", 127, 138], ["cardiac", "ANATOMY", 143, 150], ["respiratory and cardiac complications", "DISEASE", 127, 164], ["tracheal lumen", "MULTI-TISSUE_STRUCTURE", 35, 49], ["PaO2", "SIMPLE_CHEMICAL", 100, 104], ["cardiac", "ORGAN", 143, 150], ["Bronchoscope", "TREATMENT", 0, 12], ["the tracheal lumen", "TREATMENT", 31, 49], ["increase respiration efforts", "PROBLEM", 58, 86], ["PaO2", "TEST", 100, 104], ["respiratory and cardiac complications", "PROBLEM", 127, 164], ["tracheal", "ANATOMY", 35, 43], ["lumen", "ANATOMY_MODIFIER", 44, 49], ["increase", "OBSERVATION_MODIFIER", 58, 66], ["respiration efforts", "OBSERVATION", 67, 86], ["cardiac", "ANATOMY", 143, 150], ["complications", "OBSERVATION", 151, 164]]], ["Additionally, BAL sampling may cause worsening of oxygen desaturation [19].", [["BAL", "ANATOMY", 14, 17], ["oxygen", "CHEMICAL", 50, 56], ["desaturation", "DISEASE", 57, 69], ["oxygen", "CHEMICAL", 50, 56], ["oxygen", "SIMPLE_CHEMICAL", 50, 56], ["BAL sampling", "TEST", 14, 26], ["oxygen desaturation", "PROBLEM", 50, 69], ["worsening", "OBSERVATION_MODIFIER", 37, 46], ["oxygen desaturation", "OBSERVATION", 50, 69]]], ["The American Thoracic Society recommends avoiding FOB and BAL in patients with hypoxemia (PaO2 < 75 mmHg or oxygen saturation <90 % with supplemental oxygen) [20].", [["hypoxemia", "DISEASE", 79, 88], ["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 150, 156], ["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 150, 156], ["BAL", "ORGANISM_SUBSTANCE", 58, 61], ["patients", "ORGANISM", 65, 73], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["oxygen", "SIMPLE_CHEMICAL", 150, 156], ["patients", "SPECIES", 65, 73], ["FOB and BAL", "TEST", 50, 61], ["hypoxemia", "PROBLEM", 79, 88], ["PaO2", "TEST", 90, 94], ["oxygen saturation", "TEST", 108, 125], ["supplemental oxygen)", "TREATMENT", 137, 157], ["Thoracic", "ANATOMY", 13, 21]]], ["Although alternative approaches in these patients with higher-risk are empirical treatments or intubation for FOB, the observational study and the randomized controlled trials have shown that NIV may be an alternative to endotracheal intubation in these critically ill patients who are not previously ventilated [10, 11, 21].DiscussionEarly etiological diagnosis in critically ill patients is important for appropriate treatment.", [["endotracheal", "ANATOMY", 221, 233], ["critically ill", "DISEASE", 254, 268], ["critically ill", "DISEASE", 366, 380], ["NIV", "CHEMICAL", 192, 195], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 269, 277], ["patients", "ORGANISM", 381, 389], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 269, 277], ["patients", "SPECIES", 381, 389], ["empirical treatments", "TREATMENT", 71, 91], ["intubation", "TREATMENT", 95, 105], ["FOB", "TEST", 110, 113], ["the observational study", "TEST", 115, 138], ["the randomized controlled trials", "TREATMENT", 143, 175], ["NIV", "TREATMENT", 192, 195], ["endotracheal intubation", "TREATMENT", 221, 244], ["appropriate treatment", "TREATMENT", 407, 428]]], ["Baumann et al. [12] showed that BAL during NIV yielded diagnostic information in 68 % of the patients with acute respiratory failure.", [["BAL", "ANATOMY", 32, 35], ["respiratory", "ANATOMY", 113, 124], ["respiratory failure", "DISEASE", 113, 132], ["BAL", "ORGANISM_SUBSTANCE", 32, 35], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["BAL", "TEST", 32, 35], ["NIV", "TREATMENT", 43, 46], ["acute respiratory failure", "PROBLEM", 107, 132], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory failure", "OBSERVATION", 113, 132]]], ["Diagnostic success of FOB was 59 % in another study in which oxygen supplementation or NIV application was used during the procedure [22].", [["oxygen", "CHEMICAL", 61, 67], ["oxygen", "CHEMICAL", 61, 67], ["NIV", "CHEMICAL", 87, 90], ["oxygen", "SIMPLE_CHEMICAL", 61, 67], ["FOB", "TEST", 22, 25], ["another study", "TEST", 38, 51], ["oxygen supplementation", "TREATMENT", 61, 83], ["NIV application", "TREATMENT", 87, 102], ["the procedure", "TREATMENT", 119, 132]]], ["Our immunosuppressed patient ratio was higher than the study population of Bauman et al. and Cracco et al. (71.4 % vs 53 %, 53 %, respectively).", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["Our immunosuppressed patient ratio", "TEST", 0, 34], ["Cracco et al.", "TEST", 93, 106], ["immunosuppressed", "OBSERVATION", 4, 20]]], ["Clouzeau et al. [16] found that diagnostic or therapeutic information ratio was 75 % in patients who underwent FOB under NIV.", [["NIV", "CHEMICAL", 121, 124], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["NIV", "TREATMENT", 121, 124]]], ["83.3 % of their patients were immunocompromise.", [["immunocompromise", "DISEASE", 30, 46], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["immunocompromise", "PROBLEM", 30, 46]]], ["In our study, diagnostic accuracy of FOB in ARDS patients was 96.4 %.", [["ARDS", "DISEASE", 44, 48], ["FOB", "MULTI-TISSUE_STRUCTURE", 37, 40], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["our study", "TEST", 3, 12], ["diagnostic accuracy", "TEST", 14, 33], ["FOB", "TEST", 37, 40], ["ARDS", "PROBLEM", 44, 48]]], ["High diagnostic rate in our study can be interpreted with the fact that we performed sampling with FOB just as the patients apply to ICU.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["our study", "TEST", 24, 33], ["FOB", "TREATMENT", 99, 102]]], ["At the same time, FOB application allowed the therapeutic approaches such as aspiration.", [["FOB application", "TREATMENT", 18, 33], ["the therapeutic approaches", "TREATMENT", 42, 68], ["aspiration", "PROBLEM", 77, 87], ["aspiration", "OBSERVATION", 77, 87]]], ["Furthermore, Agarwal et al. [23] have shown that NIV-assisted bronchoscopic lung biopsy is another diagnostic method in hypoxemic patients with diffuse lung infiltrates.DiscussionAzoulay et al. [24] found that deterioration in respiratory status occurred in 44.8 % of patients who had BAL with oxygen.", [["lung", "ANATOMY", 76, 80], ["lung", "ANATOMY", 152, 156], ["respiratory", "ANATOMY", 227, 238], ["BAL", "ANATOMY", 285, 288], ["hypoxemic", "DISEASE", 120, 129], ["oxygen", "CHEMICAL", 294, 300], ["NIV", "CHEMICAL", 49, 52], ["oxygen", "CHEMICAL", 294, 300], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 76, 87], ["patients", "ORGANISM", 130, 138], ["lung", "ORGAN", 152, 156], ["patients", "ORGANISM", 268, 276], ["BAL", "ORGANISM_SUBSTANCE", 285, 288], ["oxygen", "SIMPLE_CHEMICAL", 294, 300], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 268, 276], ["NIV", "TREATMENT", 49, 52], ["bronchoscopic lung biopsy", "TEST", 62, 87], ["diffuse lung infiltrates", "PROBLEM", 144, 168], ["deterioration in respiratory status", "PROBLEM", 210, 245], ["oxygen", "TREATMENT", 294, 300], ["lung", "ANATOMY", 76, 80], ["biopsy", "OBSERVATION", 81, 87], ["hypoxemic", "OBSERVATION_MODIFIER", 120, 129], ["diffuse", "OBSERVATION_MODIFIER", 144, 151], ["lung", "ANATOMY", 152, 156], ["infiltrates", "OBSERVATION", 157, 168], ["respiratory", "ANATOMY", 227, 238]]], ["But only 18.7 % of their patients underwent BAL with NIV.", [["BAL", "ANATOMY", 44, 47], ["NIV", "CHEMICAL", 53, 56], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["NIV", "TREATMENT", 53, 56]]], ["Chiner et al. [21] showed that there were no significant differences in arterial blood gas levels in patients with acute respiratory failure before FOB and 2 h after FOB.", [["arterial blood", "ANATOMY", 72, 86], ["respiratory", "ANATOMY", 121, 132], ["acute respiratory failure", "DISEASE", 115, 140], ["arterial", "ORGANISM_SUBSTANCE", 72, 80], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["significant differences", "PROBLEM", 45, 68], ["arterial blood gas levels", "TEST", 72, 97], ["acute respiratory failure", "PROBLEM", 115, 140], ["FOB", "TEST", 166, 169], ["no", "UNCERTAINTY", 42, 44], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["differences", "OBSERVATION", 57, 68], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["respiratory", "ANATOMY", 121, 132], ["failure", "OBSERVATION", 133, 140]]], ["Another study showed a significant improvement in arterial blood gas levels of patients with acute decompensated COPD due to community-acquired pneumonia second hour after FOB with NIV [25].", [["arterial blood", "ANATOMY", 50, 64], ["COPD", "DISEASE", 113, 117], ["pneumonia", "DISEASE", 144, 153], ["NIV", "CHEMICAL", 181, 184], ["arterial", "ORGANISM_SUBSTANCE", 50, 58], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Another study", "TEST", 0, 13], ["arterial blood gas levels", "TEST", 50, 75], ["acute decompensated COPD", "PROBLEM", 93, 117], ["community-acquired pneumonia", "PROBLEM", 125, 153], ["NIV", "TREATMENT", 181, 184], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["improvement", "OBSERVATION", 35, 46], ["arterial", "ANATOMY", 50, 58], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["decompensated", "OBSERVATION_MODIFIER", 99, 112], ["COPD", "OBSERVATION", 113, 117], ["pneumonia", "OBSERVATION", 144, 153]]], ["Secretion aspiration might lead to improvement.", [["Secretion aspiration", "PROBLEM", 0, 20], ["aspiration", "OBSERVATION", 10, 20], ["improvement", "OBSERVATION_MODIFIER", 35, 46]]], ["In our study, there were no significant changes in arterial blood gas analyses and cardiac parameters after FOB.", [["arterial blood", "ANATOMY", 51, 65], ["cardiac", "ANATOMY", 83, 90], ["arterial", "MULTI-TISSUE_STRUCTURE", 51, 59], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["cardiac", "ORGAN", 83, 90], ["our study", "TEST", 3, 12], ["significant changes", "PROBLEM", 28, 47], ["arterial blood gas analyses", "TEST", 51, 78], ["cardiac parameters", "TEST", 83, 101], ["FOB", "TEST", 108, 111], ["no", "UNCERTAINTY", 25, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["changes", "OBSERVATION", 40, 47], ["cardiac", "ANATOMY", 83, 90]]], ["Other complications such as cardiac arrhythmia, pneumothorax or hemoptysis did not occur in our study population.DiscussionOnly three patients (10.7 %) were intubated within 8 h after FOB (5 h, 7 h and 8 h, respectively).", [["cardiac", "ANATOMY", 28, 35], ["cardiac arrhythmia", "DISEASE", 28, 46], ["pneumothorax", "DISEASE", 48, 60], ["hemoptysis", "DISEASE", 64, 74], ["cardiac", "ORGAN", 28, 35], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["Other complications", "PROBLEM", 0, 19], ["cardiac arrhythmia", "PROBLEM", 28, 46], ["pneumothorax", "PROBLEM", 48, 60], ["hemoptysis", "PROBLEM", 64, 74], ["intubated", "TREATMENT", 157, 166], ["cardiac", "ANATOMY", 28, 35], ["arrhythmia", "OBSERVATION", 36, 46], ["pneumothorax", "OBSERVATION", 48, 60], ["hemoptysis", "OBSERVATION", 64, 74]]], ["Underlying diseases of these patients were interstitial lung disease and lung involvement due to connective tissue disease.", [["interstitial lung", "ANATOMY", 43, 60], ["lung", "ANATOMY", 73, 77], ["connective tissue", "ANATOMY", 97, 114], ["interstitial lung disease", "DISEASE", 43, 68], ["connective tissue disease", "DISEASE", 97, 122], ["patients", "ORGANISM", 29, 37], ["lung", "ORGAN", 56, 60], ["lung", "ORGAN", 73, 77], ["connective tissue", "TISSUE", 97, 114], ["patients", "SPECIES", 29, 37], ["Underlying diseases", "PROBLEM", 0, 19], ["interstitial lung disease", "PROBLEM", 43, 68], ["lung involvement", "PROBLEM", 73, 89], ["connective tissue disease", "PROBLEM", 97, 122], ["diseases", "OBSERVATION", 11, 19], ["interstitial", "ANATOMY_MODIFIER", 43, 55], ["lung", "ANATOMY", 56, 60], ["disease", "OBSERVATION", 61, 68], ["lung", "ANATOMY", 73, 77], ["connective tissue disease", "OBSERVATION", 97, 122]]], ["The patients were receiving systemic corticosteroid therapy before admission to hospital and FOB was applied to diagnose opportunistic infections.", [["opportunistic infections", "DISEASE", 121, 145], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["systemic corticosteroid therapy", "TREATMENT", 28, 59], ["FOB", "TREATMENT", 93, 96], ["opportunistic infections", "PROBLEM", 121, 145], ["opportunistic", "OBSERVATION_MODIFIER", 121, 134], ["infections", "OBSERVATION", 135, 145]]], ["Three patients died within 24 h after the procedure.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["the procedure", "TREATMENT", 38, 51]]], ["FOB should not be considered in these cases, because they had severe underlying diseases and infections when they were admitted.", [["infections", "DISEASE", 93, 103], ["FOB", "TREATMENT", 0, 3], ["severe underlying diseases", "PROBLEM", 62, 88], ["infections", "PROBLEM", 93, 103], ["diseases", "OBSERVATION", 80, 88], ["infections", "OBSERVATION", 93, 103]]], ["Identified mixt infectious agents had a major effect in their fast progression.", [["mixt infectious agents", "PROBLEM", 11, 33], ["infectious", "OBSERVATION", 16, 26], ["fast", "OBSERVATION_MODIFIER", 62, 66], ["progression", "OBSERVATION_MODIFIER", 67, 78]]], ["Cytomegalovirus and Pneumocystis jiroveci in two patients, Acremonium and Cytomegalovirus in another patient were shown as opportunistic infectious agents.", [["Cytomegalovirus", "DISEASE", 0, 15], ["Pneumocystis jiroveci", "DISEASE", 20, 41], ["Cytomegalovirus", "DISEASE", 74, 89], ["Cytomegalovirus", "ORGANISM", 0, 15], ["Pneumocystis jiroveci", "ORGANISM", 20, 41], ["patients", "ORGANISM", 49, 57], ["Cytomegalovirus", "ORGANISM", 74, 89], ["patient", "ORGANISM", 101, 108], ["Pneumocystis jiroveci", "SPECIES", 20, 41], ["patients", "SPECIES", 49, 57], ["patient", "SPECIES", 101, 108], ["Pneumocystis jiroveci", "SPECIES", 20, 41], ["Cytomegalovirus", "PROBLEM", 0, 15], ["Pneumocystis jiroveci", "PROBLEM", 20, 41], ["Acremonium", "PROBLEM", 59, 69], ["Cytomegalovirus", "PROBLEM", 74, 89], ["opportunistic infectious agents", "TREATMENT", 123, 154], ["Pneumocystis jiroveci", "OBSERVATION", 20, 41], ["Cytomegalovirus", "OBSERVATION", 74, 89]]], ["Fiberoptic bronchoscopy usually causes alteration in gas exchange.", [["Fiberoptic bronchoscopy", "TREATMENT", 0, 23], ["alteration in gas exchange", "PROBLEM", 39, 65], ["gas exchange", "OBSERVATION", 53, 65]]], ["In hypoxemic intubated patients, PaO2 returns to baseline within 2 h [26].", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["hypoxemic intubated", "TREATMENT", 3, 22], ["PaO2", "TEST", 33, 37], ["hypoxemic", "OBSERVATION", 3, 12]]], ["None of the patients in the current study needed intubation within 2 h after FOB.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["the current study", "TEST", 24, 41], ["intubation", "TREATMENT", 49, 59], ["FOB", "TEST", 77, 80]]], ["Based on this information, FOB may not have led to intubation in three patients.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["intubation", "TREATMENT", 51, 61]]], ["Baumann et al. [12] found that 40 patients required NIV prior to the decision to use FOB.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["NIV", "TREATMENT", 52, 55], ["FOB", "TREATMENT", 85, 88]]], ["Four of them (10 %) required IMV within 8 h.", [["IMV", "TREATMENT", 29, 32]]], ["Within 48 h, 45 % of their patients were intubated.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["intubated", "TREATMENT", 41, 50]]], ["In Baumann et al.\u2019s study, mean baseline PaO2/FiO2 value was 176 \u00b1 54 which is higher than the values of the current study.", [["\u2019s study", "TEST", 17, 25], ["mean baseline PaO2", "TEST", 27, 45], ["FiO2 value", "TEST", 46, 56], ["the current study", "TEST", 105, 122], ["higher", "OBSERVATION_MODIFIER", 79, 85]]], ["In the current study 10.7, 32.1 and 39.3 % of patients required IMV within 8 h, 24 h and 48 h, respectively.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["the current study", "TEST", 3, 20], ["IMV", "TREATMENT", 64, 67]]], ["Clouzeau et al. [16] assessed BAL application under NIV in which PaO2/FiO2 of their patients was 181 \u00b1 50 before FOB.", [["NIV", "CHEMICAL", 52, 55], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["BAL application", "TEST", 30, 45], ["NIV", "TREATMENT", 52, 55], ["PaO2", "TEST", 65, 69], ["FiO2", "TREATMENT", 70, 74]]], ["None of the patients was intubated within 2 h, four of 23 patients (17.4 %) were required IMV within 24 h after the procedure.", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 58, 66], ["intubated", "TREATMENT", 25, 34], ["IMV", "TREATMENT", 90, 93], ["the procedure", "TREATMENT", 112, 125]]], ["Presence of the COPD and immunosuppression were shown as risk factors for intubation [22].", [["COPD", "DISEASE", 16, 20], ["the COPD", "PROBLEM", 12, 20], ["immunosuppression", "TREATMENT", 25, 42], ["intubation", "TREATMENT", 74, 84], ["COPD", "OBSERVATION", 16, 20]]], ["Intubation rate in the current study is acceptable according to presented rates in the literature.", [["Intubation rate", "TEST", 0, 15], ["the current study", "TEST", 19, 36]]], ["Intubation rate reached to 54 % in patients with acute respiratory failure who received NIV.", [["respiratory", "ANATOMY", 55, 66], ["acute respiratory failure", "DISEASE", 49, 74], ["NIV", "CHEMICAL", 88, 91], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["Intubation rate", "TEST", 0, 15], ["acute respiratory failure", "PROBLEM", 49, 74], ["NIV", "TREATMENT", 88, 91], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["respiratory", "ANATOMY", 55, 66], ["failure", "OBSERVATION", 67, 74]]], ["Also, NIV failure ratio was 62 % in moderate and 84 % in severe ARDS [27].", [["ARDS", "DISEASE", 64, 68], ["NIV", "CHEMICAL", 6, 9], ["NIV failure ratio", "TEST", 6, 23], ["severe ARDS", "PROBLEM", 57, 68], ["moderate", "OBSERVATION_MODIFIER", 36, 44], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["ARDS", "OBSERVATION", 64, 68]]], ["Cases in the current study were not intubated due to sudden gas exchanges and hemodynamic deterioration after bronchoscopy.", [["the current study", "TEST", 9, 26], ["intubated", "TREATMENT", 36, 45], ["sudden gas exchanges", "PROBLEM", 53, 73], ["hemodynamic deterioration", "PROBLEM", 78, 103], ["bronchoscopy", "TEST", 110, 122], ["hemodynamic deterioration", "OBSERVATION", 78, 103]]], ["Severe underlying diseases and infection situations should be taken into consideration for IMV.DiscussionThe authors of this study aware of the discussions about using NIV in patients with ARDS.", [["infection", "DISEASE", 31, 40], ["ARDS", "DISEASE", 189, 193], ["NIV", "CHEMICAL", 168, 171], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["IMV", "SPECIES", 91, 94], ["Severe underlying diseases", "PROBLEM", 0, 26], ["infection situations", "PROBLEM", 31, 51], ["IMV", "TREATMENT", 91, 94], ["this study", "TEST", 120, 130], ["NIV", "TREATMENT", 168, 171], ["ARDS", "PROBLEM", 189, 193], ["diseases", "OBSERVATION", 18, 26], ["infection", "OBSERVATION", 31, 40], ["ARDS", "OBSERVATION", 189, 193]]], ["But a recent study which assessed intubation rate and risk factors of NIV failure in patients with non-hypercapnic acute hypoxemic respiratory failure showed significant differences for intubation rate among four groups (non-ARDS, mild ARDS, moderate ARDS, severe ARDS).", [["respiratory", "ANATOMY", 131, 142], ["NIV failure", "DISEASE", 70, 81], ["hypoxemic respiratory failure", "DISEASE", 121, 150], ["ARDS", "DISEASE", 225, 229], ["ARDS", "DISEASE", 236, 240], ["ARDS", "DISEASE", 251, 255], ["ARDS", "DISEASE", 264, 268], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["a recent study", "TEST", 4, 18], ["intubation rate", "TEST", 34, 49], ["NIV failure", "PROBLEM", 70, 81], ["non-hypercapnic acute hypoxemic respiratory failure", "PROBLEM", 99, 150], ["intubation rate", "TEST", 186, 201], ["non-ARDS", "PROBLEM", 221, 229], ["mild ARDS", "PROBLEM", 231, 240], ["moderate ARDS", "PROBLEM", 242, 255], ["severe ARDS", "PROBLEM", 257, 268], ["NIV failure", "OBSERVATION", 70, 81], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["hypoxemic", "OBSERVATION_MODIFIER", 121, 130], ["respiratory failure", "OBSERVATION", 131, 150], ["significant", "OBSERVATION_MODIFIER", 158, 169], ["ARDS", "OBSERVATION", 225, 229], ["mild", "OBSERVATION_MODIFIER", 231, 235], ["ARDS", "OBSERVATION", 236, 240], ["moderate", "OBSERVATION_MODIFIER", 242, 250], ["ARDS", "OBSERVATION", 251, 255], ["severe", "OBSERVATION_MODIFIER", 257, 263], ["ARDS", "OBSERVATION", 264, 268]]], ["However, the mortality rate was not statistically significant and the time to intubation had no effect on patient mortality [27].", [["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["the mortality rate", "TEST", 9, 27], ["intubation", "TREATMENT", 78, 88]]], ["In patients with hematologic malignancies and acute respiratory failure, delayed (after NIV failure) vs. immediate IMV was associated with increased hospital mortality which was not statistically significant (65 % vs. 58 %) [28].", [["hematologic malignancies", "ANATOMY", 17, 41], ["respiratory", "ANATOMY", 52, 63], ["hematologic malignancies", "DISEASE", 17, 41], ["acute respiratory failure", "DISEASE", 46, 71], ["patients", "ORGANISM", 3, 11], ["hematologic malignancies", "CANCER", 17, 41], ["patients", "SPECIES", 3, 11], ["IMV", "SPECIES", 115, 118], ["hematologic malignancies", "PROBLEM", 17, 41], ["acute respiratory failure", "PROBLEM", 46, 71], ["NIV failure", "PROBLEM", 88, 99], ["immediate IMV", "TREATMENT", 105, 118], ["increased hospital mortality", "PROBLEM", 139, 167], ["hematologic malignancies", "OBSERVATION", 17, 41], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory failure", "OBSERVATION", 52, 71]]], ["Early diagnosis and beginning time of true treatment in patients with immunosuppression may be as important as ARDS severity.", [["ARDS", "DISEASE", 111, 115], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["true treatment", "TREATMENT", 38, 52], ["immunosuppression", "TREATMENT", 70, 87], ["ARDS severity", "PROBLEM", 111, 124]]], ["The authors think that FOB under NIV treatment due to ARDS may be applied to patients whose PaO2/FiO2 ratio is close to 100 when their hemodynamic status is stable and procedure is performed in ICU where all intubation equipment for emergency intubation exist.DiscussionThis study has some limitations.", [["ARDS", "DISEASE", 54, 58], ["NIV", "CHEMICAL", 33, 36], ["FiO2", "CHEMICAL", 97, 101], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["NIV treatment", "TREATMENT", 33, 46], ["ARDS", "PROBLEM", 54, 58], ["PaO2/FiO2 ratio", "TEST", 92, 107], ["procedure", "TREATMENT", 168, 177], ["all intubation equipment", "TREATMENT", 204, 228], ["emergency intubation", "TREATMENT", 233, 253], ["This study", "TEST", 270, 280], ["ARDS", "OBSERVATION", 54, 58]]], ["First, there are no control groups.", [["no", "UNCERTAINTY", 17, 19]]], ["Enrolment of a control group was not possible due to ethical reasons, because treatment with NIV requires in patients with acute respiratory failure.", [["respiratory", "ANATOMY", 129, 140], ["acute respiratory failure", "DISEASE", 123, 148], ["NIV", "CHEMICAL", 93, 96], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["a control group", "TREATMENT", 13, 28], ["NIV", "TREATMENT", 93, 96], ["acute respiratory failure", "PROBLEM", 123, 148], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory failure", "OBSERVATION", 129, 148]]], ["In other words, it is believed that intubation is not advisable solely for FOB applications.", [["intubation", "TREATMENT", 36, 46], ["FOB applications", "TREATMENT", 75, 91]]], ["Second, the study population in the current study was small.", [["the study population", "TEST", 8, 28], ["the current study", "TEST", 32, 49], ["small", "OBSERVATION_MODIFIER", 54, 59]]], ["Third, the study population was composed of patients with hypoxemic and hypercapnic respiratory failure.", [["respiratory", "ANATOMY", 84, 95], ["hypercapnic respiratory failure", "DISEASE", 72, 103], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["the study population", "TEST", 7, 27], ["hypoxemic", "PROBLEM", 58, 67], ["hypercapnic respiratory failure", "PROBLEM", 72, 103], ["hypoxemic", "OBSERVATION", 58, 67], ["hypercapnic", "OBSERVATION_MODIFIER", 72, 83], ["respiratory failure", "OBSERVATION", 84, 103]]], ["Fourth, the data about excluded patients was not given and limited number arterial blood gas analyses were assessed after FOB.", [["arterial blood", "ANATOMY", 74, 88], ["patients", "ORGANISM", 32, 40], ["arterial", "MULTI-TISSUE_STRUCTURE", 74, 82], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["patients", "SPECIES", 32, 40], ["arterial blood gas analyses", "TEST", 74, 101], ["FOB", "TEST", 122, 125]]], ["Fifth, these results were from a single center.ConclusionsIn conclusion, FOB under NIV may be safely and effectively applied for diagnosis and treatment of patients with ARDS in ICU units that is adequately equipped and staffed for intubation.", [["ARDS", "DISEASE", 170, 174], ["NIV", "CHEMICAL", 83, 86], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["FOB under NIV", "TREATMENT", 73, 86], ["treatment", "TREATMENT", 143, 152], ["ARDS", "PROBLEM", 170, 174], ["intubation", "TREATMENT", 232, 242]]], ["There are high risks associated with intubation during FOB and after procedure.", [["intubation", "TREATMENT", 37, 47], ["procedure", "TREATMENT", 69, 78], ["high", "OBSERVATION_MODIFIER", 10, 14]]], ["Therefore, these patients should be closely followed up for ventilation and for other vital parameters.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["ventilation", "TREATMENT", 60, 71], ["other vital parameters", "TEST", 80, 102]]], ["FOB with NIV may be considered in patients with ARDS for diagnosis and treatment, so intubation and its complications may be avoided in this patient group.", [["ARDS", "DISEASE", 48, 52], ["NIV", "CHEMICAL", 9, 12], ["FOB", "MULTI-TISSUE_STRUCTURE", 0, 3], ["patients", "ORGANISM", 34, 42], ["patient", "ORGANISM", 141, 148], ["patients", "SPECIES", 34, 42], ["patient", "SPECIES", 141, 148], ["NIV", "TREATMENT", 9, 12], ["ARDS", "PROBLEM", 48, 52], ["treatment", "TREATMENT", 71, 80], ["intubation", "TREATMENT", 85, 95], ["its complications", "PROBLEM", 100, 117]]], ["More studies with large sample sizes are required to make a more thorough assessment of FOB application under NIV in patients with ARDS.", [["ARDS", "DISEASE", 131, 135], ["NIV", "CHEMICAL", 110, 113], ["FOB", "MULTI-TISSUE_STRUCTURE", 88, 91], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["large sample sizes", "PROBLEM", 18, 36], ["thorough assessment", "TEST", 65, 84], ["FOB application", "TREATMENT", 88, 103], ["NIV", "TREATMENT", 110, 113], ["ARDS", "PROBLEM", 131, 135], ["large", "OBSERVATION_MODIFIER", 18, 23], ["ARDS", "OBSERVATION", 131, 135]]]], "PMC6363457": [["IntroductionCellular membranes must undergo dynamic remodeling to facilitate essential cellular processes, including formation of trafficking vesicles (Conner and Schmid, 2003), viral egress (Hurley et al., 2010), and cytokinesis (Mierzwa and Gerlich, 2014).", [["Cellular membranes", "ANATOMY", 12, 30], ["cellular", "ANATOMY", 87, 95], ["vesicles", "ANATOMY", 142, 150], ["Cellular membranes", "CELLULAR_COMPONENT", 12, 30], ["cellular", "CELL", 87, 95], ["vesicles", "CELLULAR_COMPONENT", 142, 150], ["IntroductionCellular membranes", "TREATMENT", 0, 30], ["dynamic remodeling", "TREATMENT", 44, 62], ["essential cellular processes", "PROBLEM", 77, 105], ["trafficking vesicles", "PROBLEM", 130, 150], ["cytokinesis", "PROBLEM", 218, 229], ["Cellular membranes", "OBSERVATION", 12, 30], ["cellular processes", "OBSERVATION", 87, 105], ["trafficking vesicles", "OBSERVATION", 130, 150]]], ["Since membranes resist deformation (Helfrich, 1973), cells employ specialized protein machines to drive membrane remodeling (Zimmerberg and Kozlov, 2006).", [["membranes", "ANATOMY", 6, 15], ["cells", "ANATOMY", 53, 58], ["membrane", "ANATOMY", 104, 112], ["membranes", "CELLULAR_COMPONENT", 6, 15], ["cells", "CELL", 53, 58], ["membrane", "CELLULAR_COMPONENT", 104, 112], ["membranes resist deformation", "PROBLEM", 6, 34]]], ["For example, the crescent-shaped, dimeric bin-amphiphysin-rvs (BAR) domains (Frost et al., 2009; Mim and Unger, 2012; Simunovic et al., 2015) polymerize into cylindrical scaffolds on membrane surfaces, forcing the underlying membrane to adopt the tubular geometry of the scaffold (Frost et al., 2008; Mim et al., 2012; Adam et al., 2015).", [["membrane surfaces", "ANATOMY", 183, 200], ["membrane", "ANATOMY", 225, 233], ["tubular", "ANATOMY", 247, 254], ["membrane surfaces", "CELLULAR_COMPONENT", 183, 200], ["membrane", "CELLULAR_COMPONENT", 225, 233], ["tubular", "TISSUE", 247, 254], ["dimeric bin-amphiphysin", "PROTEIN", 34, 57], ["rvs (BAR) domains", "PROTEIN", 58, 75], ["polymerize into cylindrical scaffolds on membrane surfaces", "TREATMENT", 142, 200], ["crescent", "OBSERVATION_MODIFIER", 17, 25], ["shaped", "OBSERVATION_MODIFIER", 26, 32], ["dimeric", "OBSERVATION_MODIFIER", 34, 41], ["bin-amphiphysin", "OBSERVATION_MODIFIER", 42, 57], ["membrane surfaces", "OBSERVATION", 183, 200], ["underlying membrane", "OBSERVATION", 214, 233], ["tubular geometry", "OBSERVATION", 247, 263]]], ["This rigid scaffold has been hypothesized to stabilize membrane tubules, preventing their division into separate membrane compartments through the process of membrane fission (Boucrot et al., 2012).", [["membrane tubules", "ANATOMY", 55, 71], ["membrane compartments", "ANATOMY", 113, 134], ["membrane", "ANATOMY", 158, 166], ["membrane tubules", "CELLULAR_COMPONENT", 55, 71], ["membrane compartments", "CELLULAR_COMPONENT", 113, 134], ["membrane", "CELLULAR_COMPONENT", 158, 166], ["This rigid scaffold", "PROBLEM", 0, 19], ["membrane tubules", "PROBLEM", 55, 71], ["membrane tubules", "OBSERVATION", 55, 71], ["membrane fission", "OBSERVATION", 158, 174]]], ["In living cells, BAR scaffolds are thought to assemble into more limited scaffolds that shape membranes in concert with other proteins, including the dynamin fission machine and the actin cytoskeleton (Itoh et al., 2005; Ferguson et al., 2009; Renard et al., 2015).IntroductionImportantly, many in vitro studies on the membrane shaping behavior of BAR domains have examined the BAR domain in isolation, with significant portions of the protein removed.", [["cells", "ANATOMY", 10, 15], ["membranes", "ANATOMY", 94, 103], ["cytoskeleton", "ANATOMY", 188, 200], ["membrane", "ANATOMY", 319, 327], ["cells", "CELL", 10, 15], ["BAR", "GENE_OR_GENE_PRODUCT", 17, 20], ["membranes", "CELLULAR_COMPONENT", 94, 103], ["dynamin", "GENE_OR_GENE_PRODUCT", 150, 157], ["actin", "GENE_OR_GENE_PRODUCT", 182, 187], ["cytoskeleton", "CELLULAR_COMPONENT", 188, 200], ["membrane", "CELLULAR_COMPONENT", 319, 327], ["BAR", "GENE_OR_GENE_PRODUCT", 348, 351], ["BAR", "GENE_OR_GENE_PRODUCT", 378, 381], ["BAR", "PROTEIN", 17, 20], ["dynamin fission machine", "PROTEIN", 150, 173], ["actin", "PROTEIN", 182, 187], ["BAR domains", "PROTEIN", 348, 359], ["BAR domain", "PROTEIN", 378, 388], ["BAR scaffolds", "TREATMENT", 17, 30], ["other proteins", "PROBLEM", 120, 134], ["the dynamin fission machine", "TREATMENT", 146, 173], ["vitro studies", "TEST", 298, 311], ["the protein", "TREATMENT", 432, 443], ["shape membranes", "OBSERVATION", 88, 103], ["protein removed", "OBSERVATION", 436, 451]]], ["Examples include the N-terminal amphipathic helix BAR (N-BAR) domain of amphiphysin (Peter et al., 2004), the FCH BAR (F-BAR) domain of FCHo1/2 (Henne et al., 2007, 2010), the F-BAR domain of the neuronal migration protein srGAP2 (Guerrier et al., 2009), the F-BAR domains of the cytokinesis proteins Imp2 (McDonald et al., 2016) and Cdc15 (McDonald et al., 2015), and the inverted BAR (I-BAR) domains of MIM and ABBA (Mattila et al., 2007; Saarikangas et al., 2009), among others.", [["neuronal", "ANATOMY", 196, 204], ["N-", "CHEMICAL", 21, 23], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 72, 83], ["FCH BAR", "GENE_OR_GENE_PRODUCT", 110, 117], ["F-BAR", "GENE_OR_GENE_PRODUCT", 119, 124], ["F-BAR", "GENE_OR_GENE_PRODUCT", 176, 181], ["neuronal", "CELL", 196, 204], ["srGAP2", "GENE_OR_GENE_PRODUCT", 223, 229], ["F-BAR", "GENE_OR_GENE_PRODUCT", 259, 264], ["Imp2", "GENE_OR_GENE_PRODUCT", 301, 305], ["BAR", "GENE_OR_GENE_PRODUCT", 382, 385], ["N-terminal amphipathic helix BAR (N-BAR) domain", "PROTEIN", 21, 68], ["amphiphysin", "PROTEIN", 72, 83], ["FCH BAR (F-BAR) domain", "PROTEIN", 110, 132], ["FCHo1", "PROTEIN", 136, 141], ["F-BAR domain", "PROTEIN", 176, 188], ["neuronal migration protein", "PROTEIN", 196, 222], ["srGAP2", "PROTEIN", 223, 229], ["F-BAR domains", "PROTEIN", 259, 272], ["cytokinesis proteins", "PROTEIN", 280, 300], ["Imp2", "PROTEIN", 301, 305], ["BAR (I-BAR) domains", "PROTEIN", 382, 401], ["MIM", "PROTEIN", 405, 408], ["the N-terminal amphipathic helix BAR", "PROBLEM", 17, 53], ["the FCH BAR", "TEST", 106, 117], ["domains of MIM", "PROBLEM", 394, 408], ["ABBA", "TEST", 413, 417], ["terminal", "OBSERVATION_MODIFIER", 23, 31], ["amphipathic helix", "OBSERVATION", 32, 49], ["amphiphysin", "ANATOMY", 72, 83]]], ["These results have provided critical insight into the detailed geometry of BAR domain arrangement at membrane surfaces, helping to elucidate their mechanisms of membrane curvature sensing and induction.", [["membrane surfaces", "ANATOMY", 101, 118], ["membrane", "ANATOMY", 161, 169], ["BAR", "GENE_OR_GENE_PRODUCT", 75, 78], ["membrane surfaces", "CELLULAR_COMPONENT", 101, 118], ["membrane", "CELLULAR_COMPONENT", 161, 169], ["BAR domain", "PROTEIN", 75, 85], ["membrane curvature sensing", "TREATMENT", 161, 187], ["membrane curvature", "OBSERVATION", 161, 179]]], ["However, BAR domains do not typically exist in isolation in the cell, but rather as part of large, multi-domain proteins that also frequently contain long, intrinsically disordered protein (IDP) domains of several hundred amino acids (Miele et al., 2004; Lee et al., 2007; Henne et al., 2010; Roberts-Galbraith and Gould, 2010; Wuertenberger and Groemping, 2015).", [["cell", "ANATOMY", 64, 68], ["amino acids", "CHEMICAL", 222, 233], ["amino acids", "CHEMICAL", 222, 233], ["BAR", "GENE_OR_GENE_PRODUCT", 9, 12], ["cell", "CELL", 64, 68], ["amino acids", "AMINO_ACID", 222, 233], ["BAR domains", "PROTEIN", 9, 20], ["multi-domain proteins", "PROTEIN", 99, 120], ["intrinsically disordered protein (IDP) domains", "PROTEIN", 156, 202], ["large, multi-domain proteins", "PROBLEM", 92, 120], ["isolation", "OBSERVATION", 47, 56], ["cell", "ANATOMY", 64, 68], ["large", "OBSERVATION_MODIFIER", 92, 97]]], ["How might these disordered domains influence the membrane remodeling behavior of BAR domains?IntroductionRecent work from our laboratory (Stachowiak et al., 2010, 2012) and others (Vennema et al., 1996; Bhagatji et al., 2009; Copic et al., 2012; Jiang et al., 2013; Wu et al., 2014) has revealed that molecular crowding among proteins attached to membrane surfaces at high density generates steric pressure, which provides a potent force for membrane shaping.", [["membrane", "ANATOMY", 49, 57], ["membrane surfaces", "ANATOMY", 347, 364], ["membrane", "ANATOMY", 442, 450], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["BAR", "GENE_OR_GENE_PRODUCT", 81, 84], ["membrane surfaces", "CELLULAR_COMPONENT", 347, 364], ["membrane", "CELLULAR_COMPONENT", 442, 450], ["disordered domains", "PROTEIN", 16, 34], ["BAR domains", "PROTEIN", 81, 92], ["molecular crowding among proteins", "PROBLEM", 301, 334], ["membrane shaping", "TREATMENT", 442, 458], ["crowding", "OBSERVATION", 311, 319], ["high density", "OBSERVATION", 368, 380], ["steric pressure", "OBSERVATION", 391, 406]]], ["Further, previous work found that disordered domains, which occupy large footprints on the membrane surface in comparison to well-folded proteins of equal molecular weight (Hofmann et al., 2012), enhanced the efficiency of membrane bending and fission (Busch et al., 2015; Snead et al., 2017).", [["membrane surface", "ANATOMY", 91, 107], ["membrane", "ANATOMY", 223, 231], ["membrane surface", "CELLULAR_COMPONENT", 91, 107], ["membrane", "CELLULAR_COMPONENT", 223, 231], ["folded proteins", "PROTEIN", 130, 145], ["disordered domains", "PROBLEM", 34, 52], ["large", "OBSERVATION_MODIFIER", 67, 72], ["footprints", "OBSERVATION", 73, 83], ["membrane", "ANATOMY_MODIFIER", 91, 99], ["membrane bending", "OBSERVATION", 223, 239]]], ["However, a fundamental, unanswered question has limited the potential of protein crowding to explain membrane remodeling in cells\u2014what brings bulky domains together to generate steric pressure?", [["membrane", "ANATOMY", 101, 109], ["cells", "ANATOMY", 124, 129], ["membrane", "CELLULAR_COMPONENT", 101, 109], ["cells", "CELL", 124, 129], ["protein crowding", "PROBLEM", 73, 89], ["membrane remodeling in cells", "PROBLEM", 101, 129], ["steric pressure", "TEST", 177, 192], ["membrane remodeling", "OBSERVATION", 101, 120], ["steric pressure", "OBSERVATION", 177, 192]]], ["In particular, what keeps crowded proteins from simply diffusing away from one another, dissipating steric pressure and inhibiting membrane shaping?", [["membrane", "ANATOMY", 131, 139], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["steric pressure", "OBSERVATION", 100, 115]]], ["Proteins such as amphiphysin (Miele et al., 2004; Peter et al., 2004) and FCHo1/2 (Henne et al., 2007, 2010), which contain both scaffold-forming BAR domains and bulky disordered domains, present a possible solution to this problem.", [["amphiphysin", "GENE_OR_GENE_PRODUCT", 17, 28], ["BAR", "GENE_OR_GENE_PRODUCT", 146, 149], ["amphiphysin", "PROTEIN", 17, 28], ["BAR domains", "PROTEIN", 146, 157], ["bulky disordered domains", "PROTEIN", 162, 186], ["bulky disordered domains", "PROBLEM", 162, 186], ["bulky", "OBSERVATION_MODIFIER", 162, 167]]], ["Specifically, the ability of BAR domains to form scaffolds has the potential to locally concentrate disordered domains such that steric pressure is amplified rather than dissipated.IntroductionTherefore, we set out to investigate the impact of disordered domains on the membrane remodeling ability of BAR proteins.", [["membrane", "ANATOMY", 270, 278], ["BAR", "GENE_OR_GENE_PRODUCT", 29, 32], ["membrane", "CELLULAR_COMPONENT", 270, 278], ["BAR", "GENE_OR_GENE_PRODUCT", 301, 304], ["BAR domains", "PROTEIN", 29, 40], ["disordered domains", "PROTEIN", 100, 118], ["disordered domains", "PROTEIN", 244, 262], ["BAR proteins", "PROTEIN", 301, 313], ["scaffolds", "TREATMENT", 49, 58], ["locally concentrate disordered domains", "PROBLEM", 80, 118], ["steric pressure", "TEST", 129, 144], ["disordered domains", "PROBLEM", 244, 262], ["steric pressure", "OBSERVATION", 129, 144]]], ["To our surprise, we found that while isolated BAR domains formed stable membrane tubules, full-length amphiphysin (Amph-FL) and FCHo1 destabilized these tubules, leading to highly efficient membrane vesiculation.", [["membrane tubules", "ANATOMY", 72, 88], ["tubules", "ANATOMY", 153, 160], ["membrane", "ANATOMY", 190, 198], ["BAR", "GENE_OR_GENE_PRODUCT", 46, 49], ["membrane tubules", "CELLULAR_COMPONENT", 72, 88], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 102, 113], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 115, 122], ["FCHo1", "GENE_OR_GENE_PRODUCT", 128, 133], ["tubules", "TISSUE", 153, 160], ["membrane", "CELLULAR_COMPONENT", 190, 198], ["BAR domains", "PROTEIN", 46, 57], ["amphiphysin", "PROTEIN", 102, 113], ["Amph", "PROTEIN", 115, 119], ["FL", "PROTEIN", 120, 122], ["FCHo1", "PROTEIN", 128, 133], ["highly efficient membrane vesiculation", "PROBLEM", 173, 211], ["stable", "OBSERVATION_MODIFIER", 65, 71], ["membrane tubules", "OBSERVATION", 72, 88], ["highly", "OBSERVATION_MODIFIER", 173, 179], ["efficient", "OBSERVATION_MODIFIER", 180, 189], ["membrane vesiculation", "OBSERVATION", 190, 211]]], ["These results suggest that BAR domain\u2013containing proteins can act as templates that locally amplify steric pressure among disordered domains, leading to membrane fission.While the amphiphysin N-BAR domain stabilizes membrane tubules, Amph-FL drives membrane vesiculation ::: ResultsAmphiphysin, an important component of the vesicle recycling machinery (Di Paolo et al., 2002), is composed of an N-BAR domain, followed by an IDP domain of \u223c383 amino acids in humans, and a C-terminal SH3 domain (Owen et al., 1998, 2004; Miele et al., 2004; Peter et al., 2004; Fig. 1 A).", [["membrane", "ANATOMY", 153, 161], ["membrane tubules", "ANATOMY", 216, 232], ["membrane", "ANATOMY", 249, 257], ["vesicle", "ANATOMY", 325, 332], ["ResultsAmphiphysin", "CHEMICAL", 275, 293], ["amino acids", "CHEMICAL", 444, 455], ["amino acids", "CHEMICAL", 444, 455], ["C", "CHEMICAL", 473, 474], ["BAR", "GENE_OR_GENE_PRODUCT", 27, 30], ["membrane", "CELLULAR_COMPONENT", 153, 161], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 180, 191], ["membrane tubules", "CELLULAR_COMPONENT", 216, 232], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 234, 241], ["membrane", "CELLULAR_COMPONENT", 249, 257], ["ResultsAmphiphysin", "GENE_OR_GENE_PRODUCT", 275, 293], ["vesicle", "CELLULAR_COMPONENT", 325, 332], ["amino acids", "AMINO_ACID", 444, 455], ["humans", "ORGANISM", 459, 465], ["BAR domain\u2013containing proteins", "PROTEIN", 27, 57], ["disordered domains", "PROTEIN", 122, 140], ["amphiphysin N-BAR domain", "PROTEIN", 180, 204], ["Amph", "PROTEIN", 234, 238], ["FL", "PROTEIN", 239, 241], ["N-BAR domain", "PROTEIN", 396, 408], ["IDP domain", "PROTEIN", 425, 435], ["C-terminal SH3 domain", "PROTEIN", 473, 494], ["humans", "SPECIES", 459, 465], ["BAR domain\u2013containing proteins", "PROBLEM", 27, 57], ["steric pressure among disordered domains", "PROBLEM", 100, 140], ["membrane fission", "PROBLEM", 153, 169], ["an IDP domain", "TEST", 422, 435], ["amino acids", "TEST", 444, 455], ["a C-terminal SH3 domain", "PROBLEM", 471, 494], ["membrane fission", "OBSERVATION", 153, 169], ["membrane tubules", "OBSERVATION", 216, 232], ["vesicle recycling", "OBSERVATION", 325, 342]]], ["To compare the membrane remodeling abilities of Amph-FL to those of the N-BAR domain alone, we first examined the effects of each protein on giant unilamellar vesicles (GUVs).", [["membrane", "ANATOMY", 15, 23], ["giant unilamellar vesicles", "ANATOMY", 141, 167], ["GUVs", "ANATOMY", 169, 173], ["membrane", "CELLULAR_COMPONENT", 15, 23], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 48, 55], ["unilamellar vesicles", "MULTI-TISSUE_STRUCTURE", 147, 167], ["GUVs", "CELLULAR_COMPONENT", 169, 173], ["Amph", "PROTEIN", 48, 52], ["FL", "PROTEIN", 53, 55], ["N-BAR domain", "PROTEIN", 72, 84], ["Amph-FL", "TREATMENT", 48, 55], ["the N-BAR domain", "TREATMENT", 68, 84]]], ["These experiments revealed that both the N-BAR domain and Amph-FL drove potent membrane bending within 10 min of mixing vesicles and protein, forming mobile, diffraction-limited tubules that extended from the GUV surface (Fig. S1 A and Videos 1 and 2).", [["membrane", "ANATOMY", 79, 87], ["vesicles", "ANATOMY", 120, 128], ["tubules", "ANATOMY", 178, 185], ["GUV surface", "ANATOMY", 209, 220], ["Amph-FL", "CHEMICAL", 58, 65], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 58, 65], ["membrane", "CELLULAR_COMPONENT", 79, 87], ["vesicles", "CELLULAR_COMPONENT", 120, 128], ["tubules", "TISSUE", 178, 185], ["GUV surface", "CELLULAR_COMPONENT", 209, 220], ["Videos 1", "GENE_OR_GENE_PRODUCT", 236, 244], ["N-BAR domain", "PROTEIN", 41, 53], ["Amph", "PROTEIN", 58, 62], ["FL", "PROTEIN", 63, 65], ["These experiments", "TEST", 0, 17], ["Amph-FL", "TREATMENT", 58, 65], ["potent membrane bending", "PROBLEM", 72, 95], ["mixing vesicles and protein", "PROBLEM", 113, 140], ["limited tubules", "PROBLEM", 170, 185]]], ["These GUVs often collapsed or broke apart into smaller tubules and fragments later during imaging (Fig. S1 A and Videos 3, 4, and 5), suggesting that lipid tubule formation was not the endpoint of the membrane remodeling process.While the amphiphysin N-BAR domain stabilizes membrane tubules, Amph-FL drives membrane vesiculation ::: ResultsTo directly visualize membrane morphology at the end of remodeling (after 30 min incubation at 37\u00b0C), we used negative stain transmission EM (TEM) to resolve membrane structures below the optical diffraction limit.", [["GUVs", "ANATOMY", 6, 10], ["tubules", "ANATOMY", 55, 62], ["fragments", "ANATOMY", 67, 76], ["lipid tubule", "ANATOMY", 150, 162], ["membrane", "ANATOMY", 201, 209], ["membrane tubules", "ANATOMY", 275, 291], ["membrane", "ANATOMY", 308, 316], ["membrane", "ANATOMY", 363, 371], ["membrane structures", "ANATOMY", 499, 518], ["tubules", "TISSUE", 55, 62], ["Videos 3", "GENE_OR_GENE_PRODUCT", 113, 121], ["4", "GENE_OR_GENE_PRODUCT", 123, 124], ["lipid tubule", "MULTI-TISSUE_STRUCTURE", 150, 162], ["membrane", "CELLULAR_COMPONENT", 201, 209], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 239, 250], ["membrane tubules", "CELLULAR_COMPONENT", 275, 291], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 293, 300], ["membrane", "CELLULAR_COMPONENT", 308, 316], ["membrane", "CELLULAR_COMPONENT", 363, 371], ["Videos 3, 4, and 5", "DNA", 113, 131], ["amphiphysin N-BAR domain", "PROTEIN", 239, 263], ["Amph", "PROTEIN", 293, 297], ["FL", "PROTEIN", 298, 300], ["imaging", "TEST", 90, 97], ["lipid tubule formation", "PROBLEM", 150, 172], ["the membrane remodeling process", "PROBLEM", 197, 228], ["membrane structures", "PROBLEM", 499, 518], ["collapsed", "OBSERVATION", 17, 26], ["smaller", "OBSERVATION_MODIFIER", 47, 54], ["tubules", "OBSERVATION_MODIFIER", 55, 62], ["fragments", "OBSERVATION_MODIFIER", 67, 76], ["lipid tubule", "OBSERVATION", 150, 162], ["membrane remodeling", "OBSERVATION", 201, 220], ["membrane tubules", "OBSERVATION", 275, 291], ["membrane", "OBSERVATION_MODIFIER", 363, 371], ["morphology", "OBSERVATION_MODIFIER", 372, 382], ["optical diffraction", "OBSERVATION", 529, 548]]], ["As expected from previous findings (Peter et al., 2004; Gallop et al., 2006), the N-BAR domain transformed vesicles that had an average initial diameter of 200 nm into long tubules with average outer diameter 44 \u00b1 6 nm SD (Fig. 1, B and C; and Fig. S1, B and C).", [["vesicles", "ANATOMY", 107, 115], ["long tubules", "ANATOMY", 168, 180], ["1, B and C", "CHEMICAL", 228, 238], ["vesicles", "CELLULAR_COMPONENT", 107, 115], ["tubules", "TISSUE", 173, 180], ["B", "GENE_OR_GENE_PRODUCT", 253, 254], ["C", "GENE_OR_GENE_PRODUCT", 259, 260], ["N-BAR domain", "PROTEIN", 82, 94], ["S1", "PROTEIN", 249, 251], ["B", "PROTEIN", 253, 254], ["the N-BAR domain transformed vesicles", "PROBLEM", 78, 115], ["average outer diameter", "TEST", 186, 208], ["diameter", "OBSERVATION_MODIFIER", 144, 152], ["diameter", "OBSERVATION_MODIFIER", 200, 208]]], ["In contrast, Amph-FL did not drive appreciable membrane tubule formation in TEM experiments.", [["membrane tubule", "ANATOMY", 47, 62], ["Amph-FL", "CHEMICAL", 13, 20], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 13, 20], ["membrane tubule", "CELLULAR_COMPONENT", 47, 62], ["Amph", "PROTEIN", 13, 17], ["FL", "PROTEIN", 18, 20], ["Amph", "TEST", 13, 17], ["membrane tubule formation", "PROBLEM", 47, 72], ["membrane tubule", "OBSERVATION", 47, 62]]], ["Rather, Amph-FL divided the vesicles of initially 200-nm diameter into a population of highly curved vesicles with a peak diameter centered near 22 nm (Fig. 1, D and E; and Fig. S1 D).", [["vesicles", "ANATOMY", 28, 36], ["vesicles", "ANATOMY", 101, 109], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 8, 15], ["vesicles", "CELLULAR_COMPONENT", 28, 36], ["vesicles", "CELLULAR_COMPONENT", 101, 109], ["S1 D", "GENE_OR_GENE_PRODUCT", 178, 182], ["Amph", "PROTEIN", 8, 12], ["FL", "PROTEIN", 13, 15], ["S1 D", "PROTEIN", 178, 182], ["Amph", "TEST", 8, 12], ["a peak diameter", "TEST", 115, 130], ["highly", "OBSERVATION_MODIFIER", 87, 93], ["curved", "OBSERVATION_MODIFIER", 94, 100], ["peak", "OBSERVATION_MODIFIER", 117, 121], ["diameter", "OBSERVATION_MODIFIER", 122, 130], ["22 nm", "OBSERVATION_MODIFIER", 145, 150]]], ["This finding suggests that formation of membrane tubules is not a stable endpoint of membrane remodeling driven by Amph-FL, as observed in GUV experiments (Fig. S1 A).", [["membrane tubules", "ANATOMY", 40, 56], ["membrane", "ANATOMY", 85, 93], ["Amph-FL", "CHEMICAL", 115, 122], ["membrane tubules", "CELLULAR_COMPONENT", 40, 56], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 115, 122], ["Amph", "PROTEIN", 115, 119], ["FL", "PROTEIN", 120, 122], ["S1 A", "PROTEIN", 161, 165], ["membrane tubules", "PROBLEM", 40, 56], ["membrane remodeling", "PROBLEM", 85, 104], ["membrane tubules", "OBSERVATION", 40, 56], ["stable", "OBSERVATION_MODIFIER", 66, 72], ["membrane remodeling", "OBSERVATION", 85, 104]]], ["In contrast, N-BAR did not drive a substantial shift in the vesicle diameter distribution in TEM experiments (Fig. 1 E).", [["vesicle", "ANATOMY", 60, 67], ["N-BAR", "SIMPLE_CHEMICAL", 13, 18], ["vesicle", "CELLULAR_COMPONENT", 60, 67], ["BAR", "PROTEIN", 15, 18], ["substantial", "OBSERVATION_MODIFIER", 35, 46], ["shift", "OBSERVATION", 47, 52], ["vesicle", "ANATOMY_MODIFIER", 60, 67], ["diameter", "OBSERVATION_MODIFIER", 68, 76]]], ["Collectively, these results suggest that Amph-FL is capable of driving membrane fission, a more energetically demanding process than membrane tubule formation (Campelo and Malhotra, 2012).Amph-FL generates highly curved fission products ::: ResultsTo better understand the ability of amphiphysin to drive membrane fission, we compared N-BAR and Amph-FL in two additional assays of membrane fission.", [["membrane", "ANATOMY", 71, 79], ["membrane tubule", "ANATOMY", 133, 148], ["membrane", "ANATOMY", 305, 313], ["membrane", "ANATOMY", 381, 389], ["Amph-FL", "CHEMICAL", 41, 48], ["Amph-FL", "CHEMICAL", 188, 195], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 41, 48], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["membrane tubule", "CELLULAR_COMPONENT", 133, 148], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 188, 195], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 284, 295], ["membrane", "CELLULAR_COMPONENT", 305, 313], ["N-BAR", "GENE_OR_GENE_PRODUCT", 335, 340], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 345, 352], ["membrane", "CELLULAR_COMPONENT", 381, 389], ["Amph", "PROTEIN", 41, 45], ["FL", "PROTEIN", 46, 48], ["Amph", "PROTEIN", 188, 192], ["FL", "PROTEIN", 193, 195], ["amphiphysin", "PROTEIN", 284, 295], ["N", "PROTEIN", 335, 336], ["BAR", "PROTEIN", 337, 340], ["Amph", "PROTEIN", 345, 349], ["FL", "PROTEIN", 350, 352], ["Amph", "TEST", 41, 45], ["Amph", "TEST", 188, 192], ["Amph-FL", "TREATMENT", 345, 352], ["membrane fission", "TREATMENT", 381, 397], ["membrane tubule", "OBSERVATION", 133, 148], ["membrane fission", "OBSERVATION", 381, 397]]], ["In the first of these experiments, we used supported bilayers with extra membrane reservoir (SUPER) templates, which are glass beads surrounded by a low-tension membrane.", [["membrane", "ANATOMY", 73, 81], ["membrane", "ANATOMY", 161, 169], ["membrane", "CELLULAR_COMPONENT", 161, 169], ["extra membrane reservoir (SUPER) templates", "TREATMENT", 67, 109], ["a low-tension membrane", "PROBLEM", 147, 169], ["glass beads", "OBSERVATION", 121, 132], ["low-", "OBSERVATION_MODIFIER", 149, 153], ["tension membrane", "OBSERVATION", 153, 169]]], ["Exposure of SUPER templates to fission-driving proteins results in measurable membrane release from the beads (Pucadyil and Schmid, 2008; Liu et al., 2011; Neumann et al., 2013).", [["membrane", "ANATOMY", 78, 86], ["membrane", "CELLULAR_COMPONENT", 78, 86], ["SUPER templates", "DNA", 12, 27], ["fission-driving proteins", "PROTEIN", 31, 55]]], ["SUPER template experiments revealed that while both N-BAR and Amph-FL drove membrane release in the concentration range of 50 to 1,000 nM, Amph-FL drove more than twice as much (2.6 to 4.7-fold greater) membrane release at each concentration (Fig. 1 F).", [["membrane", "ANATOMY", 76, 84], ["membrane", "ANATOMY", 203, 211], ["N-BAR", "CHEMICAL", 52, 57], ["Amph-FL", "CHEMICAL", 62, 69], ["Amph-FL", "CHEMICAL", 139, 146], ["N-BAR", "SIMPLE_CHEMICAL", 52, 57], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 62, 69], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 139, 146], ["membrane", "CELLULAR_COMPONENT", 203, 211], ["BAR", "PROTEIN", 54, 57], ["Amph", "PROTEIN", 62, 66], ["FL", "PROTEIN", 67, 69], ["SUPER template experiments", "TEST", 0, 26], ["Amph-FL drove membrane release", "TREATMENT", 62, 92], ["Amph", "TEST", 139, 143]]], ["Amph-FL also drove consistently greater levels of membrane release compared with the epsin N-terminal homology (ENTH) domain, a protein previously shown to drive membrane fission (Snead et al., 2017; Fig. S1 E).", [["membrane", "ANATOMY", 50, 58], ["membrane", "ANATOMY", 162, 170], ["N", "CHEMICAL", 91, 92], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 0, 7], ["membrane", "CELLULAR_COMPONENT", 50, 58], ["membrane", "CELLULAR_COMPONENT", 162, 170], ["Amph", "PROTEIN", 0, 4], ["FL", "PROTEIN", 5, 7], ["epsin N-terminal homology (ENTH) domain", "PROTEIN", 85, 124], ["S1 E", "DNA", 205, 209], ["Amph", "TEST", 0, 4], ["a protein", "TEST", 126, 135]]], ["Notably, the apparent plateau in membrane release (Fig. 1 F) may be due to the fact that some of the SUPER template membrane interacts closely with the bead surface, increasing the barrier to membrane release, as seen in previous reports (Liu et al., 2011; Neumann and Schmid, 2013; Snead et al., 2017).", [["membrane", "ANATOMY", 33, 41], ["membrane", "ANATOMY", 116, 124], ["bead surface", "ANATOMY", 152, 164], ["membrane", "ANATOMY", 192, 200], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["membrane", "CELLULAR_COMPONENT", 116, 124], ["bead surface", "CELLULAR_COMPONENT", 152, 164], ["membrane", "CELLULAR_COMPONENT", 192, 200], ["the bead surface", "TREATMENT", 148, 164], ["plateau", "OBSERVATION_MODIFIER", 22, 29]]], ["However, substantially higher concentrations of Amph-FL up to 10 \u00b5M drove further membrane release (Fig. S1 E).Amph-FL generates highly curved fission products ::: ResultsNotably, membrane release does not directly imply efficient membrane vesiculation, as both vesicles and lipid tubules can be shed from SUPER templates.", [["membrane", "ANATOMY", 82, 90], ["membrane", "ANATOMY", 180, 188], ["membrane", "ANATOMY", 231, 239], ["vesicles", "ANATOMY", 262, 270], ["lipid tubules", "ANATOMY", 275, 288], ["Amph-FL", "CHEMICAL", 48, 55], ["Amph-FL", "CHEMICAL", 111, 118], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 48, 55], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 111, 118], ["membrane", "CELLULAR_COMPONENT", 180, 188], ["membrane", "CELLULAR_COMPONENT", 231, 239], ["vesicles", "CELLULAR_COMPONENT", 262, 270], ["lipid tubules", "CELLULAR_COMPONENT", 275, 288], ["Amph", "PROTEIN", 48, 52], ["FL", "PROTEIN", 53, 55], ["S1 E", "DNA", 105, 109], ["Amph", "PROTEIN", 111, 115], ["FL", "PROTEIN", 116, 118], ["Amph", "TEST", 48, 52], ["further membrane release", "TREATMENT", 74, 98], ["Amph", "TEST", 111, 115], ["efficient membrane vesiculation", "PROBLEM", 221, 252], ["lipid tubules", "OBSERVATION", 275, 288]]], ["Therefore, we next employed a tethered vesicle assay to quantify the distributions of vesicle diameter over a range of protein concentrations (Snead et al., 2017).", [["vesicle", "ANATOMY", 39, 46], ["vesicle", "ANATOMY", 86, 93], ["vesicle", "CELLULAR_COMPONENT", 39, 46], ["vesicle", "CELLULAR_COMPONENT", 86, 93], ["a tethered vesicle assay", "TEST", 28, 52], ["vesicle diameter", "OBSERVATION", 86, 102]]], ["Specifically, we tethered fluorescent vesicles to a coverslip passivated with polyethylene glycol (PEG) and PEG-biotin (Fig. 2 A).", [["vesicles", "ANATOMY", 38, 46], ["polyethylene glycol", "CHEMICAL", 78, 97], ["PEG", "CHEMICAL", 99, 102], ["PEG-biotin", "CHEMICAL", 108, 118], ["polyethylene glycol", "CHEMICAL", 78, 97], ["PEG", "CHEMICAL", 99, 102], ["PEG-biotin", "CHEMICAL", 108, 118], ["polyethylene glycol", "SIMPLE_CHEMICAL", 78, 97], ["PEG", "SIMPLE_CHEMICAL", 99, 102], ["PEG-biotin", "SIMPLE_CHEMICAL", 108, 118], ["Fig. 2 A", "SIMPLE_CHEMICAL", 120, 128], ["tethered fluorescent vesicles", "PROBLEM", 17, 46], ["a coverslip passivated with polyethylene glycol (PEG)", "TREATMENT", 50, 103], ["PEG-biotin", "TREATMENT", 108, 118]]], ["Vesicles in these experiments contained a biotinylated lipid, which facilitated tethering to the substrate through binding to neutravidin.", [["Vesicles", "ANATOMY", 0, 8], ["neutravidin", "CHEMICAL", 126, 137], ["neutravidin", "CHEMICAL", 126, 137], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["lipid", "SIMPLE_CHEMICAL", 55, 60], ["neutravidin", "SIMPLE_CHEMICAL", 126, 137], ["neutravidin", "PROTEIN", 126, 137], ["a biotinylated lipid", "TREATMENT", 40, 60], ["neutravidin", "TREATMENT", 126, 137], ["biotinylated lipid", "OBSERVATION", 42, 60]]], ["Vesicles also contained the fluorescent lipid Oregon Green 488\u20131,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (DHPE), which we used to quantify the brightness of each vesicle after imaging in confocal fluorescence microscopy (Aguet et al., 2013; Fig. 2 B).", [["Vesicles", "ANATOMY", 0, 8], ["vesicle", "ANATOMY", 172, 179], ["Green 488\u20131,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine", "CHEMICAL", 53, 114], ["DHPE", "CHEMICAL", 116, 120], ["488\u20131,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine", "CHEMICAL", 59, 114], ["DHPE", "CHEMICAL", 116, 120], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["Green 488\u20131,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine", "SIMPLE_CHEMICAL", 53, 114], ["DHPE", "SIMPLE_CHEMICAL", 116, 120], ["vesicle", "CELLULAR_COMPONENT", 172, 179], ["dihexadecanoyl", "TEST", 67, 81], ["glycero", "TREATMENT", 85, 92], ["phosphoethanolamine (DHPE)", "TREATMENT", 95, 121], ["imaging", "TEST", 186, 193], ["confocal fluorescence microscopy", "TEST", 197, 229]]], ["We then converted the resulting distributions of vesicle brightness to approximate distributions of vesicle diameter by calibrating against the initial vesicle diameter distribution measured using dynamic light scattering (see Materials and methods).Amph-FL generates highly curved fission products ::: ResultsUsing this assay, we found that Amph-FL in the concentration range of 50\u2013150 nM transformed vesicles with an average initial diameter of 200 nm (Fig. 2, B and C) to a population of high curvature fission products (Fig. 2, B and D) with a median diameter of 22 nm at 150 nM, in agreement with results from TEM (Fig. 1, D and E).", [["vesicle", "ANATOMY", 49, 56], ["vesicle", "ANATOMY", 100, 107], ["vesicle", "ANATOMY", 152, 159], ["vesicles", "ANATOMY", 402, 410], ["Amph-FL", "CHEMICAL", 250, 257], ["Amph-FL", "CHEMICAL", 342, 349], ["2, B and C", "CHEMICAL", 460, 470], ["vesicle", "CELLULAR_COMPONENT", 49, 56], ["vesicle", "CELLULAR_COMPONENT", 100, 107], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 250, 257], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 342, 349], ["vesicles", "CELLULAR_COMPONENT", 402, 410], ["D", "SIMPLE_CHEMICAL", 538, 539], ["D", "SIMPLE_CHEMICAL", 628, 629], ["Amph", "PROTEIN", 250, 254], ["FL", "PROTEIN", 255, 257], ["Amph", "PROTEIN", 342, 346], ["FL", "PROTEIN", 347, 349], ["vesicle brightness", "PROBLEM", 49, 67], ["Amph", "TEST", 250, 254], ["this assay", "TEST", 316, 326], ["Amph", "TEST", 342, 346], ["high curvature fission products", "TREATMENT", 491, 522], ["distributions", "OBSERVATION_MODIFIER", 32, 45], ["vesicle brightness", "OBSERVATION", 49, 67], ["distributions", "OBSERVATION_MODIFIER", 83, 96], ["vesicle diameter", "OBSERVATION", 100, 116], ["initial", "OBSERVATION_MODIFIER", 144, 151], ["vesicle", "OBSERVATION_MODIFIER", 152, 159], ["diameter", "OBSERVATION_MODIFIER", 160, 168], ["distribution", "OBSERVATION_MODIFIER", 169, 181], ["diameter", "OBSERVATION_MODIFIER", 435, 443], ["200 nm", "OBSERVATION_MODIFIER", 447, 453], ["high curvature", "OBSERVATION", 491, 505]]], ["The proportion of vesicles that fell within the high curvature group (diameters below \u223c45 nm) increased with increasing protein concentration, from less than 1% at 50 nM to \u223c38% at 150 nM (Fig. 2 F).", [["vesicles", "ANATOMY", 18, 26], ["vesicles", "CELLULAR_COMPONENT", 18, 26], ["increasing protein concentration", "PROBLEM", 109, 141], ["vesicles", "OBSERVATION", 18, 26], ["high", "OBSERVATION_MODIFIER", 48, 52], ["curvature", "OBSERVATION_MODIFIER", 53, 62]]], ["Importantly, the biotinylated lipid alone did not drive fission in the absence of protein (Fig. 2 C).", [["lipid", "SIMPLE_CHEMICAL", 30, 35], ["Fig. 2 C", "PROTEIN", 91, 99], ["the biotinylated lipid alone", "TREATMENT", 13, 41]]], ["Interestingly, fission by Amph-FL was highly cooperative, leading to a bimodal distribution of vesicle diameter (Fig. 2 D).", [["vesicle", "ANATOMY", 95, 102], ["Amph-FL", "CHEMICAL", 26, 33], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 26, 33], ["vesicle", "CELLULAR_COMPONENT", 95, 102], ["Amph", "PROTEIN", 26, 30], ["FL", "PROTEIN", 31, 33], ["vesicle diameter", "OBSERVATION", 95, 111]]], ["In contrast, previous studies using the same assay found that membrane fission by the ENTH domain resulted in a gradual shift of the size distribution toward smaller diameters (Snead et al., 2017).", [["membrane", "ANATOMY", 62, 70], ["membrane", "CELLULAR_COMPONENT", 62, 70], ["ENTH domain", "PROTEIN", 86, 97], ["previous studies", "TEST", 13, 29], ["the same assay", "TEST", 36, 50], ["the ENTH domain", "TEST", 82, 97], ["gradual", "OBSERVATION_MODIFIER", 112, 119], ["shift", "OBSERVATION_MODIFIER", 120, 125], ["size", "OBSERVATION_MODIFIER", 133, 137], ["distribution", "OBSERVATION_MODIFIER", 138, 150], ["smaller", "OBSERVATION_MODIFIER", 158, 165], ["diameters", "OBSERVATION_MODIFIER", 166, 175]]], ["We speculate that local self-assembly of Amph-FL into membrane-bound scaffolds may drive budding of small vesicles directly from larger vesicles, resulting in a bimodal distribution of vesicle diameter.Amph-FL generates highly curved fission products ::: ResultsThe isolated N-BAR domain did not drive fission even at higher protein concentrations in comparison to Amph-FL (Fig. 2, B, E, and F).", [["membrane", "ANATOMY", 54, 62], ["vesicles", "ANATOMY", 106, 114], ["vesicles", "ANATOMY", 136, 144], ["vesicle", "ANATOMY", 185, 192], ["Amph-FL", "CHEMICAL", 41, 48], ["Amph-FL", "CHEMICAL", 202, 209], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 41, 48], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["small vesicles", "CELLULAR_COMPONENT", 100, 114], ["vesicles", "CELLULAR_COMPONENT", 136, 144], ["vesicle", "CELLULAR_COMPONENT", 185, 192], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 202, 209], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 365, 372], ["B", "GENE_OR_GENE_PRODUCT", 382, 383], ["Amph", "PROTEIN", 41, 45], ["FL", "PROTEIN", 46, 48], ["Amph", "PROTEIN", 202, 206], ["FL", "PROTEIN", 207, 209], ["N-BAR domain", "PROTEIN", 275, 287], ["Amph", "PROTEIN", 365, 369], ["FL", "PROTEIN", 370, 372], ["B", "PROTEIN", 382, 383], ["Amph-FL into membrane-bound scaffolds", "TREATMENT", 41, 78], ["small vesicles", "PROBLEM", 100, 114], ["Amph", "TEST", 202, 206], ["The isolated N-BAR domain", "TREATMENT", 262, 287], ["Amph", "TEST", 365, 369], ["Fig.", "TEST", 374, 378], ["small vesicles", "OBSERVATION", 100, 114], ["larger vesicles", "OBSERVATION", 129, 144], ["bimodal", "OBSERVATION_MODIFIER", 161, 168], ["distribution", "OBSERVATION_MODIFIER", 169, 181], ["vesicle diameter", "OBSERVATION", 185, 201]]], ["Some long, nondiffraction-limited lipid tubules were visible on occasion in tethered vesicle experiments with N-BAR (Fig. 2 B), but our estimations of vesicle diameter did not change substantially if such puncta were excluded (Fig. S1 F).", [["lipid tubules", "ANATOMY", 34, 47], ["vesicle", "ANATOMY", 85, 92], ["vesicle", "ANATOMY", 151, 158], ["puncta", "ANATOMY", 205, 211], ["lipid tubules", "MULTI-TISSUE_STRUCTURE", 34, 47], ["vesicle", "CELLULAR_COMPONENT", 85, 92], ["N-BAR", "GENE_OR_GENE_PRODUCT", 110, 115], ["vesicle", "CELLULAR_COMPONENT", 151, 158], ["puncta", "CELLULAR_COMPONENT", 205, 211], ["S1 F", "GENE_OR_GENE_PRODUCT", 232, 236], ["BAR", "PROTEIN", 112, 115], ["S1 F", "PROTEIN", 232, 236], ["Some long, nondiffraction-limited lipid tubules", "PROBLEM", 0, 47], ["such puncta", "PROBLEM", 200, 211], ["long", "OBSERVATION_MODIFIER", 5, 9], ["lipid tubules", "OBSERVATION", 34, 47], ["vesicle diameter", "OBSERVATION", 151, 167]]], ["Tubules became more prevalent at micromolar N-BAR concentrations (Fig. S1 G), consistent with the tubules formed in TEM experiments (Fig. 1 C).", [["Tubules", "ANATOMY", 0, 7], ["tubules", "ANATOMY", 98, 105], ["N-BAR", "CHEMICAL", 44, 49], ["N-BAR", "CHEMICAL", 44, 49], ["N-BAR", "SIMPLE_CHEMICAL", 44, 49], ["S1 G", "GENE_OR_GENE_PRODUCT", 71, 75], ["tubules", "TISSUE", 98, 105], ["BAR", "PROTEIN", 46, 49], ["S1 G", "PROTEIN", 71, 75], ["more prevalent", "OBSERVATION_MODIFIER", 15, 29], ["consistent with", "UNCERTAINTY", 78, 93], ["tubules", "OBSERVATION", 98, 105]]], ["However, N-BAR did not drive substantial vesiculation at micromolar concentrations, consistent with our findings from TEM (Fig. 2, E and F).", [["N-BAR", "CHEMICAL", 9, 14], ["N-BAR", "GENE_OR_GENE_PRODUCT", 9, 14], ["BAR", "PROTEIN", 11, 14], ["substantial vesiculation at micromolar concentrations", "PROBLEM", 29, 82], ["micromolar concentrations", "OBSERVATION", 57, 82]]], ["Our results are in agreement with previous studies that have reported membrane tubulation by N-BAR at protein to lipid ratios of \u223c1:100 (Peter et al., 2004; Ambroso et al., 2014; Isas et al., 2015), the range in which we observed potent membrane fission by Amph-FL (Fig. 2 F).", [["membrane", "ANATOMY", 70, 78], ["membrane", "ANATOMY", 237, 245], ["N-BAR", "CHEMICAL", 93, 98], ["membrane", "CELLULAR_COMPONENT", 70, 78], ["N-BAR", "GENE_OR_GENE_PRODUCT", 93, 98], ["lipid", "SIMPLE_CHEMICAL", 113, 118], ["membrane", "CELLULAR_COMPONENT", 237, 245], ["BAR", "PROTEIN", 95, 98], ["Amph-FL", "PROTEIN", 257, 264], ["previous studies", "TEST", 34, 50], ["membrane tubulation", "PROBLEM", 70, 89], ["potent membrane fission", "OBSERVATION", 230, 253]]], ["However, previous work has reported membrane vesiculation by the isolated N-BAR domain of amphiphysin at substantially higher protein-to-lipid ratios (Peter et al., 2004), in contrast with our findings at similarly high ratios (Fig. 2 F).", [["membrane", "ANATOMY", 36, 44], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 90, 101], ["lipid", "SIMPLE_CHEMICAL", 137, 142], ["N-BAR domain", "PROTEIN", 74, 86], ["amphiphysin", "PROTEIN", 90, 101], ["membrane vesiculation", "PROBLEM", 36, 57], ["the isolated N-BAR domain of amphiphysin", "PROBLEM", 61, 101], ["membrane vesiculation", "OBSERVATION", 36, 57]]], ["Additionally, the isolated N-BAR domain of endophilin at a protein to lipid ratio of \u223c1:100 has been reported to drive membrane vesiculation (Poudel et al., 2016).", [["membrane", "ANATOMY", 119, 127], ["endophilin", "GENE_OR_GENE_PRODUCT", 43, 53], ["membrane", "CELLULAR_COMPONENT", 119, 127], ["N-BAR domain", "PROTEIN", 27, 39], ["endophilin", "PROTEIN", 43, 53], ["lipid ratio", "TEST", 70, 81]]], ["The differences between these reports and our findings may be due to differences in lipid composition, differences between the amphiphysin and endophilin N-BAR domains, or differences in other experimental parameters.", [["lipid", "SIMPLE_CHEMICAL", 84, 89], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 127, 138], ["endophilin N-BAR", "GENE_OR_GENE_PRODUCT", 143, 159], ["amphiphysin", "PROTEIN", 127, 138], ["endophilin N-BAR domains", "PROTEIN", 143, 167], ["lipid composition", "TEST", 84, 101], ["the amphiphysin", "TEST", 123, 138], ["may be due to", "UNCERTAINTY", 55, 68], ["lipid composition", "OBSERVATION", 84, 101]]], ["Notably, higher concentrations of Amph-FL were required to observe fission in TEM experiments compared with tethered vesicle experiments.", [["vesicle", "ANATOMY", 117, 124], ["Amph-FL", "CHEMICAL", 34, 41], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 34, 41], ["vesicle", "CELLULAR_COMPONENT", 117, 124], ["Amph", "PROTEIN", 34, 38], ["FL", "PROTEIN", 39, 41], ["Amph-FL", "TREATMENT", 34, 41], ["higher", "OBSERVATION_MODIFIER", 9, 15], ["concentrations", "OBSERVATION_MODIFIER", 16, 30]]], ["This increase is due to the high lipid concentration used in TEM experiments (\u223c100-fold greater than tethered vesicle experiments), which is necessary to obtain an adequate density of lipid structures for TEM (Fig. 2 F; see Materials and methods).", [["vesicle", "ANATOMY", 110, 117], ["lipid", "SIMPLE_CHEMICAL", 33, 38], ["the high lipid concentration", "PROBLEM", 24, 52], ["TEM experiments", "TEST", 61, 76], ["adequate", "OBSERVATION_MODIFIER", 164, 172], ["density", "OBSERVATION", 173, 180]]], ["Taken together, our results from EM and tethered vesicle experiments confirm that Amph-FL is a potent driver of membrane fission, while the isolated N-BAR domain primarily forms membrane tubules.The ability of Amph-FL to drive membrane fission does not arise from greater membrane binding affinity in comparison to isolated N-BAR ::: ResultsHow can we explain the ability of Amph-FL to drive membrane fission?", [["vesicle", "ANATOMY", 49, 56], ["membrane", "ANATOMY", 112, 120], ["membrane tubules", "ANATOMY", 178, 194], ["membrane", "ANATOMY", 227, 235], ["membrane", "ANATOMY", 272, 280], ["membrane", "ANATOMY", 392, 400], ["Amph-FL", "CHEMICAL", 82, 89], ["Amph-FL", "CHEMICAL", 210, 217], ["vesicle", "CELLULAR_COMPONENT", 49, 56], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 82, 89], ["membrane", "CELLULAR_COMPONENT", 112, 120], ["membrane tubules", "CELLULAR_COMPONENT", 178, 194], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 210, 217], ["membrane", "CELLULAR_COMPONENT", 227, 235], ["membrane", "CELLULAR_COMPONENT", 272, 280], ["N-BAR", "SIMPLE_CHEMICAL", 324, 329], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 375, 382], ["membrane", "CELLULAR_COMPONENT", 392, 400], ["Amph", "PROTEIN", 82, 86], ["FL", "PROTEIN", 87, 89], ["N-BAR domain", "PROTEIN", 149, 161], ["Amph", "PROTEIN", 210, 214], ["FL", "PROTEIN", 215, 217], ["BAR", "PROTEIN", 326, 329], ["Amph", "PROTEIN", 375, 379], ["FL", "PROTEIN", 380, 382], ["tethered vesicle experiments", "TEST", 40, 68], ["membrane fission", "PROBLEM", 112, 128], ["Amph-FL to drive membrane fission", "TREATMENT", 210, 243], ["Amph-FL", "TREATMENT", 375, 382], ["membrane tubules", "OBSERVATION", 178, 194]]], ["One possible explanation could be that the full-length protein may bind more strongly to membrane surfaces compared with the N-BAR domain alone, resulting in more potent membrane remodeling.", [["membrane surfaces", "ANATOMY", 89, 106], ["membrane", "ANATOMY", 170, 178], ["membrane surfaces", "CELLULAR_COMPONENT", 89, 106], ["membrane", "CELLULAR_COMPONENT", 170, 178], ["full-length protein", "PROTEIN", 43, 62], ["N-BAR domain", "PROTEIN", 125, 137], ["the full-length protein", "PROBLEM", 39, 62], ["possible explanation could be", "UNCERTAINTY", 4, 33], ["more potent", "OBSERVATION_MODIFIER", 158, 169], ["membrane remodeling", "OBSERVATION", 170, 189]]], ["To examine this possibility, we used a tethered vesicle assay similar to the experiments described above to quantify the relative extent of protein\u2013membrane binding.", [["vesicle", "ANATOMY", 48, 55], ["protein\u2013membrane", "ANATOMY", 140, 156], ["vesicle", "CELLULAR_COMPONENT", 48, 55], ["protein\u2013membrane", "SIMPLE_CHEMICAL", 140, 156], ["a tethered vesicle assay", "TEST", 37, 61], ["protein\u2013membrane binding", "PROBLEM", 140, 164], ["protein\u2013membrane binding", "OBSERVATION", 140, 164]]], ["In this assay, proteins were labeled with Atto 594 dye, while vesicles contained the lipid Oregon Green 488\u2013DHPE.", [["vesicles", "ANATOMY", 62, 70], ["Atto 594 dye", "CHEMICAL", 42, 54], ["Atto 594", "CHEMICAL", 42, 50], ["Atto 594 dye", "SIMPLE_CHEMICAL", 42, 54], ["vesicles", "CELLULAR_COMPONENT", 62, 70], ["this assay", "TEST", 3, 13]]], ["We quantified vesicle diameter as described above, and used measurements of single fluorophore brightness to quantify the number of bound proteins per vesicle (Snead et al., 2017; see Materials and methods).", [["vesicle", "ANATOMY", 14, 21], ["vesicle", "ANATOMY", 151, 158], ["vesicle", "CELLULAR_COMPONENT", 14, 21], ["vesicle", "CELLULAR_COMPONENT", 151, 158], ["bound proteins", "PROTEIN", 132, 146], ["single fluorophore brightness", "TREATMENT", 76, 105], ["vesicle", "OBSERVATION_MODIFIER", 14, 21], ["diameter", "OBSERVATION_MODIFIER", 22, 30]]], ["From these measurements we determined the density of membrane-bound proteins, which increased with increasing protein concentration in solution (Fig. S2, A\u2013C).", [["membrane", "ANATOMY", 53, 61], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["membrane-bound proteins", "PROTEIN", 53, 76], ["S2", "PROTEIN", 150, 152], ["A\u2013C", "PROTEIN", 154, 157], ["these measurements", "TEST", 5, 23], ["increasing protein concentration in solution", "TREATMENT", 99, 143]]], ["These experiments revealed that over the range of protein concentrations in which membrane remodeling and vesiculation began to occur, Amph-FL and N-BAR reached similar number densities of membrane-bound protein, indicating that the two proteins bind membranes with similar affinity (Fig. 2 G).", [["membrane", "ANATOMY", 82, 90], ["membrane", "ANATOMY", 189, 197], ["membranes", "ANATOMY", 251, 260], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 135, 142], ["N-BAR", "GENE_OR_GENE_PRODUCT", 147, 152], ["membrane", "CELLULAR_COMPONENT", 189, 197], ["membranes", "CELLULAR_COMPONENT", 251, 260], ["Amph", "PROTEIN", 135, 139], ["FL", "PROTEIN", 140, 142], ["N", "PROTEIN", 147, 148], ["BAR", "PROTEIN", 149, 152], ["membrane-bound protein", "PROTEIN", 189, 211], ["These experiments", "TEST", 0, 17], ["protein concentrations", "PROBLEM", 50, 72], ["vesiculation", "PROBLEM", 106, 118], ["Amph", "TEST", 135, 139], ["membrane-bound protein", "TEST", 189, 211], ["the two proteins bind membranes", "PROBLEM", 229, 260], ["vesiculation", "OBSERVATION", 106, 118]]], ["Specifically, these results suggest that the disordered domain did not significantly enhance protein\u2013lipid and protein\u2013protein interactions, either of which would be expected to increase the density of membrane-bound protein.", [["membrane", "ANATOMY", 202, 210], ["protein\u2013lipid", "SIMPLE_CHEMICAL", 93, 106], ["membrane", "CELLULAR_COMPONENT", 202, 210], ["membrane-bound protein", "PROTEIN", 202, 224], ["the disordered domain", "PROBLEM", 41, 62], ["density", "OBSERVATION", 191, 198]]], ["Indeed, the isolated disordered domain of amphiphysin showed no detectable binding to the membranes used in fission studies with Amph-FL (Fig. S2 D).", [["membranes", "ANATOMY", 90, 99], ["Amph-FL", "CHEMICAL", 129, 136], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 42, 53], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 129, 136], ["S2 D", "GENE_OR_GENE_PRODUCT", 143, 147], ["isolated disordered domain", "PROTEIN", 12, 38], ["amphiphysin", "PROTEIN", 42, 53], ["Amph", "PROTEIN", 129, 133], ["FL", "PROTEIN", 134, 136], ["the isolated disordered domain of amphiphysin", "PROBLEM", 8, 53], ["detectable binding", "PROBLEM", 64, 82], ["Amph", "TEST", 129, 133], ["no", "UNCERTAINTY", 61, 63]]], ["Therefore, the ability of Amph-FL to drive membrane fission cannot be explained by differences in membrane recruitment.", [["membrane", "ANATOMY", 43, 51], ["membrane", "ANATOMY", 98, 106], ["Amph-FL", "CHEMICAL", 26, 33], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 26, 33], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["membrane", "CELLULAR_COMPONENT", 98, 106], ["Amph", "PROTEIN", 26, 30], ["FL", "PROTEIN", 31, 33], ["Amph-FL to drive membrane fission", "TREATMENT", 26, 59], ["cannot be explained", "UNCERTAINTY", 60, 79], ["membrane recruitment", "OBSERVATION", 98, 118]]], ["However, Amph-FL reached a high coverage of the membrane surface at substantially lower protein concentration compared with N-BAR, owing to the larger membrane footprint of Amph-FL (Fig. 2 H; see Materials and methods).", [["membrane surface", "ANATOMY", 48, 64], ["membrane", "ANATOMY", 151, 159], ["Amph-FL", "CHEMICAL", 9, 16], ["N-BAR", "CHEMICAL", 124, 129], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 9, 16], ["membrane surface", "CELLULAR_COMPONENT", 48, 64], ["N-BAR", "SIMPLE_CHEMICAL", 124, 129], ["membrane", "CELLULAR_COMPONENT", 151, 159], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 173, 180], ["Amph", "PROTEIN", 9, 13], ["FL", "PROTEIN", 14, 16], ["BAR", "PROTEIN", 126, 129], ["Amph", "PROTEIN", 173, 177], ["FL", "PROTEIN", 178, 180], ["Amph", "TEST", 9, 13], ["the membrane surface", "TREATMENT", 44, 64], ["substantially lower protein concentration", "PROBLEM", 68, 109], ["Amph-FL", "TREATMENT", 173, 180]]], ["These findings help explain how Amph-FL reached a crowded coverage of the membrane surface, sufficient to drive membrane vesiculation.The disordered domain of amphiphysin drives membrane fission on its own, but requires higher protein concentration compared with Amph-FL ::: ResultsAnother possible explanation for the ability of amphiphysin to drive membrane fission is that its substantial disordered domain (residues 240\u2013622) generates steric pressure that promotes fission, in line with previous studies on other membrane-bound disordered domains (Busch et al., 2015; Snead et al., 2017).", [["membrane surface", "ANATOMY", 74, 90], ["membrane", "ANATOMY", 112, 120], ["membrane", "ANATOMY", 178, 186], ["membrane", "ANATOMY", 351, 359], ["membrane", "ANATOMY", 517, 525], ["Amph-FL", "CHEMICAL", 32, 39], ["residues 240\u2013622", "CHEMICAL", 411, 427], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 32, 39], ["membrane surface", "CELLULAR_COMPONENT", 74, 90], ["membrane", "CELLULAR_COMPONENT", 112, 120], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 159, 170], ["membrane", "CELLULAR_COMPONENT", 178, 186], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 330, 341], ["membrane", "CELLULAR_COMPONENT", 351, 359], ["\u2013622", "AMINO_ACID", 423, 427], ["membrane", "CELLULAR_COMPONENT", 517, 525], ["Amph", "PROTEIN", 32, 36], ["FL", "PROTEIN", 37, 39], ["disordered domain", "PROTEIN", 138, 155], ["amphiphysin", "PROTEIN", 159, 170], ["amphiphysin", "PROTEIN", 330, 341], ["disordered domain", "PROTEIN", 392, 409], ["residues 240\u2013622", "PROTEIN", 411, 427], ["membrane-bound disordered domains", "PROTEIN", 517, 550], ["The disordered domain of amphiphysin drives membrane fission", "TREATMENT", 134, 194], ["amphiphysin", "PROBLEM", 330, 341], ["steric pressure", "TREATMENT", 439, 454], ["previous studies", "TEST", 491, 507], ["membrane surface", "OBSERVATION", 74, 90], ["membrane vesiculation", "OBSERVATION", 112, 133], ["amphiphysin drives", "OBSERVATION", 159, 177], ["steric pressure", "OBSERVATION", 439, 454]]], ["If so, the isolated disordered domain should be able to drive membrane fission when bound to membrane surfaces at sufficient density.", [["membrane", "ANATOMY", 62, 70], ["membrane surfaces", "ANATOMY", 93, 110], ["membrane", "CELLULAR_COMPONENT", 62, 70], ["membrane surfaces", "CELLULAR_COMPONENT", 93, 110], ["the isolated disordered domain", "PROBLEM", 7, 37], ["density", "OBSERVATION", 125, 132]]], ["To test this idea, we purified the disordered domain of amphiphysin, lacking the C-terminal SH3 domain (Amph CTD \u0394SH3; Fig. 3 A).", [["C", "CHEMICAL", 81, 82], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 56, 67], ["disordered domain", "PROTEIN", 35, 52], ["amphiphysin", "PROTEIN", 56, 67], ["C-terminal SH3 domain", "PROTEIN", 81, 102], ["Amph CTD \u0394SH3", "PROTEIN", 104, 117], ["Fig. 3 A", "PROTEIN", 119, 127], ["the disordered domain of amphiphysin", "PROBLEM", 31, 67], ["the C-terminal SH3 domain", "PROBLEM", 77, 102], ["Amph CTD \u0394SH3", "TEST", 104, 117]]], ["We first performed fluorescence correlation spectroscopy (FCS) measurements to quantify the hydrodynamic radius of this domain.", [["fluorescence correlation spectroscopy", "TEST", 19, 56], ["hydrodynamic radius", "OBSERVATION", 92, 111]]], ["Specifically, we calibrated the diffusion time of Amph CTD \u0394SH3 against the diffusion times of two protein standards with known hydrodynamic radii, transferrin (Hall et al., 2002) and the C-terminal domain of AP180 (AP180 CTD; Busch et al., 2015).", [["C", "CHEMICAL", 188, 189], ["transferrin", "GENE_OR_GENE_PRODUCT", 148, 159], ["Amph CTD \u0394SH3", "PROTEIN", 50, 63], ["transferrin", "PROTEIN", 148, 159], ["C-terminal domain", "PROTEIN", 188, 205], ["AP180", "PROTEIN", 209, 214], ["AP180 CTD", "PROTEIN", 216, 225], ["Amph CTD \u0394SH3", "TEST", 50, 63], ["hydrodynamic radii", "OBSERVATION", 128, 146]]], ["These experiments yielded an approximate hydrodynamic radius for Amph CTD \u0394SH3 of 4 nm (Fig. S2, E\u2013G; see Materials and methods), which corresponds to a radius of gyration of \u223c5 nm (Sherman and Haran, 2006; Hofmann et al., 2012), comparable to other disordered domains of similar molecular weight (Kalthoff et al., 2002; Busch et al., 2015).", [["Amph CTD \u0394SH3", "PROTEIN", 65, 78], ["S2", "PROTEIN", 93, 95], ["E\u2013G", "PROTEIN", 97, 100], ["disordered domains", "PROTEIN", 250, 268], ["an approximate hydrodynamic radius", "TREATMENT", 26, 60], ["Amph CTD \u0394SH3", "TEST", 65, 78], ["E\u2013G", "TEST", 97, 100], ["hydrodynamic radius", "OBSERVATION", 41, 60], ["E\u2013G", "ANATOMY", 97, 100], ["radius", "OBSERVATION_MODIFIER", 153, 159]]], ["FCS experiments also showed that the size of Amph CTD \u0394SH3 varied with the concentration of monovalent salt in the buffer (Fig. S2 H), consistent with the known sensitivity of highly charged disordered proteins to changes in ionic strength (Srinivasan et al., 2014).", [["Amph CTD", "GENE_OR_GENE_PRODUCT", 45, 53], ["Amph CTD \u0394SH3", "PROTEIN", 45, 58], ["highly charged disordered proteins", "PROTEIN", 176, 210], ["FCS experiments", "TEST", 0, 15], ["Amph CTD \u0394SH3", "TEST", 45, 58], ["monovalent salt", "TREATMENT", 92, 107], ["size", "OBSERVATION_MODIFIER", 37, 41], ["Amph CTD", "OBSERVATION", 45, 53], ["consistent with", "UNCERTAINTY", 135, 150]]], ["We next performed tethered vesicle experiments to assess membrane fission by Amph CTD \u0394SH3.", [["vesicle", "ANATOMY", 27, 34], ["membrane", "ANATOMY", 57, 65], ["vesicle", "CELLULAR_COMPONENT", 27, 34], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 77, 85], ["Amph CTD \u0394SH3", "PROTEIN", 77, 90], ["tethered vesicle experiments", "TEST", 18, 46]]], ["The protein included an N-terminal hexa-histidine (6his) tag to facilitate binding to membranes by the lipid 1,2-dioleoyl-sn-glycero-3-([N-[5-amino-1-carboxypentyl]iminodiacetic acid]succinyl), nickel salt (DOGS-NTA-Ni; Fig. 3 A).", [["membranes", "ANATOMY", 86, 95], ["1,2-dioleoyl-sn-glycero-3-([N-[5-amino-1-carboxypentyl]iminodiacetic acid", "CHEMICAL", 109, 182], ["succinyl", "CHEMICAL", 183, 191], ["nickel", "CHEMICAL", 194, 200], ["DOGS-NTA-Ni", "CHEMICAL", 207, 218], ["N", "CHEMICAL", 24, 25], ["hexa-histidine", "CHEMICAL", 35, 49], ["1,2-dioleoyl-sn-glycero-3-([N-[5-amino-1-carboxypentyl]iminodiacetic acid]succinyl", "CHEMICAL", 109, 191], ["nickel salt", "CHEMICAL", 194, 205], ["DOGS", "CHEMICAL", 207, 211], ["NTA", "CHEMICAL", 212, 215], ["Ni", "CHEMICAL", 216, 218], ["Fig. 3 A", "CHEMICAL", 220, 228], ["membranes", "CELLULAR_COMPONENT", 86, 95], ["lipid 1,2-dioleoyl-sn-glycero-3-([N-[5-amino-1-carboxypentyl]iminodiacetic acid]succinyl", "SIMPLE_CHEMICAL", 103, 191], ["nickel salt", "SIMPLE_CHEMICAL", 194, 205], ["DOGS-NTA", "SIMPLE_CHEMICAL", 207, 215], ["Fig. 3 A", "SIMPLE_CHEMICAL", 220, 228], ["N-terminal hexa-histidine (6his) tag", "PROTEIN", 24, 60], ["The protein", "TEST", 0, 11], ["an N-terminal hexa-histidine (6his) tag", "TREATMENT", 21, 60], ["the lipid", "TEST", 99, 108], ["dioleoyl", "TEST", 113, 121], ["glycero", "TREATMENT", 125, 132], ["amino", "TREATMENT", 142, 147], ["carboxypentyl]iminodiacetic acid]succinyl)", "TREATMENT", 150, 192], ["nickel salt (DOGS", "TREATMENT", 194, 211]]], ["Experiments revealed that Amph CTD \u0394SH3 drove the formation of highly curved fission products (Fig. 3, B and C).", [["Amph CTD", "GENE_OR_GENE_PRODUCT", 26, 34], ["Amph CTD \u0394SH3", "PROTEIN", 26, 39], ["fission products", "PROTEIN", 77, 93], ["Fig. 3, B and C", "PROTEIN", 95, 110], ["Amph CTD \u0394SH3", "PROBLEM", 26, 39]]], ["However, 100-fold greater concentration of Amph CTD \u0394SH3 in solution (10 \u00b5M) was required to generate fission products of similar curvature to those observed with Amph-FL (100 nM; Fig. 2, D and F).", [["Amph", "CHEMICAL", 43, 47], ["\u0394SH3", "CHEMICAL", 52, 56], ["Amph-FL", "CHEMICAL", 163, 170], ["Amph-FL", "CHEMICAL", 163, 170], ["Amph CTD \u0394SH3", "SIMPLE_CHEMICAL", 43, 56], ["Amph-FL", "SIMPLE_CHEMICAL", 163, 170], ["Amph CTD \u0394SH3", "PROTEIN", 43, 56], ["fission products", "PROTEIN", 102, 118], ["Amph-FL", "PROTEIN", 163, 170], ["Amph CTD \u0394SH3 in solution", "TREATMENT", 43, 68], ["Amph-FL", "TREATMENT", 163, 170]]], ["Importantly, the DOGS-NTA-Ni lipids alone did not generate high curvature vesicles before protein exposure (Fig. 3 B, top histogram).", [["vesicles", "ANATOMY", 74, 82], ["NTA", "CHEMICAL", 22, 25], ["Ni", "CHEMICAL", 26, 28], ["NTA", "CHEMICAL", 22, 25], ["Ni", "CHEMICAL", 26, 28], ["DOGS-NTA-Ni lipids", "SIMPLE_CHEMICAL", 17, 35], ["vesicles", "CELLULAR_COMPONENT", 74, 82], ["the DOGS", "TEST", 13, 21], ["Ni lipids", "TREATMENT", 26, 35], ["high curvature vesicles", "PROBLEM", 59, 82], ["protein exposure", "PROBLEM", 90, 106], ["top histogram", "TEST", 118, 131], ["high curvature", "OBSERVATION_MODIFIER", 59, 73]]], ["Moreover, isolated 6his tags were not found to drive membrane remodeling (Fig. S2 I).The disordered domain of amphiphysin drives membrane fission on its own, but requires higher protein concentration compared with Amph-FL ::: ResultsMembrane binding experiments with fluorescently labeled Amph CTD \u0394SH3 showed that when 10 \u00b5M of protein was present in solution, the protein covered \u223c40% of the membrane surface (Fig. 3 D and Fig. S2, J\u2013L).", [["membrane", "ANATOMY", 53, 61], ["membrane", "ANATOMY", 129, 137], ["membrane surface", "ANATOMY", 394, 410], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 110, 121], ["membrane", "CELLULAR_COMPONENT", 129, 137], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 289, 297], ["membrane surface", "CELLULAR_COMPONENT", 394, 410], ["J\u2013L", "GENE_OR_GENE_PRODUCT", 434, 437], ["6his tags", "DNA", 19, 28], ["S2 I", "PROTEIN", 79, 83], ["disordered domain", "PROTEIN", 89, 106], ["amphiphysin", "PROTEIN", 110, 121], ["Amph CTD \u0394SH3", "PROTEIN", 289, 302], ["S2", "PROTEIN", 430, 432], ["J\u2013L", "PROTEIN", 434, 437], ["6his tags", "TEST", 19, 28], ["The disordered domain of amphiphysin drives membrane fission", "TREATMENT", 85, 145], ["Amph CTD \u0394SH3", "TEST", 289, 302], ["the protein", "TEST", 362, 373], ["the membrane surface", "TREATMENT", 390, 410], ["amphiphysin drives", "OBSERVATION", 110, 128]]], ["At this coverage, steric pressure from protein crowding is expected to be sufficient to overcome the energetic barrier to membrane fission (Snead et al., 2017).", [["membrane", "ANATOMY", 122, 130], ["membrane", "CELLULAR_COMPONENT", 122, 130], ["steric pressure", "TEST", 18, 33], ["protein crowding", "PROBLEM", 39, 55], ["steric pressure", "OBSERVATION", 18, 33], ["protein crowding", "OBSERVATION", 39, 55]]], ["Therefore, the requirement for a high solution concentration of Amph CTD \u0394SH3 reflects the conditions necessary to promote crowded binding to the membrane surface.", [["membrane surface", "ANATOMY", 146, 162], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 64, 72], ["membrane surface", "CELLULAR_COMPONENT", 146, 162], ["Amph CTD \u0394SH3", "PROTEIN", 64, 77], ["a high solution concentration", "TREATMENT", 31, 60], ["Amph CTD \u0394SH3", "TREATMENT", 64, 77], ["the conditions", "PROBLEM", 87, 101], ["crowded binding", "OBSERVATION", 123, 138]]], ["In contrast, Amph-FL showed substantially stronger binding compared with Amph CTD \u0394SH3 (Fig. 3 D), likely owing to polymerization of the BAR scaffold, which enables multivalent membrane binding (Sorre et al., 2012; Simunovic et al., 2016).", [["membrane", "ANATOMY", 177, 185], ["Amph-FL", "CHEMICAL", 13, 20], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 13, 20], ["Fig. 3 D", "GENE_OR_GENE_PRODUCT", 88, 96], ["BAR", "GENE_OR_GENE_PRODUCT", 137, 140], ["membrane", "CELLULAR_COMPONENT", 177, 185], ["Amph", "PROTEIN", 13, 17], ["FL", "PROTEIN", 18, 20], ["Amph CTD \u0394SH3", "PROTEIN", 73, 86], ["Fig. 3 D", "PROTEIN", 88, 96], ["BAR scaffold", "PROTEIN", 137, 149], ["Amph-FL", "TEST", 13, 20], ["substantially stronger binding", "PROBLEM", 28, 58], ["Amph CTD \u0394SH3", "TEST", 73, 86], ["polymerization of the BAR scaffold", "PROBLEM", 115, 149], ["BAR scaffold", "OBSERVATION", 137, 149]]], ["However, plotting membrane vesiculation by Amph CTD \u0394SH3 and Amph-FL together as a function of the coverage of the membrane surface by proteins revealed that data for the two proteins fall along a similar trend (Fig. 3 E).", [["membrane", "ANATOMY", 18, 26], ["membrane surface", "ANATOMY", 115, 131], ["membrane", "CELLULAR_COMPONENT", 18, 26], ["Amph CTD \u0394SH3", "GENE_OR_GENE_PRODUCT", 43, 56], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 61, 68], ["membrane surface", "CELLULAR_COMPONENT", 115, 131], ["Amph CTD \u0394SH3", "PROTEIN", 43, 56], ["Amph", "PROTEIN", 61, 65], ["FL", "PROTEIN", 66, 68], ["plotting membrane vesiculation", "TEST", 9, 39], ["Amph CTD \u0394SH3", "TEST", 43, 56], ["Amph-FL", "TREATMENT", 61, 68], ["the two proteins fall", "PROBLEM", 167, 188]]], ["This finding suggests that the requirement for a high concentration of Amph CTD \u0394SH3 to drive membrane vesiculation arises primarily from weaker membrane binding in comparison to Amph-FL, rather than from the absence of the N-BAR domain.A chimera consisting of N-BAR fused to an alternative disordered domain drives fission with similar efficiency to wild-type amphiphysin ::: ResultsExperiments comparing membrane remodeling by Amph-FL and N-BAR imply that assembly of the N-BAR scaffold at the membrane surface facilitates local crowding of the bulky disordered domains in Amph-FL.", [["membrane", "ANATOMY", 94, 102], ["membrane", "ANATOMY", 145, 153], ["membrane", "ANATOMY", 406, 414], ["membrane surface", "ANATOMY", 496, 512], ["Amph-FL", "ANATOMY", 575, 582], ["Amph-FL", "CHEMICAL", 575, 582], ["N", "CHEMICAL", 474, 475], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 71, 79], ["\u0394SH3", "GENE_OR_GENE_PRODUCT", 80, 84], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["membrane", "CELLULAR_COMPONENT", 145, 153], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 179, 186], ["N-BAR", "GENE_OR_GENE_PRODUCT", 261, 266], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 361, 372], ["membrane", "CELLULAR_COMPONENT", 406, 414], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 429, 436], ["N-BAR", "GENE_OR_GENE_PRODUCT", 441, 446], ["membrane surface", "CELLULAR_COMPONENT", 496, 512], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 575, 582], ["Amph CTD", "PROTEIN", 71, 79], ["\u0394SH3", "PROTEIN", 80, 84], ["Amph", "PROTEIN", 179, 183], ["FL", "PROTEIN", 184, 186], ["N-BAR domain", "PROTEIN", 224, 236], ["N", "PROTEIN", 261, 262], ["BAR", "PROTEIN", 263, 266], ["alternative disordered domain", "PROTEIN", 279, 308], ["wild-type amphiphysin", "PROTEIN", 351, 372], ["Amph", "PROTEIN", 429, 433], ["FL", "PROTEIN", 434, 436], ["N", "PROTEIN", 441, 442], ["BAR", "PROTEIN", 443, 446], ["N-BAR scaffold", "PROTEIN", 474, 488], ["bulky disordered domains", "PROTEIN", 547, 571], ["Amph", "PROTEIN", 575, 579], ["FL", "PROTEIN", 580, 582], ["Amph CTD \u0394SH3", "TREATMENT", 71, 84], ["membrane vesiculation", "PROBLEM", 94, 115], ["weaker membrane binding", "PROBLEM", 138, 161], ["Amph-FL", "TEST", 179, 186], ["A chimera consisting of N-BAR fused", "PROBLEM", 237, 272], ["an alternative disordered domain drives fission", "PROBLEM", 276, 323], ["the N-BAR scaffold at the membrane surface", "TREATMENT", 470, 512], ["the bulky disordered domains", "PROBLEM", 543, 571], ["weaker membrane binding", "OBSERVATION", 138, 161], ["local crowding", "OBSERVATION", 525, 539], ["bulky", "OBSERVATION_MODIFIER", 547, 552]]], ["This reasoning implies that any bulky disordered domain that is brought to the membrane surface by a BAR scaffold should be capable of driving membrane fission.", [["membrane surface", "ANATOMY", 79, 95], ["membrane", "ANATOMY", 143, 151], ["membrane surface", "CELLULAR_COMPONENT", 79, 95], ["BAR", "GENE_OR_GENE_PRODUCT", 101, 104], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["bulky disordered domain", "PROTEIN", 32, 55], ["BAR scaffold", "PROTEIN", 101, 113], ["any bulky disordered domain", "PROBLEM", 28, 55], ["a BAR scaffold", "TREATMENT", 99, 113]]], ["To test this prediction, we created a chimera consisting of the amphiphysin N-BAR domain fused to the C-terminal disordered domain of rat epsin1 (N-BAR-epsin CTD; Fig. 3 F).", [["C", "CHEMICAL", 102, 103], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 64, 75], ["rat", "ORGANISM", 134, 137], ["epsin1", "GENE_OR_GENE_PRODUCT", 138, 144], ["N-BAR-epsin CTD", "GENE_OR_GENE_PRODUCT", 146, 161], ["Fig. 3 F", "GENE_OR_GENE_PRODUCT", 163, 171], ["amphiphysin N-BAR domain", "PROTEIN", 64, 88], ["C-terminal disordered domain", "PROTEIN", 102, 130], ["rat epsin1", "PROTEIN", 134, 144], ["N-BAR", "PROTEIN", 146, 151], ["epsin CTD", "PROTEIN", 152, 161], ["Fig. 3 F", "PROTEIN", 163, 171], ["rat", "SPECIES", 134, 137], ["the amphiphysin N", "TREATMENT", 60, 77], ["rat epsin1", "TREATMENT", 134, 144], ["N-BAR-epsin CTD", "TREATMENT", 146, 161]]], ["Importantly, the disordered domain of epsin1 is comparable to the disordered domain of amphiphysin in terms of length (432 versus 383 amino acids, respectively) as well as hydrodynamic radius (Busch et al., 2015).", [["amino acids", "CHEMICAL", 134, 145], ["amino acids", "CHEMICAL", 134, 145], ["epsin1", "GENE_OR_GENE_PRODUCT", 38, 44], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 87, 98], ["amino acids", "AMINO_ACID", 134, 145], ["disordered domain", "PROTEIN", 17, 34], ["epsin1", "PROTEIN", 38, 44], ["disordered domain", "PROTEIN", 66, 83], ["amphiphysin", "PROTEIN", 87, 98], ["the disordered domain of epsin1", "PROBLEM", 13, 44], ["length", "TEST", 111, 117], ["amino acids", "TEST", 134, 145], ["amphiphysin", "OBSERVATION", 87, 98], ["hydrodynamic radius", "OBSERVATION", 172, 191]]], ["Tethered vesicle fission experiments revealed that N-BAR-epsin CTD generated highly curved fission products from vesicles with an initial average diameter of 200 nm within a similar range of protein concentrations to Amph-FL (Fig. 3 G; compare to Fig. 2 D).", [["vesicle", "ANATOMY", 9, 16], ["vesicles", "ANATOMY", 113, 121], ["vesicle", "CELLULAR_COMPONENT", 9, 16], ["N-BAR", "GENE_OR_GENE_PRODUCT", 51, 56], ["vesicles", "CELLULAR_COMPONENT", 113, 121], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 217, 224], ["BAR", "PROTEIN", 53, 56], ["epsin CTD", "PROTEIN", 57, 66], ["fission products", "PROTEIN", 91, 107], ["Amph", "PROTEIN", 217, 221], ["FL", "PROTEIN", 222, 224], ["Tethered vesicle fission experiments", "TEST", 0, 36], ["N-BAR", "TEST", 51, 56], ["epsin CTD", "PROBLEM", 57, 66], ["Amph", "TEST", 217, 221], ["diameter", "OBSERVATION_MODIFIER", 146, 154], ["200 nm", "OBSERVATION_MODIFIER", 158, 164]]], ["Further, both N-BAR-epsin CTD and Amph-FL produced a very similar fraction of fission products with diameters below 45 nm at equivalent concentrations in solution (Fig. 3 H).", [["Amph-FL", "CHEMICAL", 34, 41], ["N-BAR", "SIMPLE_CHEMICAL", 14, 19], ["Amph-FL", "SIMPLE_CHEMICAL", 34, 41], ["BAR", "PROTEIN", 16, 19], ["epsin CTD", "PROTEIN", 20, 29], ["Amph", "PROTEIN", 34, 38], ["FL", "PROTEIN", 39, 41], ["fission products", "PROTEIN", 78, 94], ["Amph", "TEST", 34, 38], ["fission products", "OBSERVATION", 78, 94], ["diameters", "OBSERVATION_MODIFIER", 100, 109]]], ["Finally, SUPER template membrane shedding experiments revealed that in the concentration range of 50\u20131,000 nM, N-BAR-epsin CTD drove greater membrane release compared with the isolated N-BAR domain (Fig. 3 I), similar to the results of SUPER template experiments comparing N-BAR and Amph-FL (Fig. 1 F).", [["membrane", "ANATOMY", 24, 32], ["membrane", "ANATOMY", 141, 149], ["membrane", "CELLULAR_COMPONENT", 24, 32], ["membrane", "CELLULAR_COMPONENT", 141, 149], ["N-BAR", "SIMPLE_CHEMICAL", 273, 278], ["Amph-FL", "SIMPLE_CHEMICAL", 283, 290], ["BAR", "PROTEIN", 113, 116], ["epsin CTD", "PROTEIN", 117, 126], ["N-BAR domain", "PROTEIN", 185, 197], ["Fig. 3 I", "PROTEIN", 199, 207], ["BAR", "PROTEIN", 275, 278], ["Amph-FL", "PROTEIN", 283, 290], ["N-BAR", "TEST", 111, 116], ["SUPER template experiments", "TREATMENT", 236, 262], ["Amph-FL", "TREATMENT", 283, 290]]], ["Importantly, the isolated disordered domain of epsin showed no detectable binding to membranes used in fission studies (Fig. S2 D), suggesting that the disordered domain did not enhance membrane recruitment.", [["membranes", "ANATOMY", 85, 94], ["membrane", "ANATOMY", 186, 194], ["epsin", "GENE_OR_GENE_PRODUCT", 47, 52], ["membranes", "CELLULAR_COMPONENT", 85, 94], ["S2 D", "GENE_OR_GENE_PRODUCT", 125, 129], ["membrane", "CELLULAR_COMPONENT", 186, 194], ["epsin", "PROTEIN", 47, 52], ["S2 D", "PROTEIN", 125, 129], ["the isolated disordered domain of epsin", "PROBLEM", 13, 52], ["detectable binding to membranes", "PROBLEM", 63, 94], ["fission studies", "TEST", 103, 118], ["the disordered domain", "PROBLEM", 148, 169], ["no detectable", "UNCERTAINTY", 60, 73]]], ["These findings illustrate the ability of N-BAR scaffolds to promote membrane fission by crowding arbitrary disordered domains at membrane surfaces.A chimera consisting of N-BAR fused to an alternative disordered domain drives fission with similar efficiency to wild-type amphiphysin ::: ResultsHow does crowding among disordered domains overcome the ability of BAR scaffolds to stabilize lipid tubules?", [["membrane", "ANATOMY", 68, 76], ["membrane surfaces", "ANATOMY", 129, 146], ["lipid tubules", "ANATOMY", 388, 401], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["membrane surfaces", "CELLULAR_COMPONENT", 129, 146], ["N-BAR", "GENE_OR_GENE_PRODUCT", 171, 176], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 271, 282], ["BAR", "GENE_OR_GENE_PRODUCT", 361, 364], ["lipid tubules", "MULTI-TISSUE_STRUCTURE", 388, 401], ["N", "PROTEIN", 171, 172], ["BAR", "PROTEIN", 173, 176], ["alternative disordered domain", "PROTEIN", 189, 218], ["wild-type amphiphysin", "PROTEIN", 261, 282], ["N-BAR scaffolds", "TREATMENT", 41, 56], ["membrane fission", "PROBLEM", 68, 84], ["crowding arbitrary disordered domains at membrane surfaces", "PROBLEM", 88, 146], ["A chimera consisting of N-BAR fused", "PROBLEM", 147, 182], ["an alternative disordered domain drives fission", "PROBLEM", 186, 233], ["crowding among disordered domains", "PROBLEM", 303, 336], ["BAR scaffolds", "TREATMENT", 361, 374], ["lipid tubules", "PROBLEM", 388, 401], ["membrane fission", "OBSERVATION", 68, 84], ["crowding arbitrary", "OBSERVATION", 88, 106], ["lipid tubules", "OBSERVATION", 388, 401]]], ["One explanation is that steric pressure among the bulky disordered domains of Amph-FL inhibits the assembly of a long-range N-BAR scaffold, which, if allowed to form, would inhibit fission.", [["Amph-FL", "CHEMICAL", 78, 85], ["Amph-FL", "CHEMICAL", 78, 85], ["N", "CHEMICAL", 124, 125], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 78, 85], ["bulky disordered domains", "PROTEIN", 50, 74], ["Amph", "PROTEIN", 78, 82], ["FL", "PROTEIN", 83, 85], ["N-BAR scaffold", "PROTEIN", 124, 138], ["steric pressure", "TEST", 24, 39], ["Amph-FL", "TREATMENT", 78, 85], ["a long-range N-BAR scaffold", "TREATMENT", 111, 138]]], ["In support of this hypothesis, when Amph-FL reached \u223c70% surface coverage as shown above (Fig. 2 H), the underlying N-BAR domain covered only \u223c14% of the membrane, based on membrane footprints for Amph-FL and N-BAR of 79 and 16.5 nm2 per monomer, respectively (see Materials and methods).", [["surface", "ANATOMY", 57, 64], ["membrane", "ANATOMY", 154, 162], ["membrane", "ANATOMY", 173, 181], ["Amph-FL", "CHEMICAL", 36, 43], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 36, 43], ["membrane", "CELLULAR_COMPONENT", 154, 162], ["membrane", "CELLULAR_COMPONENT", 173, 181], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 197, 204], ["N-BAR", "GENE_OR_GENE_PRODUCT", 209, 214], ["Amph", "PROTEIN", 36, 40], ["FL", "PROTEIN", 41, 43], ["N-BAR domain", "PROTEIN", 116, 128], ["Amph", "PROTEIN", 197, 201], ["FL", "PROTEIN", 202, 204], ["BAR", "PROTEIN", 211, 214], ["this hypothesis", "PROBLEM", 14, 29], ["Amph", "TEST", 36, 40], ["FL", "TEST", 41, 43], ["the underlying N-BAR domain", "TREATMENT", 101, 128], ["Amph", "TEST", 197, 201], ["N-BAR", "TEST", 209, 214]]], ["This coverage is significantly lower than expected for a fully assembled N-BAR scaffold, which approaches complete coverage (Mim et al., 2012; Adam et al., 2015).", [["N-BAR scaffold", "PROTEIN", 73, 87], ["N-BAR scaffold", "TREATMENT", 73, 87], ["significantly lower", "OBSERVATION_MODIFIER", 17, 36]]], ["Furthermore, the volume available per amphiphysin disordered domain above the N-BAR scaffold is only \u223c50% of the volume that each domain would be expected to occupy in solution, based on its radius of gyration (Fig. 3 J; see calculation in Materials and methods).", [["amphiphysin", "GENE_OR_GENE_PRODUCT", 38, 49], ["amphiphysin disordered domain", "PROTEIN", 38, 67], ["N-BAR scaffold", "PROTEIN", 78, 92], ["amphiphysin disordered domain", "PROBLEM", 38, 67], ["the N-BAR scaffold", "TREATMENT", 74, 92]]], ["Notably, this calculation assumes that the disordered domains are incompressible, demonstrating that they would have to compress substantially in order to fit around the scaffold.", [["disordered domains", "PROTEIN", 43, 61], ["this calculation", "TEST", 9, 25], ["the disordered domains", "PROBLEM", 39, 61], ["incompressible", "OBSERVATION", 66, 80], ["scaffold", "ANATOMY", 170, 178]]], ["Previous work has shown that substantial compression of disordered domains is energetically costly, likely exceeding the cost of membrane deformation (Busch et al., 2015).", [["membrane", "ANATOMY", 129, 137], ["membrane", "CELLULAR_COMPONENT", 129, 137], ["disordered domains", "PROTEIN", 56, 74], ["substantial compression of disordered domains", "PROBLEM", 29, 74], ["membrane deformation", "PROBLEM", 129, 149], ["substantial", "OBSERVATION_MODIFIER", 29, 40], ["compression", "OBSERVATION", 41, 52], ["disordered", "OBSERVATION", 56, 66]]], ["Collectively, these arguments suggest that the presence of amphiphysin\u2019s bulky disordered domains inhibits assembly of long-range N-BAR scaffolds.A chimera consisting of N-BAR fused to an alternative disordered domain drives fission with similar efficiency to wild-type amphiphysin ::: ResultsInterestingly, previous structural studies using cryo-EM have reported limited observations of tubular N-BAR scaffolds formed from Amph-FL (Mim et al., 2012; Adam et al., 2015).", [["tubular", "ANATOMY", 388, 395], ["Amph-FL", "CHEMICAL", 424, 431], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 59, 70], ["N-BAR", "GENE_OR_GENE_PRODUCT", 170, 175], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 270, 281], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 424, 431], ["amphiphysin", "PROTEIN", 59, 70], ["bulky disordered domains", "PROTEIN", 73, 97], ["long-range N-BAR scaffolds", "DNA", 119, 145], ["N", "PROTEIN", 170, 171], ["BAR", "PROTEIN", 172, 175], ["alternative disordered domain", "PROTEIN", 188, 217], ["amphiphysin", "PROTEIN", 270, 281], ["tubular N-BAR scaffolds", "PROTEIN", 388, 411], ["amphiphysin\u2019s bulky disordered domains inhibits", "PROBLEM", 59, 106], ["long-range N-BAR scaffolds", "TREATMENT", 119, 145], ["A chimera consisting of N-BAR fused", "PROBLEM", 146, 181], ["an alternative disordered domain drives fission", "PROBLEM", 185, 232], ["tubular N-BAR scaffolds", "TREATMENT", 388, 411], ["amphiphysin", "OBSERVATION", 59, 70], ["tubular", "ANATOMY", 388, 395]]], ["These structures have been observed on membrane substrates containing a majority of negatively charged lipids, which are thought to provide a strong electrostatic driving force for scaffold assembly (Mim et al., 2012; Adam et al., 2015).", [["membrane", "ANATOMY", 39, 47], ["membrane", "CELLULAR_COMPONENT", 39, 47], ["lipids", "SIMPLE_CHEMICAL", 103, 109], ["membrane substrates", "TREATMENT", 39, 58]]], ["Therefore, we performed tethered vesicle fission experiments using a similar membrane composition (Fig. S3).", [["vesicle", "ANATOMY", 33, 40], ["membrane", "ANATOMY", 77, 85], ["vesicle", "CELLULAR_COMPONENT", 33, 40], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["tethered vesicle fission experiments", "TREATMENT", 24, 60], ["a similar membrane composition", "TREATMENT", 67, 97], ["vesicle fission", "OBSERVATION", 33, 48]]], ["Here, the onset of membrane fission occurred at somewhat higher Amph-FL concentration, 350 nM (Fig. S3) in comparison to 75 nM (Fig. 2, B\u2013F).", [["membrane", "ANATOMY", 19, 27], ["Amph-FL", "CHEMICAL", 64, 71], ["membrane", "CELLULAR_COMPONENT", 19, 27], ["Amph", "PROTEIN", 64, 68], ["FL", "PROTEIN", 69, 71], ["membrane fission", "PROBLEM", 19, 35], ["membrane fission", "OBSERVATION", 19, 35]]], ["These results demonstrate that high concentrations of negatively charged lipids cannot prevent membrane fission as protein concentration increases.", [["membrane", "ANATOMY", 95, 103], ["lipids", "SIMPLE_CHEMICAL", 73, 79], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["negatively charged lipids", "TREATMENT", 54, 79], ["membrane fission", "TREATMENT", 95, 111]]], ["Indeed, the cryo-EM studies cited above suggest that long-range scaffolds assembled from full-length protein were more rare (Mim et al., 2012).", [["long-range scaffolds", "DNA", 53, 73], ["full-length protein", "PROTEIN", 89, 108], ["the cryo-EM studies", "TEST", 8, 27], ["long-range scaffolds", "TREATMENT", 53, 73], ["full-length protein", "TEST", 89, 108]]], ["Moreover, these studies employed buffers that lacked small monovalent ions (Mim et al., 2012; Adam et al., 2015), conditions known to favor extension of disordered domains owing to reduced electrostatic screening (Srinivasan et al., 2014).", [["disordered domains", "PROTEIN", 153, 171], ["these studies", "TEST", 10, 23], ["disordered domains", "PROBLEM", 153, 171], ["small", "OBSERVATION_MODIFIER", 53, 58]]], ["This environment likely enabled the disordered domains to pack more efficiently around the scaffold, in line with the needle-like densities seen protruding from the N-BAR scaffold (Adam et al., 2015).Disordered domains inhibit tubule formation by BAR scaffolds in live cells ::: ResultsWe next sought to evaluate the influence of disordered domains on the membrane remodeling behavior of BAR domains in live mammalian cells.", [["tubule", "ANATOMY", 227, 233], ["cells", "ANATOMY", 269, 274], ["membrane", "ANATOMY", 356, 364], ["cells", "ANATOMY", 418, 423], ["tubule", "TISSUE", 227, 233], ["BAR", "GENE_OR_GENE_PRODUCT", 247, 250], ["cells", "CELL", 269, 274], ["membrane", "CELLULAR_COMPONENT", 356, 364], ["BAR", "GENE_OR_GENE_PRODUCT", 388, 391], ["mammalian cells", "CELL", 408, 423], ["BAR", "PROTEIN", 247, 250], ["live cells", "CELL_TYPE", 264, 274], ["disordered domains", "PROTEIN", 330, 348], ["BAR domains", "PROTEIN", 388, 399], ["live mammalian cells", "CELL_TYPE", 403, 423], ["the disordered domains", "PROBLEM", 32, 54], ["the needle-like densities", "PROBLEM", 114, 139], ["Disordered domains inhibit tubule formation", "PROBLEM", 200, 243], ["disordered domains", "PROBLEM", 330, 348], ["needle", "ANATOMY", 118, 124], ["densities", "OBSERVATION", 130, 139], ["protruding", "OBSERVATION_MODIFIER", 145, 155], ["inhibit tubule", "OBSERVATION", 219, 233], ["BAR scaffolds", "OBSERVATION", 247, 260], ["mammalian cells", "OBSERVATION", 408, 423]]], ["Multiple previous studies have established that overexpression of BAR domains leads to formation of lipid tubules in the cytosol that are coated by BAR scaffolds (Peter et al., 2004; Frost et al., 2008; Boucrot et al., 2012; McDonald et al., 2015).", [["lipid tubules", "ANATOMY", 100, 113], ["cytosol", "ANATOMY", 121, 128], ["BAR", "GENE_OR_GENE_PRODUCT", 66, 69], ["lipid tubules", "TISSUE", 100, 113], ["cytosol", "CELLULAR_COMPONENT", 121, 128], ["BAR", "GENE_OR_GENE_PRODUCT", 148, 151], ["BAR domains", "PROTEIN", 66, 77], ["Multiple previous studies", "TEST", 0, 25], ["overexpression of BAR domains", "PROBLEM", 48, 77], ["lipid tubules in the cytosol", "PROBLEM", 100, 128], ["lipid tubules", "OBSERVATION", 100, 113], ["cytosol", "ANATOMY", 121, 128]]], ["We first replicated these findings by overexpressing the N-BAR domain of human amphiphysin tagged with mCherry (Fig. 4 A) in retinal pigmented epithelial (RPE) cells.", [["retinal pigmented epithelial (RPE) cells", "ANATOMY", 125, 165], ["human", "ORGANISM", 73, 78], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 79, 90], ["mCherry", "GENE_OR_GENE_PRODUCT", 103, 110], ["Fig. 4 A", "GENE_OR_GENE_PRODUCT", 112, 120], ["retinal pigmented epithelial (RPE) cells", "CELL", 125, 165], ["N-BAR domain", "PROTEIN", 57, 69], ["human amphiphysin", "PROTEIN", 73, 90], ["mCherry", "PROTEIN", 103, 110], ["Fig. 4 A", "PROTEIN", 112, 120], ["retinal pigmented epithelial (RPE) cells", "CELL_TYPE", 125, 165], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["human amphiphysin", "TREATMENT", 73, 90], ["retinal pigmented", "ANATOMY", 125, 142], ["epithelial", "ANATOMY_MODIFIER", 143, 153]]], ["We found that N-BAR generated a dense network of tubules inside the cells (Fig. 4 B), in agreement with previous findings (Peter et al., 2004).", [["tubules", "ANATOMY", 49, 56], ["cells", "ANATOMY", 68, 73], ["N-BAR", "GENE_OR_GENE_PRODUCT", 14, 19], ["tubules", "TISSUE", 49, 56], ["cells", "CELL", 68, 73], ["Fig. 4 B", "CELL", 75, 83], ["N-BAR", "PROTEIN", 14, 19], ["dense", "OBSERVATION_MODIFIER", 32, 37], ["cells", "ANATOMY", 68, 73]]], ["The number of tubules per cell increased with the expression level of N-BAR (Fig. 4 C), and colocalized with a plasma membrane stain (Fig. S4 A), indicating that many of the tubules originated from the plasma membrane as previously observed (McDonald et al., 2015, 2016).", [["tubules", "ANATOMY", 14, 21], ["cell", "ANATOMY", 26, 30], ["plasma membrane", "ANATOMY", 111, 126], ["tubules", "ANATOMY", 174, 181], ["plasma membrane", "ANATOMY", 202, 217], ["tubules", "TISSUE", 14, 21], ["cell", "CELL", 26, 30], ["N-BAR", "GENE_OR_GENE_PRODUCT", 70, 75], ["Fig. 4 C", "GENE_OR_GENE_PRODUCT", 77, 85], ["plasma membrane", "CELLULAR_COMPONENT", 111, 126], ["tubules", "TISSUE", 174, 181], ["plasma membrane", "CELLULAR_COMPONENT", 202, 217], ["N", "PROTEIN", 70, 71], ["BAR", "PROTEIN", 72, 75], ["Fig. 4 C", "PROTEIN", 77, 85], ["a plasma membrane stain", "TEST", 109, 132], ["tubules", "OBSERVATION_MODIFIER", 14, 21], ["per cell", "OBSERVATION_MODIFIER", 22, 30], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["plasma membrane", "OBSERVATION", 202, 217]]], ["In contrast, overexpression of Amph-FL tagged with mCherry (Fig. 4 A) led to significantly fewer tubules per cell compared with N-BAR (Fig. 4, B\u2013D), suggesting that the disordered domain of Amph-FL inhibited tubule formation.", [["tubules", "ANATOMY", 97, 104], ["cell", "ANATOMY", 109, 113], ["tubule", "ANATOMY", 208, 214], ["Amph-FL", "CHEMICAL", 190, 197], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 31, 38], ["mCherry", "GENE_OR_GENE_PRODUCT", 51, 58], ["Fig. 4 A", "GENE_OR_GENE_PRODUCT", 60, 68], ["tubules", "TISSUE", 97, 104], ["cell", "CELL", 109, 113], ["N-BAR", "GENE_OR_GENE_PRODUCT", 128, 133], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 190, 197], ["tubule", "TISSUE", 208, 214], ["Amph", "PROTEIN", 31, 35], ["FL", "PROTEIN", 36, 38], ["mCherry", "PROTEIN", 51, 58], ["Fig. 4 A", "PROTEIN", 60, 68], ["BAR", "PROTEIN", 130, 133], ["B\u2013D", "PROTEIN", 143, 146], ["disordered domain", "PROTEIN", 169, 186], ["Amph", "PROTEIN", 190, 194], ["FL", "PROTEIN", 195, 197], ["Amph", "TEST", 31, 35], ["significantly fewer tubules per cell", "PROBLEM", 77, 113], ["N-BAR", "TREATMENT", 128, 133], ["tubule formation", "PROBLEM", 208, 224]]], ["Notably, Amph-FL interacts with the clathrin adaptor network and may therefore recruit other membrane remodeling proteins.", [["membrane", "ANATOMY", 93, 101], ["Amph-FL", "CHEMICAL", 9, 16], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 9, 16], ["clathrin", "GENE_OR_GENE_PRODUCT", 36, 44], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["Amph", "PROTEIN", 9, 13], ["FL", "PROTEIN", 14, 16], ["clathrin adaptor network", "PROTEIN", 36, 60], ["membrane remodeling proteins", "PROTEIN", 93, 121], ["the clathrin adaptor network", "TREATMENT", 32, 60], ["other membrane remodeling proteins", "PROBLEM", 87, 121]]], ["As such, it is unclear whether the lack of stable tubules in Amph-FL\u2013expressing cells arose from the disordered domain or from other binding partners recruited by Amph-FL.", [["tubules", "ANATOMY", 50, 57], ["Amph-FL\u2013expressing cells", "ANATOMY", 61, 85], ["Amph-FL", "CHEMICAL", 163, 170], ["tubules", "TISSUE", 50, 57], ["Amph-FL\u2013expressing cells", "CELL", 61, 85], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 163, 170], ["Amph-FL\u2013expressing cells", "CELL_LINE", 61, 85], ["Amph", "PROTEIN", 163, 167], ["FL", "PROTEIN", 168, 170], ["Amph", "TEST", 61, 65], ["FL\u2013expressing cells", "PROBLEM", 66, 85], ["the disordered domain", "PROBLEM", 97, 118], ["stable", "OBSERVATION_MODIFIER", 43, 49]]], ["To distinguish between these possibilities, we created a chimera of N-BAR fused to an alternative disordered domain, from the neuronal protein neurofilament-M (N-BAR-NfM CTD), tagged with mCherry (Fig. 4 A).", [["neuronal", "ANATOMY", 126, 134], ["N-BAR", "GENE_OR_GENE_PRODUCT", 68, 73], ["neuronal", "CELL", 126, 134], ["neurofilament-M", "GENE_OR_GENE_PRODUCT", 143, 158], ["N-BAR-NfM CTD", "GENE_OR_GENE_PRODUCT", 160, 173], ["mCherry", "GENE_OR_GENE_PRODUCT", 188, 195], ["N", "PROTEIN", 68, 69], ["BAR", "PROTEIN", 70, 73], ["alternative disordered domain", "PROTEIN", 86, 115], ["neuronal protein neurofilament-M", "PROTEIN", 126, 158], ["N-BAR", "PROTEIN", 160, 165], ["NfM CTD", "PROTEIN", 166, 173], ["mCherry", "PROTEIN", 188, 195], ["Fig. 4 A", "PROTEIN", 197, 205], ["an alternative disordered domain", "PROBLEM", 83, 115], ["the neuronal protein neurofilament", "TEST", 122, 156]]], ["The disordered C-terminal domain of neurofilament-M acts as an entropic brush, radiating outward along the length of neurofilaments and sterically repelling neighboring disordered domains to control axon diameter (Brown and Hoh, 1997; Kumar et al., 2002).", [["brush", "ANATOMY", 72, 77], ["neurofilaments", "ANATOMY", 117, 131], ["axon", "ANATOMY", 199, 203], ["C", "CHEMICAL", 15, 16], ["neurofilament-M", "GENE_OR_GENE_PRODUCT", 36, 51], ["neurofilaments", "CELLULAR_COMPONENT", 117, 131], ["axon", "MULTI-TISSUE_STRUCTURE", 199, 203], ["disordered C-terminal domain", "PROTEIN", 4, 32], ["neurofilament-M", "PROTEIN", 36, 51], ["neurofilaments", "PROTEIN", 117, 131], ["disordered domains", "PROTEIN", 169, 187], ["an entropic brush", "TREATMENT", 60, 77], ["axon diameter", "OBSERVATION_MODIFIER", 199, 212]]], ["The neurofilament-M disordered domain is similar in length to that of amphiphysin (438 versus 383 amino acids, respectively) but is not involved in endocytosis and therefore contains no binding domains for endocytic proteins.", [["amino acids", "CHEMICAL", 98, 109], ["amino acids", "CHEMICAL", 98, 109], ["neurofilament-M", "GENE_OR_GENE_PRODUCT", 4, 19], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 70, 81], ["amino acids", "AMINO_ACID", 98, 109], ["neurofilament-M disordered domain", "PROTEIN", 4, 37], ["amphiphysin", "PROTEIN", 70, 81], ["binding domains", "PROTEIN", 186, 201], ["endocytic proteins", "PROTEIN", 206, 224], ["The neurofilament-M disordered domain", "PROBLEM", 0, 37], ["amphiphysin", "TEST", 70, 81], ["amino acids", "TEST", 98, 109], ["binding domains", "PROBLEM", 186, 201], ["endocytic proteins", "PROBLEM", 206, 224], ["similar", "OBSERVATION_MODIFIER", 41, 48], ["length", "OBSERVATION_MODIFIER", 52, 58], ["not involved", "UNCERTAINTY", 132, 144], ["endocytosis", "OBSERVATION", 148, 159]]], ["Overexpressing N-BAR-NfM CTD in RPE cells resulted in a similar phenotype to Amph-FL, in which the number of tubules per cell was significantly reduced compared with the isolated N-BAR domain (Fig. 4, B\u2013D).", [["RPE cells", "ANATOMY", 32, 41], ["Amph-FL", "ANATOMY", 77, 84], ["tubules", "ANATOMY", 109, 116], ["cell", "ANATOMY", 121, 125], ["N-BAR-NfM CTD", "GENE_OR_GENE_PRODUCT", 15, 28], ["RPE cells", "CELL", 32, 41], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 77, 84], ["tubules", "TISSUE", 109, 116], ["cell", "CELL", 121, 125], ["N-BAR", "PROTEIN", 15, 20], ["NfM CTD", "PROTEIN", 21, 28], ["RPE cells", "CELL_TYPE", 32, 41], ["Amph", "PROTEIN", 77, 81], ["BAR domain", "PROTEIN", 181, 191], ["B\u2013D", "PROTEIN", 201, 204], ["CTD", "OBSERVATION", 25, 28], ["RPE cells", "OBSERVATION", 32, 41]]], ["We reach similar conclusions whether protein expression level is matched in terms of the fluorescent protein intensity at the plasma membrane (Fig. 4 C) or in the cytosol (Fig. S4 B).", [["plasma membrane", "ANATOMY", 126, 141], ["cytosol", "ANATOMY", 163, 170], ["plasma membrane", "CELLULAR_COMPONENT", 126, 141], ["cytosol", "CELLULAR_COMPONENT", 163, 170], ["S4 B", "GENE_OR_GENE_PRODUCT", 177, 181], ["S4 B", "PROTEIN", 177, 181], ["protein expression level", "PROBLEM", 37, 61], ["the fluorescent protein intensity", "PROBLEM", 85, 118], ["the plasma membrane", "TREATMENT", 122, 141], ["the cytosol (Fig", "TREATMENT", 159, 175]]], ["However, the disordered domains of Amph-FL and N-BAR-epsin CTD appeared to reduce plasma membrane binding slightly (Fig. S4 C).", [["plasma membrane", "ANATOMY", 82, 97], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 35, 42], ["N-BAR-epsin CTD", "GENE_OR_GENE_PRODUCT", 47, 62], ["plasma membrane", "CELLULAR_COMPONENT", 82, 97], ["disordered domains", "PROTEIN", 13, 31], ["Amph", "PROTEIN", 35, 39], ["FL", "PROTEIN", 40, 42], ["N", "PROTEIN", 47, 48], ["BAR", "PROTEIN", 49, 52], ["epsin CTD", "PROTEIN", 53, 62], ["Amph", "TEST", 35, 39], ["N-BAR", "TREATMENT", 47, 52], ["epsin CTD", "TREATMENT", 53, 62], ["plasma membrane binding", "PROBLEM", 82, 105]]], ["Furthermore, while tubules in N-BAR\u2013expressing cells had an average length of 6.0 \u00b1 0.2 \u00b5m SEM, tubule lengths in cells expressing Amph-FL and N-BAR-NfM CTD were significantly shorter, 3.5 \u00b1 0.1 and 3.6 \u00b1 0.1 \u00b5m SEM, respectively (Fig. 4 E).Disordered domains inhibit tubule formation by BAR scaffolds in live cells ::: ResultsTime-lapse imaging of live cells revealed that the tubules formed by Amph-FL and N-BAR-NfM CTD were more transient in comparison to isolated N-BAR (Fig. 4 F and Video 6).", [["tubules", "ANATOMY", 19, 26], ["N-BAR\u2013expressing cells", "ANATOMY", 30, 52], ["tubule", "ANATOMY", 96, 102], ["cells", "ANATOMY", 114, 119], ["tubule", "ANATOMY", 268, 274], ["cells", "ANATOMY", 310, 315], ["cells", "ANATOMY", 354, 359], ["tubules", "ANATOMY", 378, 385], ["tubules", "TISSUE", 19, 26], ["N-BAR\u2013expressing cells", "CELL", 30, 52], ["tubule", "MULTI-TISSUE_STRUCTURE", 96, 102], ["cells", "CELL", 114, 119], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 131, 138], ["N-BAR-NfM CTD", "GENE_OR_GENE_PRODUCT", 143, 156], ["tubule", "TISSUE", 268, 274], ["BAR", "GENE_OR_GENE_PRODUCT", 288, 291], ["cells", "CELL", 310, 315], ["cells", "CELL", 354, 359], ["tubules", "TISSUE", 378, 385], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 396, 403], ["N-BAR", "GENE_OR_GENE_PRODUCT", 408, 413], ["N-BAR\u2013expressing cells", "CELL_LINE", 30, 52], ["Amph", "PROTEIN", 131, 135], ["FL", "PROTEIN", 136, 138], ["N", "PROTEIN", 143, 144], ["BAR", "PROTEIN", 145, 148], ["NfM CTD", "PROTEIN", 149, 156], ["BAR", "PROTEIN", 288, 291], ["live cells", "CELL_TYPE", 305, 315], ["live cells", "CELL_TYPE", 349, 359], ["Amph", "PROTEIN", 396, 400], ["FL", "PROTEIN", 401, 403], ["N", "PROTEIN", 408, 409], ["BAR", "PROTEIN", 410, 413], ["NfM CTD", "PROTEIN", 414, 421], ["BAR", "PROTEIN", 470, 473], ["Video 6", "PROTEIN", 488, 495], ["tubules in N-BAR\u2013expressing cells", "PROBLEM", 19, 52], ["an average length", "TEST", 57, 74], ["SEM", "TEST", 91, 94], ["tubule lengths in cells", "TEST", 96, 119], ["Amph", "TEST", 131, 135], ["FL", "TEST", 136, 138], ["N", "TEST", 143, 144], ["NfM CTD", "TEST", 149, 156], ["SEM", "TEST", 212, 215], ["Disordered domains inhibit tubule formation", "PROBLEM", 241, 284], ["lapse imaging of live cells", "TEST", 332, 359], ["Amph", "TEST", 396, 400], ["NfM CTD", "PROBLEM", 414, 421], ["average", "OBSERVATION_MODIFIER", 60, 67], ["length", "OBSERVATION_MODIFIER", 68, 74], ["tubule", "OBSERVATION_MODIFIER", 96, 102], ["lengths", "OBSERVATION_MODIFIER", 103, 110], ["inhibit tubule", "OBSERVATION", 260, 274], ["BAR scaffolds", "OBSERVATION", 288, 301]]], ["Specifically, the tubules in cells expressing N-BAR had an average lifetime of \u223c75 \u00b1 5 s SEM, whereas tubule lifetime was significantly shorter in cells expressing Amph-FL and N-BAR-NfM CTD, \u223c29 \u00b1 3 and 35 \u00b1 4 s SEM, respectively (Fig. 4 F).", [["tubules", "ANATOMY", 18, 25], ["cells", "ANATOMY", 29, 34], ["tubule", "ANATOMY", 102, 108], ["cells", "ANATOMY", 147, 152], ["tubules", "TISSUE", 18, 25], ["cells", "CELL", 29, 34], ["N-BAR", "GENE_OR_GENE_PRODUCT", 46, 51], ["tubule", "MULTI-TISSUE_STRUCTURE", 102, 108], ["cells", "CELL", 147, 152], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 164, 171], ["N-BAR", "GENE_OR_GENE_PRODUCT", 176, 181], ["N-BAR", "PROTEIN", 46, 51], ["Amph", "PROTEIN", 164, 168], ["FL", "PROTEIN", 169, 171], ["N", "PROTEIN", 176, 177], ["BAR", "PROTEIN", 178, 181], ["NfM CTD", "PROTEIN", 182, 189], ["significantly shorter in cells", "PROBLEM", 122, 152], ["Amph", "TEST", 164, 168], ["s SEM", "TEST", 210, 215]]], ["The tubules formed by N-BAR also had greater fluorescence intensity in the protein channel relative to the local background in comparison to Amph-FL and N-BAR-NfM CTD (Fig. S4, D and E).", [["tubules", "ANATOMY", 4, 11], ["tubules", "TISSUE", 4, 11], ["N-BAR", "GENE_OR_GENE_PRODUCT", 22, 27], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 141, 148], ["N-BAR-NfM CTD", "GENE_OR_GENE_PRODUCT", 153, 166], ["D", "SIMPLE_CHEMICAL", 177, 178], ["N-BAR", "PROTEIN", 22, 27], ["protein channel", "PROTEIN", 75, 90], ["Amph", "PROTEIN", 141, 145], ["FL", "PROTEIN", 146, 148], ["N", "PROTEIN", 153, 154], ["BAR", "PROTEIN", 155, 158], ["NfM CTD", "PROTEIN", 159, 166], ["greater fluorescence intensity in the protein channel", "PROBLEM", 37, 90], ["Amph", "TEST", 141, 145], ["greater", "OBSERVATION_MODIFIER", 37, 44], ["fluorescence intensity", "OBSERVATION", 45, 67]]], ["This finding indicates that the disordered domains of Amph-FL and N-BAR-NfM CTD did not promote tubule fission by enhancing protein binding to the membrane surface.", [["tubule", "ANATOMY", 96, 102], ["membrane surface", "ANATOMY", 147, 163], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 54, 61], ["N-BAR", "GENE_OR_GENE_PRODUCT", 66, 71], ["tubule", "MULTI-TISSUE_STRUCTURE", 96, 102], ["membrane surface", "CELLULAR_COMPONENT", 147, 163], ["Amph", "PROTEIN", 54, 58], ["FL", "PROTEIN", 59, 61], ["N", "PROTEIN", 66, 67], ["BAR", "PROTEIN", 68, 71], ["NfM CTD", "PROTEIN", 72, 79], ["Amph", "TEST", 54, 58], ["N-BAR", "TREATMENT", 66, 71], ["NfM CTD", "PROBLEM", 72, 79], ["tubule fission", "OBSERVATION", 96, 110], ["enhancing", "OBSERVATION_MODIFIER", 114, 123], ["protein binding", "OBSERVATION", 124, 139]]], ["Collectively, results from experiments in live cells indicate that bulky disordered domains are capable of disrupting the formation of stable tubules scaffolded by BAR domains, similar to observations in vitro (Fig. 1, C and D).", [["cells", "ANATOMY", 47, 52], ["tubules", "ANATOMY", 142, 149], ["cells", "CELL", 47, 52], ["tubules", "TISSUE", 142, 149], ["BAR", "GENE_OR_GENE_PRODUCT", 164, 167], ["D", "SIMPLE_CHEMICAL", 225, 226], ["live cells", "CELL_TYPE", 42, 52], ["bulky disordered domains", "PROTEIN", 67, 91], ["BAR domains", "PROTEIN", 164, 175], ["bulky disordered domains", "PROBLEM", 67, 91], ["vitro (Fig", "TREATMENT", 204, 214], ["bulky", "OBSERVATION_MODIFIER", 67, 72], ["stable", "OBSERVATION_MODIFIER", 135, 141], ["tubules", "OBSERVATION", 142, 149]]], ["The disordered domains may have inhibited tubule formation in these experiments by driving membrane fission, though future work is needed to test whether steric pressure from disordered domain crowding plays a substantial role in physiological fission events.Crowding among disordered domains opposes the ability of I-BAR scaffolds to drive inward membrane bending ::: ResultsWe next asked how the membrane remodeling ability of crowded disordered domains compares with that of BAR scaffolds.", [["tubule", "ANATOMY", 42, 48], ["membrane", "ANATOMY", 91, 99], ["membrane", "ANATOMY", 348, 356], ["membrane", "ANATOMY", 398, 406], ["Crowding", "DISEASE", 259, 267], ["tubule", "TISSUE", 42, 48], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["membrane", "CELLULAR_COMPONENT", 348, 356], ["membrane", "CELLULAR_COMPONENT", 398, 406], ["BAR", "GENE_OR_GENE_PRODUCT", 478, 481], ["crowded disordered domains", "PROTEIN", 429, 455], ["BAR", "PROTEIN", 478, 481], ["The disordered domains", "PROBLEM", 0, 22], ["tubule formation", "PROBLEM", 42, 58], ["steric pressure", "PROBLEM", 154, 169], ["disordered domain crowding", "PROBLEM", 175, 201], ["Crowding among disordered domains", "PROBLEM", 259, 292], ["crowded disordered domains", "PROBLEM", 429, 455], ["BAR scaffolds", "TREATMENT", 478, 491], ["tubule formation", "OBSERVATION", 42, 58], ["substantial", "OBSERVATION_MODIFIER", 210, 221]]], ["To make this comparison, we created a chimeric protein that places the two mechanisms in direct competition within the same molecule.", [["chimeric protein", "PROTEIN", 38, 54], ["a chimeric protein", "PROBLEM", 36, 54]]], ["Specifically, we fused the I-BAR domain of human IRSp53 to the bulky, C-terminal disordered domain of rat AP180 (569 disordered amino acids) to form I-BAR-AP180 CTD (Fig. 5 A).", [["amino acids", "CHEMICAL", 128, 139], ["C", "CHEMICAL", 70, 71], ["amino acids", "CHEMICAL", 128, 139], ["human", "ORGANISM", 43, 48], ["IRSp53", "GENE_OR_GENE_PRODUCT", 49, 55], ["rat", "ORGANISM", 102, 105], ["AP180", "GENE_OR_GENE_PRODUCT", 106, 111], ["amino acids", "AMINO_ACID", 128, 139], ["I-BAR domain", "PROTEIN", 27, 39], ["human IRSp53", "PROTEIN", 43, 55], ["bulky, C-terminal disordered domain", "PROTEIN", 63, 98], ["rat AP180", "PROTEIN", 102, 111], ["569 disordered amino acids", "PROTEIN", 113, 139], ["I", "PROTEIN", 149, 150], ["BAR", "PROTEIN", 151, 154], ["AP180 CTD", "PROTEIN", 155, 164], ["Fig. 5 A", "PROTEIN", 166, 174], ["human", "SPECIES", 43, 48], ["rat", "SPECIES", 102, 105], ["human", "SPECIES", 43, 48], ["human IRSp", "TREATMENT", 43, 53], ["amino acids", "TEST", 128, 139]]], ["While the I-BAR domain is known to generate inverted membrane curvature (Mattila et al., 2007; Saarikangas et al., 2009), the attached disordered domains should generate steric pressure that will tend to bend the membrane in the opposite direction.", [["membrane", "ANATOMY", 53, 61], ["membrane", "ANATOMY", 213, 221], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["membrane", "CELLULAR_COMPONENT", 213, 221], ["I-BAR domain", "PROTEIN", 10, 22], ["the attached disordered domains", "PROBLEM", 122, 153], ["steric pressure", "TREATMENT", 170, 185], ["membrane curvature", "OBSERVATION", 53, 71], ["steric pressure", "OBSERVATION", 170, 185]]], ["Exposing GUVs to the I-BAR domain alone drove inverted membrane tubulation, as expected (Fig. 5 B, left; and Video 7).", [["membrane", "ANATOMY", 55, 63], ["GUVs", "GENE_OR_GENE_PRODUCT", 9, 13], ["I-BAR", "GENE_OR_GENE_PRODUCT", 21, 26], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["I-BAR domain", "PROTEIN", 21, 33], ["inverted membrane tubulation", "TREATMENT", 46, 74], ["GUVs", "OBSERVATION", 9, 13], ["membrane tubulation", "OBSERVATION", 55, 74], ["left", "ANATOMY_MODIFIER", 99, 103]]], ["In contrast, the I-BAR-AP180 CTD chimera drove neither inward nor outward tubulation.", [["I-BAR", "GENE_OR_GENE_PRODUCT", 17, 22], ["I-BAR", "PROTEIN", 17, 22], ["AP180 CTD chimera", "PROTEIN", 23, 40], ["the I-BAR", "TEST", 13, 22], ["outward tubulation", "OBSERVATION", 66, 84]]], ["Instead, the protein caused the GUV membrane to fluctuate dynamically through nonspherical shapes in which regions of gentle membrane curvature extending both inward and outward were apparent (Fig. 5 B, right; and Video 8).", [["GUV membrane", "ANATOMY", 32, 44], ["membrane", "ANATOMY", 125, 133], ["GUV membrane", "CELLULAR_COMPONENT", 32, 44], ["membrane", "CELLULAR_COMPONENT", 125, 133], ["the protein", "TEST", 9, 20], ["the GUV membrane", "PROBLEM", 28, 44], ["nonspherical shapes", "PROBLEM", 78, 97], ["gentle membrane curvature", "PROBLEM", 118, 143], ["nonspherical shapes", "OBSERVATION", 78, 97], ["gentle", "OBSERVATION_MODIFIER", 118, 124], ["membrane curvature", "OBSERVATION", 125, 143], ["inward", "OBSERVATION_MODIFIER", 159, 165], ["outward", "OBSERVATION_MODIFIER", 170, 177], ["right", "ANATOMY_MODIFIER", 203, 208]]], ["These \u201cfrustrated\u201d fluctuations demonstrate that the disordered domain effectively neutralized the ability of the I-BAR domain to drive inward membrane bending.", [["membrane", "ANATOMY", 143, 151], ["inward membrane", "CELLULAR_COMPONENT", 136, 151], ["disordered domain", "PROTEIN", 53, 70], ["I-BAR domain", "PROTEIN", 114, 126], ["the disordered domain", "PROBLEM", 49, 70], ["inward membrane bending", "PROBLEM", 136, 159], ["membrane bending", "OBSERVATION", 143, 159]]], ["This result suggests that crowding among disordered domains and scaffolding by BAR domains make comparable contributions to membrane remodeling.Crowding among disordered domains opposes the ability of I-BAR scaffolds to drive inward membrane bending ::: ResultsMembrane release experiments using SUPER templates showed that exposure to the I-BAR domain (100 nM\u20135 \u00b5M) decreased the amount of membrane shedding to levels lower than the amount of nonspecific shedding that occurred in protein-free buffer (Fig. 5 C, negative values).", [["membrane", "ANATOMY", 124, 132], ["membrane", "ANATOMY", 233, 241], ["membrane", "ANATOMY", 391, 399], ["Crowding", "DISEASE", 144, 152], ["BAR", "GENE_OR_GENE_PRODUCT", 79, 82], ["membrane", "CELLULAR_COMPONENT", 124, 132], ["membrane", "CELLULAR_COMPONENT", 233, 241], ["I-BAR", "GENE_OR_GENE_PRODUCT", 340, 345], ["membrane", "CELLULAR_COMPONENT", 391, 399], ["5 C", "SIMPLE_CHEMICAL", 508, 511], ["BAR domains", "PROTEIN", 79, 90], ["I-BAR domain", "PROTEIN", 340, 352], ["crowding among disordered domains", "PROBLEM", 26, 59], ["membrane remodeling", "PROBLEM", 124, 143], ["Crowding among disordered domains", "PROBLEM", 144, 177], ["membrane shedding", "PROBLEM", 391, 408], ["nonspecific shedding", "PROBLEM", 444, 464], ["crowding", "OBSERVATION", 26, 34], ["membrane remodeling", "OBSERVATION", 124, 143], ["amount", "OBSERVATION_MODIFIER", 381, 387], ["nonspecific", "OBSERVATION_MODIFIER", 444, 455]]], ["This result suggests that assembly of the I-BAR scaffold stabilized the membrane against shedding.", [["membrane", "ANATOMY", 72, 80], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["I-BAR scaffold", "PROTEIN", 42, 56]]], ["In contrast, I-BAR-AP180 CTD drove positive membrane release at all concentrations (Fig. 5 C), demonstrating that the disordered domain of AP180 is capable of disrupting the membrane-stabilizing effect of I-BAR.", [["membrane", "ANATOMY", 44, 52], ["membrane", "ANATOMY", 174, 182], ["I-BAR-AP180 CTD", "GENE_OR_GENE_PRODUCT", 13, 28], ["membrane", "CELLULAR_COMPONENT", 44, 52], ["AP180", "GENE_OR_GENE_PRODUCT", 139, 144], ["membrane", "CELLULAR_COMPONENT", 174, 182], ["I-BAR", "GENE_OR_GENE_PRODUCT", 205, 210], ["I-BAR", "PROTEIN", 13, 18], ["AP180 CTD", "PROTEIN", 19, 28], ["AP180", "PROTEIN", 139, 144], ["I", "PROTEIN", 205, 206], ["BAR", "PROTEIN", 207, 210], ["I-BAR", "TEST", 13, 18]]], ["Interestingly, tethered vesicle fission experiments revealed that the highest concentration of I-BAR-AP180 CTD that we tested, 5 \u00b5M, drove membrane fission, generating a population of vesicles centered near 30 nm diameter (Fig. 5 D).", [["vesicle", "ANATOMY", 24, 31], ["membrane", "ANATOMY", 139, 147], ["vesicles", "ANATOMY", 184, 192], ["vesicle", "CELLULAR_COMPONENT", 24, 31], ["I-BAR", "GENE_OR_GENE_PRODUCT", 95, 100], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["vesicles", "CELLULAR_COMPONENT", 184, 192], ["BAR", "PROTEIN", 97, 100], ["AP180 CTD", "PROTEIN", 101, 110], ["tethered vesicle fission experiments", "TEST", 15, 51], ["CTD", "PROBLEM", 107, 110], ["drove membrane fission", "TREATMENT", 133, 155], ["a population of vesicles", "TREATMENT", 168, 192], ["30 nm", "OBSERVATION_MODIFIER", 207, 212], ["diameter", "OBSERVATION_MODIFIER", 213, 221]]], ["This result demonstrates that, under appropriate conditions, steric pressure among crowded disordered domains is sufficient to overcome the structure-based curvature preference of the I-BAR scaffold.", [["crowded disordered domains", "PROTEIN", 83, 109], ["I-BAR scaffold", "PROTEIN", 184, 198], ["crowded disordered domains", "PROBLEM", 83, 109], ["curvature", "OBSERVATION_MODIFIER", 156, 165]]], ["Importantly, while wild-type IRSp53 does not naturally contain a large disordered domain, the I-BAR domain\u2013containing proteins MIM and ABBA do contain regions of substantial disorder (\u223c475 amino acids in MIM; Lee et al., 2007).", [["disorder", "DISEASE", 174, 182], ["amino acids", "CHEMICAL", 189, 200], ["amino acids", "CHEMICAL", 189, 200], ["IRSp53", "GENE_OR_GENE_PRODUCT", 29, 35], ["I-BAR", "GENE_OR_GENE_PRODUCT", 94, 99], ["MIM", "GENE_OR_GENE_PRODUCT", 127, 130], ["amino acids", "AMINO_ACID", 189, 200], ["IRSp53", "PROTEIN", 29, 35], ["I-BAR domain\u2013containing proteins", "PROTEIN", 94, 126], ["MIM", "PROTEIN", 127, 130], ["ABBA", "PROTEIN", 135, 139], ["a large disordered domain", "PROBLEM", 63, 88], ["the I-BAR domain\u2013containing proteins MIM", "TREATMENT", 90, 130], ["substantial disorder", "PROBLEM", 162, 182], ["amino acids", "TEST", 189, 200], ["substantial", "OBSERVATION_MODIFIER", 162, 173], ["disorder", "OBSERVATION", 174, 182]]], ["Therefore, our observations raise the question of whether the presumed role of these proteins in driving cellular membrane protrusions can be justified on the basis of in vitro studies of their isolated I-BAR domains (Mattila et al., 2007; Saarikangas et al., 2009).An F-BAR scaffold drives fission by locally crowding bulky disordered domains ::: ResultsIf BAR scaffolds drive membrane fission by concentrating large disordered domains at membrane surfaces, then the ability of Amph-FL to drive fission (Figs.", [["cellular membrane", "ANATOMY", 105, 122], ["membrane", "ANATOMY", 378, 386], ["membrane surfaces", "ANATOMY", 440, 457], ["cellular", "CELL", 105, 113], ["F-BAR", "GENE_OR_GENE_PRODUCT", 269, 274], ["BAR", "GENE_OR_GENE_PRODUCT", 358, 361], ["membrane", "CELLULAR_COMPONENT", 378, 386], ["membrane surfaces", "CELLULAR_COMPONENT", 440, 457], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 479, 486], ["I-BAR domains", "PROTEIN", 203, 216], ["F-BAR scaffold", "PROTEIN", 269, 283], ["bulky disordered domains", "PROTEIN", 319, 343], ["BAR", "PROTEIN", 358, 361], ["Amph", "PROTEIN", 479, 483], ["FL", "PROTEIN", 484, 486], ["these proteins", "PROBLEM", 79, 93], ["driving cellular membrane protrusions", "PROBLEM", 97, 134], ["vitro studies", "TEST", 171, 184], ["An F-BAR scaffold drives fission", "TREATMENT", 266, 298], ["locally crowding bulky disordered domains", "PROBLEM", 302, 343], ["ResultsIf BAR scaffolds drive membrane fission", "TREATMENT", 348, 394], ["concentrating large disordered domains at membrane surfaces", "PROBLEM", 398, 457], ["Amph-FL", "TREATMENT", 479, 486], ["proteins", "OBSERVATION", 85, 93], ["cellular membrane protrusions", "OBSERVATION", 105, 134], ["locally", "OBSERVATION_MODIFIER", 302, 309], ["crowding bulky", "OBSERVATION", 310, 324], ["scaffolds drive", "OBSERVATION", 362, 377], ["large", "OBSERVATION_MODIFIER", 412, 417], ["disordered", "OBSERVATION", 418, 428]]], ["1 and 2) should extend to other proteins that contain both BAR domains and substantial regions of intrinsic disorder.", [["intrinsic disorder", "DISEASE", 98, 116], ["BAR", "GENE_OR_GENE_PRODUCT", 59, 62], ["BAR domains", "PROTEIN", 59, 70], ["intrinsic disorder", "PROBLEM", 98, 116], ["both BAR", "OBSERVATION", 54, 62], ["substantial", "OBSERVATION_MODIFIER", 75, 86], ["regions", "OBSERVATION_MODIFIER", 87, 94], ["intrinsic disorder", "OBSERVATION", 98, 116]]], ["Interestingly, many proteins that contain the modestly curved F-BAR domain also have this architecture (Roberts-Galbraith and Gould, 2010), including the endocytic proteins FCHo1/2 (Henne et al., 2010), its yeast homologue Syp1 (Reider et al., 2009), the srGAP proteins involved in neuronal development (Wuertenberger and Groemping, 2015), the cytokinesis proteins Cdc15 (Roberts-Galbraith et al., 2010) and Imp2 (McDonald et al., 2016) in Schizosaccharomyces pombe, and Hof1 (Meitinger et al., 2011) in Saccharomyces cerevisiae.", [["neuronal", "ANATOMY", 282, 290], ["F-BAR", "GENE_OR_GENE_PRODUCT", 62, 67], ["Syp1", "GENE_OR_GENE_PRODUCT", 223, 227], ["srGAP", "GENE_OR_GENE_PRODUCT", 255, 260], ["neuronal", "CELL", 282, 290], ["Cdc15", "GENE_OR_GENE_PRODUCT", 365, 370], ["Schizosaccharomyces pombe", "ORGANISM", 440, 465], ["Hof1", "GENE_OR_GENE_PRODUCT", 471, 475], ["Saccharomyces cerevisiae", "ORGANISM", 504, 528], ["F", "PROTEIN", 62, 63], ["BAR domain", "PROTEIN", 64, 74], ["endocytic proteins", "PROTEIN", 154, 172], ["FCHo1/2", "PROTEIN", 173, 180], ["yeast homologue Syp1", "PROTEIN", 207, 227], ["srGAP proteins", "PROTEIN", 255, 269], ["cytokinesis proteins", "PROTEIN", 344, 364], ["Cdc15", "PROTEIN", 365, 370], ["yeast", "SPECIES", 207, 212], ["Schizosaccharomyces pombe", "SPECIES", 440, 465], ["Saccharomyces cerevisiae", "SPECIES", 504, 528], ["yeast", "SPECIES", 207, 212], ["Schizosaccharomyces pombe", "SPECIES", 440, 465], ["Saccharomyces cerevisiae", "SPECIES", 504, 528], ["its yeast homologue", "TEST", 203, 222], ["the srGAP proteins", "TEST", 251, 269], ["the cytokinesis proteins", "TEST", 340, 364], ["modestly", "OBSERVATION_MODIFIER", 46, 54], ["curved", "OBSERVATION_MODIFIER", 55, 61]]], ["To test this idea, we examined FCHo1 (Caenorhabditis elegans), which consists of an N-terminal F-BAR domain followed by an intrinsically disordered domain of 412 amino acids and a C-terminal \u00b5-homology domain (Henne et al., 2010; Umasankar et al., 2014; Ma et al., 2016; Wang et al., 2016; Fig. 5 E).", [["amino acids", "CHEMICAL", 162, 173], ["N-", "CHEMICAL", 84, 86], ["amino acids", "CHEMICAL", 162, 173], ["C", "CHEMICAL", 180, 181], ["FCHo1", "GENE_OR_GENE_PRODUCT", 31, 36], ["Caenorhabditis elegans", "ORGANISM", 38, 60], ["amino acids", "AMINO_ACID", 162, 173], ["FCHo1", "PROTEIN", 31, 36], ["N-terminal F-BAR domain", "PROTEIN", 84, 107], ["intrinsically disordered domain", "PROTEIN", 123, 154], ["C-terminal \u00b5-homology domain", "PROTEIN", 180, 208], ["Caenorhabditis elegans", "SPECIES", 38, 60], ["Caenorhabditis elegans", "SPECIES", 38, 60], ["amino acids", "TEST", 162, 173]]], ["Negative stain TEM revealed that exposure of vesicles with an initial average diameter of 200 nm to the F-BAR domain of FCHo1 drove formation of lipid tubules with an average diameter of 21 \u00b1 2 nm SD (Fig. 5, F and G; and Fig. S5, A and B), in agreement with previous findings (Henne et al., 2007, 2010).", [["vesicles", "ANATOMY", 45, 53], ["lipid tubules", "ANATOMY", 145, 158], ["vesicles", "CELLULAR_COMPONENT", 45, 53], ["FCHo1", "GENE_OR_GENE_PRODUCT", 120, 125], ["lipid tubules", "MULTI-TISSUE_STRUCTURE", 145, 158], ["B", "GENE_OR_GENE_PRODUCT", 237, 238], ["F-BAR domain", "PROTEIN", 104, 116], ["FCHo1", "PROTEIN", 120, 125], ["S5", "PROTEIN", 227, 229], ["stain TEM", "TEST", 9, 18], ["exposure of vesicles", "PROBLEM", 33, 53], ["an average diameter", "TEST", 164, 183], ["vesicles", "ANATOMY", 45, 53], ["initial", "OBSERVATION_MODIFIER", 62, 69], ["average", "OBSERVATION_MODIFIER", 70, 77], ["diameter", "OBSERVATION_MODIFIER", 78, 86], ["200 nm", "OBSERVATION_MODIFIER", 90, 96], ["lipid tubules", "OBSERVATION", 145, 158], ["average", "OBSERVATION_MODIFIER", 167, 174], ["diameter", "OBSERVATION_MODIFIER", 175, 183]]], ["In contrast, full-length FCHo1 (FCHo1-FL) did not generate lipid tubules, but instead divided the 200-nm-diameter vesicles into a population of highly curved vesicles with average diameter 17 \u00b1 7 nm SD (Fig. 5 H and Fig. S5, C and D).", [["lipid tubules", "ANATOMY", 59, 72], ["vesicles", "ANATOMY", 114, 122], ["vesicles", "ANATOMY", 158, 166], ["FCHo1", "GENE_OR_GENE_PRODUCT", 25, 30], ["FCHo1-FL", "GENE_OR_GENE_PRODUCT", 32, 40], ["lipid tubules", "TISSUE", 59, 72], ["vesicles", "CELLULAR_COMPONENT", 114, 122], ["vesicles", "CELLULAR_COMPONENT", 158, 166], ["D", "SIMPLE_CHEMICAL", 231, 232], ["FCHo1", "PROTEIN", 25, 30], ["FCHo1", "PROTEIN", 32, 37], ["FL", "PROTEIN", 38, 40], ["S5", "PROTEIN", 221, 223], ["average diameter", "TEST", 172, 188], ["average", "OBSERVATION_MODIFIER", 172, 179], ["diameter", "OBSERVATION_MODIFIER", 180, 188]]], ["F-BAR also generated a population of high curvature vesicles in TEM experiments (Fig. S5 D); however, such vesicles accounted for only 20% of the overall distribution, while they accounted for 96% of the vesicle population after exposure to FCHo1-FL at a substantially lower protein-to-lipid ratio (1:30 versus 1:500 for F-BAR and FCHo1-FL, respectively; Fig. 5 K).An F-BAR scaffold drives fission by locally crowding bulky disordered domains ::: ResultsSimilarly, tethered vesicle fission experiments revealed that FCHo1-FL drove potent membrane fission over the concentration range of 10\u2013250 nM (Fig. 5, I and K), a comparable range to Amph-FL (50\u2013150 nM; Fig. 2, D and F), with a mean diameter of 19 \u00b1 1 nm SEM at 250 nM of FCHo1-FL.", [["vesicles", "ANATOMY", 52, 60], ["vesicles", "ANATOMY", 107, 115], ["vesicle", "ANATOMY", 204, 211], ["vesicle", "ANATOMY", 474, 481], ["membrane", "ANATOMY", 538, 546], ["FCHo1-FL", "CHEMICAL", 241, 249], ["FCHo1-FL", "CHEMICAL", 516, 524], ["Amph-FL", "CHEMICAL", 638, 645], ["Amph-FL", "CHEMICAL", 638, 645], ["F-BAR", "GENE_OR_GENE_PRODUCT", 0, 5], ["vesicles", "CELLULAR_COMPONENT", 52, 60], ["vesicles", "CELLULAR_COMPONENT", 107, 115], ["vesicle", "CELLULAR_COMPONENT", 204, 211], ["FCHo1-FL", "SIMPLE_CHEMICAL", 241, 249], ["lipid", "SIMPLE_CHEMICAL", 286, 291], ["F-BAR", "GENE_OR_GENE_PRODUCT", 321, 326], ["FCHo1-FL", "GENE_OR_GENE_PRODUCT", 331, 339], ["F-BAR", "GENE_OR_GENE_PRODUCT", 368, 373], ["vesicle", "CELLULAR_COMPONENT", 474, 481], ["FCHo1-FL", "GENE_OR_GENE_PRODUCT", 516, 524], ["membrane", "CELLULAR_COMPONENT", 538, 546], ["Amph-FL", "SIMPLE_CHEMICAL", 638, 645], ["BAR", "PROTEIN", 2, 5], ["F", "PROTEIN", 321, 322], ["BAR", "PROTEIN", 323, 326], ["FCHo1", "PROTEIN", 331, 336], ["FL", "PROTEIN", 337, 339], ["F-BAR scaffold", "PROTEIN", 368, 382], ["bulky disordered domains", "PROTEIN", 418, 442], ["FCHo1", "PROTEIN", 516, 521], ["FL", "PROTEIN", 522, 524], ["high curvature vesicles", "PROBLEM", 37, 60], ["such vesicles", "PROBLEM", 102, 115], ["FCHo1", "TEST", 241, 246], ["FCHo1", "TEST", 331, 336], ["An F-BAR scaffold drives fission", "TREATMENT", 365, 397], ["locally crowding bulky disordered domains", "PROBLEM", 401, 442], ["tethered vesicle fission experiments", "TEST", 465, 501], ["FCHo1", "TEST", 516, 521], ["Amph-FL", "TEST", 638, 645], ["a mean diameter", "TEST", 681, 696], ["nm SEM", "TEST", 707, 713], ["FCHo1", "TEST", 727, 732], ["high curvature", "OBSERVATION", 37, 51], ["overall", "OBSERVATION_MODIFIER", 146, 153], ["distribution", "OBSERVATION_MODIFIER", 154, 166], ["locally", "OBSERVATION_MODIFIER", 401, 408], ["crowding bulky", "OBSERVATION", 409, 423]]], ["However, the F-BAR domain alone did not drive fission in these experiments, even at substantially higher concentrations up to 2 \u00b5M (Fig. 5, J and K).", [["F-BAR", "GENE_OR_GENE_PRODUCT", 13, 18], ["F-BAR domain", "PROTEIN", 13, 25]]], ["Interestingly, in both tethered vesicle and TEM experiments, the fission products of FCHo1-FL had a peak diameter of slightly less than 20 nm, with some vesicles as small as 10 nm.", [["vesicle", "ANATOMY", 32, 39], ["vesicles", "ANATOMY", 153, 161], ["FCHo1-FL", "CHEMICAL", 85, 93], ["vesicle", "CELLULAR_COMPONENT", 32, 39], ["FCHo1-FL", "GENE_OR_GENE_PRODUCT", 85, 93], ["vesicles", "CELLULAR_COMPONENT", 153, 161], ["fission products", "PROTEIN", 65, 81], ["FCHo1", "PROTEIN", 85, 90], ["FL", "PROTEIN", 91, 93], ["a peak diameter", "TEST", 98, 113], ["both", "ANATOMY_MODIFIER", 18, 22], ["tethered vesicle", "OBSERVATION", 23, 39], ["TEM experiments", "OBSERVATION", 44, 59], ["fission", "OBSERVATION_MODIFIER", 65, 72], ["products", "OBSERVATION_MODIFIER", 73, 81], ["FL", "OBSERVATION_MODIFIER", 91, 93], ["peak", "OBSERVATION_MODIFIER", 100, 104], ["diameter", "OBSERVATION_MODIFIER", 105, 113], ["slightly", "OBSERVATION_MODIFIER", 117, 125], ["less than 20 nm", "OBSERVATION_MODIFIER", 126, 141], ["some", "OBSERVATION_MODIFIER", 148, 152], ["vesicles", "OBSERVATION", 153, 161], ["small", "OBSERVATION_MODIFIER", 165, 170], ["10 nm", "OBSERVATION_MODIFIER", 174, 179]]], ["These small diameters suggest that FCHo1-FL may stabilize the formation of membrane micelles, which are similar in morphology to the hemifusion intermediates that form during membrane fission (Campelo and Malhotra, 2012; Frolov et al., 2015).", [["membrane micelles", "ANATOMY", 75, 92], ["membrane", "ANATOMY", 175, 183], ["FCHo1-FL", "CHEMICAL", 35, 43], ["FCHo1-FL", "CHEMICAL", 35, 43], ["FCHo1-FL", "GENE_OR_GENE_PRODUCT", 35, 43], ["membrane micelles", "CELLULAR_COMPONENT", 75, 92], ["membrane", "CELLULAR_COMPONENT", 175, 183], ["FCHo1", "PROTEIN", 35, 40], ["FL", "PROTEIN", 41, 43], ["membrane micelles", "PROBLEM", 75, 92], ["small", "OBSERVATION_MODIFIER", 6, 11], ["diameters", "OBSERVATION_MODIFIER", 12, 21], ["membrane micelles", "OBSERVATION", 75, 92], ["similar", "OBSERVATION_MODIFIER", 104, 111]]], ["Notably, vesicles in these experiments were composed primarily of the lipid 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), which has a lower bending rigidity than physiological membranes (Dimova, 2014).", [["vesicles", "ANATOMY", 9, 17], ["membranes", "ANATOMY", 179, 188], ["1,2-dioleoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 76, 116], ["DOPC", "CHEMICAL", 118, 122], ["rigidity", "DISEASE", 151, 159], ["1,2-dioleoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 76, 116], ["DOPC", "CHEMICAL", 118, 122], ["vesicles", "CELLULAR_COMPONENT", 9, 17], ["lipid 1,2-dioleoyl-sn-glycero-3-phosphocholine", "SIMPLE_CHEMICAL", 70, 116], ["DOPC", "SIMPLE_CHEMICAL", 118, 122], ["membranes", "CELLULAR_COMPONENT", 179, 188], ["the lipid", "TEST", 66, 75], ["dioleoyl", "TEST", 80, 88], ["glycero", "TREATMENT", 92, 99], ["phosphocholine (DOPC", "TREATMENT", 102, 122], ["a lower bending rigidity than physiological membranes", "PROBLEM", 135, 188], ["vesicles", "OBSERVATION", 9, 17], ["lower", "OBSERVATION_MODIFIER", 137, 142], ["bending rigidity", "OBSERVATION", 143, 159]]], ["In contrast, when we increased bilayer rigidity by replacing DOPC with the substantially more rigid, fully saturated lipid 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC; Lee et al., 2001; Dimova, 2014), the average diameter of fission products increased to \u223c50 nm at 50 nM of FCHo1-FL, consistent with bilayer vesicles (Fig. S5, E\u2013G).", [["bilayer", "ANATOMY", 31, 38], ["bilayer vesicles", "ANATOMY", 306, 322], ["rigidity", "DISEASE", 39, 47], ["DOPC", "CHEMICAL", 61, 65], ["1,2-dipalmitoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 123, 166], ["DPPC", "CHEMICAL", 168, 172], ["FCHo1-FL", "CHEMICAL", 280, 288], ["DOPC", "CHEMICAL", 61, 65], ["1,2-dipalmitoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 123, 166], ["DPPC", "CHEMICAL", 168, 172], ["DOPC", "SIMPLE_CHEMICAL", 61, 65], ["lipid 1,2-dipalmitoyl-sn-glycero-3-phosphocholine", "SIMPLE_CHEMICAL", 117, 166], ["DPPC", "SIMPLE_CHEMICAL", 168, 172], ["FCHo1-FL", "GENE_OR_GENE_PRODUCT", 280, 288], ["bilayer vesicles", "CELLULAR_COMPONENT", 306, 322], ["S5", "GENE_OR_GENE_PRODUCT", 329, 331], ["E\u2013G", "GENE_OR_GENE_PRODUCT", 333, 336], ["fission products", "PROTEIN", 231, 247], ["FCHo1", "PROTEIN", 280, 285], ["FL", "PROTEIN", 286, 288], ["S5", "PROTEIN", 329, 331], ["E\u2013G", "PROTEIN", 333, 336], ["increased bilayer rigidity", "PROBLEM", 21, 47], ["replacing DOPC", "TREATMENT", 51, 65], ["lipid", "TEST", 117, 122], ["dipalmitoyl", "TEST", 127, 138], ["glycero", "TREATMENT", 142, 149], ["the average diameter of fission products", "TREATMENT", 207, 247], ["bilayer vesicles", "PROBLEM", 306, 322], ["FL", "ANATOMY", 286, 288], ["consistent with", "UNCERTAINTY", 290, 305], ["bilayer vesicles", "OBSERVATION", 306, 322]]], ["Collectively, these studies show that, despite their gentle curvature, F-BAR scaffolds are also capable of collaborating with disordered domain crowding to drive efficient membrane fission, producing highly curved vesicles.", [["membrane", "ANATOMY", 172, 180], ["vesicles", "ANATOMY", 214, 222], ["membrane", "CELLULAR_COMPONENT", 172, 180], ["vesicles", "CELLULAR_COMPONENT", 214, 222], ["these studies", "TEST", 14, 27], ["F-BAR scaffolds", "TREATMENT", 71, 86], ["disordered domain crowding", "PROBLEM", 126, 152], ["membrane fission", "OBSERVATION", 172, 188]]], ["These findings suggest that the ability of BAR domains to assemble into scaffolds that concentrate disordered domains, regardless of their intrinsic structural curvature, makes an important contribution to membrane fission.DiscussionHere we report that membrane scaffolding by BAR domains works synergistically with steric pressure among bulky disordered domains to drive membrane fission.", [["membrane", "ANATOMY", 206, 214], ["membrane", "ANATOMY", 253, 261], ["membrane", "ANATOMY", 372, 380], ["BAR", "GENE_OR_GENE_PRODUCT", 43, 46], ["membrane", "CELLULAR_COMPONENT", 206, 214], ["membrane", "CELLULAR_COMPONENT", 253, 261], ["BAR", "GENE_OR_GENE_PRODUCT", 277, 280], ["membrane", "CELLULAR_COMPONENT", 372, 380], ["BAR domains", "PROTEIN", 43, 54], ["BAR domains", "PROTEIN", 277, 288], ["bulky disordered domains", "PROTEIN", 338, 362], ["concentrate disordered domains", "PROBLEM", 87, 117], ["membrane fission", "PROBLEM", 206, 222], ["membrane scaffolding", "PROBLEM", 253, 273], ["steric pressure among bulky disordered domains", "TREATMENT", 316, 362], ["structural curvature", "OBSERVATION", 149, 169], ["membrane fission", "OBSERVATION", 206, 222]]], ["By highlighting the ability of BAR scaffolds to locally concentrate disordered domains, this work helps to explain how steric pressure can be generated and locally sustained at membrane surfaces.", [["membrane surfaces", "ANATOMY", 177, 194], ["BAR", "GENE_OR_GENE_PRODUCT", 31, 34], ["membrane surfaces", "CELLULAR_COMPONENT", 177, 194], ["BAR", "PROTEIN", 31, 34], ["BAR scaffolds", "TREATMENT", 31, 44], ["locally concentrate disordered domains", "PROBLEM", 48, 86]]], ["Further, our findings are in contrast with the established view that BAR scaffolds prevent fission by stabilizing membrane tubes (Boucrot et al., 2012).", [["membrane tubes", "ANATOMY", 114, 128], ["BAR", "GENE_OR_GENE_PRODUCT", 69, 72], ["membrane tubes", "CELLULAR_COMPONENT", 114, 128], ["BAR scaffolds", "TREATMENT", 69, 82], ["stabilizing membrane tubes", "TREATMENT", 102, 128], ["membrane tubes", "OBSERVATION", 114, 128]]], ["Instead, our work suggests that BAR proteins that contain substantial disordered regions may be drivers of membrane fission.", [["membrane", "ANATOMY", 107, 115], ["BAR", "GENE_OR_GENE_PRODUCT", 32, 35], ["membrane", "CELLULAR_COMPONENT", 107, 115], ["BAR proteins", "PROTEIN", 32, 44], ["BAR proteins", "PROBLEM", 32, 44], ["substantial disordered regions", "PROBLEM", 58, 88], ["membrane fission", "PROBLEM", 107, 123], ["substantial", "OBSERVATION_MODIFIER", 58, 69], ["disordered", "OBSERVATION", 70, 80], ["membrane fission", "OBSERVATION", 107, 123]]], ["Importantly, previous reports have observed that Amph-FL generates lipid tubules shortly after protein exposure (Takei et al., 1999; Neumann and Schmid, 2013), in agreement with the findings of our experiments with GUVs at early time points (Fig. S1 A).", [["lipid tubules", "ANATOMY", 67, 80], ["Amph-FL", "CHEMICAL", 49, 56], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 49, 56], ["lipid tubules", "TISSUE", 67, 80], ["GUVs", "SIMPLE_CHEMICAL", 215, 219], ["Amph", "PROTEIN", 49, 53], ["FL", "PROTEIN", 54, 56], ["S1 A", "PROTEIN", 247, 251], ["Amph", "TEST", 49, 53], ["lipid tubules", "PROBLEM", 67, 80]]], ["However, we found that at later time points, Amph-FL drove membrane fission in each of our assays (Fig. S1 A and Figs.", [["membrane", "ANATOMY", 59, 67], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 45, 52], ["membrane", "CELLULAR_COMPONENT", 59, 67], ["Amph", "PROTEIN", 45, 49], ["FL", "PROTEIN", 50, 52], ["Amph-FL drove membrane fission", "TREATMENT", 45, 75], ["our assays", "TEST", 87, 97], ["Figs", "OBSERVATION", 113, 117]]], ["1 D and 2 D).DiscussionImportantly, our in vitro studies do not fully explain the mechanisms by which proteins drive membrane fission in live cells.", [["membrane", "ANATOMY", 117, 125], ["cells", "ANATOMY", 142, 147], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["cells", "CELL", 142, 147], ["live cells", "CELL_TYPE", 137, 147], ["our in vitro studies", "TEST", 36, 56]]], ["However, previous studies in live cells suggest that amphiphysin could be playing a supporting role in membrane fission, potentially via a protein crowding mechanism.", [["cells", "ANATOMY", 34, 39], ["membrane", "ANATOMY", 103, 111], ["cells", "CELL", 34, 39], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 53, 64], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["amphiphysin", "PROTEIN", 53, 64], ["previous studies", "TEST", 9, 25], ["amphiphysin", "PROBLEM", 53, 64], ["a protein crowding mechanism", "PROBLEM", 137, 165], ["amphiphysin", "OBSERVATION", 53, 64], ["membrane fission", "OBSERVATION", 103, 119]]], ["For example, deletion of the yeast amphiphysins Rvs161/167 leads to a defect in the entry of clathrin-coated pits into cells (Kaksonen et al., 2005; Kishimoto et al., 2011), suggesting that Rvs161/167 may support membrane fission.", [["cells", "ANATOMY", 119, 124], ["membrane", "ANATOMY", 213, 221], ["clathrin", "GENE_OR_GENE_PRODUCT", 93, 101], ["cells", "CELL", 119, 124], ["Rvs161/167", "GENE_OR_GENE_PRODUCT", 190, 200], ["membrane", "CELLULAR_COMPONENT", 213, 221], ["yeast amphiphysins Rvs161/167", "PROTEIN", 29, 58], ["clathrin", "PROTEIN", 93, 101], ["Rvs161/167", "PROTEIN", 190, 200], ["yeast", "SPECIES", 29, 34], ["yeast", "SPECIES", 29, 34], ["the yeast amphiphysins", "PROBLEM", 25, 47], ["a defect", "PROBLEM", 68, 76], ["membrane fission", "PROBLEM", 213, 229], ["yeast amphiphysins", "OBSERVATION", 29, 47], ["defect", "OBSERVATION", 70, 76], ["membrane fission", "OBSERVATION", 213, 229]]], ["However, Rvs161/167 is a heterodimer, and only Rvs167 contains a large disordered domain (Ren et al., 2006).", [["Rvs161/167", "GENE_OR_GENE_PRODUCT", 9, 19], ["Rvs167", "GENE_OR_GENE_PRODUCT", 47, 53], ["Rvs161", "PROTEIN", 9, 15], ["heterodimer", "PROTEIN", 25, 36], ["Rvs167", "PROTEIN", 47, 53], ["disordered domain", "PROTEIN", 71, 88], ["Rvs", "TEST", 47, 50], ["a large disordered domain", "PROBLEM", 63, 88], ["large", "OBSERVATION_MODIFIER", 65, 70]]], ["Additionally, depletion of amphiphysin by RNA interference inhibits clathrin-mediated endocytosis in mammalian cells (Meinecke et al., 2013), although this endocytic defect has been previously attributed to a reduction in dynamin recruitment.DiscussionOur finding that modestly curved F-BAR domains can also collaborate with bulky disordered domains to drive potent fission is surprising, as it suggests that proteins such as FCHo1/2 may participate in membrane shaping throughout the maturation of clathrin-coated pits, and may even help drive the final fission event.", [["cells", "ANATOMY", 111, 116], ["membrane", "ANATOMY", 453, 461], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 27, 38], ["clathrin", "GENE_OR_GENE_PRODUCT", 68, 76], ["mammalian cells", "CELL", 101, 116], ["dynamin", "GENE_OR_GENE_PRODUCT", 222, 229], ["F-BAR", "GENE_OR_GENE_PRODUCT", 285, 290], ["FCHo1/2", "GENE_OR_GENE_PRODUCT", 426, 433], ["membrane", "CELLULAR_COMPONENT", 453, 461], ["clathrin", "GENE_OR_GENE_PRODUCT", 499, 507], ["amphiphysin", "PROTEIN", 27, 38], ["clathrin", "PROTEIN", 68, 76], ["mammalian cells", "CELL_TYPE", 101, 116], ["dynamin", "PROTEIN", 222, 229], ["F-BAR domains", "PROTEIN", 285, 298], ["bulky disordered domains", "PROTEIN", 325, 349], ["FCHo1/2", "PROTEIN", 426, 433], ["clathrin", "PROTEIN", 499, 507], ["depletion of amphiphysin", "PROBLEM", 14, 38], ["RNA interference", "PROBLEM", 42, 58], ["clathrin-mediated endocytosis in mammalian cells", "PROBLEM", 68, 116], ["this endocytic defect", "PROBLEM", 151, 172], ["a reduction in dynamin recruitment", "TREATMENT", 207, 241], ["modestly curved F-BAR domains", "PROBLEM", 269, 298], ["bulky disordered domains", "PROBLEM", 325, 349], ["depletion", "OBSERVATION_MODIFIER", 14, 23], ["amphiphysin", "OBSERVATION", 27, 38], ["endocytosis", "OBSERVATION_MODIFIER", 86, 97], ["mammalian cells", "OBSERVATION", 101, 116], ["endocytic defect", "OBSERVATION", 156, 172], ["reduction", "OBSERVATION_MODIFIER", 209, 218], ["dynamin recruitment", "OBSERVATION", 222, 241]]], ["This hypothesis is in contrast to the idea that FCHo1/2 are primarily involved in the initiation of clathrin-coated pits (Henne et al., 2010; Ma et al., 2016).", [["FCHo1/2", "GENE_OR_GENE_PRODUCT", 48, 55], ["clathrin", "GENE_OR_GENE_PRODUCT", 100, 108], ["FCHo1", "PROTEIN", 48, 53], ["clathrin", "PROTEIN", 100, 108]]], ["However, previous work showed that FCHo2 is present throughout the lifetime of clathrin-coated pits (Taylor et al., 2011), supporting the possible role of FCHo2 in membrane shaping.", [["membrane", "ANATOMY", 164, 172], ["FCHo2", "CHEMICAL", 35, 40], ["FCHo2", "GENE_OR_GENE_PRODUCT", 35, 40], ["clathrin", "GENE_OR_GENE_PRODUCT", 79, 87], ["FCHo2", "GENE_OR_GENE_PRODUCT", 155, 160], ["membrane", "CELLULAR_COMPONENT", 164, 172], ["FCHo2", "PROTEIN", 35, 40], ["clathrin", "PROTEIN", 79, 87], ["FCHo2", "PROTEIN", 155, 160], ["FCHo2 in membrane shaping", "TREATMENT", 155, 180]]], ["Moreover, many F-BAR proteins involved in other cellular pathways such as cytokinesis also contain large regions of intrinsic disorder (Roberts-Galbraith et al., 2010; Meitinger et al., 2011; McDonald et al., 2016).", [["cellular", "ANATOMY", 48, 56], ["intrinsic disorder", "DISEASE", 116, 134], ["F-BAR", "GENE_OR_GENE_PRODUCT", 15, 20], ["cellular", "CELL", 48, 56], ["F-BAR proteins", "PROTEIN", 15, 29], ["cytokinesis", "PROBLEM", 74, 85], ["intrinsic disorder", "PROBLEM", 116, 134], ["large", "OBSERVATION_MODIFIER", 99, 104], ["intrinsic disorder", "OBSERVATION", 116, 134]]], ["As such, our findings raise the question of whether F-BAR scaffolds facilitate membrane fission in a variety of contexts beyond membrane traffic.DiscussionMore broadly, our work raises the possibility that protein assemblies beyond BAR domains may serve as scaffolds for crowding bulky disordered domains in order to ensure efficient membrane fission.", [["membrane", "ANATOMY", 79, 87], ["membrane", "ANATOMY", 128, 136], ["membrane", "ANATOMY", 334, 342], ["F-BAR", "GENE_OR_GENE_PRODUCT", 52, 57], ["membrane", "CELLULAR_COMPONENT", 79, 87], ["membrane", "CELLULAR_COMPONENT", 128, 136], ["BAR", "GENE_OR_GENE_PRODUCT", 232, 235], ["membrane", "CELLULAR_COMPONENT", 334, 342], ["F-BAR scaffolds", "DNA", 52, 67], ["BAR domains", "PROTEIN", 232, 243], ["bulky disordered domains", "PROTEIN", 280, 304], ["F-BAR scaffolds", "TREATMENT", 52, 67], ["membrane fission", "PROBLEM", 79, 95], ["protein assemblies beyond BAR domains", "PROBLEM", 206, 243], ["crowding bulky disordered domains", "PROBLEM", 271, 304], ["efficient membrane fission", "PROBLEM", 324, 350], ["membrane fission", "OBSERVATION", 79, 95], ["membrane traffic", "OBSERVATION", 128, 144], ["membrane fission", "OBSERVATION", 334, 350]]], ["One potential example is dynamin, a scaffold-forming GTPase involved in fission of clathrin-coated pits (Antonny et al., 2016).", [["dynamin", "GENE_OR_GENE_PRODUCT", 25, 32], ["clathrin", "GENE_OR_GENE_PRODUCT", 83, 91], ["dynamin", "PROTEIN", 25, 32], ["scaffold-forming GTPase", "PROTEIN", 36, 59], ["clathrin", "PROTEIN", 83, 91], ["dynamin", "PROBLEM", 25, 32], ["a scaffold", "TREATMENT", 34, 44], ["dynamin", "OBSERVATION", 25, 32]]], ["Dynamin plays an essential role in driving membrane fission in diverse cellular contexts (Ramachandran and Schmid, 2018).", [["membrane", "ANATOMY", 43, 51], ["cellular", "ANATOMY", 71, 79], ["Dynamin", "CHEMICAL", 0, 7], ["Dynamin", "GENE_OR_GENE_PRODUCT", 0, 7], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["cellular", "CELL", 71, 79], ["Dynamin", "PROTEIN", 0, 7], ["essential", "OBSERVATION_MODIFIER", 17, 26]]], ["While dynamin itself does not contain substantial regions of disorder, it assembles with proteins that contain such domains, including amphiphysin and SNX9 (Daumke et al., 2014).", [["disorder", "DISEASE", 61, 69], ["dynamin", "GENE_OR_GENE_PRODUCT", 6, 13], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 135, 146], ["SNX9", "GENE_OR_GENE_PRODUCT", 151, 155], ["dynamin", "PROTEIN", 6, 13], ["amphiphysin", "PROTEIN", 135, 146], ["SNX9", "PROTEIN", 151, 155], ["substantial regions of disorder", "PROBLEM", 38, 69], ["amphiphysin", "TEST", 135, 146], ["substantial", "OBSERVATION_MODIFIER", 38, 49], ["disorder", "OBSERVATION", 61, 69]]], ["We speculate that once recruited by dynamin, these proteins may generate significant steric pressure at membrane necks.", [["membrane necks", "ANATOMY", 104, 118], ["dynamin", "GENE_OR_GENE_PRODUCT", 36, 43], ["membrane necks", "CELLULAR_COMPONENT", 104, 118], ["dynamin", "PROTEIN", 36, 43], ["significant steric pressure at membrane necks", "PROBLEM", 73, 118], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["steric pressure", "OBSERVATION", 85, 100], ["membrane necks", "OBSERVATION", 104, 118]]], ["In line with this thinking, the yeast dynamin homologue, Vps1, is dispensable for fission, but is necessary for proper localization and accumulation of amphiphysin at clathrin-coated pits (Smaczynska-de Rooij et al., 2010; Kishimoto et al., 2011).", [["dynamin", "GENE_OR_GENE_PRODUCT", 38, 45], ["Vps1", "GENE_OR_GENE_PRODUCT", 57, 61], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 152, 163], ["clathrin", "GENE_OR_GENE_PRODUCT", 167, 175], ["yeast dynamin homologue", "PROTEIN", 32, 55], ["Vps1", "PROTEIN", 57, 61], ["amphiphysin", "PROTEIN", 152, 163], ["clathrin", "PROTEIN", 167, 175], ["yeast", "SPECIES", 32, 37], ["yeast", "SPECIES", 32, 37], ["the yeast dynamin homologue", "TEST", 28, 55], ["amphiphysin at clathrin", "TREATMENT", 152, 175], ["yeast", "OBSERVATION", 32, 37], ["dynamin homologue", "OBSERVATION", 38, 55]]], ["A function of Vps1 could therefore be to organize and concentrate bulky disordered domains at membrane necks to promote fission.", [["membrane necks", "ANATOMY", 94, 108], ["Vps1", "GENE_OR_GENE_PRODUCT", 14, 18], ["membrane necks", "CELLULAR_COMPONENT", 94, 108], ["Vps1", "PROTEIN", 14, 18], ["bulky disordered domains", "PROTEIN", 66, 90], ["Vps1", "TREATMENT", 14, 18], ["bulky disordered domains at membrane necks", "PROBLEM", 66, 108], ["bulky", "OBSERVATION_MODIFIER", 66, 71], ["membrane necks", "OBSERVATION", 94, 108]]], ["Moreover, previous studies found that amphiphysin acts synergistically with dynamin to enhance membrane fission (Meinecke et al., 2013; Neumann and Schmid, 2013).", [["membrane", "ANATOMY", 95, 103], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 38, 49], ["dynamin", "GENE_OR_GENE_PRODUCT", 76, 83], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["amphiphysin", "PROTEIN", 38, 49], ["dynamin", "PROTEIN", 76, 83], ["previous studies", "TEST", 10, 26]]], ["However, one report found that amphiphysin alone did not drive membrane fission in the absence of dynamin (Meinecke et al., 2013), in contrast with our findings.", [["membrane", "ANATOMY", 63, 71], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 31, 42], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["dynamin", "GENE_OR_GENE_PRODUCT", 98, 105], ["amphiphysin", "PROTEIN", 31, 42], ["dynamin", "PROTEIN", 98, 105], ["amphiphysin", "PROBLEM", 31, 42], ["amphiphysin", "OBSERVATION", 31, 42]]], ["Notably, this study used rat amphiphysin 2\u20136 (Meinecke et al., 2013), a splice variant that contains a disordered domain that is only 30% of the length of the disordered domain in human amphiphysin used in our study (Wigge et al., 1997).", [["rat", "ORGANISM", 25, 28], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 29, 40], ["human", "ORGANISM", 180, 185], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 186, 197], ["rat amphiphysin 2\u20136", "PROTEIN", 25, 44], ["disordered domain", "PROTEIN", 159, 176], ["human amphiphysin", "PROTEIN", 180, 197], ["rat", "SPECIES", 25, 28], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["this study", "TEST", 9, 19], ["rat amphiphysin", "TEST", 25, 40], ["a splice variant", "PROBLEM", 70, 86], ["a disordered domain", "PROBLEM", 101, 120], ["the disordered domain in human amphiphysin", "PROBLEM", 155, 197], ["our study", "TEST", 206, 215], ["splice variant", "OBSERVATION", 72, 86], ["human amphiphysin", "OBSERVATION", 180, 197]]], ["The substantially shorter disordered domain likely generates lower steric pressure, which may explain its reduced capacity for membrane vesiculation.DiscussionNotably, our results apply specifically to BAR domain proteins that contain bulky disordered regions, while other BAR proteins with shorter disordered domains shape membranes using other mechanisms (Simunovic et al., 2017).", [["membrane", "ANATOMY", 127, 135], ["membranes", "ANATOMY", 324, 333], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["BAR", "GENE_OR_GENE_PRODUCT", 202, 205], ["BAR", "GENE_OR_GENE_PRODUCT", 273, 276], ["membranes", "CELLULAR_COMPONENT", 324, 333], ["disordered domain", "PROTEIN", 26, 43], ["BAR domain proteins", "PROTEIN", 202, 221], ["bulky disordered regions", "PROTEIN", 235, 259], ["BAR proteins", "PROTEIN", 273, 285], ["The substantially shorter disordered domain", "PROBLEM", 0, 43], ["lower steric pressure", "PROBLEM", 61, 82], ["its reduced capacity", "PROBLEM", 102, 122], ["membrane vesiculation", "PROBLEM", 127, 148], ["BAR domain proteins", "TEST", 202, 221], ["bulky disordered regions", "PROBLEM", 235, 259], ["shorter disordered domains shape membranes", "PROBLEM", 291, 333], ["substantially", "OBSERVATION_MODIFIER", 4, 17], ["shorter", "OBSERVATION_MODIFIER", 18, 25], ["lower", "OBSERVATION_MODIFIER", 61, 66], ["steric pressure", "OBSERVATION", 67, 82], ["may explain", "UNCERTAINTY", 90, 101], ["reduced", "OBSERVATION_MODIFIER", 106, 113], ["capacity", "OBSERVATION_MODIFIER", 114, 122], ["membrane vesiculation", "OBSERVATION", 127, 148], ["bulky", "OBSERVATION_MODIFIER", 235, 240]]], ["The lengths of disordered domains found in BAR domain\u2013containing proteins vary widely (Roberts-Galbraith and Gould, 2010; Salzer et al., 2017), from \u223c50 to 400 amino acids in N-BAR\u2013containing proteins (Pietrosemoli et al., 2013).", [["amino acids", "CHEMICAL", 160, 171], ["amino acids", "CHEMICAL", 160, 171], ["BAR", "GENE_OR_GENE_PRODUCT", 43, 46], ["amino acids", "AMINO_ACID", 160, 171], ["disordered domains", "PROTEIN", 15, 33], ["BAR domain\u2013containing proteins", "PROTEIN", 43, 73], ["N-BAR\u2013containing proteins", "PROTEIN", 175, 200], ["disordered domains", "PROBLEM", 15, 33], ["amino acids", "TEST", 160, 171], ["lengths", "OBSERVATION_MODIFIER", 4, 11]]], ["Similarly, the lengths of disordered regions in F-BAR\u2013containing proteins span from less than 100 amino acids in PSTPIP2 (Roberts-Galbraith and Gould, 2010) to greater than 400 in FCHo1 (Pietrosemoli et al., 2013), while in I-BAR\u2013containing proteins, disordered domains span from less than 200 amino acids in IRSp53 (Heung et al., 2008) to greater than 400 in MIM/ABBA (Lee et al., 2007).", [["amino acids", "CHEMICAL", 98, 109], ["amino acids", "CHEMICAL", 294, 305], ["amino acids", "CHEMICAL", 98, 109], ["amino acids", "CHEMICAL", 294, 305], ["F-BAR\u2013containing", "GENE_OR_GENE_PRODUCT", 48, 64], ["amino acids", "AMINO_ACID", 98, 109], ["I-BAR\u2013containing proteins", "GENE_OR_GENE_PRODUCT", 224, 249], ["amino acids", "AMINO_ACID", 294, 305], ["disordered regions", "PROTEIN", 26, 44], ["F-BAR\u2013containing proteins", "PROTEIN", 48, 73], ["I-BAR\u2013containing proteins", "PROTEIN", 224, 249], ["disordered domains", "PROTEIN", 251, 269], ["disordered regions", "PROBLEM", 26, 44], ["amino acids", "TEST", 98, 109], ["disordered domains span", "PROBLEM", 251, 274], ["amino acids", "TEST", 294, 305], ["lengths", "OBSERVATION_MODIFIER", 15, 22], ["disordered", "OBSERVATION_MODIFIER", 26, 36], ["regions", "OBSERVATION_MODIFIER", 37, 44]]], ["Future work is needed to better understand the minimal length for which a disordered domain will make a significant contribution to membrane remodeling.DiscussionRecent work revealed that endophilin, which contains a BAR domain but lacks a bulky disordered region, promotes membrane fission by acting as a diffusion barrier to lipids (Renard et al., 2015; Simunovic et al., 2017).", [["membrane", "ANATOMY", 132, 140], ["membrane", "ANATOMY", 274, 282], ["endophilin", "CHEMICAL", 188, 198], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["endophilin", "GENE_OR_GENE_PRODUCT", 188, 198], ["membrane", "CELLULAR_COMPONENT", 274, 282], ["lipids", "SIMPLE_CHEMICAL", 327, 333], ["endophilin", "PROTEIN", 188, 198], ["BAR domain", "PROTEIN", 217, 227], ["bulky disordered region", "PROTEIN", 240, 263], ["a disordered domain", "PROBLEM", 72, 91], ["membrane remodeling", "PROBLEM", 132, 151], ["endophilin", "PROBLEM", 188, 198], ["a BAR domain", "PROBLEM", 215, 227], ["a bulky disordered region", "PROBLEM", 238, 263], ["a diffusion barrier to lipids", "TREATMENT", 304, 333], ["remodeling", "OBSERVATION", 141, 151], ["bulky", "OBSERVATION_MODIFIER", 240, 245], ["membrane fission", "OBSERVATION", 274, 290]]], ["This friction-driven scission mechanism may be responsible for fission in a clathrin-independent endocytic pathway (Renard et al., 2015; Simunovic et al., 2017).", [["clathrin", "GENE_OR_GENE_PRODUCT", 76, 84], ["clathrin", "PROTEIN", 76, 84], ["This friction", "PROBLEM", 0, 13], ["may be responsible", "UNCERTAINTY", 40, 58]]], ["While friction-driven scission and disordered domain crowding are distinct mechanisms, they are not mutually exclusive and may work together to drive fission of endocytic structures.", [["endocytic structures", "ANATOMY", 161, 181], ["endocytic structures", "CELLULAR_COMPONENT", 161, 181], ["disordered domain crowding", "PROBLEM", 35, 61]]], ["Future work is needed to better understand the potential collaboration between these BAR domain\u2013mediated fission mechanisms.DiscussionOur work reveals a synergistic relationship between structured protein assemblies and disordered pressure generators, which can be harnessed to drive membrane fission.", [["membrane", "ANATOMY", 284, 292], ["BAR", "GENE_OR_GENE_PRODUCT", 85, 88], ["membrane", "CELLULAR_COMPONENT", 284, 292], ["BAR", "PROTEIN", 85, 88], ["a synergistic relationship between structured protein assemblies", "PROBLEM", 151, 215], ["disordered pressure generators", "PROBLEM", 220, 250], ["pressure generators", "OBSERVATION", 231, 250]]], ["It is increasingly recognized that structural disorder is prevalent in membrane trafficking, and that disordered domains are often coupled to structured domains within the same protein molecules (Pietrosemoli et al., 2013).", [["membrane", "ANATOMY", 71, 79], ["structural disorder", "DISEASE", 35, 54], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["disordered domains", "PROTEIN", 102, 120], ["protein molecules", "PROTEIN", 177, 194], ["structural disorder", "PROBLEM", 35, 54], ["disordered domains", "PROBLEM", 102, 120], ["structural disorder", "OBSERVATION", 35, 54], ["membrane trafficking", "OBSERVATION", 71, 91]]], ["While previous work has focused primarily on structure\u2013function relationships revealed by studying individual protein domains, our findings highlight the importance of examining the collective contributions from both structure and disorder to understand how proteins shape membranes in diverse cellular contexts.Chemical reagents ::: Materials and methodsMOPS, Hepes, Tris hydrochloride, NaCl, DTT, IPTG, \u03b2-mercaptoethanol, thrombin protease, and Triton X-100 were purchased from Thermo Fisher Scientific.", [["membranes", "ANATOMY", 273, 282], ["cellular", "ANATOMY", 294, 302], ["disorder", "DISEASE", 231, 239], ["Tris hydrochloride", "CHEMICAL", 368, 386], ["NaCl", "CHEMICAL", 388, 392], ["DTT", "CHEMICAL", 394, 397], ["IPTG", "CHEMICAL", 399, 403], ["\u03b2-mercaptoethanol", "CHEMICAL", 405, 422], ["Triton X-100", "CHEMICAL", 447, 459], ["MOPS", "CHEMICAL", 355, 359], ["Tris hydrochloride", "CHEMICAL", 368, 386], ["NaCl", "CHEMICAL", 388, 392], ["DTT", "CHEMICAL", 394, 397], ["IPTG", "CHEMICAL", 399, 403], ["\u03b2-mercaptoethanol", "CHEMICAL", 405, 422], ["Triton X-100", "CHEMICAL", 447, 459], ["membranes", "CELLULAR_COMPONENT", 273, 282], ["cellular", "CELL", 294, 302], ["Tris hydrochloride", "SIMPLE_CHEMICAL", 368, 386], ["NaCl", "SIMPLE_CHEMICAL", 388, 392], ["DTT", "SIMPLE_CHEMICAL", 394, 397], ["IPTG", "SIMPLE_CHEMICAL", 399, 403], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 405, 422], ["thrombin protease", "GENE_OR_GENE_PRODUCT", 424, 441], ["Triton X-100", "SIMPLE_CHEMICAL", 447, 459], ["protein domains", "PROTEIN", 110, 125], ["thrombin protease", "PROTEIN", 424, 441], ["individual protein domains", "PROBLEM", 99, 125], ["disorder", "PROBLEM", 231, 239], ["methodsMOPS", "TREATMENT", 348, 359], ["Hepes", "TREATMENT", 361, 366], ["Tris hydrochloride", "TREATMENT", 368, 386], ["NaCl", "TREATMENT", 388, 392], ["DTT", "TREATMENT", 394, 397], ["IPTG", "TREATMENT", 399, 403], ["\u03b2-mercaptoethanol", "TREATMENT", 405, 422], ["thrombin protease", "TREATMENT", 424, 441], ["Triton", "TREATMENT", 447, 453], ["diverse", "OBSERVATION_MODIFIER", 286, 293], ["cellular contexts", "OBSERVATION", 294, 311]]], ["EDTA, EGTA, tris(2-carboxyethyl)phosphine hydrochloride (TCEP), PMSF, EDTA-free protease inhibitor tablets, Thrombin CleanCleave Kit, poly-l-lysine (PLL), Atto 488 NHS-ester, and Atto 594 NHS-ester were purchased from Sigma-Aldrich.", [["EDTA", "CHEMICAL", 0, 4], ["EGTA", "CHEMICAL", 6, 10], ["tris(2-carboxyethyl)phosphine hydrochloride", "CHEMICAL", 12, 55], ["TCEP", "CHEMICAL", 57, 61], ["PMSF", "CHEMICAL", 64, 68], ["EDTA", "CHEMICAL", 70, 74], ["poly-l-lysine", "CHEMICAL", 134, 147], ["PLL", "CHEMICAL", 149, 152], ["Atto 488 NHS-ester", "CHEMICAL", 155, 173], ["Atto 594 NHS-ester", "CHEMICAL", 179, 197], ["EDTA", "CHEMICAL", 0, 4], ["EGTA", "CHEMICAL", 6, 10], ["tris(2-carboxyethyl)phosphine hydrochloride", "CHEMICAL", 12, 55], ["TCEP", "CHEMICAL", 57, 61], ["PMSF", "CHEMICAL", 64, 68], ["EDTA", "CHEMICAL", 70, 74], ["poly-l-lysine", "CHEMICAL", 134, 147], ["PLL", "CHEMICAL", 149, 152], ["Atto 488 NHS-ester", "CHEMICAL", 155, 173], ["Atto 594 NHS-ester", "CHEMICAL", 179, 197], ["EDTA", "SIMPLE_CHEMICAL", 0, 4], ["EGTA", "SIMPLE_CHEMICAL", 6, 10], ["tris(2-carboxyethyl)phosphine hydrochloride", "SIMPLE_CHEMICAL", 12, 55], ["TCEP", "SIMPLE_CHEMICAL", 57, 61], ["PMSF", "SIMPLE_CHEMICAL", 64, 68], ["EDTA-free protease", "SIMPLE_CHEMICAL", 70, 88], ["Thrombin CleanCleave Kit", "SIMPLE_CHEMICAL", 108, 132], ["poly-l-lysine", "SIMPLE_CHEMICAL", 134, 147], ["PLL", "SIMPLE_CHEMICAL", 149, 152], ["Atto 488 NHS-ester", "SIMPLE_CHEMICAL", 155, 173], ["Atto 594 NHS-ester", "SIMPLE_CHEMICAL", 179, 197], ["Sigma-Aldrich", "ORGANISM", 218, 231], ["Thrombin", "PROTEIN", 108, 116], ["EDTA", "TEST", 0, 4], ["EGTA", "TEST", 6, 10], ["tris", "TREATMENT", 12, 16], ["carboxyethyl)phosphine hydrochloride (TCEP", "TREATMENT", 19, 61], ["PMSF", "TEST", 64, 68], ["EDTA", "TREATMENT", 70, 74], ["free protease inhibitor tablets", "TREATMENT", 75, 106], ["Thrombin CleanCleave Kit", "TREATMENT", 108, 132], ["poly-l-lysine (PLL", "TREATMENT", 134, 152]]], ["Human rhinovirus-3C (HRV-3C) protease, neutravidin, Oregon Green 488\u2013DHPE, and Texas Red\u2013DHPE were purchased from Thermo Fisher Scientific. mPEG\u2013succinimidyl valerate (SVA), biotin-PEG-SVA, mPEG-silane, and biotin-PEG-silane (all PEGs were molecular weight 5,000 D) were purchased from Laysan Bio.", [["neutravidin", "CHEMICAL", 39, 50], ["mPEG\u2013succinimidyl valerate", "CHEMICAL", 140, 166], ["SVA", "CHEMICAL", 168, 171], ["biotin-PEG-SVA", "CHEMICAL", 174, 188], ["mPEG-silane", "CHEMICAL", 190, 201], ["biotin-PEG-silane", "CHEMICAL", 207, 224], ["PEGs", "CHEMICAL", 230, 234], ["neutravidin", "CHEMICAL", 39, 50], ["mPEG\u2013succinimidyl valerate", "CHEMICAL", 140, 166], ["SVA", "CHEMICAL", 168, 171], ["biotin", "CHEMICAL", 174, 180], ["PEG-SVA", "CHEMICAL", 181, 188], ["mPEG-silane", "CHEMICAL", 190, 201], ["biotin", "CHEMICAL", 207, 213], ["PEG", "CHEMICAL", 214, 217], ["silane", "CHEMICAL", 218, 224], ["PEGs", "CHEMICAL", 230, 234], ["Human", "ORGANISM", 0, 5], ["rhinovirus-3C", "ORGANISM", 6, 19], ["HRV-3C", "ORGANISM", 21, 27], ["neutravidin", "SIMPLE_CHEMICAL", 39, 50], ["Green 488\u2013DHPE", "SIMPLE_CHEMICAL", 59, 73], ["mPEG\u2013succinimidyl valerate", "SIMPLE_CHEMICAL", 140, 166], ["SVA", "SIMPLE_CHEMICAL", 168, 171], ["biotin-PEG-SVA", "SIMPLE_CHEMICAL", 174, 188], ["mPEG-silane", "SIMPLE_CHEMICAL", 190, 201], ["biotin-PEG-silane", "SIMPLE_CHEMICAL", 207, 224], ["PEGs", "SIMPLE_CHEMICAL", 230, 234], ["Human", "SPECIES", 0, 5], ["Human rhinovirus-3C", "SPECIES", 0, 19], ["Human rhinovirus", "TEST", 0, 16], ["HRV", "TEST", 21, 24], ["protease", "TREATMENT", 29, 37], ["neutravidin", "TREATMENT", 39, 50], ["mPEG\u2013succinimidyl valerate (SVA)", "TREATMENT", 140, 172], ["biotin", "TREATMENT", 174, 180], ["PEG", "TREATMENT", 181, 184], ["SVA, mPEG-silane", "TREATMENT", 185, 201], ["biotin-PEG-silane (all PEGs", "TREATMENT", 207, 234]]], ["Dipalmitoyl-decaethylene glycol-biotin (DP-EG10-biotin) was provided by D. Sasaki of Sandia National Laboratories, Livermore, CA (Momin et al., 2015).", [["Dipalmitoyl-decaethylene glycol-biotin", "CHEMICAL", 0, 38], ["DP-EG10-biotin", "CHEMICAL", 40, 54], ["Dipalmitoyl-decaethylene glycol-biotin", "CHEMICAL", 0, 38], ["DP-EG10-biotin", "CHEMICAL", 40, 54], ["Dipalmitoyl-decaethylene glycol-biotin", "SIMPLE_CHEMICAL", 0, 38], ["DP-EG10-biotin", "SIMPLE_CHEMICAL", 40, 54], ["Dipalmitoyl", "TREATMENT", 0, 11], ["decaethylene glycol", "TREATMENT", 12, 31], ["biotin (DP-EG10-biotin)", "TREATMENT", 32, 55]]], ["All other lipids were purchased from Avanti Polar Lipids, including l-\u03b1-phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2; from porcine brain), DOGS-NTA-Ni, DOPC, and 1,2-dioleoyl-sn-glycero-3-phospho-l-serine (DOPS; sodium salt).", [["brain", "ANATOMY", 139, 144], ["l-\u03b1-phosphatidylinositol-4,5-bisphosphate", "CHEMICAL", 68, 109], ["PtdIns", "CHEMICAL", 111, 117], ["DOGS-NTA-Ni", "CHEMICAL", 147, 158], ["DOPC", "CHEMICAL", 160, 164], ["1,2-dioleoyl-sn-glycero-3-phospho-l-serine", "CHEMICAL", 170, 212], ["DOPS", "CHEMICAL", 214, 218], ["sodium salt", "CHEMICAL", 220, 231], ["l-\u03b1-phosphatidylinositol-4,5-bisphosphate", "CHEMICAL", 68, 109], ["PtdIns(4,5)P2", "CHEMICAL", 111, 124], ["NTA", "CHEMICAL", 152, 155], ["Ni", "CHEMICAL", 156, 158], ["DOPC", "CHEMICAL", 160, 164], ["1,2-dioleoyl-sn-glycero-3-phospho-l-serine", "CHEMICAL", 170, 212], ["DOPS", "CHEMICAL", 214, 218], ["sodium salt", "CHEMICAL", 220, 231], ["lipids", "SIMPLE_CHEMICAL", 10, 16], ["Avanti Polar Lipids", "SIMPLE_CHEMICAL", 37, 56], ["l-\u03b1-phosphatidylinositol-4,5-bisphosphate", "SIMPLE_CHEMICAL", 68, 109], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 111, 124], ["porcine", "ORGANISM", 131, 138], ["brain", "ORGAN", 139, 144], ["DOGS-NTA-Ni", "SIMPLE_CHEMICAL", 147, 158], ["DOPC", "SIMPLE_CHEMICAL", 160, 164], ["1,2-dioleoyl-sn-glycero-3-phospho-l-serine", "SIMPLE_CHEMICAL", 170, 212], ["DOPS", "SIMPLE_CHEMICAL", 214, 218], ["sodium salt", "SIMPLE_CHEMICAL", 220, 231], ["porcine", "SPECIES", 131, 138], ["All other lipids", "TREATMENT", 0, 16], ["Avanti Polar Lipids", "TREATMENT", 37, 56], ["l-\u03b1-phosphatidylinositol", "TREATMENT", 68, 92], ["bisphosphate (PtdIns", "TREATMENT", 97, 117], ["DOGS", "TEST", 147, 151], ["NTA", "TEST", 152, 155], ["Ni", "TEST", 156, 158], ["DOPC", "TEST", 160, 164], ["dioleoyl", "TEST", 174, 182], ["glycero", "TEST", 186, 193], ["brain", "ANATOMY", 139, 144]]], ["The lipid compositions for all experiments are listed in the figure captions.Plasmids ::: Materials and methodsThe pGex6P bacterial expression vector containing full-length human amphiphysin (residues 2\u2013695) was provided by the Baumgart laboratory, University of Pennsylvania, Philadelphia, PA.", [["pGex6P", "GENE_OR_GENE_PRODUCT", 115, 121], ["human", "ORGANISM", 173, 178], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 179, 190], ["pGex6P bacterial expression vector", "DNA", 115, 149], ["full-length human amphiphysin", "PROTEIN", 161, 190], ["residues 2\u2013695", "PROTEIN", 192, 206], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178], ["The lipid compositions", "TREATMENT", 0, 22], ["Materials", "TREATMENT", 90, 99], ["methods", "TREATMENT", 104, 111], ["The pGex6P bacterial expression vector", "TREATMENT", 111, 149], ["full-length human amphiphysin (residues", "TREATMENT", 161, 200]]], ["The N-BAR domain of human amphiphysin (residues 2\u2013242) was cloned into the pGex4T2 bacterial expression vector using BamHI and EcoRI restriction sites.", [["human", "ORGANISM", 20, 25], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 26, 37], ["pGex4T2", "GENE_OR_GENE_PRODUCT", 75, 82], ["BamHI", "GENE_OR_GENE_PRODUCT", 117, 122], ["EcoRI", "GENE_OR_GENE_PRODUCT", 127, 132], ["N-BAR domain", "PROTEIN", 4, 16], ["human amphiphysin", "PROTEIN", 20, 37], ["residues 2\u2013242", "PROTEIN", 39, 53], ["pGex4T2 bacterial expression vector", "DNA", 75, 110], ["BamHI and EcoRI restriction sites", "DNA", 117, 150], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["The N-BAR domain of human amphiphysin (residues", "TREATMENT", 0, 47], ["the pGex4T2 bacterial expression vector", "TREATMENT", 71, 110], ["BamHI and EcoRI restriction sites", "TREATMENT", 117, 150]]], ["The C-terminal domain of human amphiphysin lacking the SH3 domain (Amph CTD \u0394SH3, residues 240\u2013622) with N-terminal GST and 6his tags was cloned using a previously generated plasmid template, GST-6his-AP180 CTD in pGex4T2 (Busch et al., 2015).", [["plasmid", "ANATOMY", 174, 181], ["N-", "CHEMICAL", 105, 107], ["human", "ORGANISM", 25, 30], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 31, 42], ["SH3", "GENE_OR_GENE_PRODUCT", 55, 58], ["N-terminal GST", "GENE_OR_GENE_PRODUCT", 105, 119], ["GST-6his", "GENE_OR_GENE_PRODUCT", 192, 200], ["C-terminal domain", "PROTEIN", 4, 21], ["human amphiphysin", "PROTEIN", 25, 42], ["SH3 domain", "PROTEIN", 55, 65], ["Amph CTD \u0394SH3", "PROTEIN", 67, 80], ["residues 240\u2013622", "PROTEIN", 82, 98], ["N-terminal GST", "PROTEIN", 105, 119], ["plasmid template", "DNA", 174, 190], ["GST", "PROTEIN", 192, 195], ["6his", "PROTEIN", 196, 200], ["AP180 CTD", "PROTEIN", 201, 210], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["The C-terminal domain of human amphiphysin", "PROBLEM", 0, 42], ["N-terminal GST", "TEST", 105, 119], ["a previously generated plasmid template", "TREATMENT", 151, 190], ["GST", "TEST", 192, 195], ["human amphiphysin", "OBSERVATION", 25, 42]]], ["AP180 CTD was excised from the template using SalI and XhoI restriction sites, and the Amph CTD \u0394SH3 insert was ligated in using the same SalI and XhoI sites.", [["AP180", "GENE_OR_GENE_PRODUCT", 0, 5], ["SalI", "GENE_OR_GENE_PRODUCT", 46, 50], ["XhoI", "GENE_OR_GENE_PRODUCT", 55, 59], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 87, 95], ["SalI", "GENE_OR_GENE_PRODUCT", 138, 142], ["XhoI", "GENE_OR_GENE_PRODUCT", 147, 151], ["AP180 CTD", "PROTEIN", 0, 9], ["SalI and XhoI restriction sites", "DNA", 46, 77], ["Amph CTD \u0394SH3 insert", "DNA", 87, 107], ["SalI and XhoI sites", "DNA", 138, 157], ["SalI and XhoI restriction sites", "TREATMENT", 46, 77], ["the Amph CTD \u0394SH3 insert", "TREATMENT", 83, 107], ["the same SalI and XhoI sites", "TREATMENT", 129, 157]]], ["The N-BAR domain of human amphiphysin fused to the C-terminal domain of rat epsin1 (N-BAR-epsin CTD, residues 144\u2013575 of rat epsin1) was cloned by first ligating the N-BAR domain of human amphiphysin (residues 2\u2013242) into pGex4T2 using BamHI and EcoRI restriction sites.", [["C", "CHEMICAL", 51, 52], ["human", "ORGANISM", 20, 25], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 26, 37], ["rat", "ORGANISM", 72, 75], ["epsin1", "GENE_OR_GENE_PRODUCT", 76, 82], ["N-BAR-epsin CTD", "GENE_OR_GENE_PRODUCT", 84, 99], ["rat", "ORGANISM", 121, 124], ["epsin1", "GENE_OR_GENE_PRODUCT", 125, 131], ["human", "ORGANISM", 182, 187], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 188, 199], ["pGex4T2", "GENE_OR_GENE_PRODUCT", 222, 229], ["BamHI", "GENE_OR_GENE_PRODUCT", 236, 241], ["EcoRI", "GENE_OR_GENE_PRODUCT", 246, 251], ["N-BAR domain", "PROTEIN", 4, 16], ["human amphiphysin", "PROTEIN", 20, 37], ["C-terminal domain", "PROTEIN", 51, 68], ["rat epsin1", "PROTEIN", 72, 82], ["N-BAR", "PROTEIN", 84, 89], ["epsin CTD", "PROTEIN", 90, 99], ["residues 144\u2013575", "PROTEIN", 101, 117], ["rat epsin1", "PROTEIN", 121, 131], ["N-BAR domain", "PROTEIN", 166, 178], ["human amphiphysin", "PROTEIN", 182, 199], ["residues 2\u2013242", "PROTEIN", 201, 215], ["pGex4T2", "PROTEIN", 222, 229], ["BamHI and EcoRI restriction sites", "DNA", 236, 269], ["human", "SPECIES", 20, 25], ["rat", "SPECIES", 72, 75], ["rat", "SPECIES", 121, 124], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 182, 187], ["human amphiphysin", "PROBLEM", 20, 37], ["human amphiphysin (residues", "TREATMENT", 182, 209], ["BamHI and EcoRI restriction sites", "TREATMENT", 236, 269]]], ["Epsin CTD was then ligated in frame with N-BAR using SalI and NotI restriction sites.", [["Epsin CTD", "GENE_OR_GENE_PRODUCT", 0, 9], ["N-BAR", "GENE_OR_GENE_PRODUCT", 41, 46], ["SalI", "GENE_OR_GENE_PRODUCT", 53, 57], ["NotI", "GENE_OR_GENE_PRODUCT", 62, 66], ["Epsin CTD", "PROTEIN", 0, 9], ["N-BAR", "DNA", 41, 46], ["SalI and NotI restriction sites", "DNA", 53, 84], ["Epsin CTD", "PROBLEM", 0, 9], ["N-BAR using SalI and NotI restriction sites", "TREATMENT", 41, 84]]], ["The I-BAR domain of human IRSp53 (residues 1\u2013250) was cloned by using site-directed mutagenesis to introduce a stop codon at residue 251 in the pGex6P2 plasmid containing full-length IRSp53.", [["plasmid", "ANATOMY", 152, 159], ["I-BAR", "GENE_OR_GENE_PRODUCT", 4, 9], ["human", "ORGANISM", 20, 25], ["IRSp53", "GENE_OR_GENE_PRODUCT", 26, 32], ["I-BAR domain", "PROTEIN", 4, 16], ["human IRSp53", "PROTEIN", 20, 32], ["residues 1\u2013250", "PROTEIN", 34, 48], ["pGex6P2 plasmid", "DNA", 144, 159], ["full-length IRSp53", "DNA", 171, 189], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["a stop codon at residue", "TREATMENT", 109, 132]]], ["The I-BAR domain of human IRSp53 fused to the C-terminal domain of rat AP180 (I-BAR-AP180 CTD, residues 328\u2013896 of rat AP180) was cloned by first ligating the I-BAR domain of human IRSp53 (residues 1\u2013250) into pGex4T2 using BamHI and EcoRI restriction sites.", [["C", "CHEMICAL", 46, 47], ["I-BAR", "GENE_OR_GENE_PRODUCT", 4, 9], ["human", "ORGANISM", 20, 25], ["IRSp53", "GENE_OR_GENE_PRODUCT", 26, 32], ["rat", "ORGANISM", 67, 70], ["AP180", "GENE_OR_GENE_PRODUCT", 71, 76], ["I-BAR-AP180 CTD", "GENE_OR_GENE_PRODUCT", 78, 93], ["rat", "ORGANISM", 115, 118], ["AP180", "GENE_OR_GENE_PRODUCT", 119, 124], ["human", "ORGANISM", 175, 180], ["IRSp53", "GENE_OR_GENE_PRODUCT", 181, 187], ["pGex4T2", "GENE_OR_GENE_PRODUCT", 210, 217], ["BamHI", "GENE_OR_GENE_PRODUCT", 224, 229], ["EcoRI", "GENE_OR_GENE_PRODUCT", 234, 239], ["I-BAR domain", "PROTEIN", 4, 16], ["human IRSp53", "PROTEIN", 20, 32], ["C-terminal domain", "PROTEIN", 46, 63], ["rat AP180", "PROTEIN", 67, 76], ["I", "PROTEIN", 78, 79], ["BAR", "PROTEIN", 80, 83], ["AP180 CTD", "PROTEIN", 84, 93], ["residues 328\u2013896", "PROTEIN", 95, 111], ["rat AP180", "PROTEIN", 115, 124], ["I-BAR domain", "PROTEIN", 159, 171], ["human IRSp53", "PROTEIN", 175, 187], ["residues 1\u2013250", "PROTEIN", 189, 203], ["pGex4T2", "PROTEIN", 210, 217], ["BamHI and EcoRI restriction sites", "DNA", 224, 257], ["human", "SPECIES", 20, 25], ["rat", "SPECIES", 67, 70], ["rat", "SPECIES", 115, 118], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 175, 180], ["human IRSp53 (residues", "TREATMENT", 175, 197], ["BamHI and EcoRI restriction sites", "TREATMENT", 224, 257]]], ["AP180 CTD was then ligated in frame with I-BAR using SalI and XhoI restriction sites.", [["AP180", "GENE_OR_GENE_PRODUCT", 0, 5], ["I-BAR", "GENE_OR_GENE_PRODUCT", 41, 46], ["SalI", "GENE_OR_GENE_PRODUCT", 53, 57], ["XhoI", "GENE_OR_GENE_PRODUCT", 62, 66], ["AP180 CTD", "PROTEIN", 0, 9], ["BAR", "PROTEIN", 43, 46], ["SalI and XhoI restriction sites", "DNA", 53, 84], ["I-BAR", "TREATMENT", 41, 46], ["SalI and XhoI restriction sites", "TREATMENT", 53, 84]]], ["The pGex6P1 vector containing full-length C. elegans FCHo1 (residues 1\u2013968) was provided by the Audhya laboratory, University of Wisconsin, Madison, WI (Wang et al., 2016).", [["pGex6P1", "GENE_OR_GENE_PRODUCT", 4, 11], ["C. elegans", "ORGANISM", 42, 52], ["FCHo1", "GENE_OR_GENE_PRODUCT", 53, 58], ["pGex6P1 vector", "DNA", 4, 18], ["FCHo1", "DNA", 53, 58], ["C. elegans", "SPECIES", 42, 52], ["C. elegans", "SPECIES", 42, 52], ["The pGex6P1 vector", "TREATMENT", 0, 18]]], ["The F-BAR domain of C. elegans FCHo1 (residues 1\u2013276) was cloned into the pGex4T2 vector using BamHI and EcoRI restriction sites.Plasmids ::: Materials and methodsThe pCAGEN mammalian expression vector containing the N-BAR domain of human amphiphysin (residues 1\u2013256), tagged at the C terminus with mCherry, was a gift from T. Meyer, Stanford University, Stanford, CA (Addgene plasmid 85130).", [["F-", "CHEMICAL", 4, 6], ["F-BAR", "GENE_OR_GENE_PRODUCT", 4, 9], ["C. elegans", "ORGANISM", 20, 30], ["FCHo1", "GENE_OR_GENE_PRODUCT", 31, 36], ["1\u2013276", "AMINO_ACID", 47, 52], ["pGex4T2", "GENE_OR_GENE_PRODUCT", 74, 81], ["BamHI", "GENE_OR_GENE_PRODUCT", 95, 100], ["EcoRI", "GENE_OR_GENE_PRODUCT", 105, 110], ["human", "ORGANISM", 233, 238], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 239, 250], ["mCherry", "GENE_OR_GENE_PRODUCT", 299, 306], ["F-BAR domain", "PROTEIN", 4, 16], ["C. elegans FCHo1", "PROTEIN", 20, 36], ["residues 1\u2013276", "PROTEIN", 38, 52], ["pGex4T2 vector", "DNA", 74, 88], ["BamHI and EcoRI restriction sites", "DNA", 95, 128], ["pCAGEN mammalian expression vector", "DNA", 167, 201], ["N-BAR domain", "PROTEIN", 217, 229], ["human amphiphysin", "PROTEIN", 233, 250], ["residues 1\u2013256", "PROTEIN", 252, 266], ["C terminus", "PROTEIN", 283, 293], ["mCherry", "PROTEIN", 299, 306], ["C. elegans", "SPECIES", 20, 30], ["human", "SPECIES", 233, 238], ["C. elegans", "SPECIES", 20, 30], ["human", "SPECIES", 233, 238], ["C. elegans FCHo1", "TREATMENT", 20, 36], ["BamHI and EcoRI restriction sites", "TREATMENT", 95, 128], ["The pCAGEN mammalian expression vector", "TREATMENT", 163, 201], ["the N-BAR domain of human amphiphysin (residues", "TREATMENT", 213, 260], ["CA (Addgene plasmid", "TREATMENT", 365, 384]]], ["Full-length human amphiphysin (residues 1\u2013695) was cloned into the pCAGEN vector, in frame with mCherry at the C terminus, by first excising the N-BAR domain from the template using EcoRI and AgeI restriction sites, and then ligating in Amph-FL using the same EcoRI and AgeI restriction sites.", [["human", "ORGANISM", 12, 17], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 18, 29], ["mCherry", "GENE_OR_GENE_PRODUCT", 96, 103], ["EcoRI", "GENE_OR_GENE_PRODUCT", 182, 187], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 237, 244], ["EcoRI", "GENE_OR_GENE_PRODUCT", 260, 265], ["Full-length human amphiphysin", "PROTEIN", 0, 29], ["residues 1\u2013695", "PROTEIN", 31, 45], ["pCAGEN vector", "DNA", 67, 80], ["C terminus", "PROTEIN", 111, 121], ["N-BAR domain", "PROTEIN", 145, 157], ["EcoRI and AgeI restriction sites", "DNA", 182, 214], ["Amph-FL", "DNA", 237, 244], ["EcoRI and AgeI restriction sites", "DNA", 260, 292], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["Full-length human amphiphysin (residues", "TREATMENT", 0, 39], ["mCherry at the C terminus", "TREATMENT", 96, 121], ["the N-BAR domain", "TREATMENT", 141, 157], ["EcoRI and AgeI restriction sites", "TREATMENT", 182, 214], ["Amph-FL", "TREATMENT", 237, 244], ["the same EcoRI and AgeI restriction sites", "TREATMENT", 251, 292]]], ["The N-BAR domain of human amphiphysin fused to the C-terminal domain of mouse neurofilament-M (N-BAR-NfM CTD, residues 411\u2013848 of mouse neurofilament-M) was cloned by ligating neurofilament-M CTD into the existing N-BAR-mCherry pCAGEN template, between N-BAR and mCherry, using a single AgeI restriction site.", [["C", "CHEMICAL", 51, 52], ["human", "ORGANISM", 20, 25], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 26, 37], ["mouse", "ORGANISM", 72, 77], ["neurofilament-M", "GENE_OR_GENE_PRODUCT", 78, 93], ["N-BAR-NfM CTD", "GENE_OR_GENE_PRODUCT", 95, 108], ["mouse", "ORGANISM", 130, 135], ["neurofilament-M", "GENE_OR_GENE_PRODUCT", 136, 151], ["neurofilament-M CTD", "GENE_OR_GENE_PRODUCT", 176, 195], ["N-BAR", "GENE_OR_GENE_PRODUCT", 253, 258], ["mCherry", "GENE_OR_GENE_PRODUCT", 263, 270], ["N-BAR domain", "PROTEIN", 4, 16], ["human amphiphysin", "PROTEIN", 20, 37], ["C-terminal domain", "PROTEIN", 51, 68], ["mouse neurofilament-M", "PROTEIN", 72, 93], ["N-BAR", "PROTEIN", 95, 100], ["NfM CTD", "PROTEIN", 101, 108], ["mouse neurofilament-M", "PROTEIN", 130, 151], ["ligating neurofilament-M CTD", "PROTEIN", 167, 195], ["N-BAR-mCherry pCAGEN template", "DNA", 214, 243], ["N", "PROTEIN", 253, 254], ["BAR", "PROTEIN", 255, 258], ["mCherry", "PROTEIN", 263, 270], ["AgeI restriction site", "DNA", 287, 308], ["human", "SPECIES", 20, 25], ["mouse", "SPECIES", 72, 77], ["mouse", "SPECIES", 130, 135], ["human", "SPECIES", 20, 25], ["mouse", "SPECIES", 72, 77], ["human amphiphysin", "PROBLEM", 20, 37], ["the existing N-BAR", "TREATMENT", 201, 219], ["mCherry pCAGEN template", "TREATMENT", 220, 243], ["a single AgeI restriction site", "TREATMENT", 278, 308], ["amphiphysin fused", "OBSERVATION", 26, 43]]], ["The resulting plasmid contained a GPV linker between N-BAR and neurofilament-M CTD and a GPVAT linker between neurofilament-M CTD and mCherry.", [["plasmid", "ANATOMY", 14, 21], ["N-BAR", "GENE_OR_GENE_PRODUCT", 53, 58], ["neurofilament-M CTD", "GENE_OR_GENE_PRODUCT", 63, 82], ["neurofilament-M CTD", "GENE_OR_GENE_PRODUCT", 110, 129], ["mCherry", "GENE_OR_GENE_PRODUCT", 134, 141], ["GPV linker", "PROTEIN", 34, 44], ["N", "PROTEIN", 53, 54], ["BAR", "PROTEIN", 55, 58], ["neurofilament-M CTD", "PROTEIN", 63, 82], ["GPVAT linker", "PROTEIN", 89, 101], ["neurofilament-M CTD", "PROTEIN", 110, 129], ["mCherry", "PROTEIN", 134, 141], ["The resulting plasmid", "TREATMENT", 0, 21], ["a GPV linker", "TREATMENT", 32, 44], ["a GPVAT linker", "TREATMENT", 87, 101], ["GPV linker", "OBSERVATION", 34, 44]]], ["All plasmids were confirmed by DNA sequencing.Protein purification ::: Materials and methodsAll proteins were expressed as N-terminal GST fusion constructs in BL21 Escherichia coli cells following induction with 1 mM IPTG.", [["plasmids", "ANATOMY", 4, 12], ["cells", "ANATOMY", 181, 186], ["IPTG", "CHEMICAL", 217, 221], ["N-", "CHEMICAL", 123, 125], ["IPTG", "CHEMICAL", 217, 221], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["GST", "GENE_OR_GENE_PRODUCT", 134, 137], ["BL21 Escherichia coli cells", "CELL", 159, 186], ["plasmids", "DNA", 4, 12], ["N-terminal GST fusion constructs", "DNA", 123, 155], ["BL21 Escherichia coli cells", "CELL_LINE", 159, 186], ["BL21 Escherichia coli", "SPECIES", 159, 180], ["BL21", "SPECIES", 159, 163], ["Escherichia coli", "SPECIES", 164, 180], ["All plasmids", "TREATMENT", 0, 12], ["All proteins", "PROBLEM", 92, 104], ["N-terminal GST fusion constructs", "TREATMENT", 123, 155], ["BL21 Escherichia coli cells", "PROBLEM", 159, 186], ["1 mM IPTG", "TREATMENT", 212, 221], ["plasmids", "OBSERVATION", 4, 12], ["fusion constructs", "OBSERVATION", 138, 155], ["BL21 Escherichia coli cells", "OBSERVATION", 159, 186]]], ["Amph-FL, N-BAR, Amph CTD \u0394SH3, I-BAR, I-BAR-AP180 CTD, and F-BAR were induced at 30\u00b0C for 6\u20138 h.", [["Amph-FL", "GENE_OR_GENE_PRODUCT", 0, 7], ["N-BAR", "GENE_OR_GENE_PRODUCT", 9, 14], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 16, 24], ["I-BAR", "GENE_OR_GENE_PRODUCT", 31, 36], ["I-BAR-AP180 CTD", "GENE_OR_GENE_PRODUCT", 38, 53], ["F-BAR", "GENE_OR_GENE_PRODUCT", 59, 64], ["Amph", "PROTEIN", 0, 4], ["FL", "PROTEIN", 5, 7], ["N-BAR", "PROTEIN", 9, 14], ["Amph CTD", "PROTEIN", 16, 24], ["\u0394SH3", "PROTEIN", 25, 29], ["I", "PROTEIN", 31, 32], ["BAR", "PROTEIN", 33, 36], ["I", "PROTEIN", 38, 39], ["BAR", "PROTEIN", 40, 43], ["AP180 CTD", "PROTEIN", 44, 53], ["F", "PROTEIN", 59, 60], ["BAR", "PROTEIN", 61, 64], ["Amph", "TEST", 0, 4], ["CTD", "PROBLEM", 50, 53], ["FL", "ANATOMY", 5, 7]]], ["N-BAR-epsin CTD was induced at 16\u00b0C for 20 h.", [["N-BAR-epsin CTD", "PROTEIN", 0, 15], ["epsin CTD", "PROBLEM", 6, 15]]], ["FCHo1-FL was induced at 12\u00b0C for 24 h.", [["FCHo1-FL", "CHEMICAL", 0, 8], ["FCHo1", "GENE_OR_GENE_PRODUCT", 0, 5], ["FCHo1", "PROTEIN", 0, 5], ["FL", "PROTEIN", 6, 8]]], ["Cells were harvested, and bacteria were lysed using lysis buffer and probe sonication.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["bacteria", "PROBLEM", 26, 34], ["lysis buffer", "TREATMENT", 52, 64], ["probe sonication", "TREATMENT", 69, 85], ["bacteria", "OBSERVATION_MODIFIER", 26, 34]]], ["For FCHo1-FL, lysis buffer was 100 mM sodium phosphate, pH 8.0, 5 mM EDTA, 5 mM DTT, 10% glycerol, 1 mM PMSF, 1% Triton X-100, and 1\u00d7 Roche protease inhibitor cocktail.", [["FCHo1-FL", "CHEMICAL", 4, 12], ["sodium phosphate", "CHEMICAL", 38, 54], ["glycerol", "CHEMICAL", 89, 97], ["Triton X-100", "CHEMICAL", 113, 125], ["sodium phosphate", "CHEMICAL", 38, 54], ["EDTA", "CHEMICAL", 69, 73], ["DTT", "CHEMICAL", 80, 83], ["glycerol", "CHEMICAL", 89, 97], ["PMSF", "CHEMICAL", 104, 108], ["FCHo1-FL", "SIMPLE_CHEMICAL", 4, 12], ["sodium phosphate", "SIMPLE_CHEMICAL", 38, 54], ["EDTA", "SIMPLE_CHEMICAL", 69, 73], ["DTT", "SIMPLE_CHEMICAL", 80, 83], ["glycerol", "SIMPLE_CHEMICAL", 89, 97], ["PMSF", "SIMPLE_CHEMICAL", 104, 108], ["Triton X-100", "SIMPLE_CHEMICAL", 113, 125], ["Roche protease", "GENE_OR_GENE_PRODUCT", 134, 148], ["FCHo1", "TEST", 4, 9], ["lysis buffer", "TREATMENT", 14, 26], ["sodium phosphate", "TEST", 38, 54], ["pH", "TEST", 56, 58], ["EDTA", "TEST", 69, 73], ["5 mM DTT", "TREATMENT", 75, 83], ["10% glycerol", "TREATMENT", 85, 97], ["Roche protease inhibitor cocktail", "TREATMENT", 134, 167]]], ["For all other proteins, lysis buffer was 500 mM Tris-HCl, pH 8.0, 5 mM EDTA, 10 mM \u03b2-mercaptoethanol or 5 mM TCEP, 5% glycerol, 1 mM PMSF, 1% Triton X-100, and 1\u00d7 Roche or Pierce protease inhibitor cocktail.", [["Tris-HCl", "CHEMICAL", 48, 56], ["\u03b2-mercaptoethanol", "CHEMICAL", 83, 100], ["glycerol", "CHEMICAL", 118, 126], ["Triton X-100", "CHEMICAL", 142, 154], ["Tris-HCl", "CHEMICAL", 48, 56], ["EDTA", "CHEMICAL", 71, 75], ["\u03b2-mercaptoethanol", "CHEMICAL", 83, 100], ["TCEP", "CHEMICAL", 109, 113], ["glycerol", "CHEMICAL", 118, 126], ["PMSF", "CHEMICAL", 133, 137], ["Tris-HCl", "SIMPLE_CHEMICAL", 48, 56], ["EDTA", "SIMPLE_CHEMICAL", 71, 75], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 83, 100], ["TCEP", "SIMPLE_CHEMICAL", 109, 113], ["glycerol", "SIMPLE_CHEMICAL", 118, 126], ["PMSF", "SIMPLE_CHEMICAL", 133, 137], ["Triton X-100", "SIMPLE_CHEMICAL", 142, 154], ["Roche", "ORGANISM_SUBSTANCE", 163, 168], ["Pierce protease", "GENE_OR_GENE_PRODUCT", 172, 187], ["lysis buffer", "TREATMENT", 24, 36], ["Tris", "TEST", 48, 52], ["pH", "TEST", 58, 60], ["EDTA", "TEST", 71, 75], ["mercaptoethanol", "TREATMENT", 85, 100], ["5 mM TCEP", "TREATMENT", 104, 113], ["5% glycerol", "TREATMENT", 115, 126], ["Pierce protease inhibitor cocktail", "TREATMENT", 172, 206]]], ["Proteins were purified from bacterial extracts by incubating with glutathione resin, followed by extensive washing (at least 10\u00d7 column volumes).", [["extracts", "ANATOMY", 38, 46], ["glutathione", "CHEMICAL", 66, 77], ["glutathione", "CHEMICAL", 66, 77], ["bacterial extracts", "ORGANISM_SUBSTANCE", 28, 46], ["glutathione", "SIMPLE_CHEMICAL", 66, 77], ["bacterial extracts", "PROBLEM", 28, 46], ["glutathione resin", "TREATMENT", 66, 83], ["extensive washing", "TREATMENT", 97, 114], ["bacterial extracts", "OBSERVATION_MODIFIER", 28, 46]]], ["Amph-FL, N-BAR, Amph CTD \u0394SH3, and F-BAR were cleaved directly from the resin using soluble HRV-3C (Thermo Fisher Scientific) or thrombin (GE Healthcare) proteases overnight at 4\u00b0C with rocking.", [["Amph-FL", "GENE_OR_GENE_PRODUCT", 0, 7], ["N-BAR", "GENE_OR_GENE_PRODUCT", 9, 14], ["Amph CTD \u0394SH3", "GENE_OR_GENE_PRODUCT", 16, 29], ["F-BAR", "GENE_OR_GENE_PRODUCT", 35, 40], ["thrombin", "GENE_OR_GENE_PRODUCT", 129, 137], ["Amph", "PROTEIN", 0, 4], ["FL", "PROTEIN", 5, 7], ["N", "PROTEIN", 9, 10], ["BAR", "PROTEIN", 11, 14], ["Amph CTD \u0394SH3", "PROTEIN", 16, 29], ["F", "PROTEIN", 35, 36], ["BAR", "PROTEIN", 37, 40], ["thrombin (GE Healthcare) proteases", "PROTEIN", 129, 163], ["Amph", "TEST", 0, 4], ["Amph CTD \u0394SH3", "TREATMENT", 16, 29], ["soluble HRV", "TREATMENT", 84, 95], ["3C (Thermo Fisher Scientific", "TREATMENT", 96, 124], ["thrombin (GE Healthcare) proteases", "TREATMENT", 129, 163], ["FL", "ANATOMY", 5, 7]]], ["HRV-3C, which contained a GST tag, was removed by passage through a glutathione agarose column.", [["glutathione", "CHEMICAL", 68, 79], ["glutathione", "CHEMICAL", 68, 79], ["HRV-3C", "GENE_OR_GENE_PRODUCT", 0, 6], ["GST", "GENE_OR_GENE_PRODUCT", 26, 29], ["glutathione", "SIMPLE_CHEMICAL", 68, 79], ["GST tag", "PROTEIN", 26, 33], ["HRV", "TEST", 0, 3], ["a GST tag", "TREATMENT", 24, 33], ["a glutathione agarose column", "TREATMENT", 66, 94]]], ["Thrombin was removed with p-aminobenzamidine-agarose resin (Sigma-Aldrich).", [["p-aminobenzamidine-agarose", "CHEMICAL", 26, 52], ["p-aminobenzamidine", "CHEMICAL", 26, 44], ["Thrombin", "GENE_OR_GENE_PRODUCT", 0, 8], ["p-aminobenzamidine-agarose resin", "SIMPLE_CHEMICAL", 26, 58], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 60, 73], ["Thrombin", "PROTEIN", 0, 8], ["Thrombin", "TREATMENT", 0, 8], ["p-aminobenzamidine", "TREATMENT", 26, 44], ["agarose resin", "TREATMENT", 45, 58]]], ["N-BAR-epsin CTD, I-BAR, and I-BAR-AP180 CTD were eluted with 15 mM reduced glutathione in 500 mM Tris-HCl, pH 8.0, 5 mM EDTA, 10 mM \u03b2-mercaptoethanol or 5 mM TCEP, 5% glycerol, and 1 mM PMSF buffer.", [["glutathione", "CHEMICAL", 75, 86], ["Tris-HCl", "CHEMICAL", 97, 105], ["\u03b2-mercaptoethanol", "CHEMICAL", 132, 149], ["TCEP", "CHEMICAL", 158, 162], ["glycerol", "CHEMICAL", 167, 175], ["reduced glutathione", "CHEMICAL", 67, 86], ["Tris-HCl", "CHEMICAL", 97, 105], ["EDTA", "CHEMICAL", 120, 124], ["\u03b2-mercaptoethanol", "CHEMICAL", 132, 149], ["TCEP", "CHEMICAL", 158, 162], ["glycerol", "CHEMICAL", 167, 175], ["PMSF", "CHEMICAL", 186, 190], ["N-BAR", "GENE_OR_GENE_PRODUCT", 0, 5], ["I-BAR", "GENE_OR_GENE_PRODUCT", 17, 22], ["I-BAR", "GENE_OR_GENE_PRODUCT", 28, 33], ["glutathione", "SIMPLE_CHEMICAL", 75, 86], ["Tris-HCl", "SIMPLE_CHEMICAL", 97, 105], ["EDTA", "SIMPLE_CHEMICAL", 120, 124], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 132, 149], ["TCEP", "SIMPLE_CHEMICAL", 158, 162], ["glycerol", "SIMPLE_CHEMICAL", 167, 175], ["PMSF", "SIMPLE_CHEMICAL", 186, 190], ["BAR", "PROTEIN", 2, 5], ["epsin CTD", "PROTEIN", 6, 15], ["I", "PROTEIN", 17, 18], ["BAR", "PROTEIN", 19, 22], ["I", "PROTEIN", 28, 29], ["BAR", "PROTEIN", 30, 33], ["AP180 CTD", "PROTEIN", 34, 43], ["15 mM reduced glutathione", "TREATMENT", 61, 86], ["Tris", "TEST", 97, 101], ["pH", "TEST", 107, 109], ["EDTA", "TEST", 120, 124], ["mercaptoethanol", "TREATMENT", 134, 149], ["5 mM TCEP", "TREATMENT", 153, 162], ["5% glycerol", "TREATMENT", 164, 175], ["1 mM PMSF buffer", "TREATMENT", 181, 197]]], ["FCHo1-FL was eluted with 15 mM reduced glutathione in 100 mM sodium phosphate, pH 8.0, 5 mM EDTA, 5 mM DTT, 10% glycerol, and 1 mM PMSF buffer.", [["FCHo1-FL", "CHEMICAL", 0, 8], ["glutathione", "CHEMICAL", 39, 50], ["sodium phosphate", "CHEMICAL", 61, 77], ["glycerol", "CHEMICAL", 112, 120], ["reduced glutathione", "CHEMICAL", 31, 50], ["sodium phosphate", "CHEMICAL", 61, 77], ["EDTA", "CHEMICAL", 92, 96], ["DTT", "CHEMICAL", 103, 106], ["glycerol", "CHEMICAL", 112, 120], ["PMSF", "CHEMICAL", 131, 135], ["FCHo1", "SIMPLE_CHEMICAL", 0, 5], ["glutathione", "SIMPLE_CHEMICAL", 39, 50], ["sodium phosphate", "SIMPLE_CHEMICAL", 61, 77], ["EDTA", "SIMPLE_CHEMICAL", 92, 96], ["DTT", "SIMPLE_CHEMICAL", 103, 106], ["glycerol", "SIMPLE_CHEMICAL", 112, 120], ["PMSF", "SIMPLE_CHEMICAL", 131, 135], ["FCHo1", "PROTEIN", 0, 5], ["FCHo1", "TEST", 0, 5], ["15 mM reduced glutathione", "TREATMENT", 25, 50], ["mM sodium phosphate", "TEST", 58, 77], ["pH", "TEST", 79, 81], ["EDTA", "TEST", 92, 96], ["5 mM DTT", "TREATMENT", 98, 106], ["10% glycerol", "TREATMENT", 108, 120], ["1 mM PMSF buffer", "TREATMENT", 126, 142]]], ["The proteins were concentrated with EMD Millipore Amicon centrifugal filter units, desalted with Zeba Spin Desalting Columns (Thermo Fisher Scientific), and then incubated with the Thrombin CleanCleave Kit (Sigma-Aldrich), soluble HRV-3C, or soluble thrombin overnight at 4\u00b0C with rocking.", [["Thrombin", "GENE_OR_GENE_PRODUCT", 181, 189], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 207, 220], ["HRV-3C", "GENE_OR_GENE_PRODUCT", 231, 237], ["thrombin", "GENE_OR_GENE_PRODUCT", 250, 258], ["Thrombin", "PROTEIN", 181, 189], ["thrombin", "PROTEIN", 250, 258], ["EMD Millipore Amicon centrifugal filter units", "TREATMENT", 36, 81], ["Zeba Spin Desalting Columns", "TREATMENT", 97, 124], ["the Thrombin CleanCleave Kit", "TREATMENT", 177, 205], ["soluble HRV", "TREATMENT", 223, 234], ["soluble thrombin", "TREATMENT", 242, 258]]], ["Cleaved GST was removed by passage through a glutathione agarose column.", [["glutathione", "CHEMICAL", 45, 56], ["glutathione", "CHEMICAL", 45, 56], ["GST", "GENE_OR_GENE_PRODUCT", 8, 11], ["glutathione", "SIMPLE_CHEMICAL", 45, 56], ["GST", "PROTEIN", 8, 11], ["Cleaved GST", "PROBLEM", 0, 11], ["a glutathione agarose column", "TREATMENT", 43, 71]]], ["I-BAR-AP180 CTD and N-BAR-epsin CTD were further purified by gel filtration chromatography using a Superose 6 column equilibrated with 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 5 mM EGTA, 1 mM PMSF, and 5 mM DTT.", [["Tris-HCl", "CHEMICAL", 141, 149], ["NaCl", "CHEMICAL", 166, 170], ["EGTA", "CHEMICAL", 188, 192], ["Tris-HCl", "CHEMICAL", 141, 149], ["NaCl", "CHEMICAL", 166, 170], ["EDTA", "CHEMICAL", 177, 181], ["EGTA", "CHEMICAL", 188, 192], ["PMSF", "CHEMICAL", 199, 203], ["DTT", "CHEMICAL", 214, 217], ["I-BAR", "GENE_OR_GENE_PRODUCT", 0, 5], ["N-BAR-epsin CTD", "GENE_OR_GENE_PRODUCT", 20, 35], ["Tris-HCl", "SIMPLE_CHEMICAL", 141, 149], ["EDTA", "SIMPLE_CHEMICAL", 177, 181], ["EGTA", "SIMPLE_CHEMICAL", 188, 192], ["PMSF", "SIMPLE_CHEMICAL", 199, 203], ["DTT", "SIMPLE_CHEMICAL", 214, 217], ["BAR", "PROTEIN", 2, 5], ["AP180 CTD", "PROTEIN", 6, 15], ["N-BAR", "PROTEIN", 20, 25], ["epsin CTD", "PROTEIN", 26, 35], ["N-BAR", "TEST", 20, 25], ["gel filtration chromatography", "TEST", 61, 90], ["a Superose 6 column", "TREATMENT", 97, 116], ["Tris", "TEST", 141, 145], ["pH", "TEST", 151, 153], ["NaCl", "TEST", 166, 170], ["EDTA", "TEST", 177, 181], ["5 mM EGTA", "TREATMENT", 183, 192], ["1 mM PMSF", "TREATMENT", 194, 203], ["5 mM DTT", "TREATMENT", 209, 217]]], ["All proteins were stored as small aliquots or liquid nitrogen pellets at \u221280\u00b0C. All proteins except FCHo1-FL were stored in glycerol-free buffer, and all experiments were performed in glycerol-free buffer.", [["glycerol", "CHEMICAL", 124, 132], ["glycerol", "CHEMICAL", 184, 192], ["nitrogen", "CHEMICAL", 53, 61], ["glycerol", "CHEMICAL", 124, 132], ["glycerol", "CHEMICAL", 184, 192], ["FCHo1-FL", "GENE_OR_GENE_PRODUCT", 100, 108], ["glycerol", "SIMPLE_CHEMICAL", 124, 132], ["glycerol", "SIMPLE_CHEMICAL", 184, 192], ["FCHo1", "PROTEIN", 100, 105], ["FL", "PROTEIN", 106, 108], ["All proteins", "TREATMENT", 0, 12], ["liquid nitrogen pellets", "TREATMENT", 46, 69], ["All proteins", "TEST", 80, 92], ["glycerol-free buffer", "TREATMENT", 124, 144], ["glycerol-free buffer", "TREATMENT", 184, 204]]], ["FCHo1-FL was stored in the presence of 10 vol% glycerol to improve protein stability, but dilutions during experiments reduced the glycerol concentration to 0.1 vol% or less, which is not expected to affect membrane properties (Pocivavsek et al., 2011).Protein labeling ::: Materials and methodsProteins were labeled using amine-reactive, NHS ester-functionalized dyes (Atto-Tec) in 25 mM Hepes, pH 7.35, 150 mM NaCl, and 5 mM TCEP buffer.", [["membrane", "ANATOMY", 207, 215], ["FCHo1-FL", "CHEMICAL", 0, 8], ["glycerol", "CHEMICAL", 47, 55], ["glycerol", "CHEMICAL", 131, 139], ["amine", "CHEMICAL", 323, 328], ["NHS ester", "CHEMICAL", 339, 348], ["NaCl", "CHEMICAL", 412, 416], ["glycerol", "CHEMICAL", 47, 55], ["glycerol", "CHEMICAL", 131, 139], ["amine", "CHEMICAL", 323, 328], ["ester", "CHEMICAL", 343, 348], ["NaCl", "CHEMICAL", 412, 416], ["TCEP", "CHEMICAL", 427, 431], ["glycerol", "SIMPLE_CHEMICAL", 47, 55], ["glycerol", "SIMPLE_CHEMICAL", 131, 139], ["membrane", "CELLULAR_COMPONENT", 207, 215], ["amine-reactive", "SIMPLE_CHEMICAL", 323, 337], ["NHS ester-functionalized dyes", "SIMPLE_CHEMICAL", 339, 368], ["Atto-Tec", "SIMPLE_CHEMICAL", 370, 378], ["FCHo1", "PROTEIN", 0, 5], ["FL", "PROTEIN", 6, 8], ["10 vol% glycerol", "TREATMENT", 39, 55], ["protein stability", "PROBLEM", 67, 84], ["the glycerol concentration", "TREATMENT", 127, 153], ["methodsProteins", "TEST", 288, 303], ["amine", "TEST", 323, 328], ["NHS ester", "TEST", 339, 348], ["Atto", "TEST", 370, 374], ["Hepes", "TEST", 389, 394], ["pH", "TEST", 396, 398], ["NaCl", "TEST", 412, 416], ["5 mM TCEP buffer", "TREATMENT", 422, 438], ["protein stability", "OBSERVATION", 67, 84]]], ["The concentration of dye was adjusted experimentally to obtain the desired labeling ratio of 0.5\u20131 dye molecules per protein, typically 2\u20135 times molar excess of dye.", [["The concentration of dye", "TREATMENT", 0, 24]]], ["Reactions were performed for 20\u201330 min at room temperature, and labeled protein was separated from unconjugated dye using Princeton CentriSpin-20 size exclusion spin columns (Princeton Separations).TEM ::: Materials and methodsVesicles for EM were composed of 5 mol% PtdIns(4,5)P2, 15 mol% DOPS, and 80 mol% DOPC.", [["Vesicles", "ANATOMY", 227, 235], ["PtdIns", "CHEMICAL", 267, 273], ["DOPS", "CHEMICAL", 290, 294], ["DOPC", "CHEMICAL", 308, 312], ["PtdIns(4,5)P2", "CHEMICAL", 267, 280], ["DOPS", "CHEMICAL", 290, 294], ["DOPC", "CHEMICAL", 308, 312], ["unconjugated dye", "SIMPLE_CHEMICAL", 99, 115], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 267, 280], ["DOPS", "SIMPLE_CHEMICAL", 290, 294], ["DOPC", "SIMPLE_CHEMICAL", 308, 312], ["labeled protein", "TEST", 64, 79], ["unconjugated dye", "TREATMENT", 99, 115], ["Princeton CentriSpin", "TREATMENT", 122, 142], ["20 size exclusion spin columns (Princeton Separations", "TREATMENT", 143, 196], ["methodsVesicles", "TEST", 220, 235], ["EM", "TEST", 240, 242], ["DOPS", "TEST", 290, 294]]], ["Dried lipid films were hydrated in 20 mM MOPS, pH 7.35, 150 mM NaCl, 0.5 mM EGTA, and EDTA buffer and extruded though a 200-nm pore filter (Whatman).", [["NaCl", "CHEMICAL", 63, 67], ["EGTA", "CHEMICAL", 76, 80], ["MOPS", "CHEMICAL", 41, 45], ["NaCl", "CHEMICAL", 63, 67], ["EGTA", "CHEMICAL", 76, 80], ["EDTA", "CHEMICAL", 86, 90], ["EGTA", "SIMPLE_CHEMICAL", 76, 80], ["EDTA", "SIMPLE_CHEMICAL", 86, 90], ["Dried lipid films", "TEST", 0, 17], ["pH", "TEST", 47, 49], ["NaCl", "TEST", 63, 67], ["0.5 mM EGTA", "TREATMENT", 69, 80], ["EDTA buffer", "TREATMENT", 86, 97], ["a 200-nm pore filter (Whatman", "TREATMENT", 118, 147]]], ["Proteins were diluted to the indicated concentrations in the same MOPS buffer with 5 mM TCEP and incubated with vesicles at 37\u00b0C for 30 min (Amph-FL and N-BAR) or 60 min (FCHo1-FL and F-BAR).", [["vesicles", "ANATOMY", 112, 120], ["TCEP", "CHEMICAL", 88, 92], ["TCEP", "CHEMICAL", 88, 92], ["TCEP", "SIMPLE_CHEMICAL", 88, 92], ["F-BAR", "GENE_OR_GENE_PRODUCT", 184, 189], ["BAR", "PROTEIN", 155, 158], ["FCHo1", "PROTEIN", 171, 176], ["BAR", "PROTEIN", 186, 189], ["Proteins", "TEST", 0, 8], ["5 mM TCEP", "TREATMENT", 83, 92], ["vesicles", "TREATMENT", 112, 120], ["Amph", "TEST", 141, 145]]], ["The vesicle concentration was 1 mM in experiments with Amph-FL, FCHo1-FL, and F-BAR, and 0.1 mM in experiments with N-BAR and in protein-free controls.", [["vesicle", "ANATOMY", 4, 11], ["Amph-FL", "CHEMICAL", 55, 62], ["FCHo1-FL", "CHEMICAL", 64, 72], ["N-BAR", "CHEMICAL", 116, 121], ["vesicle", "CELLULAR_COMPONENT", 4, 11], ["Amph-FL", "SIMPLE_CHEMICAL", 55, 62], ["FCHo1-FL", "SIMPLE_CHEMICAL", 64, 72], ["F-BAR", "GENE_OR_GENE_PRODUCT", 78, 83], ["N-BAR", "GENE_OR_GENE_PRODUCT", 116, 121], ["BAR", "PROTEIN", 80, 83], ["BAR", "PROTEIN", 118, 121], ["Amph", "TEST", 55, 59], ["N-BAR", "TREATMENT", 116, 121], ["vesicle", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25], ["1 mM", "OBSERVATION_MODIFIER", 30, 34], ["FL", "ANATOMY", 60, 62], ["FL", "ANATOMY", 70, 72]]], ["5 \u00b5l of the mixture was placed onto a glow-discharged, 300 square mesh, carbon-coated grid and stained with 2% uranyl acetate (Electron Microscopy Sciences).", [["uranyl acetate", "CHEMICAL", 111, 125], ["carbon", "CHEMICAL", 72, 78], ["uranyl acetate", "CHEMICAL", 111, 125], ["uranyl acetate", "SIMPLE_CHEMICAL", 111, 125], ["the mixture", "TREATMENT", 8, 19], ["carbon-coated grid", "TREATMENT", 72, 90], ["2% uranyl acetate", "TREATMENT", 108, 125]]], ["Images were collected on a Tecnai Spirit BioTwin T12 electron microscope (Tecnai).", [["Images", "TEST", 0, 6]]], ["Vesicle and tubule diameters were measured using ImageJ software.Fluorescence microscopy ::: Materials and methodsA spinning disc confocal microscope (Zeiss Axio Observer Z1 with Yokagawa CSU-X1M) was used to image GUVs, tethered vesicles, and live RPE cells.", [["Vesicle", "ANATOMY", 0, 7], ["tubule", "ANATOMY", 12, 18], ["GUVs", "ANATOMY", 215, 219], ["vesicles", "ANATOMY", 230, 238], ["RPE cells", "ANATOMY", 249, 258], ["Vesicle", "CELLULAR_COMPONENT", 0, 7], ["tubule", "TISSUE", 12, 18], ["vesicles", "CELLULAR_COMPONENT", 230, 238], ["RPE cells", "CELL", 249, 258], ["Yokagawa CSU-X1M", "DNA", 179, 195], ["live RPE cells", "CELL_TYPE", 244, 258], ["ImageJ software", "TEST", 49, 64], ["Fluorescence microscopy", "TEST", 65, 88], ["methodsA spinning disc confocal microscope", "TEST", 107, 149], ["tethered vesicles", "PROBLEM", 221, 238], ["tubule", "OBSERVATION_MODIFIER", 12, 18], ["diameters", "OBSERVATION_MODIFIER", 19, 28], ["vesicles", "ANATOMY", 230, 238]]], ["Laser wavelengths of 488 and 561 nm were used for excitation.", [["Laser wavelengths", "TEST", 0, 17]]], ["Emission filters were centered at 525 nm with a 50-nm width, and 629 nm with a 62-nm width.", [["Emission filters", "TREATMENT", 0, 16], ["629 nm", "OBSERVATION_MODIFIER", 65, 71], ["62-nm", "OBSERVATION_MODIFIER", 79, 84]]], ["A triple-pass dichroic mirror was used: 405/488/561 nm.", [["A triple-pass dichroic mirror", "TREATMENT", 0, 29]]], ["The microscope objective was a Plan-Apochromat 100\u00d7, 1.4 numerical aperture oil immersion objective.", [["Apochromat", "TREATMENT", 36, 46]]], ["Images were collected on a cooled (\u221270\u00b0C) EMCCD iXon3 897 camera (Andor Technology).GUV preparation ::: Materials and methodsGUVs were prepared according to published protocols (Angelova and Dimitrov, 1986).", [["Images", "TEST", 0, 6], ["methodsGUVs", "TREATMENT", 118, 129]]], ["For experiments with N-BAR and Amph-FL, the lipid mixture was 5 mol% PtdIns(4,5)P2, 15 mol% DOPS, 79.5 mol% DOPC, and 0.5 mol% Oregon Green 488\u2013DHPE.", [["N-BAR", "CHEMICAL", 21, 26], ["Amph-FL", "CHEMICAL", 31, 38], ["PtdIns", "CHEMICAL", 69, 75], ["DOPS", "CHEMICAL", 92, 96], ["DOPC", "CHEMICAL", 108, 112], ["PtdIns(4,5)P2", "CHEMICAL", 69, 82], ["DOPS", "CHEMICAL", 92, 96], ["DOPC", "CHEMICAL", 108, 112], ["Oregon Green 488", "CHEMICAL", 127, 143], ["N-BAR", "SIMPLE_CHEMICAL", 21, 26], ["Amph-FL", "SIMPLE_CHEMICAL", 31, 38], ["lipid", "SIMPLE_CHEMICAL", 44, 49], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 69, 82], ["DOPS", "SIMPLE_CHEMICAL", 92, 96], ["DOPC", "SIMPLE_CHEMICAL", 108, 112], ["Green 488\u2013DHPE", "SIMPLE_CHEMICAL", 134, 148], ["BAR", "PROTEIN", 23, 26], ["Amph", "PROTEIN", 31, 35], ["FL", "PROTEIN", 36, 38], ["Amph", "TEST", 31, 35], ["the lipid mixture", "TEST", 40, 57], ["PtdIns", "TEST", 69, 75], ["DOPC", "TEST", 108, 112]]], ["For experiments with 6his peptide, the lipid mixture was 20 mol% DOGS-NTA-Ni, 79.5 mol% DOPC, and 0.5 mol% Texas Red\u2013DHPE.", [["DOGS-NTA-Ni", "CHEMICAL", 65, 76], ["DOPC", "CHEMICAL", 88, 92], ["NTA", "CHEMICAL", 70, 73], ["Ni", "CHEMICAL", 74, 76], ["DOPC", "CHEMICAL", 88, 92], ["6his peptide", "SIMPLE_CHEMICAL", 21, 33], ["lipid", "SIMPLE_CHEMICAL", 39, 44], ["NTA-Ni", "SIMPLE_CHEMICAL", 70, 76], ["DOPC", "SIMPLE_CHEMICAL", 88, 92], ["Red\u2013DHPE", "SIMPLE_CHEMICAL", 113, 121], ["the lipid mixture", "TEST", 35, 52], ["NTA", "TEST", 70, 73], ["Ni", "TEST", 74, 76], ["DOPC", "TEST", 88, 92]]], ["Lipid mixtures were dried into a film on an indium-tin-oxide\u2013coated glass slide and further dried under vacuum overnight.", [["indium-tin", "CHEMICAL", 44, 54], ["indium", "CHEMICAL", 44, 50], ["tin", "CHEMICAL", 51, 54], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["Lipid mixtures", "TREATMENT", 0, 14], ["a film", "TEST", 31, 37], ["an indium-tin-oxide\u2013coated glass slide", "TREATMENT", 41, 79]]], ["Electroformation was performed at 55\u00b0C in 350 milliosmolar sucrose solution.", [["sucrose", "CHEMICAL", 59, 66], ["sucrose", "CHEMICAL", 59, 66], ["350 milliosmolar sucrose solution", "TREATMENT", 42, 75]]], ["Vesicles were mixed with protein solution at the specified concentration in 20 mM MOPS, pH 7.35, 150 mM NaCl, and 5 mM TCEP buffer.", [["Vesicles", "ANATOMY", 0, 8], ["NaCl", "CHEMICAL", 104, 108], ["MOPS", "CHEMICAL", 82, 86], ["NaCl", "CHEMICAL", 104, 108], ["TCEP", "CHEMICAL", 119, 123], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["protein solution", "TREATMENT", 25, 41], ["pH", "TEST", 88, 90], ["NaCl", "TEST", 104, 108], ["5 mM TCEP buffer", "TREATMENT", 114, 130]]], ["0.5 mM EGTA and EDTA were included in the buffer and sucrose solution when working with PtdIns(4,5)P2-containing vesicles to prevent clustering of PtdIns(4,5)P2.", [["vesicles", "ANATOMY", 113, 121], ["EGTA", "CHEMICAL", 7, 11], ["EDTA", "CHEMICAL", 16, 20], ["sucrose", "CHEMICAL", 53, 60], ["PtdIns(4,5)", "CHEMICAL", 88, 99], ["EGTA", "CHEMICAL", 7, 11], ["EDTA", "CHEMICAL", 16, 20], ["sucrose", "CHEMICAL", 53, 60], ["PtdIns(4,5)P2", "CHEMICAL", 88, 101], ["PtdIns(4,5)P2", "CHEMICAL", 147, 160], ["EGTA", "SIMPLE_CHEMICAL", 7, 11], ["EDTA", "SIMPLE_CHEMICAL", 16, 20], ["sucrose", "SIMPLE_CHEMICAL", 53, 60], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 88, 101], ["vesicles", "CELLULAR_COMPONENT", 113, 121], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 147, 160], ["PtdIns(4,5)P2", "PROTEIN", 147, 160], ["0.5 mM EGTA", "TREATMENT", 0, 11], ["EDTA", "TREATMENT", 16, 20], ["the buffer and sucrose solution", "TREATMENT", 38, 69], ["PtdIns(4,5)P2-containing vesicles", "TREATMENT", 88, 121], ["PtdIns", "PROBLEM", 147, 153], ["vesicles", "ANATOMY", 113, 121]]], ["Prior to mixing, the osmolarity of the GUV solution and experiment buffer was measured using a vapor pressure osmometer (Wescor).SUPER template preparation ::: Materials and methodsSUPER templates were prepared according to the protocol of Neumann et al. (2013).", [["the osmolarity of the GUV solution", "TREATMENT", 17, 51], ["experiment buffer", "TREATMENT", 56, 73], ["a vapor pressure osmometer", "TREATMENT", 93, 119], ["Materials and methodsSUPER templates", "TREATMENT", 160, 196]]], ["A lipid mixture of 5 mol% PtdIns(4,5)P2, 15 mol% DOPS, 1 mol% Texas Red DHPE, and 79 mol% DOPC was mixed in a clean glass test tube, the solvent was evaporated, and the lipid film was further dried under vacuum.", [["PtdIns", "CHEMICAL", 26, 32], ["DOPS", "CHEMICAL", 49, 53], ["DOPC", "CHEMICAL", 90, 94], ["PtdIns(4,5)P2", "CHEMICAL", 26, 39], ["DOPS", "CHEMICAL", 49, 53], ["Texas Red", "CHEMICAL", 62, 71], ["DOPC", "CHEMICAL", 90, 94], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 26, 39], ["DOPS", "SIMPLE_CHEMICAL", 49, 53], ["Texas Red DHPE", "SIMPLE_CHEMICAL", 62, 76], ["DOPC", "SIMPLE_CHEMICAL", 90, 94], ["A lipid mixture", "TREATMENT", 0, 15], ["Red DHPE", "TEST", 68, 76], ["DOPC", "TREATMENT", 90, 94], ["a clean glass test tube", "TREATMENT", 108, 131], ["the solvent", "TREATMENT", 133, 144], ["the lipid film", "TEST", 165, 179], ["vacuum", "TREATMENT", 204, 210], ["vacuum", "OBSERVATION", 204, 210]]], ["The lipid film was hydrated in Milli-Q water, subjected to three freeze-thaw cycles in liquid nitrogen, and extruded through a 100-nm pore filter (Whatman).", [["nitrogen", "CHEMICAL", 94, 102], ["lipid film", "SIMPLE_CHEMICAL", 4, 14], ["The lipid film", "TEST", 0, 14], ["liquid nitrogen", "TREATMENT", 87, 102], ["a 100-nm pore filter (Whatman", "TREATMENT", 125, 154], ["liquid nitrogen", "OBSERVATION", 87, 102]]], ["SUPER templates were made by creating a 100 \u00b5l mixture consisting of 200 \u00b5M liposomes, 1 M NaCl, and 5 \u00d7 106 of 2.5 \u00b5m m-type silica beads (Corpuscular) in a low-adhesion microcentrifuge tube.", [["NaCl", "CHEMICAL", 91, 95], ["NaCl", "CHEMICAL", 91, 95], ["silica", "CHEMICAL", 126, 132], ["liposomes", "SIMPLE_CHEMICAL", 76, 85], ["silica beads", "SIMPLE_CHEMICAL", 126, 138], ["tube", "TISSUE", 187, 191], ["2.5 \u00b5m m-type silica beads", "TREATMENT", 112, 138], ["a low-adhesion microcentrifuge tube", "TREATMENT", 156, 191], ["microcentrifuge tube", "OBSERVATION", 171, 191]]], ["The mixture was incubated for 30 min at room temperature and gently agitated periodically.", [["gently agitated", "PROBLEM", 61, 76]]], ["The mixture was washed by adding 1 ml Milli-Q water, gently mixing, and spinning at 300 g for 2 min in a swinging bucket rotor to pellet the SUPER templates.", [["a swinging bucket rotor", "TREATMENT", 103, 126]]], ["1 ml of supernatant was removed, SUPER templates were resuspended in the remaining 100 \u00b5l, and washing was repeated a total of four times.", [["supernatant", "ANATOMY", 8, 19], ["supernatant", "TREATMENT", 8, 19], ["SUPER templates", "TREATMENT", 33, 48]]], ["SUPER templates were kept on ice and used within 4 h.Measurement of SUPER template membrane release ::: Materials and methodsSUPER template membrane shedding experiments were performed according to the protocol of Neumann et al. (2013).", [["membrane", "ANATOMY", 83, 91], ["membrane", "ANATOMY", 140, 148], ["membrane", "CELLULAR_COMPONENT", 83, 91], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["SUPER templates", "DNA", 0, 15], ["ice", "TREATMENT", 29, 32], ["methodsSUPER template membrane shedding experiments", "TREATMENT", 118, 169]]], ["10 \u00b5l of SUPER templates were gently pipetted into the top of a 90 \u00b5l solution of protein at specified concentrations in 20 mM MOPS, pH 7.35, 150 mM NaCl, 0.5 mM EGTA and EDTA, and 5 mM TCEP buffer.", [["NaCl", "CHEMICAL", 149, 153], ["EGTA", "CHEMICAL", 162, 166], ["EDTA", "CHEMICAL", 171, 175], ["MOPS", "CHEMICAL", 127, 131], ["NaCl", "CHEMICAL", 149, 153], ["EGTA", "CHEMICAL", 162, 166], ["EDTA", "CHEMICAL", 171, 175], ["TCEP", "CHEMICAL", 186, 190], ["EGTA", "SIMPLE_CHEMICAL", 162, 166], ["EDTA", "SIMPLE_CHEMICAL", 171, 175], ["TCEP", "SIMPLE_CHEMICAL", 186, 190], ["SUPER templates", "DNA", 9, 24], ["SUPER templates", "TREATMENT", 9, 24], ["a 90 \u00b5l solution of protein", "TREATMENT", 62, 89], ["pH", "TEST", 133, 135], ["NaCl", "TEST", 149, 153], ["EGTA", "TEST", 162, 166], ["EDTA", "TEST", 171, 175], ["5 mM TCEP buffer", "TREATMENT", 181, 197]]], ["SUPER templates were allowed to slowly settle for 30 min at room temperature without being disturbed.", [["SUPER templates", "DNA", 0, 15]]], ["SUPER templates containing unreleased membrane were then sedimented by gentle centrifugation at 300 g for 2 min in a swinging bucket rotor.", [["membrane", "ANATOMY", 38, 46], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["SUPER templates", "DNA", 0, 15], ["unreleased membrane", "TREATMENT", 27, 46], ["gentle centrifugation", "TREATMENT", 71, 92], ["unreleased membrane", "OBSERVATION", 27, 46], ["sedimented", "OBSERVATION_MODIFIER", 57, 67]]], ["75 \u00b5l of supernatant containing released membrane was collected and mixed in a 96-well plate with Triton X-100 at a final concentration of 0.1% and volume of 100 \u00b5l.", [["supernatant", "ANATOMY", 9, 20], ["membrane", "ANATOMY", 41, 49], ["Triton X-100", "CHEMICAL", 98, 110], ["Triton X-100", "CHEMICAL", 98, 110], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["Triton X-100", "SIMPLE_CHEMICAL", 98, 110], ["supernatant containing released membrane", "PROBLEM", 9, 49], ["Triton X", "TREATMENT", 98, 106], ["volume", "TEST", 148, 154], ["membrane", "OBSERVATION_MODIFIER", 41, 49]]], ["To measure the total fluorescence of SUPER template membrane, a detergent control consisting of SUPER templates added directly to 0.1% Triton X-100, which solubilized all SUPER template membrane, was run.", [["membrane", "ANATOMY", 52, 60], ["membrane", "ANATOMY", 186, 194], ["Triton X-100", "CHEMICAL", 135, 147], ["Triton X-100", "CHEMICAL", 135, 147], ["SUPER", "SIMPLE_CHEMICAL", 37, 42], ["membrane", "CELLULAR_COMPONENT", 52, 60], ["SUPER", "SIMPLE_CHEMICAL", 96, 101], ["Triton X-100", "SIMPLE_CHEMICAL", 135, 147], ["membrane", "CELLULAR_COMPONENT", 186, 194], ["the total fluorescence of SUPER template membrane", "TREATMENT", 11, 60], ["a detergent control", "TREATMENT", 62, 81], ["SUPER templates", "TREATMENT", 96, 111]]], ["The fluorescence intensity of released membrane was measured in a plate reader using 590-nm excitation light and an emission filter centered at 620 nm.", [["membrane", "ANATOMY", 39, 47], ["membrane", "CELLULAR_COMPONENT", 39, 47], ["-nm excitation light", "TREATMENT", 88, 108], ["an emission filter", "TREATMENT", 113, 131], ["intensity", "OBSERVATION_MODIFIER", 17, 26], ["released membrane", "OBSERVATION", 30, 47], ["emission filter", "OBSERVATION", 116, 131], ["620 nm", "OBSERVATION_MODIFIER", 144, 150]]], ["After subtracting the fluorescence of 0.1% Triton X-100 in buffer alone from all measurements, membrane release was calculated by dividing the fluorescence intensity after protein exposure by the fluorescence intensity of the detergent control.", [["membrane", "ANATOMY", 95, 103], ["Triton X-100", "CHEMICAL", 43, 55], ["Triton X-100", "CHEMICAL", 43, 55], ["Triton X-100", "SIMPLE_CHEMICAL", 43, 55], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["the fluorescence", "TEST", 18, 34], ["0.1% Triton", "TREATMENT", 38, 49], ["the detergent control", "TREATMENT", 222, 243]]], ["The background level of membrane release in the absence of protein was also measured by incubating SUPER templates in buffer alone.", [["membrane", "ANATOMY", 24, 32], ["membrane", "CELLULAR_COMPONENT", 24, 32], ["membrane release", "PROBLEM", 24, 40]]], ["This buffer control was subtracted from all measurements as background.FCS ::: Materials and methodsImaging wells for FCS used supported lipid bilayers to passivate the glass surface and prevent protein adsorption.", [["lipid bilayers", "ANATOMY", 137, 151], ["lipid bilayers", "SIMPLE_CHEMICAL", 137, 151], ["This buffer control", "TREATMENT", 0, 19], ["methodsImaging wells", "TEST", 93, 113], ["FCS", "TEST", 118, 121], ["lipid bilayers", "TREATMENT", 137, 151], ["the glass surface", "TREATMENT", 165, 182], ["protein adsorption", "PROBLEM", 195, 213], ["protein adsorption", "OBSERVATION", 195, 213]]], ["Briefly, a well was created with a silicone gasket on an ultraclean coverslip, and a solution of sonicated DOPC vesicles at 1 mM lipid was added.", [["vesicles", "ANATOMY", 112, 120], ["DOPC", "CHEMICAL", 107, 111], ["DOPC", "CHEMICAL", 107, 111], ["DOPC vesicles", "SIMPLE_CHEMICAL", 107, 120], ["lipid", "SIMPLE_CHEMICAL", 129, 134], ["a silicone gasket", "TREATMENT", 33, 50], ["an ultraclean coverslip", "TREATMENT", 54, 77], ["a solution of sonicated DOPC vesicles", "TREATMENT", 83, 120]]], ["The supported lipid bilayer was formed for 10 min and thoroughly washed in experiment buffer of 50 mM Tris, pH 8.0, 10 mM CaCl2, 150 mm NaCl, 15 mM EGTA, 5 mM EDTA, and 5 mM TCEP.", [["lipid bilayer", "ANATOMY", 14, 27], ["CaCl2", "CHEMICAL", 122, 127], ["NaCl", "CHEMICAL", 136, 140], ["EGTA", "CHEMICAL", 148, 152], ["Tris", "CHEMICAL", 102, 106], ["CaCl2", "CHEMICAL", 122, 127], ["NaCl", "CHEMICAL", 136, 140], ["EGTA", "CHEMICAL", 148, 152], ["EDTA", "CHEMICAL", 159, 163], ["TCEP", "CHEMICAL", 174, 178], ["lipid bilayer", "SIMPLE_CHEMICAL", 14, 27], ["EGTA", "SIMPLE_CHEMICAL", 148, 152], ["EDTA", "SIMPLE_CHEMICAL", 159, 163], ["TCEP", "SIMPLE_CHEMICAL", 174, 178], ["The supported lipid bilayer", "TREATMENT", 0, 27], ["Tris", "TEST", 102, 106], ["pH", "TEST", 108, 110], ["CaCl2", "TEST", 122, 127], ["NaCl", "TEST", 136, 140], ["EGTA", "TEST", 148, 152], ["5 mM EDTA", "TREATMENT", 154, 163], ["5 mM TCEP", "TREATMENT", 169, 178], ["lipid bilayer", "OBSERVATION", 14, 27]]], ["Atto 488\u2013labeled proteins were diluted in experiment buffer and added to the imaging well such that the concentration of Atto 488 dye was \u223c1 nM.", [["Atto 488 dye", "CHEMICAL", 121, 133], ["Atto 488", "CHEMICAL", 121, 129], ["Atto 488 dye", "SIMPLE_CHEMICAL", 121, 133], ["Atto 488\u2013labeled proteins", "PROTEIN", 0, 25], ["the imaging", "TEST", 73, 84]]], ["FCS measurements were acquired on a custom-built time-correlated single photon counting confocal microscope using a 486-nm ps pulsed diode laser.", [["FCS measurements", "TEST", 0, 16], ["a 486-nm ps pulsed diode laser", "TREATMENT", 114, 144]]], ["The laser was focused in solution \u223c3 \u00b5m above the bilayer passivation surface, and fluorescence signal was collected as proteins diffused through the focused laser volume.", [["The laser", "TREATMENT", 0, 9], ["the bilayer passivation surface", "TREATMENT", 46, 77], ["fluorescence signal", "TEST", 83, 102], ["laser", "OBSERVATION_MODIFIER", 4, 9], ["bilayer", "OBSERVATION_MODIFIER", 50, 57], ["passivation", "OBSERVATION_MODIFIER", 58, 69], ["surface", "OBSERVATION_MODIFIER", 70, 77], ["laser", "OBSERVATION_MODIFIER", 158, 163], ["volume", "OBSERVATION_MODIFIER", 164, 170]]], ["The signal was split onto separate GaAsP photomultiplier tubes (Hamamatsu) for cross-correlation using Becker and Hickl software.", [["GaAsP photomultiplier tubes", "DNA", 35, 62], ["separate GaAsP photomultiplier tubes", "TREATMENT", 26, 62], ["photomultiplier tubes", "OBSERVATION", 41, 62]]], ["FCS traces were collected for 120 s.", [["FCS traces", "TEST", 0, 10]]], ["The number of FCS traces acquired for Amph CTD \u0394SH3, AP180 CTD, and transferrin were 10, 5, and 3, respectively.", [["Amph CTD \u0394SH3", "GENE_OR_GENE_PRODUCT", 38, 51], ["AP180 CTD", "GENE_OR_GENE_PRODUCT", 53, 62], ["transferrin", "GENE_OR_GENE_PRODUCT", 68, 79], ["Amph CTD", "PROTEIN", 38, 46], ["\u0394SH3", "PROTEIN", 47, 51], ["AP180 CTD", "PROTEIN", 53, 62], ["transferrin", "PROTEIN", 68, 79], ["FCS traces", "TEST", 14, 24], ["Amph CTD \u0394SH3", "TEST", 38, 51], ["CTD", "TEST", 59, 62], ["transferrin", "TEST", 68, 79]]], ["Each FCS trace was fit with the 2D autocorrelation function:G(t)=(1+ae\u2212t\u03c4c)*(C1+(t\u03c4D)\u03b1)+1,where C is 1/Np, Np is the number of labeled proteins in the focused laser volume, \u03c4D is the diffusion time, and \u03b1 is the anomalous diffusion coefficient. a and \u03c4c, which correct for short time processes such as intersystem crossing, were held constant in the fitting as 0.05 and 5 \u00b5s, respectively (Houser et al., 2016).", [["C1", "PROTEIN", 77, 79], ["labeled proteins", "PROTEIN", 127, 143], ["\u03b1", "PROTEIN", 203, 204], ["the 2D autocorrelation function", "TEST", 28, 59], ["G", "TEST", 60, 61], ["ae\u2212", "TEST", 68, 71], ["C1", "TEST", 77, 79], ["Np", "TEST", 103, 105], ["Np", "TEST", 107, 109], ["labeled proteins", "TEST", 127, 143], ["laser volume", "TEST", 159, 171], ["the diffusion time", "TEST", 179, 197], ["the anomalous diffusion coefficient", "PROBLEM", 208, 243], ["short time processes", "PROBLEM", 273, 293], ["intersystem crossing", "TREATMENT", 302, 322], ["anomalous", "OBSERVATION_MODIFIER", 212, 221], ["diffusion coefficient", "OBSERVATION", 222, 243]]], ["Fitting was performed in Wolfram Mathematica 11 software. \u03b1 values were between 0.90 and 0.93 for all fits, demonstrating that a substantial correction for anomalous diffusion was not needed.FCS ::: Materials and methodsFig.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 58, 59], ["values", "TEST", 60, 66], ["anomalous diffusion", "PROBLEM", 156, 175]]], ["S2, E\u2013G, shows representative FCS traces and fits for Amph CTD \u0394SH3, AP180 CTD, and transferrin, with mean values of \u03c4D \u00b1 first SD reported next to each trace.", [["S2", "GENE_OR_GENE_PRODUCT", 0, 2], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 54, 62], ["AP180 CTD", "GENE_OR_GENE_PRODUCT", 69, 78], ["transferrin", "GENE_OR_GENE_PRODUCT", 84, 95], ["S2", "PROTEIN", 0, 2], ["E\u2013G", "PROTEIN", 4, 7], ["Amph CTD", "PROTEIN", 54, 62], ["\u0394SH3", "PROTEIN", 63, 67], ["AP180 CTD", "PROTEIN", 69, 78], ["transferrin", "PROTEIN", 84, 95], ["E\u2013G", "TEST", 4, 7], ["representative FCS traces", "PROBLEM", 15, 40], ["Amph CTD \u0394SH3", "TEST", 54, 67], ["CTD", "TEST", 75, 78], ["transferrin", "TEST", 84, 95], ["mean values", "TEST", 102, 113], ["E\u2013G", "ANATOMY", 4, 7]]], ["The hydrodynamic radius, RH, of each protein is also reported next to each trace.", [["hydrodynamic radius", "OBSERVATION", 4, 23]]], ["AP180 CTD was used as a calibration standard to compute RH of Amph CTD \u0394SH3, as \u03c4D is directly proportional to RH.", [["AP180 CTD", "PROTEIN", 0, 9], ["Amph CTD \u0394SH3", "PROTEIN", 62, 75], ["\u03c4D", "PROTEIN", 80, 82], ["a calibration standard", "TREATMENT", 22, 44]]], ["AP180 CTD is a disordered protein with a radius that has been well-characterized (Kalthoff et al., 2002; Busch et al., 2015), making it an appropriate calibration standard.", [["AP180", "CHEMICAL", 0, 5], ["AP180", "GENE_OR_GENE_PRODUCT", 0, 5], ["AP180 CTD", "PROTEIN", 0, 9], ["a disordered protein", "PROBLEM", 13, 33], ["radius", "ANATOMY", 41, 47], ["well-characterized", "OBSERVATION_MODIFIER", 62, 80]]], ["This calibration approach also yielded a radius for transferrin that was consistent with its expected radius (Hall et al., 2002), confirming the validity of our approach.", [["transferrin", "GENE_OR_GENE_PRODUCT", 52, 63], ["transferrin", "PROTEIN", 52, 63], ["This calibration approach", "TREATMENT", 0, 25], ["a radius for transferrin", "TREATMENT", 39, 63], ["consistent with", "UNCERTAINTY", 73, 88]]], ["The radius of Amph CTD \u0394SH3 was taken as 5 nm in estimates of membrane coverage by proteins in Figs.", [["membrane", "ANATOMY", 62, 70], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 14, 22], ["membrane", "CELLULAR_COMPONENT", 62, 70], ["Amph CTD \u0394SH3", "PROTEIN", 14, 27], ["Amph CTD \u0394SH3", "TREATMENT", 14, 27], ["membrane coverage", "TREATMENT", 62, 79], ["radius", "OBSERVATION_MODIFIER", 4, 10], ["Amph CTD", "OBSERVATION", 14, 22], ["membrane coverage", "OBSERVATION", 62, 79]]], ["2 H and 3 D. This value was chosen based on previous studies, which found that the radius of gyration of a disordered protein is \u223c1.2-fold greater than the hydrodynamic radius (Sherman and Haran, 2006; Hofmann et al., 2012).FCS ::: Materials and methodsFig.", [["disordered protein", "PROTEIN", 107, 125], ["previous studies", "TEST", 44, 60], ["a disordered protein", "PROBLEM", 105, 125], ["radius", "OBSERVATION_MODIFIER", 83, 89], ["gyration", "OBSERVATION", 93, 101], ["hydrodynamic radius", "OBSERVATION", 156, 175]]], ["S2 H shows the relative diffusion time, \u03c4D, of Amph CTD \u0394SH3 in 20 mM MOPS, pH 7.35, in varying concentrations of NaCl.", [["NaCl", "CHEMICAL", 114, 118], ["MOPS", "CHEMICAL", 70, 74], ["NaCl", "CHEMICAL", 114, 118], ["S2 H", "PROTEIN", 0, 4], ["Amph CTD \u0394SH3", "PROTEIN", 47, 60], ["Amph CTD \u0394SH3", "TEST", 47, 60], ["mM MOPS", "TEST", 67, 74], ["pH", "TEST", 76, 78], ["NaCl", "TREATMENT", 114, 118]]], ["Data are plotted as the relative diffusion time compared with the diffusion time at 150 mM NaCl.", [["NaCl", "CHEMICAL", 91, 95], ["NaCl", "CHEMICAL", 91, 95]]], ["Diffusion times were corrected for changes in solution viscosity with changing NaCl concentration (Zhang and Han, 1996).", [["NaCl", "CHEMICAL", 79, 83], ["NaCl", "CHEMICAL", 79, 83], ["NaCl", "SIMPLE_CHEMICAL", 79, 83], ["Diffusion times", "TEST", 0, 15], ["changes in solution viscosity", "TREATMENT", 35, 64], ["changing NaCl concentration", "TREATMENT", 70, 97]]], ["Because \u03c4D is directly proportional to RH, the increase in \u03c4D at 10 mM NaCl indicates an increase in RH, likely owing to reduced charge screening, which expands and extends the disordered protein (Srinivasan et al., 2014).", [["NaCl", "CHEMICAL", 71, 75], ["NaCl", "CHEMICAL", 71, 75], ["\u03c4D", "GENE_OR_GENE_PRODUCT", 8, 10], ["\u03c4D", "PROTEIN", 8, 10], ["the increase in \u03c4D at 10 mM NaCl", "TREATMENT", 43, 75], ["an increase in RH", "PROBLEM", 86, 103], ["reduced charge screening", "PROBLEM", 121, 145], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["increase", "OBSERVATION_MODIFIER", 89, 97]]], ["Similarly, the decrease in \u03c4D at 1 M NaCl indicates a decrease in RH, owing to enhanced charge screening, which compacts the disordered protein.Passivating glass coverslips with PEG and PEG-biotin for tethering vesicles ::: Materials and methodsGlass coverslips were passivated by either directly conjugating PEG-silane and biotin-PEG-silane to the glass, or by coating the glass with a layer of PLL conjugated to PEG and biotin-PEG.", [["vesicles", "ANATOMY", 211, 219], ["NaCl", "CHEMICAL", 37, 41], ["PEG", "CHEMICAL", 178, 181], ["PEG-biotin", "CHEMICAL", 186, 196], ["PEG-silane", "CHEMICAL", 309, 319], ["biotin-PEG-silane", "CHEMICAL", 324, 341], ["PLL", "CHEMICAL", 396, 399], ["PEG", "CHEMICAL", 414, 417], ["biotin-PEG", "CHEMICAL", 422, 432], ["NaCl", "CHEMICAL", 37, 41], ["PEG", "CHEMICAL", 178, 181], ["PEG", "CHEMICAL", 186, 189], ["biotin", "CHEMICAL", 190, 196], ["PEG", "CHEMICAL", 309, 312], ["silane", "CHEMICAL", 313, 319], ["biotin", "CHEMICAL", 324, 330], ["PEG", "CHEMICAL", 331, 334], ["silane", "CHEMICAL", 335, 341], ["PLL", "CHEMICAL", 396, 399], ["PEG", "CHEMICAL", 414, 417], ["biotin", "CHEMICAL", 422, 428], ["PEG", "CHEMICAL", 429, 432], ["PEG", "SIMPLE_CHEMICAL", 178, 181], ["PEG-biotin", "SIMPLE_CHEMICAL", 186, 196], ["vesicles", "CELLULAR_COMPONENT", 211, 219], ["PEG-silane", "SIMPLE_CHEMICAL", 309, 319], ["biotin-PEG-silane", "SIMPLE_CHEMICAL", 324, 341], ["PLL", "SIMPLE_CHEMICAL", 396, 399], ["PEG", "SIMPLE_CHEMICAL", 414, 417], ["biotin-PEG", "SIMPLE_CHEMICAL", 422, 432], ["disordered protein", "PROTEIN", 125, 143], ["a decrease in RH", "PROBLEM", 52, 68], ["enhanced charge screening", "TEST", 79, 104], ["the disordered protein", "PROBLEM", 121, 143], ["Passivating glass coverslips", "TREATMENT", 144, 172], ["PEG", "TREATMENT", 178, 181], ["PEG", "TREATMENT", 186, 189], ["Glass coverslips", "TREATMENT", 245, 261], ["directly conjugating PEG-silane and biotin-PEG-silane to the glass", "TREATMENT", 288, 354], ["a layer of PLL conjugated", "TREATMENT", 385, 410], ["PEG", "TREATMENT", 414, 417], ["biotin", "TREATMENT", 422, 428], ["PEG", "TREATMENT", 429, 432], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["decrease", "OBSERVATION_MODIFIER", 54, 62], ["glass coverslips", "OBSERVATION", 156, 172], ["vesicles", "ANATOMY", 211, 219], ["PEG", "OBSERVATION", 429, 432]]], ["For the direct silane conjugation, a 0.67% solution of PEG-silane was prepared in anhydrous isopropanol.", [["silane", "CHEMICAL", 15, 21], ["PEG-silane", "CHEMICAL", 55, 65], ["anhydrous isopropanol", "CHEMICAL", 82, 103], ["silane", "CHEMICAL", 15, 21], ["PEG-silane", "CHEMICAL", 55, 65], ["anhydrous isopropanol", "CHEMICAL", 82, 103], ["silane", "SIMPLE_CHEMICAL", 15, 21], ["PEG-silane", "SIMPLE_CHEMICAL", 55, 65], ["anhydrous isopropanol", "SIMPLE_CHEMICAL", 82, 103], ["the direct silane conjugation", "TREATMENT", 4, 33], ["a 0.67% solution of PEG-silane", "TREATMENT", 35, 65], ["anhydrous isopropanol", "TREATMENT", 82, 103]]], ["Biotin-PEG-silane comprised 5% of the total amount of PEG-silane in the solution.", [["Biotin-PEG-silane", "CHEMICAL", 0, 17], ["PEG-silane", "CHEMICAL", 54, 64], ["Biotin", "CHEMICAL", 0, 6], ["PEG", "CHEMICAL", 7, 10], ["silane", "CHEMICAL", 11, 17], ["PEG-silane", "CHEMICAL", 54, 64], ["Biotin", "SIMPLE_CHEMICAL", 0, 6], ["PEG-silane", "SIMPLE_CHEMICAL", 7, 17], ["PEG-silane", "SIMPLE_CHEMICAL", 54, 64], ["Biotin-PEG-silane", "TREATMENT", 0, 17], ["the total amount of PEG-silane in the solution", "TREATMENT", 34, 80]]], ["The mixture was held in a bath sonicator for 10\u201315 min to dissolve the PEG.", [["PEG", "CHEMICAL", 71, 74], ["PEG", "CHEMICAL", 71, 74], ["PEG", "SIMPLE_CHEMICAL", 71, 74], ["The mixture", "TREATMENT", 0, 11], ["a bath sonicator", "TREATMENT", 24, 40], ["the PEG", "TREATMENT", 67, 74], ["PEG", "OBSERVATION", 71, 74]]], ["Acetic acid was added to a concentration of 1%, and 50 \u00b5l of the reactive mixture was dropped onto a dry, ultraclean coverslip.", [["Acetic acid", "CHEMICAL", 0, 11], ["Acetic acid", "CHEMICAL", 0, 11], ["Acetic acid", "SIMPLE_CHEMICAL", 0, 11], ["Acetic acid", "TREATMENT", 0, 11], ["the reactive mixture", "PROBLEM", 61, 81], ["ultraclean coverslip", "TREATMENT", 106, 126], ["reactive", "OBSERVATION_MODIFIER", 65, 73]]], ["Another dry, ultraclean coverslip was sandwiched on top, and the slides were incubated at 70\u00b0C for 30\u201360 min.", [["ultraclean coverslip", "TREATMENT", 13, 33], ["dry", "OBSERVATION", 8, 11]]], ["Imaging wells were made by placing silicone gaskets onto the glass and hydrating in 20 mM MOPS, pH 7.35, and 150 mM NaCl buffer.", [["NaCl", "CHEMICAL", 116, 120], ["MOPS", "CHEMICAL", 90, 94], ["NaCl", "CHEMICAL", 116, 120], ["Imaging wells", "TEST", 0, 13], ["silicone gaskets onto the glass", "TREATMENT", 35, 66], ["hydrating in 20 mM MOPS", "TREATMENT", 71, 94], ["pH", "TEST", 96, 98], ["150 mM NaCl buffer", "TREATMENT", 109, 127]]], ["Neutravidin was added to the well at a final concentration of 0.2 mg ml\u22121 and incubated for 10 min, and the well was washed repeatedly with MOPS buffer before adding vesicles.Passivating glass coverslips with PEG and PEG-biotin for tethering vesicles ::: Materials and methodsThe biotinylated PLL-PEG was made according to a previous protocol (Ruiz-Taylor et al., 2001).", [["vesicles", "ANATOMY", 166, 174], ["vesicles", "ANATOMY", 242, 250], ["Neutravidin", "CHEMICAL", 0, 11], ["PEG", "CHEMICAL", 209, 212], ["PEG-biotin", "CHEMICAL", 217, 227], ["PLL-PEG", "CHEMICAL", 293, 300], ["Neutravidin", "CHEMICAL", 0, 11], ["MOPS", "CHEMICAL", 140, 144], ["PEG", "CHEMICAL", 209, 212], ["PEG", "CHEMICAL", 217, 220], ["biotin", "CHEMICAL", 221, 227], ["PLL", "CHEMICAL", 293, 296], ["PEG", "CHEMICAL", 297, 300], ["Neutravidin", "SIMPLE_CHEMICAL", 0, 11], ["vesicles", "CELLULAR_COMPONENT", 166, 174], ["PEG", "SIMPLE_CHEMICAL", 209, 212], ["PEG-biotin", "SIMPLE_CHEMICAL", 217, 227], ["vesicles", "CELLULAR_COMPONENT", 242, 250], ["PLL-PEG", "SIMPLE_CHEMICAL", 293, 300], ["Neutravidin", "TREATMENT", 0, 11], ["MOPS buffer", "TREATMENT", 140, 151], ["Passivating glass coverslips", "TREATMENT", 175, 203], ["PEG", "TREATMENT", 209, 212], ["PEG", "TREATMENT", 217, 220], ["The biotinylated PLL-PEG", "TREATMENT", 276, 300], ["a previous protocol", "TEST", 323, 342], ["vesicles", "ANATOMY", 166, 174], ["glass coverslips", "OBSERVATION", 187, 203], ["vesicles", "ANATOMY", 242, 250], ["PEG", "OBSERVATION", 297, 300]]], ["Briefly, amine-reactive PEG-SVA and biotin-PEG-SVA was added to a 40 mg ml\u22121 mixture of PLL in 50 mM sodium tetraborate, pH 8.5, at a molar ratio of one PEG per five lysine subunits.", [["amine", "CHEMICAL", 9, 14], ["PEG-SVA", "CHEMICAL", 24, 31], ["biotin-PEG-SVA", "CHEMICAL", 36, 50], ["PLL", "CHEMICAL", 88, 91], ["sodium tetraborate", "CHEMICAL", 101, 119], ["PEG", "CHEMICAL", 153, 156], ["amine", "CHEMICAL", 9, 14], ["PEG-SVA", "CHEMICAL", 24, 31], ["biotin", "CHEMICAL", 36, 42], ["PEG-SVA", "CHEMICAL", 43, 50], ["PLL", "CHEMICAL", 88, 91], ["sodium tetraborate", "CHEMICAL", 101, 119], ["PEG", "CHEMICAL", 153, 156], ["lysine", "CHEMICAL", 166, 172], ["amine-reactive PEG-SVA", "SIMPLE_CHEMICAL", 9, 31], ["biotin-PEG-SVA", "SIMPLE_CHEMICAL", 36, 50], ["PLL", "SIMPLE_CHEMICAL", 88, 91], ["sodium tetraborate", "SIMPLE_CHEMICAL", 101, 119], ["reactive PEG", "TREATMENT", 15, 27], ["SVA", "PROBLEM", 28, 31], ["biotin", "TREATMENT", 36, 42], ["PEG", "TREATMENT", 43, 46], ["SVA", "TREATMENT", 47, 50], ["a 40 mg ml\u22121 mixture of PLL", "TREATMENT", 64, 91], ["sodium tetraborate", "TEST", 101, 119], ["pH", "TEST", 121, 123], ["a molar ratio", "TEST", 132, 145], ["one PEG", "TREATMENT", 149, 156], ["five lysine subunits", "TREATMENT", 161, 181], ["reactive PEG", "OBSERVATION", 15, 27], ["lysine subunits", "OBSERVATION", 166, 181]]], ["PEG-biotin comprised 2% of the total PEG amount.", [["PEG-biotin", "CHEMICAL", 0, 10], ["PEG", "CHEMICAL", 37, 40], ["PEG-biotin", "CHEMICAL", 0, 10], ["PEG", "CHEMICAL", 37, 40], ["PEG-biotin", "SIMPLE_CHEMICAL", 0, 10], ["PEG", "SIMPLE_CHEMICAL", 37, 40], ["PEG", "TREATMENT", 0, 3], ["biotin", "TREATMENT", 4, 10], ["the total PEG amount", "TREATMENT", 27, 47], ["total", "OBSERVATION_MODIFIER", 31, 36], ["PEG amount", "OBSERVATION", 37, 47]]], ["The mixture was stirred continuously for 6 h at room temperature and buffer exchanged into PBS using Centri-Spin size exclusion columns (Princeton Separations).", [["buffer exchanged into PBS", "TREATMENT", 69, 94], ["Centri-Spin size exclusion columns (Princeton Separations", "TREATMENT", 101, 158]]], ["Imaging wells were made by placing silicone gaskets onto ultraclean coverslips.", [["Imaging wells", "TEST", 0, 13], ["silicone gaskets onto ultraclean coverslips", "TREATMENT", 35, 78]]], ["Wells were coated for 20\u201330 min with biotinylated PLL-PEG diluted tenfold in 20 mM MOPS, pH 7.35, and 150 mM NaCl buffer.", [["PLL-PEG", "CHEMICAL", 50, 57], ["NaCl", "CHEMICAL", 109, 113], ["PLL", "CHEMICAL", 50, 53], ["PEG", "CHEMICAL", 54, 57], ["MOPS", "CHEMICAL", 83, 87], ["NaCl", "CHEMICAL", 109, 113], ["PLL-PEG", "SIMPLE_CHEMICAL", 50, 57], ["biotinylated PLL-PEG diluted tenfold", "TREATMENT", 37, 73], ["pH", "TEST", 89, 91], ["150 mM NaCl buffer", "TREATMENT", 102, 120]]], ["After coating, the well was washed repeatedly with MOPS buffer to wash out excess PLL-PEG.", [["PLL-PEG", "CHEMICAL", 82, 89], ["MOPS", "CHEMICAL", 51, 55], ["PLL", "CHEMICAL", 82, 85], ["PEG", "CHEMICAL", 86, 89], ["PLL-PEG", "SIMPLE_CHEMICAL", 82, 89], ["MOPS buffer", "TREATMENT", 51, 62], ["excess PLL-PEG", "TREATMENT", 75, 89], ["PEG", "OBSERVATION", 86, 89]]], ["Neutravidin was added to the well following the same process as for PEG-silane slides.Determination of vesicle diameter from measurements of tethered vesicle brightness ::: Materials and methodsVesicle diameter distributions were measured using an assay developed by the Stamou group (Stamou et al., 2003; Kunding et al., 2008; Hatzakis et al., 2009).", [["vesicle", "ANATOMY", 103, 110], ["vesicle", "ANATOMY", 150, 157], ["Vesicle", "ANATOMY", 194, 201], ["Neutravidin", "CHEMICAL", 0, 11], ["PEG-silane", "CHEMICAL", 68, 78], ["Neutravidin", "CHEMICAL", 0, 11], ["PEG", "CHEMICAL", 68, 71], ["silane", "CHEMICAL", 72, 78], ["Neutravidin", "SIMPLE_CHEMICAL", 0, 11], ["PEG-silane slides", "SIMPLE_CHEMICAL", 68, 85], ["vesicle", "CELLULAR_COMPONENT", 103, 110], ["vesicle", "CELLULAR_COMPONENT", 150, 157], ["Vesicle", "MULTI-TISSUE_STRUCTURE", 194, 201], ["Neutravidin", "TREATMENT", 0, 11], ["PEG-silane slides", "TREATMENT", 68, 85], ["Vesicle diameter distributions", "PROBLEM", 194, 224], ["an assay", "TEST", 245, 253], ["vesicle diameter", "OBSERVATION", 103, 119], ["vesicle brightness", "OBSERVATION", 150, 168], ["diameter", "OBSERVATION_MODIFIER", 202, 210]]], ["Vesicles in experiments with Amph-FL, N-BAR, N-BAR\u2013epsin CTD, I-BAR\u2013AP180 CTD, FCHo1-FL, and F-BAR were composed of 76 mol% DOPC, 15 mol% DOPS, 5 mol% PtdIns(4,5)P2, 2 mol% DP-EG10-biotin, and 2 mol% Oregon Green 488\u2013DHPE.", [["Vesicles", "ANATOMY", 0, 8], ["DOPC", "CHEMICAL", 124, 128], ["DOPS", "CHEMICAL", 138, 142], ["PtdIns", "CHEMICAL", 151, 157], ["DP-EG10-biotin", "CHEMICAL", 173, 187], ["DOPC", "CHEMICAL", 124, 128], ["DOPS", "CHEMICAL", 138, 142], ["PtdIns(4,5)P2", "CHEMICAL", 151, 164], ["DP-EG10-biotin", "CHEMICAL", 173, 187], ["Oregon Green 488", "CHEMICAL", 200, 216], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 29, 36], ["N-BAR", "SIMPLE_CHEMICAL", 38, 43], ["N-BAR\u2013epsin CTD", "SIMPLE_CHEMICAL", 45, 60], ["I-BAR", "SIMPLE_CHEMICAL", 62, 67], ["FCHo1-FL", "SIMPLE_CHEMICAL", 79, 87], ["F-BAR", "SIMPLE_CHEMICAL", 93, 98], ["DOPC", "SIMPLE_CHEMICAL", 124, 128], ["DOPS", "SIMPLE_CHEMICAL", 138, 142], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 151, 164], ["DP-EG10-biotin", "SIMPLE_CHEMICAL", 173, 187], ["Oregon Green 488\u2013DHPE", "SIMPLE_CHEMICAL", 200, 221], ["Amph", "PROTEIN", 29, 33], ["FL", "PROTEIN", 34, 36], ["N", "PROTEIN", 38, 39], ["BAR", "PROTEIN", 40, 43], ["N-BAR\u2013epsin CTD", "PROTEIN", 45, 60], ["I", "PROTEIN", 62, 63], ["BAR", "PROTEIN", 64, 67], ["AP180", "PROTEIN", 68, 73], ["CTD", "PROTEIN", 74, 77], ["FCHo1", "PROTEIN", 79, 84], ["FL", "PROTEIN", 85, 87], ["F", "PROTEIN", 93, 94], ["BAR", "PROTEIN", 95, 98], ["Amph", "TEST", 29, 33], ["CTD", "TEST", 74, 77], ["FCHo1", "TEST", 79, 84], ["DOPC", "TEST", 124, 128], ["DOPS", "TEST", 138, 142], ["PtdIns", "TEST", 151, 157], ["P2", "TEST", 162, 164], ["DP", "TEST", 173, 175], ["EG10", "TEST", 176, 180], ["biotin", "TEST", 181, 187]]], ["Vesicles in experiments with Amph CTD \u0394SH3 were composed of a similar lipid mixture, with the exception that DOPS and PtdIns(4,5)P2 were replaced with 20 mol% DOGS-NTA-Ni.", [["Vesicles", "ANATOMY", 0, 8], ["DOPS", "CHEMICAL", 109, 113], ["PtdIns", "CHEMICAL", 118, 124], ["DOGS-NTA", "CHEMICAL", 159, 167], ["DOPS", "CHEMICAL", 109, 113], ["PtdIns(4,5)P2", "CHEMICAL", 118, 131], ["NTA", "CHEMICAL", 164, 167], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 29, 37], ["DOPS", "SIMPLE_CHEMICAL", 109, 113], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 118, 131], ["DOGS-NTA", "SIMPLE_CHEMICAL", 159, 167], ["Amph CTD \u0394SH3", "PROTEIN", 29, 42], ["Amph CTD \u0394SH3", "TREATMENT", 29, 42], ["a similar lipid mixture", "TREATMENT", 60, 83], ["PtdIns", "TEST", 118, 124], ["Amph CTD", "OBSERVATION", 29, 37]]], ["Experiments with Amph-FL and N-BAR on highly charged membranes (Fig. S3) used vesicles composed of 68 mol% DOPS, 23 mol% DOPE, 5 mol% cholesterol, 2 mol% DP-EG10-biotin, and 2 mol% Oregon Green 488\u2013DHPE, similar to Mim et al. (2012).", [["membranes", "ANATOMY", 53, 62], ["vesicles", "ANATOMY", 78, 86], ["Amph-FL", "CHEMICAL", 17, 24], ["N-BAR", "CHEMICAL", 29, 34], ["DOPS", "CHEMICAL", 107, 111], ["DOPE", "CHEMICAL", 121, 125], ["cholesterol", "CHEMICAL", 134, 145], ["DP-EG10-biotin", "CHEMICAL", 154, 168], ["DOPS", "CHEMICAL", 107, 111], ["DOPE", "CHEMICAL", 121, 125], ["cholesterol", "CHEMICAL", 134, 145], ["DP-EG10-biotin", "CHEMICAL", 154, 168], ["Oregon Green 488", "CHEMICAL", 181, 197], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 17, 24], ["N-BAR", "SIMPLE_CHEMICAL", 29, 34], ["membranes", "CELLULAR_COMPONENT", 53, 62], ["vesicles", "CELLULAR_COMPONENT", 78, 86], ["DOPS", "SIMPLE_CHEMICAL", 107, 111], ["DOPE", "SIMPLE_CHEMICAL", 121, 125], ["cholesterol", "SIMPLE_CHEMICAL", 134, 145], ["DP-EG10-biotin", "SIMPLE_CHEMICAL", 154, 168], ["Oregon Green 488\u2013DHPE", "SIMPLE_CHEMICAL", 181, 202], ["Amph", "PROTEIN", 17, 21], ["FL", "PROTEIN", 22, 24], ["N", "PROTEIN", 29, 30], ["BAR", "PROTEIN", 31, 34], ["Amph", "TEST", 17, 21], ["vesicles", "TEST", 78, 86], ["DOPS", "TEST", 107, 111], ["DOPE", "TEST", 121, 125], ["cholesterol", "TEST", 134, 145], ["DP", "TEST", 154, 156], ["EG10", "TEST", 157, 161], ["biotin", "TEST", 162, 168], ["charged membranes", "OBSERVATION", 45, 62]]], ["Dried lipid films were hydrated in 20 mM MOPS, pH 7.35, and 150 mM NaCl buffer (0.5 mM EGTA and EDTA were included in experiments with PtdIns(4,5)P2) and extruded to 200 nm.Determination of vesicle diameter from measurements of tethered vesicle brightness ::: Materials and methodsFission experiments were performed by mixing vesicles at a concentration of 10 \u00b5M with unlabeled protein at specified concentrations in the above MOPS buffer with 5 mM TCEP.", [["vesicle", "ANATOMY", 190, 197], ["vesicle", "ANATOMY", 237, 244], ["vesicles", "ANATOMY", 326, 334], ["NaCl", "CHEMICAL", 67, 71], ["EGTA", "CHEMICAL", 87, 91], ["MOPS", "CHEMICAL", 41, 45], ["NaCl", "CHEMICAL", 67, 71], ["EGTA", "CHEMICAL", 87, 91], ["EDTA", "CHEMICAL", 96, 100], ["PtdIns(4,5)P2", "CHEMICAL", 135, 148], ["TCEP", "CHEMICAL", 449, 453], ["EGTA", "SIMPLE_CHEMICAL", 87, 91], ["EDTA", "SIMPLE_CHEMICAL", 96, 100], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 135, 148], ["vesicle", "CELLULAR_COMPONENT", 190, 197], ["vesicle", "CELLULAR_COMPONENT", 237, 244], ["vesicles", "ORGANISM_SUBSTANCE", 326, 334], ["TCEP", "SIMPLE_CHEMICAL", 449, 453], ["Dried lipid films", "TEST", 0, 17], ["pH", "TEST", 47, 49], ["150 mM NaCl buffer", "TREATMENT", 60, 78], ["EGTA", "TEST", 87, 91], ["EDTA", "TEST", 96, 100], ["PtdIns", "TEST", 135, 141], ["methodsFission experiments", "TEST", 274, 300], ["unlabeled protein", "TREATMENT", 368, 385], ["the above MOPS buffer", "TREATMENT", 417, 438], ["5 mM TCEP", "TREATMENT", 444, 453], ["200 nm", "OBSERVATION_MODIFIER", 166, 172], ["vesicle diameter", "OBSERVATION", 190, 206], ["vesicle brightness", "OBSERVATION", 237, 255]]], ["The mixture was incubated at 37\u00b0C for either 30 min (Amph-FL, N-BAR, Amph CTD \u0394SH3, and N-BAR-epsin CTD) or 60 min (I-BAR-AP180 CTD, FCHo1-FL, and F-BAR).", [["N-BAR", "SIMPLE_CHEMICAL", 62, 67], ["F-BAR", "GENE_OR_GENE_PRODUCT", 147, 152], ["Amph", "PROTEIN", 53, 57], ["BAR", "PROTEIN", 64, 67], ["Amph CTD \u0394SH3", "PROTEIN", 69, 82], ["N", "PROTEIN", 88, 89], ["BAR", "PROTEIN", 90, 93], ["epsin CTD", "PROTEIN", 94, 103], ["BAR", "PROTEIN", 118, 121], ["AP180 CTD", "PROTEIN", 122, 131], ["FCHo1", "PROTEIN", 133, 138], ["FL", "PROTEIN", 139, 141], ["F", "PROTEIN", 147, 148], ["BAR", "PROTEIN", 149, 152], ["Amph", "TEST", 53, 57], ["Amph CTD \u0394SH3", "TREATMENT", 69, 82], ["CTD", "TEST", 128, 131], ["FCHo1", "TEST", 133, 138]]], ["During the incubation period, imaging wells were prepared as described above.", [["imaging wells", "TEST", 30, 43]]], ["After incubation, the mixtures were added to the wells and vesicles were allowed to tether for 10 min before washing repeatedly to remove untethered vesicles.", [["vesicles", "ANATOMY", 59, 67], ["vesicles", "ANATOMY", 149, 157], ["vesicles", "CELLULAR_COMPONENT", 59, 67], ["vesicles", "CELLULAR_COMPONENT", 149, 157], ["the mixtures", "TREATMENT", 18, 30], ["untethered vesicles", "PROBLEM", 138, 157]]], ["Multiple spinning disc confocal z-stacks of tethered vesicles were acquired with a z-step of 0.1 \u00b5m.", [["vesicles", "ANATOMY", 53, 61], ["vesicles", "CELLULAR_COMPONENT", 53, 61], ["Multiple spinning disc confocal z-stacks of tethered vesicles", "PROBLEM", 0, 61], ["a z-step", "TEST", 81, 89], ["spinning disc", "OBSERVATION", 9, 22], ["tethered vesicles", "OBSERVATION", 44, 61]]], ["The same laser power and camera gain settings were used for all experiments.", [["camera gain settings", "TREATMENT", 25, 45]]], ["Notably, we used spinning disc confocal microscopy rather than TIRF microscopy because the low penetration depth of TIRF microscopy would not evenly illuminate larger vesicles.", [["vesicles", "ANATOMY", 167, 175], ["vesicles", "CELLULAR_COMPONENT", 167, 175], ["spinning disc confocal microscopy", "TEST", 17, 50], ["TIRF microscopy", "TEST", 63, 78], ["TIRF microscopy", "TEST", 116, 131], ["larger vesicles", "OBSERVATION", 160, 175]]], ["The greater illumination depth of spinning disc confocal microscopy ensures that vesicles of a broad diameter distribution are evenly illuminated.Determination of vesicle diameter from measurements of tethered vesicle brightness ::: Materials and methodsAll images in the z-stacks were cropped to the center 171 \u00d7 171 pixels (center 1/9), and the frame with the greatest mean brightness was selected as the best focus image for analysis.", [["vesicles", "ANATOMY", 81, 89], ["vesicle", "ANATOMY", 163, 170], ["vesicle", "ANATOMY", 210, 217], ["vesicles", "CELLULAR_COMPONENT", 81, 89], ["vesicle", "CELLULAR_COMPONENT", 163, 170], ["vesicle", "CELLULAR_COMPONENT", 210, 217], ["spinning disc confocal microscopy", "TEST", 34, 67], ["All images", "TEST", 254, 264], ["pixels", "TEST", 318, 324], ["analysis", "TEST", 428, 436], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["illumination", "OBSERVATION_MODIFIER", 12, 24], ["depth", "OBSERVATION_MODIFIER", 25, 30], ["spinning disc", "OBSERVATION", 34, 47], ["vesicles", "OBSERVATION_MODIFIER", 81, 89], ["broad", "OBSERVATION_MODIFIER", 95, 100], ["diameter", "OBSERVATION_MODIFIER", 101, 109], ["evenly", "OBSERVATION_MODIFIER", 127, 133], ["illuminated", "OBSERVATION_MODIFIER", 134, 145], ["vesicle diameter", "OBSERVATION", 163, 179], ["vesicle brightness", "OBSERVATION", 210, 228]]], ["Fluorescence amplitudes of diffraction-limited puncta were obtained using cmeAnalysis particle detection software (Aguet et al., 2013).", [["puncta", "ANATOMY", 47, 53], ["puncta", "CELLULAR_COMPONENT", 47, 53], ["Fluorescence amplitudes", "TEST", 0, 23], ["diffraction", "TEST", 27, 38]]], ["Individual vesicles were detected by fitting 2D Gaussian profiles to each puncta.", [["vesicles", "ANATOMY", 11, 19], ["puncta", "ANATOMY", 74, 80], ["vesicles", "CELLULAR_COMPONENT", 11, 19], ["puncta", "CELLULAR_COMPONENT", 74, 80], ["Individual vesicles", "PROBLEM", 0, 19]]], ["The SD of the Gaussian profile was determined from the point spread function of our microscope.", [["our microscope", "TEST", 80, 94]]], ["The brightness values of detected puncta were reported as valid if they were diffraction-limited and had amplitudes significantly above their local fluorescence background.", [["puncta", "ANATOMY", 34, 40], ["puncta", "CELLULAR_COMPONENT", 34, 40], ["The brightness values", "TEST", 0, 21]]], ["To further ensure that puncta were well above the noise threshold, we only accepted puncta that persisted at the same location through five consecutive imaging frames.Determination of vesicle diameter from measurements of tethered vesicle brightness ::: Materials and methodsTo convert fluorescence brightness values to vesicle diameters, we computed a scaling factor that centered the mean of the vesicle brightness distribution of a high-curvature, sonicated vesicle sample to the average diameter of the same vesicles obtained from dynamic light scattering.", [["puncta", "ANATOMY", 23, 29], ["puncta", "ANATOMY", 84, 90], ["vesicle", "ANATOMY", 184, 191], ["vesicle", "ANATOMY", 231, 238], ["vesicle", "ANATOMY", 320, 327], ["vesicle", "ANATOMY", 398, 405], ["vesicle sample", "ANATOMY", 461, 475], ["vesicles", "ANATOMY", 512, 520], ["puncta", "CELLULAR_COMPONENT", 23, 29], ["puncta", "CELLULAR_COMPONENT", 84, 90], ["vesicle", "CELLULAR_COMPONENT", 184, 191], ["vesicle", "CELLULAR_COMPONENT", 231, 238], ["vesicle", "CELLULAR_COMPONENT", 398, 405], ["vesicles", "CELLULAR_COMPONENT", 512, 520], ["puncta", "PROBLEM", 23, 29], ["puncta", "PROBLEM", 84, 90], ["fluorescence brightness values", "TEST", 286, 316], ["a scaling factor", "PROBLEM", 351, 367], ["puncta", "OBSERVATION", 23, 29], ["puncta", "OBSERVATION", 84, 90], ["vesicle diameter", "OBSERVATION", 184, 200], ["vesicle brightness", "OBSERVATION", 231, 249], ["diameters", "OBSERVATION_MODIFIER", 328, 337], ["mean", "OBSERVATION_MODIFIER", 386, 390], ["vesicle brightness", "OBSERVATION", 398, 416], ["high", "OBSERVATION_MODIFIER", 435, 439], ["curvature", "OBSERVATION_MODIFIER", 440, 449], ["average", "OBSERVATION_MODIFIER", 483, 490], ["diameter", "OBSERVATION_MODIFIER", 491, 499], ["same vesicles", "ANATOMY", 507, 520]]], ["This scaling factor was then used to scale the vesicle brightness distributions after protein exposure to distributions of vesicle diameter.Determination of membrane coverage by proteins from measurements of vesicle and protein brightness ::: Materials and methodsVesicles in experiments with Amph-FL and N-BAR were composed of 76 mol% DOPC, 15 mol% DOPS, 5 mol% PtdIns(4,5)P2, 2 mol% DP-EG10-biotin, and 2 mol% Oregon Green 488\u2013DHPE.", [["vesicle", "ANATOMY", 47, 54], ["vesicle", "ANATOMY", 123, 130], ["membrane", "ANATOMY", 157, 165], ["vesicle", "ANATOMY", 208, 215], ["Vesicles", "ANATOMY", 264, 272], ["Amph-FL", "CHEMICAL", 293, 300], ["N-BAR", "CHEMICAL", 305, 310], ["DOPC", "CHEMICAL", 336, 340], ["DOPS", "CHEMICAL", 350, 354], ["PtdIns", "CHEMICAL", 363, 369], ["DP-EG10-biotin", "CHEMICAL", 385, 399], ["DOPC", "CHEMICAL", 336, 340], ["DOPS", "CHEMICAL", 350, 354], ["PtdIns(4,5)P2", "CHEMICAL", 363, 376], ["DP-EG10-biotin", "CHEMICAL", 385, 399], ["Oregon Green 488", "CHEMICAL", 412, 428], ["vesicle", "CELLULAR_COMPONENT", 47, 54], ["vesicle", "CELLULAR_COMPONENT", 123, 130], ["membrane", "CELLULAR_COMPONENT", 157, 165], ["vesicle", "CELLULAR_COMPONENT", 208, 215], ["Amph-FL", "SIMPLE_CHEMICAL", 293, 300], ["N-BAR", "SIMPLE_CHEMICAL", 305, 310], ["DOPC", "SIMPLE_CHEMICAL", 336, 340], ["DOPS", "SIMPLE_CHEMICAL", 350, 354], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 363, 376], ["DP-EG10-biotin", "SIMPLE_CHEMICAL", 385, 399], ["Oregon Green 488\u2013DHPE", "SIMPLE_CHEMICAL", 412, 433], ["Amph", "PROTEIN", 293, 297], ["BAR", "PROTEIN", 307, 310], ["This scaling factor", "PROBLEM", 0, 19], ["membrane coverage", "TREATMENT", 157, 174], ["Amph", "TEST", 293, 297], ["DOPC", "TEST", 336, 340], ["DP", "TEST", 385, 387], ["biotin", "TREATMENT", 393, 399], ["vesicle brightness", "OBSERVATION", 47, 65], ["protein exposure", "OBSERVATION", 86, 102], ["vesicle diameter", "OBSERVATION", 123, 139], ["membrane coverage", "OBSERVATION", 157, 174], ["vesicle", "ANATOMY", 208, 215], ["protein brightness", "OBSERVATION", 220, 238]]], ["DOPS and PtdIns(4,5)P2 were replaced with 20 mol% DOGS-NTA-Ni in experiments with Amph CTD \u0394SH3.", [["DOPS", "CHEMICAL", 0, 4], ["PtdIns", "CHEMICAL", 9, 15], ["DOGS-NTA-Ni", "CHEMICAL", 50, 61], ["DOPS", "CHEMICAL", 0, 4], ["PtdIns(4,5)P2", "CHEMICAL", 9, 22], ["NTA", "CHEMICAL", 55, 58], ["Ni", "CHEMICAL", 59, 61], ["DOPS", "SIMPLE_CHEMICAL", 0, 4], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 9, 22], ["DOGS-NTA-Ni", "SIMPLE_CHEMICAL", 50, 61], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 82, 90], ["DOPS and PtdIns(4,5)P2", "DNA", 0, 22], ["Amph CTD \u0394SH3", "PROTEIN", 82, 95], ["DOPS and PtdIns(4,5)P2", "TREATMENT", 0, 22], ["Amph CTD \u0394SH3", "TREATMENT", 82, 95]]], ["Dried lipid films were hydrated in 20 mM MOPS, pH 7.35, and 150 mM NaCl buffer (0.5 mM EGTA and EDTA were included in experiments with PtdIns(4,5)P2) and sonicated or extruded to 200 or 30 nm.", [["NaCl", "CHEMICAL", 67, 71], ["EGTA", "CHEMICAL", 87, 91], ["EDTA", "CHEMICAL", 96, 100], ["PtdIns(4,5)P2", "CHEMICAL", 135, 148], ["MOPS", "CHEMICAL", 41, 45], ["NaCl", "CHEMICAL", 67, 71], ["EGTA", "CHEMICAL", 87, 91], ["EDTA", "CHEMICAL", 96, 100], ["PtdIns(4,5)P2", "CHEMICAL", 135, 148], ["EGTA", "SIMPLE_CHEMICAL", 87, 91], ["EDTA", "SIMPLE_CHEMICAL", 96, 100], ["PtdIns(4,5)P2", "SIMPLE_CHEMICAL", 135, 148], ["Dried lipid films", "TEST", 0, 17], ["pH", "TEST", 47, 49], ["150 mM NaCl buffer", "TREATMENT", 60, 78], ["EGTA", "TEST", 87, 91], ["EDTA", "TEST", 96, 100], ["PtdIns", "TEST", 135, 141]]], ["Imaging wells were prepared as described above.", [["Imaging wells", "TEST", 0, 13]]], ["Vesicles were diluted to 5 \u00b5M in the wells and allowed to tether for 10 min.", [["Vesicles", "ANATOMY", 0, 8], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8]]], ["Untethered vesicles were removed by thorough washing with MOPS buffer.", [["vesicles", "ANATOMY", 11, 19], ["MOPS", "CHEMICAL", 58, 62], ["vesicles", "CELLULAR_COMPONENT", 11, 19], ["Untethered vesicles", "PROBLEM", 0, 19], ["MOPS buffer", "TREATMENT", 58, 69]]], ["After tethering, Atto 594\u2013labeled protein was added to the specified concentration, and multiple spinning disc confocal z-stacks of lipid and protein fluorescence were acquired, with a z-step of 0.1 \u00b5m.", [["lipid", "SIMPLE_CHEMICAL", 132, 137], ["Atto 594\u2013labeled protein", "PROTEIN", 17, 41], ["multiple spinning disc confocal z-stacks", "TEST", 88, 128], ["lipid and protein fluorescence", "TEST", 132, 162]]], ["Images were collected after \u223c15 min incubation of protein with vesicles.", [["vesicles", "ANATOMY", 63, 71], ["vesicles", "CELLULAR_COMPONENT", 63, 71], ["Images", "TEST", 0, 6]]], ["The same laser power and camera gain settings were used for all experiments.", [["camera gain settings", "TREATMENT", 25, 45]]], ["Fig. S2 A shows images of tethered vesicles with 10 and 25 nM Amph-FL-Atto 594, demonstrating increased protein brightness (and therefore membrane coverage) with increasing protein concentration.Determination of membrane coverage by proteins from measurements of vesicle and protein brightness ::: Materials and methodsImages were cropped, and individual vesicle puncta were detected using cmeAnalysis software (Aguet et al., 2013), following a similar approach described in the previous section.", [["vesicles", "ANATOMY", 35, 43], ["membrane", "ANATOMY", 138, 146], ["membrane", "ANATOMY", 212, 220], ["vesicle", "ANATOMY", 263, 270], ["vesicle puncta", "ANATOMY", 355, 369], ["Amph-FL-Atto 594", "CHEMICAL", 62, 78], ["Amph-FL-Atto 594", "CHEMICAL", 62, 78], ["vesicles", "CELLULAR_COMPONENT", 35, 43], ["membrane", "CELLULAR_COMPONENT", 138, 146], ["membrane", "CELLULAR_COMPONENT", 212, 220], ["vesicle", "CELLULAR_COMPONENT", 263, 270], ["vesicle puncta", "CELLULAR_COMPONENT", 355, 369], ["Atto 594", "PROTEIN", 70, 78], ["increased protein brightness", "PROBLEM", 94, 122], ["membrane coverage", "TREATMENT", 138, 155], ["increasing protein concentration", "TREATMENT", 162, 194], ["membrane coverage", "TREATMENT", 212, 229], ["methodsImages", "TEST", 312, 325], ["individual vesicle puncta", "TEST", 344, 369], ["Analysis software", "TEST", 393, 410], ["a similar approach", "TREATMENT", 443, 461], ["increased", "OBSERVATION_MODIFIER", 94, 103], ["protein brightness", "OBSERVATION", 104, 122], ["protein concentration", "OBSERVATION", 173, 194], ["membrane coverage", "OBSERVATION", 212, 229], ["vesicle", "ANATOMY", 263, 270], ["protein brightness", "OBSERVATION", 275, 293], ["vesicle puncta", "OBSERVATION", 355, 369]]], ["Here we only accepted puncta that persisted at the same location through three consecutive imaging frames.", [["puncta", "ANATOMY", 22, 28], ["puncta", "CELLULAR_COMPONENT", 22, 28], ["puncta", "PROBLEM", 22, 28], ["puncta", "OBSERVATION", 22, 28]]], ["The algorithm also searched for fluorescent puncta in the protein channel using the centroids of the detected fluorescent puncta in the master lipid channel.", [["puncta", "ANATOMY", 44, 50], ["puncta", "ANATOMY", 122, 128], ["puncta", "CELLULAR_COMPONENT", 44, 50], ["puncta", "CELLULAR_COMPONENT", 122, 128], ["protein channel", "PROTEIN", 58, 73], ["master lipid channel", "PROTEIN", 136, 156], ["fluorescent puncta", "PROBLEM", 32, 50], ["fluorescent puncta", "OBSERVATION", 110, 128], ["lipid channel", "OBSERVATION", 143, 156]]], ["The search region in the protein channel was three times the SD of the Gaussian fit to the point spread function of our microscope.", [["our microscope", "TEST", 116, 130], ["protein channel", "ANATOMY", 25, 40]]], ["We estimated vesicle diameters from lipid fluorescence brightnesses by calibrating against dynamic light scattering, as described in the previous section.", [["vesicle", "ANATOMY", 13, 20], ["lipid", "SIMPLE_CHEMICAL", 36, 41], ["lipid fluorescence brightnesses", "TREATMENT", 36, 67], ["vesicle", "OBSERVATION_MODIFIER", 13, 20], ["diameters", "OBSERVATION_MODIFIER", 21, 30], ["lipid fluorescence", "OBSERVATION", 36, 54]]], ["We estimated the number of bound proteins on each vesicle by comparing brightness values in the protein channel to the brightness of a single molecule of Atto 594\u2013labeled protein.", [["vesicle", "ANATOMY", 50, 57], ["Atto 594", "CHEMICAL", 154, 162], ["vesicle", "CELLULAR_COMPONENT", 50, 57], ["bound proteins", "PROTEIN", 27, 41], ["protein channel", "PROTEIN", 96, 111], ["Atto 594\u2013labeled protein", "PROTEIN", 154, 178], ["brightness values", "TEST", 71, 88], ["bound proteins", "OBSERVATION", 27, 41]]], ["Images of single molecules of Atto 594\u2013labeled proteins were obtained by adding a dilute concentration of protein to an imaging well on an ultraclean coverslip, and imaging single proteins adhered to the coverslip surface in a similar manner as described for the tethered vesicles.", [["surface", "ANATOMY", 214, 221], ["vesicles", "ANATOMY", 272, 280], ["vesicles", "CELLULAR_COMPONENT", 272, 280], ["Atto 594\u2013labeled proteins", "PROTEIN", 30, 55], ["a dilute concentration of protein", "TREATMENT", 80, 113], ["an imaging", "TEST", 117, 127], ["an ultraclean coverslip", "TREATMENT", 136, 159], ["imaging single proteins", "TEST", 165, 188], ["the tethered vesicles", "PROBLEM", 259, 280], ["tethered vesicles", "OBSERVATION", 263, 280]]], ["A linear correction for camera exposure time was applied to the single molecule brightness, as longer exposure times were required to image single molecules compared with membrane-bound protein.", [["membrane", "ANATOMY", 171, 179], ["membrane", "CELLULAR_COMPONENT", 171, 179], ["membrane-bound protein", "PROTEIN", 171, 193], ["A linear correction", "TREATMENT", 0, 19], ["camera exposure time", "TREATMENT", 24, 44], ["linear", "OBSERVATION_MODIFIER", 2, 8]]], ["Fig. S2 B shows a plot of the raw protein intensity values as a function of vesicle intensity for 10 and 25 nM Amph-FL.", [["vesicle", "ANATOMY", 76, 83], ["Amph-FL", "CHEMICAL", 111, 118], ["vesicle", "CELLULAR_COMPONENT", 76, 83], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 111, 118], ["S2 B", "PROTEIN", 5, 9], ["vesicle intensity", "TEST", 76, 93], ["S2", "ANATOMY", 5, 7], ["vesicle intensity", "OBSERVATION", 76, 93]]], ["The 25-nM data show a higher slope than 10 nM, indicating greater membrane coverage.", [["membrane", "ANATOMY", 66, 74], ["membrane", "CELLULAR_COMPONENT", 66, 74], ["The 25-nM data", "TEST", 0, 14], ["a higher slope than 10 nM", "PROBLEM", 20, 45], ["greater membrane coverage", "TREATMENT", 58, 83], ["greater membrane coverage", "OBSERVATION", 58, 83]]], ["Fig. S2 C shows this same data after processing, plotted as the number of membrane-bound proteins as a function of vesicle diameter.Determination of membrane coverage by proteins from measurements of vesicle and protein brightness ::: Materials and methodsMembrane coverage by proteins was estimated for each vesicle by dividing the area occupied by membrane-bound proteins by the corresponding vesicle surface area.", [["membrane", "ANATOMY", 74, 82], ["vesicle", "ANATOMY", 115, 122], ["membrane", "ANATOMY", 149, 157], ["vesicle", "ANATOMY", 200, 207], ["Membrane", "ANATOMY", 256, 264], ["vesicle", "ANATOMY", 309, 316], ["area", "ANATOMY", 333, 337], ["membrane", "ANATOMY", 350, 358], ["vesicle surface area", "ANATOMY", 395, 415], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["vesicle", "CELLULAR_COMPONENT", 115, 122], ["membrane", "CELLULAR_COMPONENT", 149, 157], ["vesicle", "CELLULAR_COMPONENT", 200, 207], ["Membrane", "CELLULAR_COMPONENT", 256, 264], ["vesicle", "CELLULAR_COMPONENT", 309, 316], ["membrane", "CELLULAR_COMPONENT", 350, 358], ["vesicle surface area", "CELLULAR_COMPONENT", 395, 415], ["membrane-bound proteins", "PROTEIN", 74, 97], ["membrane-bound proteins", "PROTEIN", 350, 373], ["membrane coverage", "TREATMENT", 149, 166], ["Materials", "TREATMENT", 235, 244], ["methodsMembrane coverage", "TREATMENT", 249, 273], ["S2", "ANATOMY", 5, 7], ["vesicle diameter", "OBSERVATION", 115, 131], ["membrane coverage", "OBSERVATION", 149, 166], ["vesicle", "ANATOMY", 200, 207], ["protein brightness", "OBSERVATION", 212, 230], ["area", "OBSERVATION_MODIFIER", 333, 337], ["bound proteins", "OBSERVATION", 359, 373], ["vesicle", "OBSERVATION_MODIFIER", 395, 402], ["surface", "OBSERVATION_MODIFIER", 403, 410]]], ["The projected membrane footprints of N-BAR, Amph-FL, and Amph CTD \u0394SH3 monomers were assumed to be 16.5 (Adam et al., 2015), 79, and 79 nm2, respectively.", [["membrane", "ANATOMY", 14, 22], ["membrane", "CELLULAR_COMPONENT", 14, 22], ["N-BAR", "GENE_OR_GENE_PRODUCT", 37, 42], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 44, 51], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 57, 65], ["N", "PROTEIN", 37, 38], ["BAR", "PROTEIN", 39, 42], ["Amph", "PROTEIN", 44, 48], ["FL", "PROTEIN", 49, 51], ["Amph", "PROTEIN", 57, 61], ["Amph", "TEST", 44, 48], ["Amph CTD \u0394SH3 monomers", "TEST", 57, 79], ["FL", "ANATOMY", 49, 51]]], ["The average membrane coverage was estimated as the mean of all individual vesicle coverage values.", [["membrane", "ANATOMY", 12, 20], ["vesicle", "ANATOMY", 74, 81], ["membrane", "CELLULAR_COMPONENT", 12, 20], ["vesicle", "CELLULAR_COMPONENT", 74, 81], ["The average membrane coverage", "TREATMENT", 0, 29], ["average", "OBSERVATION_MODIFIER", 4, 11], ["membrane coverage", "OBSERVATION", 12, 29], ["vesicle coverage", "OBSERVATION", 74, 90]]], ["To confirm the validity of this analysis approach, we also plotted the area of membrane-bound proteins as a function of vesicle surface area, as shown in Fig. S2 L for the 1 \u00b5M Amph CTD \u0394SH3 dataset.", [["membrane", "ANATOMY", 79, 87], ["vesicle surface area", "ANATOMY", 120, 140], ["membrane", "CELLULAR_COMPONENT", 79, 87], ["vesicle surface", "CELLULAR_COMPONENT", 120, 135], ["S2 L", "GENE_OR_GENE_PRODUCT", 159, 163], ["membrane-bound proteins", "PROTEIN", 79, 102], ["this analysis approach", "TEST", 27, 49], ["bound proteins", "PROBLEM", 88, 102], ["vesicle surface area", "TREATMENT", 120, 140], ["vesicle surface", "OBSERVATION", 120, 135]]], ["The slope of a linear fit to these data provides an alternative estimate of membrane coverage.", [["membrane", "ANATOMY", 76, 84], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["membrane coverage", "TREATMENT", 76, 93]]], ["The slope of 0.21, or 21% coverage, agrees well with 24% membrane coverage in Fig. 3 D that was estimated using the method described above.Determination of membrane coverage by proteins from measurements of vesicle and protein brightness ::: Materials and methodsData with Amph CTD \u0394SH3 in Fig. 3 D were collected using 200-nm\u2013extruded vesicles.", [["membrane", "ANATOMY", 57, 65], ["membrane", "ANATOMY", 156, 164], ["vesicle", "ANATOMY", 207, 214], ["vesicles", "ANATOMY", 336, 344], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["membrane", "CELLULAR_COMPONENT", 156, 164], ["vesicle", "CELLULAR_COMPONENT", 207, 214], ["Amph CTD \u0394SH3", "PROTEIN", 273, 286], ["The slope", "TREATMENT", 0, 9], ["24% membrane coverage in Fig", "TREATMENT", 53, 81], ["membrane coverage", "TREATMENT", 156, 173], ["methodsData", "TEST", 256, 267], ["Amph CTD", "TEST", 273, 281], ["membrane coverage", "OBSERVATION", 156, 173], ["vesicle", "ANATOMY", 207, 214], ["protein brightness", "OBSERVATION", 219, 237]]], ["However, Amph-FL and N-BAR were found to strongly deform and remodel 200-nm vesicles.", [["vesicles", "ANATOMY", 76, 84], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 9, 16], ["N-BAR", "GENE_OR_GENE_PRODUCT", 21, 26], ["vesicles", "CELLULAR_COMPONENT", 76, 84], ["Amph", "PROTEIN", 9, 13], ["FL", "PROTEIN", 14, 16], ["N", "PROTEIN", 21, 22], ["BAR", "PROTEIN", 23, 26], ["Amph", "TEST", 9, 13], ["N-BAR", "TEST", 21, 26], ["nm vesicles", "OBSERVATION", 73, 84]]], ["Therefore, data with N-BAR and Amph-FL in Fig. 2, G and H were collected using vesicles of higher initial curvature, which were found to not undergo substantial remodeling during experiments.", [["vesicles", "ANATOMY", 79, 87], ["Amph-FL", "CHEMICAL", 31, 38], ["2, G and H", "CHEMICAL", 47, 57], ["N-BAR", "GENE_OR_GENE_PRODUCT", 21, 26], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 31, 38], ["BAR", "PROTEIN", 23, 26], ["Amph", "PROTEIN", 31, 35], ["FL", "PROTEIN", 36, 38], ["Amph", "TEST", 31, 35], ["higher", "OBSERVATION_MODIFIER", 91, 97], ["initial curvature", "OBSERVATION", 98, 115], ["substantial", "OBSERVATION_MODIFIER", 149, 160], ["remodeling", "OBSERVATION", 161, 171]]], ["Specifically, N-BAR and Amph-FL data were collected using sonicated and 30-nm\u2013extruded vesicles, respectively.", [["vesicles", "ANATOMY", 87, 95], ["N-BAR", "GENE_OR_GENE_PRODUCT", 14, 19], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 24, 31], ["BAR", "PROTEIN", 16, 19], ["Amph", "PROTEIN", 24, 28], ["FL", "PROTEIN", 29, 31], ["Amph-FL data", "TEST", 24, 36]]], ["Vesicle diameters were estimated by calibrating against a sample of the same vesicles before protein exposure, with the exception of sonicated vesicles.", [["Vesicle", "ANATOMY", 0, 7], ["vesicles", "ANATOMY", 77, 85], ["vesicles", "ANATOMY", 143, 151], ["vesicles", "CELLULAR_COMPONENT", 77, 85], ["vesicles", "CELLULAR_COMPONENT", 143, 151], ["Vesicle diameters", "TEST", 0, 17], ["sonicated vesicles", "PROBLEM", 133, 151], ["diameters", "OBSERVATION_MODIFIER", 8, 17], ["protein exposure", "OBSERVATION", 93, 109], ["sonicated vesicles", "OBSERVATION", 133, 151]]], ["We found that calibrating against a 30-nm\u2013extruded vesicle sample, made from the same lipid mixture on the same day, provided a reliable estimate of the diameter distribution of sonicated vesicles.Generation of BFP-tagged clathrin light chain (BFP-CLC) RPE cell line ::: Materials and methodsA plasmid for expression of BFP-CLC was generated by replacing the mCherry domain of mCherry\u2013clathrin light chain (CLC), a gift from T. Kirchhausen, Harvard Medical School, Boston, MA (Addgene 53972).", [["vesicle sample", "ANATOMY", 51, 65], ["vesicles", "ANATOMY", 188, 196], ["BFP-CLC) RPE cell line", "ANATOMY", 244, 266], ["vesicles", "CELLULAR_COMPONENT", 188, 196], ["BFP", "GENE_OR_GENE_PRODUCT", 211, 214], ["clathrin light chain", "GENE_OR_GENE_PRODUCT", 222, 242], ["BFP", "GENE_OR_GENE_PRODUCT", 320, 323], ["mCherry\u2013clathrin light chain", "GENE_OR_GENE_PRODUCT", 377, 405], ["BFP", "PROTEIN", 211, 214], ["tagged clathrin light chain (BFP-CLC) RPE cell line", "CELL_LINE", 215, 266], ["BFP", "PROTEIN", 320, 323], ["CLC", "PROTEIN", 324, 327], ["mCherry domain", "PROTEIN", 359, 373], ["mCherry\u2013clathrin light chain", "PROTEIN", 377, 405], ["CLC", "PROTEIN", 407, 410], ["sonicated vesicles", "PROBLEM", 178, 196], ["BFP", "TEST", 211, 214], ["tagged clathrin light chain", "TEST", 215, 242], ["BFP", "TEST", 244, 247], ["methodsA plasmid", "TREATMENT", 285, 301], ["BFP", "TEST", 320, 323], ["diameter", "OBSERVATION_MODIFIER", 153, 161], ["sonicated vesicles", "OBSERVATION", 178, 196], ["RPE cell line", "OBSERVATION", 253, 266]]], ["The mCherry fluorophore was removed and replaced with tagBFP, a gift from F. Perez, Institut Curie, Paris, France (Addgene 65257). mCherry was excised from the mCherry-CLC plasmid using AgeI and XhoI restriction enzymes.", [["mCherry fluorophore", "SIMPLE_CHEMICAL", 4, 23], ["mCherry", "GENE_OR_GENE_PRODUCT", 131, 138], ["mCherry", "GENE_OR_GENE_PRODUCT", 160, 167], ["AgeI", "GENE_OR_GENE_PRODUCT", 186, 190], ["XhoI restriction enzymes", "GENE_OR_GENE_PRODUCT", 195, 219], ["mCherry-CLC plasmid", "DNA", 160, 179], ["AgeI", "PROTEIN", 186, 190], ["XhoI restriction enzymes", "PROTEIN", 195, 219], ["The mCherry fluorophore", "TREATMENT", 0, 23], ["CLC plasmid", "TREATMENT", 168, 179], ["XhoI restriction enzymes", "TEST", 195, 219]]], ["TagBFP was amplified from the li-Str_ManII-SBP-tagBFP plasmid using PCR primers, which introduced AgeI and XhoI restriction sites.", [["TagBFP", "GENE_OR_GENE_PRODUCT", 0, 6], ["AgeI", "GENE_OR_GENE_PRODUCT", 98, 102], ["XhoI", "GENE_OR_GENE_PRODUCT", 107, 111], ["TagBFP", "DNA", 0, 6], ["li-Str_ManII-SBP-tagBFP plasmid", "DNA", 30, 61], ["PCR primers", "DNA", 68, 79], ["AgeI and XhoI restriction sites", "DNA", 98, 129], ["TagBFP", "TREATMENT", 0, 6], ["SBP-tagBFP plasmid", "TREATMENT", 43, 61], ["PCR primers", "TREATMENT", 68, 79], ["XhoI restriction sites", "TREATMENT", 107, 129]]], ["The resulting tagBFP sequence was digested and ligated onto the CLC backbone to generate BFP-CLC with a linker sequence of HKGRPTR.", [["tagBFP", "GENE_OR_GENE_PRODUCT", 14, 20], ["BFP", "GENE_OR_GENE_PRODUCT", 89, 92], ["HKGRPTR", "GENE_OR_GENE_PRODUCT", 123, 130], ["tagBFP sequence", "DNA", 14, 29], ["BFP", "PROTEIN", 89, 92], ["CLC", "PROTEIN", 93, 96], ["linker sequence", "PROTEIN", 104, 119], ["HKGRPTR", "PROTEIN", 123, 130], ["The resulting tagBFP sequence", "TEST", 0, 29], ["a linker sequence of HKGRPTR", "PROBLEM", 102, 130]]], ["The CLC-BFP construct was then excised using AgeI and EcoRI restriction sites and ligated into a pLJM1 backbone obtained from Addgene as a gift from D. Sabatini, Massachusetts Institute of Technology, Cambridge, MA (Addgene 19319).", [["CLC-BFP", "GENE_OR_GENE_PRODUCT", 4, 11], ["AgeI", "GENE_OR_GENE_PRODUCT", 45, 49], ["EcoRI", "GENE_OR_GENE_PRODUCT", 54, 59], ["Addgene", "GENE_OR_GENE_PRODUCT", 126, 133], ["CLC-BFP construct", "DNA", 4, 21], ["AgeI and EcoRI restriction sites", "DNA", 45, 77], ["pLJM1 backbone", "DNA", 97, 111], ["AgeI and EcoRI restriction sites", "TREATMENT", 45, 77], ["a pLJM1 backbone", "TREATMENT", 95, 111]]], ["Once subcloned into this viral transfer plasmid, lentiviruses were generated by transfecting the BFP-CLC construct with the envelope plasmid VSVG (a gift from J. Lippincott-Schwartz, Howard Hughes Medical Institute Janelia Research Campus, Ashburn, VA; Addgene 11912) and packaging plasmid pCMV-dR8.91 (a gift from J. Zoldan, University of Texas at Austin, Austin, TX).", [["plasmid", "ANATOMY", 40, 47], ["lentiviruses", "ORGANISM", 49, 61], ["BFP", "GENE_OR_GENE_PRODUCT", 97, 100], ["VSVG", "GENE_OR_GENE_PRODUCT", 141, 145], ["viral transfer plasmid", "DNA", 25, 47], ["BFP-CLC construct", "DNA", 97, 114], ["packaging plasmid pCMV-dR8.91", "DNA", 272, 301], ["this viral transfer plasmid", "TREATMENT", 20, 47], ["lentiviruses", "PROBLEM", 49, 61], ["packaging plasmid pCMV", "TREATMENT", 272, 294]]], ["Lentiviral particles were then harvested, filtered, and incubated with human RPE recipient cells (ARPE-19, purchased from American Type Culture Collection).", [["RPE recipient cells", "ANATOMY", 77, 96], ["Lentiviral", "ORGANISM", 0, 10], ["human", "ORGANISM", 71, 76], ["RPE recipient cells", "CELL", 77, 96], ["ARPE-19", "CELL", 98, 105], ["human RPE recipient cells", "CELL_TYPE", 71, 96], ["ARPE-19", "CELL_LINE", 98, 105], ["human", "SPECIES", 71, 76], ["Lentiviral", "SPECIES", 0, 10], ["human", "SPECIES", 71, 76], ["Lentiviral particles", "TREATMENT", 0, 20], ["human RPE recipient cells", "TREATMENT", 71, 96], ["ARPE", "TEST", 98, 102]]], ["Cells were incubated with 2 \u00b5g/ml puromycin for 1 wk to select for transduced cells, which were then used to generate the monoclonal cell line stably expressing BFP-CLC.Cell culture and transfection ::: Materials and methodsBFP-CLC RPE cells were grown in 1:1 F12:DMEM supplemented with 10% FBS, 20 mM Hepes, Pen/Strep/l-glutamine (100 U/ml, 100 \u00b5g/ml, and 300 \u00b5g/ml, respectively) and incubated at 37\u00b0C with 5% CO2.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 78, 83], ["cell line", "ANATOMY", 133, 142], ["Cell", "ANATOMY", 169, 173], ["methodsBFP-CLC RPE cells", "ANATOMY", 217, 241], ["FBS", "ANATOMY", 291, 294], ["puromycin", "CHEMICAL", 34, 43], ["Pen/Strep/l-glutamine", "CHEMICAL", 309, 330], ["CO2", "CHEMICAL", 412, 415], ["puromycin", "CHEMICAL", 34, 43], ["Hepes", "CHEMICAL", 302, 307], ["l-glutamine", "CHEMICAL", 319, 330], ["CO2", "CHEMICAL", 412, 415], ["Cells", "CELL", 0, 5], ["puromycin", "SIMPLE_CHEMICAL", 34, 43], ["cells", "CELL", 78, 83], ["cell line", "CELL", 133, 142], ["BFP-CLC", "GENE_OR_GENE_PRODUCT", 161, 168], ["Cell", "CELL", 169, 173], ["methodsBFP-CLC RPE cells", "CELL", 217, 241], ["FBS", "ORGANISM_SUBSTANCE", 291, 294], ["l-glutamine", "SIMPLE_CHEMICAL", 319, 330], ["CO2", "SIMPLE_CHEMICAL", 412, 415], ["transduced cells", "CELL_LINE", 67, 83], ["monoclonal cell line", "CELL_LINE", 122, 142], ["BFP", "PROTEIN", 161, 164], ["CLC", "PROTEIN", 165, 168], ["methodsBFP-CLC RPE cells", "CELL_LINE", 217, 241], ["Cells", "TEST", 0, 5], ["puromycin", "TREATMENT", 34, 43], ["transduced cells", "PROBLEM", 67, 83], ["the monoclonal cell line", "TREATMENT", 118, 142], ["Cell culture", "TEST", 169, 181], ["Materials", "TEST", 203, 212], ["methodsBFP", "TEST", 217, 227], ["CLC RPE cells", "TEST", 228, 241], ["FBS", "TEST", 291, 294], ["mM Hepes", "TEST", 299, 307], ["Pen", "TEST", 309, 312], ["Strep", "TEST", 313, 318], ["l-glutamine", "TREATMENT", 319, 330], ["monoclonal cell line", "OBSERVATION", 122, 142]]], ["Cells were seeded onto acid-washed coverslips at a density of 5 \u00d7 104 cells per coverslip for 24 h before transfection with 1\u20132 \u00b5g of plasmid DNA using 3 \u00b5l Fugene transfection reagent per microgram of DNA (Promega).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 70, 75], ["plasmid", "ANATOMY", 134, 141], ["Cells", "CELL", 0, 5], ["cells", "CELL", 70, 75], ["DNA", "CELLULAR_COMPONENT", 142, 145], ["DNA", "CELLULAR_COMPONENT", 202, 205], ["plasmid DNA", "DNA", 134, 145], ["acid-washed coverslips", "TREATMENT", 23, 45], ["transfection", "TREATMENT", 106, 118], ["plasmid DNA", "TREATMENT", 134, 145], ["3 \u00b5l Fugene transfection reagent", "TREATMENT", 152, 184], ["DNA (Promega)", "TREATMENT", 202, 215]]], ["Cells were imaged 16\u201320 h after transfection.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["Two independent transfections were performed for each plasmid construct, and data were pooled from both transfections.Cell culture and transfection ::: Materials and methodsSpinning disc confocal z-stacks of BFP-CLC and the mCherry fusion protein were collected with a z-step of 0.25 \u00b5m. z-Stacks were analyzed for the number of tubes per cell and tube length.", [["plasmid", "ANATOMY", 54, 61], ["Cell", "ANATOMY", 118, 122], ["cell", "ANATOMY", 339, 343], ["tube", "ANATOMY", 348, 352], ["Cell", "CELL", 118, 122], ["BFP-CLC", "SIMPLE_CHEMICAL", 208, 215], ["mCherry", "GENE_OR_GENE_PRODUCT", 224, 231], ["cell", "CELL", 339, 343], ["tube", "TISSUE", 348, 352], ["plasmid construct", "DNA", 54, 71], ["BFP", "PROTEIN", 208, 211], ["CLC", "PROTEIN", 212, 215], ["mCherry fusion protein", "PROTEIN", 224, 246], ["Two independent transfections", "TEST", 0, 29], ["each plasmid construct", "TEST", 49, 71], ["Cell culture", "TEST", 118, 130], ["methodsSpinning disc confocal z-stacks", "TEST", 166, 204], ["BFP", "TEST", 208, 211], ["the mCherry fusion protein", "TEST", 220, 246], ["z-Stacks", "TREATMENT", 288, 296], ["tubes", "OBSERVATION", 329, 334], ["tube length", "OBSERVATION", 348, 359]]], ["Image analysis was performed using ImageJ software.", [["Image analysis", "TEST", 0, 14], ["ImageJ software", "TEST", 35, 50]]], ["The plasma membrane frame was chosen by identifying the BFP-CLC frame in which the clathrin-coated structures were best in focus.", [["plasma membrane", "ANATOMY", 4, 19], ["plasma membrane", "CELLULAR_COMPONENT", 4, 19], ["BFP", "GENE_OR_GENE_PRODUCT", 56, 59], ["clathrin", "GENE_OR_GENE_PRODUCT", 83, 91], ["BFP-CLC frame", "DNA", 56, 69], ["clathrin", "PROTEIN", 83, 91], ["The plasma membrane frame", "TEST", 0, 25], ["the BFP", "TEST", 52, 59], ["the clathrin-coated structures", "TREATMENT", 79, 109], ["plasma", "OBSERVATION", 4, 10], ["membrane frame", "OBSERVATION", 11, 25]]], ["The plasma membrane expression level of the mCherry fusion protein was then quantified by measuring the mean brightness on a region of the plasma membrane, away from the nucleus and bright structures.", [["plasma membrane", "ANATOMY", 4, 19], ["plasma membrane", "ANATOMY", 139, 154], ["nucleus", "ANATOMY", 170, 177], ["plasma membrane", "CELLULAR_COMPONENT", 4, 19], ["mCherry", "GENE_OR_GENE_PRODUCT", 44, 51], ["plasma membrane", "CELLULAR_COMPONENT", 139, 154], ["nucleus", "CELLULAR_COMPONENT", 170, 177], ["mCherry fusion protein", "PROTEIN", 44, 66], ["The plasma membrane expression", "TEST", 0, 30], ["the mCherry fusion protein", "TEST", 40, 66], ["mean brightness", "OBSERVATION", 104, 119], ["plasma membrane", "OBSERVATION", 139, 154], ["nucleus", "ANATOMY", 170, 177], ["bright structures", "OBSERVATION", 182, 199]]], ["Protein expression level was also quantified in the cytosol by measuring the mean brightness of the fluorescent protein 1 \u00b5m above the plasma membrane.", [["cytosol", "ANATOMY", 52, 59], ["plasma membrane", "ANATOMY", 135, 150], ["cytosol", "ORGANISM_SUBSTANCE", 52, 59], ["plasma membrane", "CELLULAR_COMPONENT", 135, 150], ["fluorescent protein", "PROTEIN", 100, 119], ["1 \u00b5m", "PROTEIN", 120, 124], ["Protein expression level", "TEST", 0, 24], ["the fluorescent protein", "TEST", 96, 119], ["plasma membrane", "ANATOMY", 135, 150]]], ["Membrane tubes were counted at one frame above the plasma membrane frame.", [["Membrane tubes", "ANATOMY", 0, 14], ["plasma membrane", "ANATOMY", 51, 66], ["Membrane tubes", "ORGANISM_SUBSTANCE", 0, 14], ["plasma membrane", "CELLULAR_COMPONENT", 51, 66], ["Membrane tubes", "TREATMENT", 0, 14], ["tubes", "OBSERVATION", 9, 14], ["plasma membrane", "OBSERVATION", 51, 66]]], ["4 C and S4 B plot the number of tubes per cell as a function of protein expression level at the plasma membrane and in the cytosol, respectively.", [["cell", "ANATOMY", 42, 46], ["plasma membrane", "ANATOMY", 96, 111], ["cytosol", "ANATOMY", 123, 130], ["cell", "CELL", 42, 46], ["plasma membrane", "CELLULAR_COMPONENT", 96, 111], ["cytosol", "CELLULAR_COMPONENT", 123, 130], ["protein expression level", "PROBLEM", 64, 88], ["the plasma membrane", "TEST", 92, 111], ["plasma membrane", "ANATOMY", 96, 111], ["cytosol", "ANATOMY", 123, 130]]], ["Tube lengths were quantified as the end-to-end distances of the tubes.Cell culture and transfection ::: Materials and methodsFig.", [["Tube", "ANATOMY", 0, 4], ["Cell", "ANATOMY", 70, 74], ["tubes", "TISSUE", 64, 69], ["Cell", "CELL", 70, 74], ["Tube lengths", "TREATMENT", 0, 12], ["the tubes", "TREATMENT", 60, 69], ["Cell culture", "TEST", 70, 82], ["lengths", "OBSERVATION_MODIFIER", 5, 12], ["tubes", "OBSERVATION", 64, 69]]], ["S4 A shows an image of a cell stained with CellMask Green plasma membrane stain (Thermo Fisher Scientific).", [["cell", "ANATOMY", 25, 29], ["plasma membrane", "ANATOMY", 58, 73], ["cell", "CELL", 25, 29], ["Green plasma membrane stain", "TEST", 52, 79]]], ["Before imaging, the cells were incubated for 5 min at 37\u00b0C in a solution of the CellMask Green stain diluted 1,000-fold in sterile PBS.", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25], ["imaging", "TEST", 7, 14], ["Green stain", "TEST", 89, 100], ["sterile PBS", "TREATMENT", 123, 134]]], ["The solution was removed, and the cells were washed three times with media before imaging.Cell culture and transfection ::: Materials and methodsA custom-built TIRF microscope was used to collect time-lapse videos of live cells.", [["cells", "ANATOMY", 34, 39], ["Cell", "ANATOMY", 90, 94], ["cells", "ANATOMY", 222, 227], ["cells", "CELL", 34, 39], ["Cell", "CELL", 90, 94], ["cells", "CELL", 222, 227], ["live cells", "CELL_TYPE", 217, 227], ["The solution", "TREATMENT", 0, 12], ["the cells", "TREATMENT", 30, 39], ["imaging", "TEST", 82, 89], ["Cell culture", "TEST", 90, 102], ["methodsA custom", "TREATMENT", 138, 153], ["built TIRF microscope", "TEST", 154, 175], ["live cells", "OBSERVATION", 217, 227]]], ["A 532-nm laser was used to excite mCherry, and a 635-nm laser was used for autofocus.", [["A 532-nm laser", "TREATMENT", 0, 14], ["a 635-nm laser", "TREATMENT", 47, 61], ["autofocus", "PROBLEM", 75, 84]]], ["An Olympus IX73 microscope body was equipped with a Photometrics Evolve Delta EMCCD camera and a Zeiss plan-apochromat 100\u00d7 1.46 NA oil immersion TIRF objective.", [["body", "ANATOMY", 27, 31], ["Photometrics Evolve Delta EMCCD camera", "DNA", 52, 90], ["An Olympus IX73 microscope body", "TEST", 0, 31], ["a Zeiss plan", "TREATMENT", 95, 107], ["apochromat", "TREATMENT", 108, 118]]], ["The objective was heated to 37\u00b0C using a Pecon TempController 2000\u20132 objective heater.", [["a Pecon TempController 2000\u20132 objective heater", "TREATMENT", 39, 85]]], ["The emission filter for the 532-nm laser was a dual bandpass filter centered at 583 nm with 37-nm width and 707 nm with 51-nm width, which minimized signal from the autofocus laser.", [["The emission filter", "TREATMENT", 0, 19], ["the 532-nm laser", "TREATMENT", 24, 40], ["a dual bandpass filter", "TREATMENT", 45, 67], ["51-nm width", "TEST", 120, 131], ["the autofocus laser", "TREATMENT", 161, 180], ["emission filter", "OBSERVATION", 4, 19], ["bandpass filter", "OBSERVATION", 52, 67], ["707 nm", "OBSERVATION_MODIFIER", 108, 114], ["nm width", "OBSERVATION_MODIFIER", 123, 131], ["autofocus", "OBSERVATION_MODIFIER", 165, 174], ["laser", "OBSERVATION_MODIFIER", 175, 180]]], ["Videos were collected at the plasma membrane just above the coverslip surface in 2-s intervals for 120 frames.", [["plasma membrane", "ANATOMY", 29, 44], ["surface", "ANATOMY", 70, 77], ["plasma membrane", "CELLULAR_COMPONENT", 29, 44]]], ["Only videos of cells with similar expression level, acquired under identical imaging settings, were used for analysis.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["identical imaging settings", "TEST", 67, 93], ["analysis", "TEST", 109, 117]]], ["For the tube lifetime analysis in Fig. 4 F, only tubes that appeared within the time course of imaging and departed before the end of the time course were included.", [["tubes", "ANATOMY", 49, 54], ["tube", "TISSUE", 8, 12], ["the tube lifetime analysis", "TEST", 4, 30], ["only tubes", "TREATMENT", 44, 54], ["imaging", "TEST", 95, 102], ["tubes", "OBSERVATION", 49, 54]]], ["For the tube intensity analysis, a single frame in the video with the maximum number of tubes was selected, and the average tube intensity was measured along a straight line drawn on the tube.", [["tube", "ANATOMY", 124, 128], ["tube", "ANATOMY", 187, 191], ["tube", "TISSUE", 8, 12], ["tube", "TISSUE", 124, 128], ["tube", "TISSUE", 187, 191], ["the tube intensity analysis", "TEST", 4, 31], ["the maximum number of tubes", "TREATMENT", 66, 93], ["the average tube intensity", "TREATMENT", 112, 138], ["a straight line", "TREATMENT", 158, 173], ["the tube", "TREATMENT", 183, 191], ["maximum", "OBSERVATION_MODIFIER", 70, 77], ["tubes", "OBSERVATION", 88, 93], ["average", "OBSERVATION_MODIFIER", 116, 123], ["tube intensity", "OBSERVATION", 124, 138], ["straight line", "OBSERVATION", 160, 173], ["tube", "OBSERVATION", 187, 191]]], ["The mean intensity along an identical line on either side of the tube was also measured, and these values were averaged to estimate the local background intensity of the tube.", [["tube", "ANATOMY", 65, 69], ["tube", "TISSUE", 65, 69], ["tube", "TISSUE", 170, 174], ["the tube", "TREATMENT", 61, 69], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["intensity", "OBSERVATION_MODIFIER", 9, 18], ["identical", "OBSERVATION_MODIFIER", 28, 37], ["line", "OBSERVATION", 38, 42], ["tube", "OBSERVATION", 65, 69], ["local", "OBSERVATION_MODIFIER", 136, 141], ["background", "OBSERVATION_MODIFIER", 142, 152], ["intensity", "OBSERVATION_MODIFIER", 153, 162], ["tube", "OBSERVATION", 170, 174]]], ["The protein enrichment on the tube was then quantified as the ratio of the tube intensity to the local background, after subtracting the camera noise background from both values.Statistics and sample sizes ::: Materials and methodsFor TEM experiments, vesicle diameter distributions in Fig. 1 E are composed of n > 400 vesicles for each condition.", [["tube", "ANATOMY", 30, 34], ["tube", "ANATOMY", 75, 79], ["vesicle", "ANATOMY", 252, 259], ["vesicles", "ANATOMY", 319, 327], ["tube", "TISSUE", 30, 34], ["tube", "TISSUE", 75, 79], ["the tube", "TREATMENT", 26, 34], ["the camera noise background", "TEST", 133, 160], ["TEM experiments", "TEST", 235, 250], ["vesicle diameter distributions in Fig", "PROBLEM", 252, 289], ["protein enrichment", "OBSERVATION", 4, 22], ["tube", "OBSERVATION", 30, 34], ["tube intensity", "OBSERVATION", 75, 89], ["vesicle", "OBSERVATION", 252, 259], ["diameter", "OBSERVATION_MODIFIER", 260, 268], ["distributions", "OBSERVATION_MODIFIER", 269, 282], ["Fig", "OBSERVATION_MODIFIER", 286, 289]]], ["Tubule diameter distributions in Fig. S1 C (N-BAR) and Fig. S5 B (F-BAR) are composed of n > 300 and n > 500 tubules, respectively.", [["Tubule", "ANATOMY", 0, 6], ["tubules", "ANATOMY", 109, 116], ["N-BAR", "GENE_OR_GENE_PRODUCT", 44, 49], ["S5 B", "GENE_OR_GENE_PRODUCT", 60, 64], ["F-BAR", "GENE_OR_GENE_PRODUCT", 66, 71], ["tubules", "TISSUE", 109, 116], ["BAR", "PROTEIN", 46, 49], ["S5 B", "PROTEIN", 60, 64], ["F", "PROTEIN", 66, 67], ["BAR", "PROTEIN", 68, 71], ["Tubule diameter distributions in Fig", "PROBLEM", 0, 36], ["diameter", "OBSERVATION_MODIFIER", 7, 15], ["distributions", "OBSERVATION_MODIFIER", 16, 29], ["Fig", "OBSERVATION_MODIFIER", 33, 36]]], ["Vesicle diameter distributions in Fig. S5 D are composed of n > 250 vesicles for each condition.", [["Vesicle", "ANATOMY", 0, 7], ["vesicles", "ANATOMY", 68, 76], ["Vesicle", "MULTI-TISSUE_STRUCTURE", 0, 7], ["S5 D", "GENE_OR_GENE_PRODUCT", 39, 43], ["S5 D", "PROTEIN", 39, 43], ["Vesicle diameter distributions in Fig", "PROBLEM", 0, 37], ["diameter", "OBSERVATION_MODIFIER", 8, 16], ["distributions", "OBSERVATION_MODIFIER", 17, 30], ["Fig", "OBSERVATION_MODIFIER", 34, 37]]], ["Exact n values are provided in the figure legends.Statistics and sample sizes ::: Materials and methodsFor SUPER template experiments, markers in Figs.", [["SUPER template experiments", "TREATMENT", 107, 133]]], ["1 F, S1 E, 3 I, and 5 C represent n = 3 independent measurements of SUPER template membrane release at each protein concentration.", [["membrane", "ANATOMY", 83, 91], ["SUPER", "SIMPLE_CHEMICAL", 68, 73], ["membrane", "CELLULAR_COMPONENT", 83, 91], ["SUPER template membrane release", "TREATMENT", 68, 99]]], ["The indicated P values were calculated using unpaired, one-tailed Student\u2019s t tests.Statistics and sample sizes ::: Materials and methodsFor tethered vesicle fission experiments, vesicle diameter distributions represent data pooled from three independent experiments at each protein concentration.", [["vesicle", "ANATOMY", 150, 157], ["vesicle", "ANATOMY", 179, 186], ["vesicle", "CELLULAR_COMPONENT", 150, 157], ["vesicle", "CELLULAR_COMPONENT", 179, 186], ["P", "DNA", 14, 15], ["P values", "TEST", 14, 22], ["tethered vesicle fission experiments", "PROBLEM", 141, 177], ["vesicle fission", "OBSERVATION", 150, 165], ["vesicle", "OBSERVATION_MODIFIER", 179, 186], ["diameter", "OBSERVATION_MODIFIER", 187, 195]]], ["Fig. 2, C\u2013E (Amph-FL and N-BAR), represents n > 3,500 vesicles for all distributions except 1 and 5 \u00b5M Amph-FL, where n > 300 vesicles.", [["vesicles", "ANATOMY", 54, 62], ["vesicles", "ANATOMY", 126, 134], ["Amph-FL", "SIMPLE_CHEMICAL", 13, 20], ["N-BAR", "SIMPLE_CHEMICAL", 25, 30], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 103, 110], ["vesicles", "CELLULAR_COMPONENT", 126, 134], ["Amph", "PROTEIN", 13, 17], ["FL", "PROTEIN", 18, 20], ["N", "PROTEIN", 25, 26], ["BAR", "PROTEIN", 27, 30], ["Amph", "PROTEIN", 103, 107], ["FL", "PROTEIN", 108, 110], ["Fig.", "TEST", 0, 4], ["C\u2013E", "TEST", 8, 11], ["Amph", "TEST", 13, 17], ["FL", "TEST", 18, 20], ["Amph", "TEST", 103, 107], ["vesicles", "ANATOMY", 126, 134]]], ["Fig. 3 B (Amph CTD \u0394SH3) represents n > 4,100.", [["Amph CTD", "GENE_OR_GENE_PRODUCT", 10, 18], ["Amph CTD \u0394SH3", "PROTEIN", 10, 23], ["Amph CTD \u0394SH3", "TEST", 10, 23]]], ["Fig. 3 G (N-BAR-epsin CTD) represents n > 1,000.", [["N-BAR-epsin CTD", "GENE_OR_GENE_PRODUCT", 10, 25], ["BAR", "PROTEIN", 12, 15], ["epsin CTD", "PROTEIN", 16, 25], ["N-BAR-epsin CTD", "TREATMENT", 10, 25]]], ["Fig. 5 D (I-BAR-AP180 CTD) represents n > 4,800.", [["BAR", "PROTEIN", 12, 15], ["AP180 CTD", "PROTEIN", 16, 25]]], ["Fig. 5, I and J (FCHo1-FL and F-BAR), represents n > 900.", [["F-BAR", "GENE_OR_GENE_PRODUCT", 30, 35], ["FCHo1", "PROTEIN", 17, 22], ["FL", "PROTEIN", 23, 25], ["F", "PROTEIN", 30, 31], ["BAR", "PROTEIN", 32, 35]]], ["Fig. S3, B\u2013D (Amph-FL and N-BAR on highly charged vesicles), represents n > 800.", [["vesicles", "ANATOMY", 50, 58], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 14, 21], ["N-BAR", "GENE_OR_GENE_PRODUCT", 26, 31], ["vesicles", "CELLULAR_COMPONENT", 50, 58], ["S3", "PROTEIN", 5, 7], ["B\u2013D", "PROTEIN", 9, 12], ["Amph", "PROTEIN", 14, 18], ["FL", "PROTEIN", 19, 21], ["N", "PROTEIN", 26, 27], ["BAR", "PROTEIN", 28, 31], ["B\u2013D", "TEST", 9, 12], ["Amph", "TEST", 14, 18]]], ["Fig. S5 E (FCHo1-FL on DPPC vesicles) represents n > 3,900.", [["DPPC vesicles", "ANATOMY", 23, 36], ["DPPC", "CHEMICAL", 23, 27], ["FCHo1-FL", "GENE_OR_GENE_PRODUCT", 11, 19], ["FCHo1", "PROTEIN", 11, 16], ["FL", "PROTEIN", 17, 19], ["S5 E (FCHo1-FL on DPPC vesicles", "TEST", 5, 36]]], ["Markers in Fig. 2 F; Fig. 3, C and H; Fig. 5 K; Fig. S3 E; and Fig. S5 G show mean \u00b1 first SD of the three independent experiments.Statistics and sample sizes ::: Materials and methodsFor membrane coverage experiments on tethered vesicles, markers in Fig. 2, G and H, show mean \u00b1 95% CI, with n > 1,700 vesicles at each concentration.", [["membrane", "ANATOMY", 188, 196], ["vesicles", "ANATOMY", 230, 238], ["vesicles", "ANATOMY", 303, 311], ["S5 G", "GENE_OR_GENE_PRODUCT", 68, 72], ["membrane", "CELLULAR_COMPONENT", 188, 196], ["vesicles", "CELLULAR_COMPONENT", 230, 238], ["Materials", "TREATMENT", 163, 172], ["methods", "TREATMENT", 177, 184], ["membrane coverage experiments", "TREATMENT", 188, 217], ["tethered vesicles", "PROBLEM", 221, 238], ["mean", "TEST", 273, 277], ["CI", "TEST", 284, 286], ["Fig", "OBSERVATION_MODIFIER", 63, 66]]], ["Amph CTD \u0394SH3 markers in Fig. 3 D show mean \u00b1 first SD from three independent experiments, with n > 2,900 total vesicles at each concentration.Statistics and sample sizes ::: Materials and methodsIn cell experiments, Fig. 4 C displays data from n > 90 cells per condition from two independent transfections.", [["vesicles", "ANATOMY", 112, 120], ["cell", "ANATOMY", 199, 203], ["cells", "ANATOMY", 252, 257], ["Amph", "GENE_OR_GENE_PRODUCT", 0, 4], ["vesicles", "CELLULAR_COMPONENT", 112, 120], ["cell", "CELL", 199, 203], ["cells", "CELL", 252, 257], ["Amph CTD \u0394SH3 markers", "PROTEIN", 0, 21], ["Amph CTD \u0394SH3 markers", "TEST", 0, 21], ["mean \u00b1 first SD", "PROBLEM", 39, 54], ["Fig", "OBSERVATION_MODIFIER", 25, 28], ["cell experiments", "OBSERVATION", 199, 215]]], ["Fig. 4 D displays a subset of the data in Fig. 4 C that is within the specified protein expression range, with n > 20 cells per condition.", [["cells", "ANATOMY", 118, 123], ["cells", "CELL", 118, 123]]], ["Bars represent mean \u00b1 SEM.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mean \u00b1 SEM", "OBSERVATION", 15, 25]]], ["Fig. 4 E displays the lengths of individual tubes from cells within the specified protein expression range, where n > 80 tubes per condition.", [["cells", "ANATOMY", 55, 60], ["cells", "CELL", 55, 60], ["individual tubes from cells", "TREATMENT", 33, 60], ["tubes", "OBSERVATION", 44, 49]]], ["Fig. 4 F displays the lifetimes of individual tubes measured from TIRF videos, where n > 40 tubes per condition.", [["individual tubes", "TREATMENT", 35, 51], ["tubes", "OBSERVATION", 46, 51]]], ["Black lines in Fig. 4, E and F, indicate means.", [["Black lines", "CELL", 0, 11], ["Black lines", "CELL_LINE", 0, 11], ["Black lines in Fig", "PROBLEM", 0, 18], ["lines", "OBSERVATION", 6, 11], ["Fig", "OBSERVATION_MODIFIER", 15, 18]]], ["The indicated P values were calculated using unpaired, two-tailed Student\u2019s t tests.Calculation of IDP compression above BAR scaffold ::: Materials and methodsThe volume per IDP attached to the BAR scaffold was estimated as the volume of a cylindrical shell surrounding a membrane tube, with thickness equal to twice the radius of gyration of the IDP domains, divided by the number of BAR domains in the scaffold.", [["membrane tube", "ANATOMY", 272, 285], ["BAR", "GENE_OR_GENE_PRODUCT", 194, 197], ["membrane tube", "TISSUE", 272, 285], ["BAR", "GENE_OR_GENE_PRODUCT", 385, 388], ["P", "DNA", 14, 15], ["BAR scaffold", "PROTEIN", 121, 133], ["BAR scaffold", "PROTEIN", 194, 206], ["IDP domains", "PROTEIN", 347, 358], ["BAR domains", "PROTEIN", 385, 396], ["P values", "TEST", 14, 22], ["The volume per IDP", "TREATMENT", 159, 177], ["the BAR scaffold", "TREATMENT", 190, 206], ["a cylindrical shell surrounding a membrane tube", "TREATMENT", 238, 285], ["IDP compression", "OBSERVATION", 99, 114], ["volume", "OBSERVATION_MODIFIER", 163, 169], ["volume", "OBSERVATION_MODIFIER", 228, 234], ["cylindrical", "OBSERVATION_MODIFIER", 240, 251], ["shell", "OBSERVATION_MODIFIER", 252, 257], ["membrane tube", "OBSERVATION", 272, 285], ["thickness", "OBSERVATION_MODIFIER", 292, 301], ["equal", "OBSERVATION_MODIFIER", 302, 307], ["radius", "OBSERVATION_MODIFIER", 321, 327], ["gyration", "OBSERVATION", 331, 339], ["IDP domains", "OBSERVATION", 347, 358], ["scaffold", "ANATOMY_MODIFIER", 404, 412]]], ["The cylindrical shell volume surrounding the membrane tube is thereforeVshell=Vo\u2212Vi=\u03c0L(Ro2\u2212Ri2),where Vo and Vi are the outer and inner radii of the shell, respectively, L is the tube length, Ri is the radius of the membrane tube, and Ro=Ri+2rIDP, with rIDP equal to the radius of gyration of amphiphysin\u2019s disordered domain.", [["membrane tube", "ANATOMY", 45, 58], ["membrane tube", "ANATOMY", 216, 229], ["\u03c0L(Ro2\u2212Ri2)", "CHEMICAL", 84, 95], ["Vo", "CHEMICAL", 102, 104], ["Ro=Ri+2rIDP", "CHEMICAL", 235, 246], ["Ro2\u2212Ri2", "SIMPLE_CHEMICAL", 87, 94], ["tube", "TISSUE", 179, 183], ["membrane tube", "CELLULAR_COMPONENT", 216, 229], ["Ro=Ri+2rIDP", "SIMPLE_CHEMICAL", 235, 246], ["amphiphysin", "GENE_OR_GENE_PRODUCT", 293, 304], ["Ro2", "PROTEIN", 87, 90], ["Ri2", "PROTEIN", 91, 94], ["Vo", "PROTEIN", 102, 104], ["Vi", "PROTEIN", 109, 111], ["rIDP", "PROTEIN", 253, 257], ["amphiphysin", "PROTEIN", 293, 304], ["disordered domain", "PROTEIN", 307, 324], ["The cylindrical shell volume surrounding the membrane tube", "TREATMENT", 0, 58], ["Vo\u2212Vi", "TEST", 78, 83], ["the outer and inner radii of the shell", "TREATMENT", 116, 154], ["rIDP", "TREATMENT", 253, 257], ["cylindrical", "OBSERVATION_MODIFIER", 4, 15], ["shell volume", "OBSERVATION", 16, 28], ["membrane tube", "OBSERVATION", 45, 58], ["outer", "ANATOMY_MODIFIER", 120, 125], ["inner", "OBSERVATION_MODIFIER", 130, 135], ["radii", "OBSERVATION_MODIFIER", 136, 141], ["shell", "ANATOMY_MODIFIER", 149, 154], ["tube", "OBSERVATION", 179, 183], ["length", "OBSERVATION_MODIFIER", 184, 190], ["Ri", "OBSERVATION_MODIFIER", 192, 194], ["radius", "ANATOMY_MODIFIER", 202, 208], ["membrane tube", "OBSERVATION", 216, 229], ["radius", "OBSERVATION_MODIFIER", 271, 277], ["gyration", "OBSERVATION", 281, 289], ["amphiphysin\u2019s", "OBSERVATION", 293, 306]]], ["The number of proteins in the scaffold isnprot=AiABAR=2\u03c0RiLABAR,where Ai is the surface area of the membrane tube and ABAR is the area occupied per BAR monomer.", [["surface area", "ANATOMY", 80, 92], ["membrane tube", "ANATOMY", 100, 113], ["membrane tube", "CELLULAR_COMPONENT", 100, 113], ["2\u03c0RiLABAR", "PROTEIN", 54, 63], ["Ai", "PROTEIN", 70, 72], ["ABAR", "PROTEIN", 118, 122], ["BAR monomer", "PROTEIN", 148, 159], ["the membrane tube", "TREATMENT", 96, 113], ["surface", "OBSERVATION_MODIFIER", 80, 87], ["membrane tube", "OBSERVATION", 100, 113], ["area", "OBSERVATION_MODIFIER", 130, 134], ["BAR monomer", "OBSERVATION", 148, 159]]], ["The volume per compressed, scaffold-anchored disordered domain isVIDP,compressed=Vshellnprot=ABAR(Ro2\u2212Ri2)2Ri,and the un-compressed volume of the disordered domain isVIDP,un\u2212compressed=43\u03c0rIDP3.Parameter values were taken as ABAR = 16.5 nm2, Ri = 14 nm (both from Adam et al., 2015), and rIDP = 5 nm.", [["Ro2\u2212Ri2)2Ri", "CHEMICAL", 98, 109], ["scaffold-anchored disordered domain", "PROTEIN", 27, 62], ["isVIDP", "PROTEIN", 63, 69], ["Vshellnprot", "PROTEIN", 81, 92], ["ABAR", "PROTEIN", 93, 97], ["Ro2", "PROTEIN", 98, 101], ["Ri2", "PROTEIN", 102, 105], ["2Ri", "PROTEIN", 106, 109], ["disordered domain", "PROTEIN", 146, 163], ["isVIDP", "PROTEIN", 164, 170], ["43\u03c0rIDP3", "PROTEIN", 185, 193], ["anchored disordered domain isVIDP", "PROBLEM", 36, 69], ["Vshellnprot", "TEST", 81, 92], ["ABAR", "TEST", 93, 97], ["the disordered domain isVIDP", "PROBLEM", 142, 170], ["Parameter values", "TEST", 194, 210], ["ABAR", "TEST", 225, 229], ["Ri", "TEST", 242, 244]]], ["Using these values, VIDP,compressed = 224 nm3 and VIDP,un-compressed = 524 nm3, corresponding to an \u223c60% compression of the disordered domain volume to accommodate the scaffold geometry.", [["these values", "TEST", 6, 18], ["VIDP", "TEST", 20, 24], ["VIDP", "TEST", 50, 54], ["un", "TEST", 55, 57], ["the disordered domain volume", "PROBLEM", 120, 148], ["the scaffold geometry", "PROBLEM", 164, 185], ["compression", "OBSERVATION", 105, 116], ["scaffold geometry", "OBSERVATION", 168, 185]]], ["Notably, the cylindrical shell was assumed to have a constant thickness of 2rIDP, which represents the volume that would be required to accommodate the disordered protein domains if they were incompressible.", [["2rIDP", "SIMPLE_CHEMICAL", 75, 80], ["2rIDP", "PROTEIN", 75, 80], ["disordered protein domains", "PROTEIN", 152, 178], ["a constant thickness of 2rIDP", "PROBLEM", 51, 80], ["the disordered protein domains", "PROBLEM", 148, 178], ["cylindrical shell", "OBSERVATION", 13, 30], ["constant", "OBSERVATION_MODIFIER", 53, 61], ["thickness", "OBSERVATION_MODIFIER", 62, 71]]], ["S1 shows GUV and TEM experiments with N-BAR and Amph-FL, SUPER template experiments comparing Amph-FL and the ENTH domain, and further analysis of tethered vesicle experiments with N-BAR and Amph-FL.", [["vesicle", "ANATOMY", 156, 163], ["N-BAR", "GENE_OR_GENE_PRODUCT", 38, 43], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 48, 55], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 94, 101], ["vesicle", "CELLULAR_COMPONENT", 156, 163], ["N-BAR", "GENE_OR_GENE_PRODUCT", 181, 186], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 191, 198], ["BAR", "PROTEIN", 40, 43], ["Amph", "PROTEIN", 48, 52], ["FL", "PROTEIN", 53, 55], ["Amph", "PROTEIN", 94, 98], ["FL", "PROTEIN", 99, 101], ["ENTH domain", "PROTEIN", 110, 121], ["N", "PROTEIN", 181, 182], ["BAR", "PROTEIN", 183, 186], ["Amph", "PROTEIN", 191, 195], ["FL", "PROTEIN", 196, 198], ["TEM experiments", "TEST", 17, 32], ["Amph-FL", "TREATMENT", 48, 55], ["the ENTH domain", "TEST", 106, 121], ["further analysis", "TEST", 127, 143], ["tethered vesicle experiments", "PROBLEM", 147, 175]]], ["Fig. S2 shows membrane coverage experiments using tethered vesicles, FCS of Amph CTD \u0394SH3, and GUV-binding experiments with 6his peptide.", [["membrane", "ANATOMY", 14, 22], ["vesicles", "ANATOMY", 59, 67], ["S2", "GENE_OR_GENE_PRODUCT", 5, 7], ["membrane", "CELLULAR_COMPONENT", 14, 22], ["vesicles", "CELLULAR_COMPONENT", 59, 67], ["Amph CTD", "GENE_OR_GENE_PRODUCT", 76, 84], ["GUV", "SIMPLE_CHEMICAL", 95, 98], ["6his peptide", "SIMPLE_CHEMICAL", 124, 136], ["S2", "PROTEIN", 5, 7], ["Amph CTD \u0394SH3", "PROTEIN", 76, 89], ["GUV", "PROTEIN", 95, 98], ["membrane coverage experiments", "TREATMENT", 14, 43], ["tethered vesicles", "PROBLEM", 50, 67], ["Amph CTD \u0394SH3", "TEST", 76, 89], ["6his peptide", "TREATMENT", 124, 136], ["membrane coverage", "OBSERVATION", 14, 31]]], ["Fig. S3 shows membrane fission experiments with N-BAR and Amph-FL on highly charged membranes.", [["membrane", "ANATOMY", 14, 22], ["membranes", "ANATOMY", 84, 93], ["Amph-FL", "CHEMICAL", 58, 65], ["S3", "GENE_OR_GENE_PRODUCT", 5, 7], ["membrane", "CELLULAR_COMPONENT", 14, 22], ["N-BAR", "SIMPLE_CHEMICAL", 48, 53], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 58, 65], ["membranes", "CELLULAR_COMPONENT", 84, 93], ["BAR", "PROTEIN", 50, 53], ["Amph", "PROTEIN", 58, 62], ["FL", "PROTEIN", 63, 65], ["membrane fission experiments", "PROBLEM", 14, 42], ["membrane fission", "OBSERVATION", 14, 30], ["charged membranes", "OBSERVATION", 76, 93]]], ["Fig. S4 shows further analysis of experiments with live RPE cells.", [["RPE cells", "ANATOMY", 56, 65], ["RPE cells", "CELL", 56, 65], ["live RPE cells", "CELL_TYPE", 51, 65], ["further analysis", "TEST", 14, 30], ["live RPE cells", "PROBLEM", 51, 65], ["RPE cells", "OBSERVATION", 56, 65]]], ["Fig. S5 shows TEM and tethered vesicle experiments with F-BAR and FCHo1-FL.", [["vesicle", "ANATOMY", 31, 38], ["vesicle", "CELLULAR_COMPONENT", 31, 38], ["F-BAR", "GENE_OR_GENE_PRODUCT", 56, 61], ["BAR", "PROTEIN", 58, 61], ["FCHo1", "PROTEIN", 66, 71], ["tethered vesicle", "OBSERVATION", 22, 38]]], ["Videos 1 and 2 show lipid tubules generated from GUVs by N-BAR and Amph-FL, respectively.", [["lipid tubules", "ANATOMY", 20, 33], ["GUVs", "ANATOMY", 49, 53], ["lipid tubules", "MULTI-TISSUE_STRUCTURE", 20, 33], ["GUVs", "SIMPLE_CHEMICAL", 49, 53], ["N-BAR", "GENE_OR_GENE_PRODUCT", 57, 62], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 67, 74], ["BAR", "PROTEIN", 59, 62], ["Amph", "PROTEIN", 67, 71], ["FL", "PROTEIN", 72, 74], ["Videos", "TEST", 0, 6]]], ["Videos 3 and 4 show collapsing of GUVs after exposure to N-BAR and Amph-FL, respectively.", [["N-BAR", "CHEMICAL", 57, 62], ["Amph-FL", "CHEMICAL", 67, 74], ["N-BAR", "GENE_OR_GENE_PRODUCT", 57, 62], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 67, 74], ["BAR", "PROTEIN", 59, 62], ["Amph", "PROTEIN", 67, 71], ["FL", "PROTEIN", 72, 74], ["Videos", "TEST", 0, 6], ["collapsing of GUVs", "PROBLEM", 20, 38], ["collapsing", "OBSERVATION", 20, 30], ["FL", "ANATOMY", 72, 74]]], ["Video 5 shows vesiculation of GUVs by Amph-FL.", [["GUVs", "ANATOMY", 30, 34], ["Amph-FL", "CHEMICAL", 38, 45], ["GUVs", "ORGANISM_SUBSTANCE", 30, 34], ["Amph-FL", "GENE_OR_GENE_PRODUCT", 38, 45], ["Amph", "PROTEIN", 38, 42]]], ["Video 6 shows TIRF microscopy of tubules in live RPE cells.", [["tubules", "ANATOMY", 33, 40], ["RPE cells", "ANATOMY", 49, 58], ["tubules", "TISSUE", 33, 40], ["RPE cells", "CELL", 49, 58], ["live RPE cells", "CELL_TYPE", 44, 58], ["TIRF microscopy", "TEST", 14, 29], ["RPE cells", "OBSERVATION", 49, 58]]], ["Videos 7 and 8 show GUV membrane remodeling driven by I-BAR and I-BAR-AP180 CTD, respectively.", [["GUV membrane", "ANATOMY", 20, 32], ["GUV membrane", "CELLULAR_COMPONENT", 20, 32], ["I-BAR", "GENE_OR_GENE_PRODUCT", 54, 59], ["I-BAR", "GENE_OR_GENE_PRODUCT", 64, 69], ["I", "PROTEIN", 54, 55], ["BAR", "PROTEIN", 56, 59], ["I", "PROTEIN", 64, 65], ["BAR", "PROTEIN", 66, 69], ["AP180 CTD", "PROTEIN", 70, 79], ["Videos", "TEST", 0, 6], ["GUV membrane remodeling", "PROBLEM", 20, 43]]]], "PMC7369341": [["IntroductionThe pandemic of the novel corona virus disease 2019 (COVID-19), which originally emerged in Wuhan, China in December 2019 has spread around the world [1, 2].", [["corona virus disease", "DISEASE", 38, 58], ["COVID-19", "CHEMICAL", 65, 73], ["corona virus", "ORGANISM", 38, 50], ["corona virus disease 2019 (COVID-19", "SPECIES", 38, 73], ["the novel corona virus disease", "PROBLEM", 28, 58], ["COVID", "TEST", 65, 70], ["corona", "OBSERVATION_MODIFIER", 38, 44]]], ["As of 5 June 2020, the WHO has reported a total of 6 535 354 COVID-19 cases and 387 155 deaths globally, with an average mortality of 5.92% and the person-to-person transmission is still continuing [3].", [["deaths", "DISEASE", 88, 94], ["person", "SPECIES", 148, 154], ["person", "SPECIES", 158, 164], ["COVID", "TEST", 61, 66]]], ["The clinical spectrum of COVID-19 appears to be wide, ranging from asymptomatic infection to mildly, severely, critically ill cases.", [["infection", "DISEASE", 80, 89], ["critically ill", "DISEASE", 111, 125], ["COVID", "TEST", 25, 30], ["asymptomatic infection", "PROBLEM", 67, 89], ["mildly, severely, critically ill cases", "PROBLEM", 93, 131], ["asymptomatic", "OBSERVATION_MODIFIER", 67, 79], ["infection", "OBSERVATION", 80, 89], ["mildly", "OBSERVATION_MODIFIER", 93, 99]]], ["Mild patients present only upper respiratory tract symptoms like cough and fever, however, respiratory failure, acute respiratory distress syndrome, heart failure, septic shock and even death can be observed in patients with critical conditions [4].", [["upper respiratory tract", "ANATOMY", 27, 50], ["respiratory", "ANATOMY", 91, 102], ["respiratory", "ANATOMY", 118, 129], ["heart", "ANATOMY", 149, 154], ["upper respiratory tract symptoms", "DISEASE", 27, 59], ["cough", "DISEASE", 65, 70], ["fever", "DISEASE", 75, 80], ["respiratory failure", "DISEASE", 91, 110], ["acute respiratory distress syndrome", "DISEASE", 112, 147], ["heart failure", "DISEASE", 149, 162], ["septic shock", "DISEASE", 164, 176], ["death", "DISEASE", 186, 191], ["patients", "ORGANISM", 5, 13], ["upper", "ORGANISM_SUBDIVISION", 27, 32], ["respiratory tract", "ORGANISM_SUBDIVISION", 33, 50], ["heart", "ORGAN", 149, 154], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 211, 219], ["upper respiratory tract symptoms", "PROBLEM", 27, 59], ["cough", "PROBLEM", 65, 70], ["fever", "PROBLEM", 75, 80], ["respiratory failure", "PROBLEM", 91, 110], ["acute respiratory distress syndrome", "PROBLEM", 112, 147], ["heart failure", "PROBLEM", 149, 162], ["septic shock", "PROBLEM", 164, 176], ["even death", "PROBLEM", 181, 191], ["upper", "ANATOMY_MODIFIER", 27, 32], ["respiratory tract", "ANATOMY", 33, 50], ["cough", "OBSERVATION", 65, 70], ["fever", "OBSERVATION", 75, 80], ["respiratory failure", "OBSERVATION", 91, 110], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory distress", "OBSERVATION", 118, 138], ["syndrome", "OBSERVATION", 139, 147], ["heart", "ANATOMY", 149, 154], ["failure", "OBSERVATION", 155, 162], ["septic shock", "OBSERVATION", 164, 176]]], ["Although most confirmed patients (81%) were classified as mild or moderate, 14% were severe and 5% were critical according to the largest investigation of 72 314 cases to date [5].", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["moderate", "OBSERVATION_MODIFIER", 66, 74]]], ["Accumulated evidences have indicated that older age, male, smoking, comorbidity, neutrophilia, coagulopathy, elevated D-dimer level and organ dysfunction were associated with increased risk of death from COVID-19 [5\u201310].", [["organ", "ANATOMY", 136, 141], ["comorbidity", "DISEASE", 68, 79], ["neutrophilia", "DISEASE", 81, 93], ["coagulopathy", "DISEASE", 95, 107], ["organ dysfunction", "DISEASE", 136, 153], ["death", "DISEASE", 193, 198], ["COVID-19", "CHEMICAL", 204, 212], ["D-dimer", "GENE_OR_GENE_PRODUCT", 118, 125], ["organ", "ORGAN", 136, 141], ["comorbidity", "PROBLEM", 68, 79], ["neutrophilia", "PROBLEM", 81, 93], ["coagulopathy", "PROBLEM", 95, 107], ["elevated D-dimer level", "PROBLEM", 109, 131], ["organ dysfunction", "PROBLEM", 136, 153], ["death", "PROBLEM", 193, 198], ["COVID", "TEST", 204, 209], ["neutrophilia", "OBSERVATION", 81, 93], ["coagulopathy", "OBSERVATION", 95, 107], ["organ", "ANATOMY", 136, 141], ["dysfunction", "OBSERVATION", 142, 153]]], ["However, investigations of determinants of severity of COVID-19 are scarce.", [["COVID-19", "CHEMICAL", 55, 63], ["COVID", "TEST", 55, 60]]], ["Early detecting cases with the potential deterioration of disease will contribute to optimising the use of limited health resources and allocating the proper care.", [["disease", "PROBLEM", 58, 65], ["limited health resources", "TREATMENT", 107, 131], ["disease", "OBSERVATION", 58, 65]]], ["Liang et al. developed a clinical risk score to predict the occurrence of critical COVID-19 based on severe or non-severe [11].", [["a clinical risk score", "PROBLEM", 23, 44], ["critical COVID", "TEST", 74, 88]]], ["To our knowledge, no previous studies have been conducted to investigate the risk factors of severity of COVID-19 based on ordinal response, namely moderate, severe and critical illness.", [["previous studies", "TEST", 21, 37], ["COVID", "TEST", 105, 110], ["moderate, severe and critical illness", "PROBLEM", 148, 185], ["moderate", "OBSERVATION_MODIFIER", 148, 156], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["critical", "OBSERVATION_MODIFIER", 169, 177], ["illness", "OBSERVATION", 178, 185]]], ["The estimation of risk factors of disease severity is therefore not very robust.IntroductionHere, we conducted a retrospective study based on COVID-19 patients from four designated hospitals in Shanghai, Hubei and Anhui provinces to describe the clinical features of COVID-19, and aimed to identify the predictors of multi-level response of severity from moderate, severe to critical illness.Study design and participants ::: MethodsThis multi-centre retrospective study encompassed COVID-19 patients classified as being moderately, severely and critically ill.", [["critically ill", "DISEASE", 546, 560], ["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 492, 500], ["patients", "SPECIES", 151, 159], ["participants", "SPECIES", 409, 421], ["patients", "SPECIES", 492, 500], ["disease severity", "PROBLEM", 34, 50], ["a retrospective study", "TEST", 111, 132], ["COVID", "TEST", 267, 272], ["moderate, severe to critical illness", "PROBLEM", 355, 391], ["Methods", "TREATMENT", 426, 433], ["This multi-centre retrospective study", "TEST", 433, 470], ["COVID", "TEST", 483, 488], ["critically ill", "PROBLEM", 546, 560], ["disease", "OBSERVATION", 34, 41], ["moderate", "OBSERVATION_MODIFIER", 355, 363], ["severe", "OBSERVATION_MODIFIER", 365, 371], ["illness", "OBSERVATION", 384, 391], ["moderately", "OBSERVATION_MODIFIER", 521, 531], ["critically", "OBSERVATION_MODIFIER", 546, 556], ["ill", "OBSERVATION", 557, 560]]], ["The illness severity of COVID-19 was defined according to the Guideline on the Diagnosis and Treatment of COVID-19 by the National Health Commission (V.5) as described previously [12].", [["illness", "DISEASE", 4, 11], ["COVID", "TEST", 24, 29], ["COVID", "TEST", 106, 111]]], ["Patients were admitted to Shanghai Public Health Clinical Center, Wuhan Jinyintan Hospital and Tongji Hospital of Tongji Medical College HUST in Hubei province and Tongling Municipal People's Hospital in Anhui province from 1 January 2020 to 8 March 2020.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["All patients recruited in this study were laboratory-confirmed COVID-19.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["this study", "TEST", 26, 36], ["COVID", "TEST", 63, 68]]], ["The study was approved by the Ethics Committees of these four hospitals, respectively.", [["The study", "TEST", 0, 9]]], ["Written informed consent was waived owing to the need of rapid emergency response to this infectious disease.Data collection ::: MethodsMedical records of COVID-19 patients were reviewed by the research team, and demographic, epidemiological, clinical, laboratory, treatment and outcome data were retrieved from electronic medical records using a standardised case report form.", [["infectious disease", "DISEASE", 90, 108], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["this infectious disease", "PROBLEM", 85, 108], ["infectious", "OBSERVATION", 90, 100]]], ["All data were cross-checked by two experienced doctors.", [["All data", "TEST", 0, 8]]], ["To ascertain the medical histories or epidemiological data, which were unavailable from electronic medical records, the patients or their close relatives were interviewed by researchers.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["epidemiological data", "TEST", 38, 58]]], ["Data from the medical records were adopted if there was a discrepancy between the subjective description and the medical records.Laboratory procedures ::: MethodsMethod of laboratory confirmation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described elsewhere [1].", [["acute respiratory syndrome coronavirus", "DISEASE", 206, 244], ["severe acute respiratory syndrome coronavirus", "SPECIES", 199, 244], ["SARS-CoV-2", "SPECIES", 248, 258], ["laboratory confirmation", "TEST", 172, 195], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 199, 244], ["SARS-CoV", "TEST", 248, 256], ["severe", "OBSERVATION_MODIFIER", 199, 205], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["respiratory syndrome", "OBSERVATION", 212, 232]]], ["Simply, the Chinese Center for Disease Control and Prevention (CDC) and local CDC were in charge of detecting SARS-CoV-2 in throat-swab specimens from the upper respiratory tract by real-time reverse transcription polymerase chain reaction assay (RT-PCR).", [["throat-swab specimens", "ANATOMY", 124, 145], ["upper respiratory tract", "ANATOMY", 155, 178], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 110, 120], ["throat", "ORGANISM", 124, 130], ["upper respiratory", "ORGANISM_SUBDIVISION", 155, 172], ["tract", "ORGANISM_SUBDIVISION", 173, 178], ["SARS-CoV", "SPECIES", 110, 118], ["Disease Control", "TREATMENT", 31, 46], ["local CDC", "TEST", 72, 81], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118], ["throat-swab specimens", "TEST", 124, 145], ["the upper respiratory tract", "PROBLEM", 151, 178], ["chain reaction assay", "TEST", 225, 245], ["RT-PCR", "TEST", 247, 253], ["throat", "ANATOMY", 124, 130], ["upper", "ANATOMY_MODIFIER", 155, 160], ["respiratory tract", "ANATOMY", 161, 178]]], ["The criteria of discharge included absence of fever for at least 3 days, remission of respiratory symptoms, complete improvement in bilateral lungs in chest CT, together with negative for 2 times in throat-swab samples for SARS-CoV-2 RNA at least 24 h apart.Laboratory procedures ::: MethodsInitial clinical laboratory examinations involved complete blood count, serum biochemical tests (including liver and kidney functions, creatine kinase, lactate dehydrogenase (LDH) and electrolytes), myocardial enzymes, D-dimer and procalcitonin (PCT).", [["respiratory", "ANATOMY", 86, 97], ["lungs", "ANATOMY", 142, 147], ["chest", "ANATOMY", 151, 156], ["samples", "ANATOMY", 211, 218], ["blood", "ANATOMY", 350, 355], ["serum", "ANATOMY", 363, 368], ["liver", "ANATOMY", 398, 403], ["kidney", "ANATOMY", 408, 414], ["myocardial", "ANATOMY", 490, 500], ["fever", "DISEASE", 46, 51], ["respiratory symptoms", "DISEASE", 86, 106], ["SARS", "DISEASE", 223, 227], ["creatine", "CHEMICAL", 426, 434], ["lactate", "CHEMICAL", 443, 450], ["creatine", "CHEMICAL", 426, 434], ["lactate", "CHEMICAL", 443, 450], ["lungs", "ORGAN", 142, 147], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["serum", "ORGANISM_SUBSTANCE", 363, 368], ["liver", "ORGAN", 398, 403], ["kidney", "ORGAN", 408, 414], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 426, 441], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 443, 464], ["LDH", "SIMPLE_CHEMICAL", 466, 469], ["electrolytes", "SIMPLE_CHEMICAL", 475, 487], ["myocardial", "MULTI-TISSUE_STRUCTURE", 490, 500], ["D-dimer", "GENE_OR_GENE_PRODUCT", 510, 517], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 522, 535], ["SARS-CoV-2 RNA", "RNA", 223, 237], ["creatine kinase", "PROTEIN", 426, 441], ["lactate dehydrogenase", "PROTEIN", 443, 464], ["LDH", "PROTEIN", 466, 469], ["myocardial enzymes", "PROTEIN", 490, 508], ["D-dimer", "PROTEIN", 510, 517], ["procalcitonin", "PROTEIN", 522, 535], ["PCT", "PROTEIN", 537, 540], ["SARS-CoV", "SPECIES", 223, 231], ["fever", "PROBLEM", 46, 51], ["respiratory symptoms", "PROBLEM", 86, 106], ["bilateral lungs in chest CT", "TEST", 132, 159], ["throat", "TEST", 199, 205], ["swab samples", "TEST", 206, 218], ["SARS", "PROBLEM", 223, 227], ["CoV", "TEST", 228, 231], ["MethodsInitial clinical laboratory examinations", "TEST", 284, 331], ["complete blood count", "TEST", 341, 361], ["serum biochemical tests", "TEST", 363, 386], ["liver and kidney functions", "TEST", 398, 424], ["creatine kinase", "TEST", 426, 441], ["lactate dehydrogenase", "TEST", 443, 464], ["LDH", "TEST", 466, 469], ["electrolytes", "TEST", 475, 487], ["myocardial enzymes", "TEST", 490, 508], ["procalcitonin", "TEST", 522, 535], ["PCT", "TEST", 537, 540], ["fever", "OBSERVATION", 46, 51], ["respiratory", "ANATOMY", 86, 97], ["bilateral", "ANATOMY_MODIFIER", 132, 141], ["lungs", "ANATOMY", 142, 147], ["chest", "ANATOMY", 151, 156], ["liver", "ANATOMY", 398, 403], ["kidney", "ANATOMY", 408, 414]]], ["Frequency of examinations was under the discretion of treating physicians.", [["examinations", "TEST", 13, 25]]], ["Chest computed tomographic (CT) scans were carried out for all COVID-19 patients.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Chest computed tomographic (CT) scans", "TEST", 0, 37], ["all COVID", "TEST", 59, 68]]], ["Two radiologists were invited to interpret chest CT scans independently and were blinded to the severity of the patient.", [["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119], ["chest CT scans", "TEST", 43, 57], ["chest", "ANATOMY", 43, 48]]], ["When disagreement arose, a third radiologist was consulted to reach a final decision.Statistical analysis ::: MethodsContinuous variables were presented as median with interquartile range (IQR) and the analysis of variance (ANOVA) or Kruskal\u2212Wallis H test were used to compare the difference among three groups as appropriate.", [["Statistical analysis", "TEST", 85, 105], ["the analysis", "TEST", 198, 210], ["Kruskal\u2212Wallis H test", "TEST", 234, 255]]], ["Categorical variables were expressed as frequency with percentages, and were analysed by Pearson's \u03c72 test or Fisher's exact test.", [["Categorical variables", "TEST", 0, 21], ["Fisher's exact test", "TEST", 110, 129]]], ["Bonferroni's correction was used for pairwise comparison.", [["Bonferroni's correction", "TREATMENT", 0, 23], ["pairwise comparison", "TEST", 37, 56]]], ["All patients were divided into moderate, severe and critical illness groups.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["moderate, severe and critical illness groups", "PROBLEM", 31, 75], ["moderate", "OBSERVATION_MODIFIER", 31, 39], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["critical", "OBSERVATION_MODIFIER", 52, 60], ["illness", "OBSERVATION", 61, 68]]], ["Potential predictive variables included the following case characteristics on admission: demographic and epidemiological features, comorbidity, clinical signs and symptoms, laboratory findings and chest imaging results.", [["chest", "ANATOMY", 197, 202], ["comorbidity", "PROBLEM", 131, 142], ["clinical signs and symptoms", "PROBLEM", 144, 171], ["laboratory findings", "TEST", 173, 192], ["chest imaging", "TEST", 197, 210], ["chest", "ANATOMY", 197, 202]]], ["To explore the risk factors associated with illness severity of COVID-19, namely moderately, severely and critically ill, which means the response variable was ordinally scaled, a cumulative logit model was used to investigate the effect of predictors of COVID-19 severity.", [["illness", "DISEASE", 44, 51], ["critically ill", "DISEASE", 106, 120], ["COVID", "TEST", 64, 69], ["critically ill", "PROBLEM", 106, 120], ["a cumulative logit model", "TREATMENT", 178, 202], ["COVID", "TEST", 255, 260]]], ["Imputation for missing variables of some patients at hospital admission was considered if missing values were less than 20%, and imputation based on the expectation\u2212maximisation algorithm method was used to replace missing values.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["missing variables", "PROBLEM", 15, 32], ["missing values", "PROBLEM", 90, 104], ["missing values", "PROBLEM", 215, 229]]], ["Before ordinal logistic regression model was fitted, continuous variables of laboratory findings were transformed into categorical variables according to their reference values.", [["laboratory findings", "TEST", 77, 96]]], ["The univariate and multivariate cumulative logit models were fitted with moderate illness as the reference level.", [["The univariate", "TREATMENT", 0, 14], ["multivariate cumulative logit models", "TREATMENT", 19, 55], ["moderate illness", "PROBLEM", 73, 89], ["moderate", "OBSERVATION_MODIFIER", 73, 81], ["illness", "OBSERVATION", 82, 89]]], ["Potential predictors of severity were investigated using univariate ordinal logistic regression firstly.", [["severity", "PROBLEM", 24, 32], ["univariate ordinal logistic regression", "TREATMENT", 57, 95]]], ["We further conducted a backward stepwise multivariate ordinal logistic regression analysis excluding variables which were not significant in univariate cumulative logit model.", [["a backward stepwise multivariate ordinal logistic regression analysis", "TEST", 21, 90]]], ["Since missing rate of 34.6% occurred in the lung imaging results and over 40% existed in urine protein and urine glucose, these variables were excluded from multivariate ordinal logistic model.", [["lung", "ANATOMY", 44, 48], ["urine", "ANATOMY", 89, 94], ["urine", "ANATOMY", 107, 112], ["glucose", "CHEMICAL", 113, 120], ["glucose", "CHEMICAL", 113, 120], ["lung", "ORGAN", 44, 48], ["urine", "ORGANISM_SUBSTANCE", 89, 94], ["urine", "ORGANISM_SUBSTANCE", 107, 112], ["glucose", "SIMPLE_CHEMICAL", 113, 120], ["urine protein", "PROTEIN", 89, 102], ["missing rate", "TEST", 6, 18], ["the lung imaging", "TEST", 40, 56], ["urine protein", "TEST", 89, 102], ["urine glucose", "TEST", 107, 120], ["these variables", "TEST", 122, 137], ["lung", "ANATOMY", 44, 48]]], ["The overall survival (OS) was estimated using the method of Kaplan\u2212Meier and the log-rank test was applied to compare the survival difference among different severity illness groups.", [["illness", "DISEASE", 167, 174], ["the log-rank test", "TEST", 77, 94]]], ["The hazard ratio with 95% confidence interval (CI) was estimated with Cox proportional hazard model.", [["The hazard ratio", "TEST", 0, 16], ["CI", "TEST", 47, 49], ["Cox proportional hazard model", "PROBLEM", 70, 99]]], ["A two-sided \u03b1 of less than 0.05 was considered statistically significant.", [["sided", "ANATOMY_MODIFIER", 6, 11], ["significant", "OBSERVATION_MODIFIER", 61, 72]]], ["All statistical analyses were conducted using SAS software (V. 9.4) (SAS Institute Inc., USA).Demographics, laboratory findings and clinical course ::: ResultsAs of 28 April 2020, data from 598 COVID-19 cases admitted to these four hospitals, including 400 (66.89%) moderate cases, 85 (14.21%) severe cases and 113 (18.90%) critical cases, had been collected to be incorporated into this study, of whom 79 cases had died during hospitalisation, with an average mortality of 13.21%, and 457 cases had recovered and been discharged.", [["All statistical analyses", "TEST", 0, 24], ["SAS software", "TEST", 46, 58], ["V.", "TEST", 60, 62], ["COVID", "TEST", 194, 199], ["severe cases", "TEST", 294, 306], ["this study", "TEST", 383, 393]]], ["The median age of the 598 patients was 57 years (IQR 42\u201366), ranging from 11 to 89 years, and 58.03% patients were male (Table 1).", [["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 101, 109], ["IQR", "TEST", 49, 52]]], ["At least one comorbidity was present in 51.54% of patients, with hypertension being the most frequent comorbidity (33.90%), followed by diabetes (13.18%) and cardiovascular disease (6.51%).", [["cardiovascular", "ANATOMY", 158, 172], ["hypertension", "DISEASE", 65, 77], ["diabetes", "DISEASE", 136, 144], ["cardiovascular disease", "DISEASE", 158, 180], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["hypertension", "PROBLEM", 65, 77], ["the most frequent comorbidity", "PROBLEM", 84, 113], ["diabetes", "PROBLEM", 136, 144], ["cardiovascular disease", "PROBLEM", 158, 180], ["one", "OBSERVATION_MODIFIER", 9, 12], ["comorbidity", "OBSERVATION", 13, 24], ["hypertension", "OBSERVATION", 65, 77], ["cardiovascular", "ANATOMY", 158, 172], ["disease", "OBSERVATION", 173, 180]]], ["The most common symptoms on admission were fever (81.22%) and dry cough (33.63%), followed by sputum production (30.77%) and shortness of breath (26.65%).", [["sputum", "ANATOMY", 94, 100], ["fever", "DISEASE", 43, 48], ["dry cough", "DISEASE", 62, 71], ["shortness of breath", "DISEASE", 125, 144], ["The most common symptoms", "PROBLEM", 0, 24], ["fever", "PROBLEM", 43, 48], ["dry cough", "PROBLEM", 62, 71], ["sputum production", "TEST", 94, 111], ["shortness of breath", "PROBLEM", 125, 144], ["cough", "OBSERVATION", 66, 71]]], ["Overall, the median interval between illness onset and confirmed diagnosis was 4 days (IQR 2\u20137), whereas the median interval between illness onset and admission was 7 days (IQR 3\u201311).", [["illness", "DISEASE", 37, 44], ["illness", "DISEASE", 133, 140]]]]}